{"title": "PDF", "author": "PDF", "url": "http://catalogoinsp.mx/files/tes/054264.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Instituto Nacional de Salud P\u00fablica\nCentro de Investigaci\u00f3n Sobre Enfermedades Infecciosas\nCISEI\nAn\u00e1lisis estructural y funcional del \nrepertorio de anticuerpos en pacientes con \nDengue Cl\u00e1sico y Dengue Hemorr\u00e1gico\nTESIS\nPara obtener el grado de Doctora en Ciencias en \nla Salud P\u00fablica con \u00e1rea de Concentraci\u00f3n \nen Enfermedades Infecciosas\nP R E S E N T A\nM. en C. Elizabeth Ernestina Godoy Lozano\nDirector de Tesis\nDr. Jes\u00fas Mart\u00ednez Barnetche\nAsesores\nDr. Juan Mauricio T\u00e9llez Sosa\nDr. Jos\u00e9 Moreno Rodr\u00edguez\nDr. Jos\u00e9 Ramos Casta\u00f1eda\nCuernavaca, MorelosFebrero, 2015!\nM.#en#C.#Elizabeth#Ernestina#Godoy#Lozano#!!!!\n2\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!#######################Uso$mi$palabra$para$que$los$dem\u00e1s$conozcan$mi$mundo,$$y$utiliz\u00f3$el$mundo,$para$que$los$dem\u00e1s$conozcan$mi$palabra;$como$joven$mujer$les$pido$que$me$acompa\u00f1en$y$en$esta$b\u00fasqueda$de$justicia,$$mi$vida$sea$tierra$que$florezca$y$fructifique.$$#Mariana#G\u00f3mez#Godoy,#2000.###!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"3\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Comit\u00e9#Asesor##Dr.#Jes\u00fas#Mart\u00ednez#Barnetche#Director(de(tesis(Direcci\u00f3n!de!Infecciones!Cr\u00f3nicas!y!C\u00e1ncer!Centro!de!Investigaci\u00f3n!Sobre!Enfermedades!Infecciosas!Instituto!Nacional!de!Salud!P\u00fablica!!!Dr.#Juan#Mauricio#T\u00e9llez#Sosa#Asesor(Departamento!de!Inmunolog\u00eda!Centro!de!Investigaci\u00f3n!Sobre!Enfermedades!Infecciosas!Instituto!Nacional!de!Salud!P\u00fablica!!!Dr.#Jos\u00e9#Ramos#Casta\u00f1eda#Asesor(Centro!de!Investigaci\u00f3n!Sobre!Enfermedades!Infecciosas!Instituto!Nacional!de!Salud!P\u00fablica!!!Dr.#Jos\u00e9#Moreno#Rodr\u00edguez #Asesor(Direcci\u00f3n!Adjunta!del!Centro!de!Investigaci\u00f3n!Sobre!Enfermedades!Infecciosas!Centro!de!Investigaci\u00f3n!Sobre!Enfermedades!Infecciosas!Instituto!Nacional!de!Salud!P\u00fablica!!!!!!!!!!!!!!!!!!!!\n4\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Jurado#del#Examen#de#Grado#!Dr.#Leopoldo#Flores#Romo#Presidente(Departamento!de!Biolog\u00eda!Celular!Centro!de!Investigaci\u00f3n!y!de!Estudios!Avanzados!Instituto!Polit\u00e9cnico!Nacional!!Dr.#Jes\u00fas#Mart\u00ednez#Barnetche#Secretario(Direcci\u00f3n!de!Infecciones!Cr\u00f3nicas!y!C\u00e1ncer!Centro!de!Investigaci\u00f3n!Sobre!Enfermedades!Infecciosas!Instituto!Nacional!de!Salud!P\u00fablica!!Dr.#Mario#Henry#Rodr\u00edguez#Sinodal(1(Direcci\u00f3n!Adjunta!!Centro!de!Investigaci\u00f3n!Sobre!Enfermedades!Infecciosas!Instituto!Nacional!de!Salud!P\u00fablica!!Dr.#Juan#E.#Ludert#Le\u00f3n#Sinodal(2(Departamento!de!Infect\u00f3mica!y!Patog\u00e9nesis!Molecular!Centro!de!Investigaci\u00f3n!y!de!Estudios!Avanzados!Instituto!Polit\u00e9cnico!Nacional!!Dr.#Pablo#Vinuesa#Sinodal(3(Centro!de!Ciencias!Gen\u00f3micas!Universidad!Nacional!Aut\u00f3noma!de!M\u00e9xico!!!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"5\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Cr\u00e9ditos#Institucionales#!Esta! tesis! se! llevo! a! cabo! en! el! Laboratorio! 1! Planta! Baja! del! Centro! de!Investigaci\u00f3n! Sobre! Enfermedades! Infecciosas! del! Instituto! Nacional! de! Salud!P\u00fablica!bajo!la!direcci\u00f3n!del!Dr.!Jes\u00fas!Mart\u00ednez!Barnetche!y!la!asesor\u00eda!del!Dr.!Juan!T\u00e9llez!Sosa.!Adicionalmente,!la!alumna!recibi\u00f3!apoyo!de!la!M.!en!C.!Marbella!Ovilla!Mu\u00f1oz,!la!M.!en!C.!Rosa!Elena!G\u00f3mez!y!el!Dr.!Humberto!Valdovinos!Torres.!!!Este!trabajo!fue!sustentado!por!el!proyecto!CBU2009U!01/133765.!INSP.C.I.:!1023!del! Consejo! Nacional! de! Ciencia! y! Tecnolog\u00eda.!El!Consejo! Nacional! de! Ciencia! y!Tecnolog\u00eda!otorg\u00f3! la! beca! 265642/217818.! Al! termin\u00f3! de! la! beca! otorgada! por!CONACyT,! la! alumna! conto! con! el! apoyo! de! la! beca!133765U21797U3151!sustentada! por! el! proyecto!CBU2009U!01/133765.! INSP.C.I.:! 1023!del! Consejo!Nacional!de!Ciencia!y!Tecnolog\u00eda.!!!!!\n6\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Agradecimientos#!A! mis! padres,! Araceli! y! Mario,! que! siempre! han! estado! ah\u00ed! para! apoyarme! de!manera!incondicional!pese!a!la!distancia.!Sin!ustedes!no!ser\u00eda!la!persona!que!soy!ahora.!Gracias! por!que! siempre! me! inculcaron! el! cari\u00f1o! por! el! conocimiento! y!siempre! me! han! impulsado! a! prepararme! m\u00e1s! y! m\u00e1s.! Gracias! por! haberme!ense\u00f1ado!a!ser!una!persona!cr\u00edtica!en!todo!lo!que!me!rodea.!Gracias!por!todos!sus!consejos!y!las!largas!llamadas!que!siempre!hacen!que!la!distancia!se!haga!chiquita.!Los!amo.!!!A!mi!pareja,!Iv\u00e1n,!gracias!por!acompa\u00f1arme!en!este!viaje!y!hacer!que!todo!fuera!m\u00e1s!sencillo.!Tu!amor!y!apoyo!siempre!me!han!impulsado!a!ser!una!mejor!persona.!Gracias!por!siempre!acompa\u00f1arme!en!cada!desvelo,!y!por!cuidarme!todo!el!tiempo.!Tu!y!mis!bebes!(Runner!y!Kira)!son!mi!motor!de!todos!los!d\u00edas.!Los!amo.!!!A!mi!hermana,!Tania,!que!pese!a!la!distancia!siempre!me!hecha!porras!para!que!salga!adelante.!Por!todo!su!cari\u00f1o!y!apoyo.!Te!quiero!hermana.!!!!A! mi! familia,! mis! primas,! primos! ,! t\u00edas! y! t\u00edos.! Su! apoyo! siempre! ha! sido!incondicional!y! un! gran! motor.! Gracias! por! mostrarme! que! la! distancia! no! es!barrera!para!sentir!su!apoyo!y!su!amor!siempre!tan!cerca!de!mi.!Los!quiero!mucho.!!!A!mis!amigos!del!laboratorio!Memo,!Helen,!Andr\u00e9s!y!Berni!que!siguen!al!pie!del!ca\u00f1\u00f3n!y!a!los!que!la!vida!les!ha!llevado!por!otro!rumbo,!Javi!y!Hugo.!!Gracias!por!acompa\u00f1arme!en!esta!etapa!y!aprender!d\u00eda!a!d\u00eda!que!el!aprendizaje!en!conjunto!es!mucho!m\u00e1s!enriquecedor.!Por!todos!los!seminarios,!por!todo!el!c\u00f3digo!que!hicimos!juntos,!por!todos!sus!consejos!pero!m\u00e1s!por!todo!su!apoyo.!!!A!mi!director!de!Tesis,!Chucho.!Gracias!a!ti!despert\u00e9!una!pasi\u00f3n!por!la!inmunolog\u00eda!de!los!linfocitos!B!y!la!bioinform\u00e1tica!que!no!sabia!que!tenia.!Gracias!por!todo!el!apoyo!que!me!brindaste,!por!siempre!creer!en!mi!y!por!impulsarme!a!ser!mejor!alumna!d\u00eda!a!d\u00eda.!Pero!m\u00e1s!que!nada!por!siempre!estar!ah\u00ed!cuando!lo!necesite.!Sin!ti!este!trabajo!no!hubiera!sido!posible.!!!A!mis!asesores.!Juan,!gracias!por!creer!en!m\u00ed!y!por!impulsarme!siempre!no!solo!a!ser!mejor!alumna!si!no!a!ser!m\u00e1s!autocr\u00edtica!en!todo!lo!que!hacia.!Gracias!por!todo!el! apoyo! que! me! brindaste! dentro! y! fuera! del! laboratorio! y! por! tus! valiosos!consejos!para!el!desarrollo!de!este!trabajo.!!A!Pepe!Moreno!y!a!Pepe!Ramos!por!sus!valiosas!aportaciones!a!este!trabajo.!!!A! Marbe,! Rosy! y! Chinito,! gracias! por! siempre! apoyarme! en! todo! lo! que! necesite.!Por!todos!los!conocimientos!que!compartieron!conmigo.!Su!apoyo!fue!fundamental!para!este!trabajo.!!!!!!!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"7\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Tabla\"de\"contenido\"Acr\u00f3nimos\".................................................................................................................\"8!Introducci\u00f3n\"............................................................................................................\"10!Biolog\u00eda!de!la!producci\u00f3n!de!anticuerpos!.................................................................................................!10!Ontogenia(de(los(linfocitos(B(...........................................................................................................................(10!Estructura(del(anticuerpo(................................................................................................................................(11!Generaci\u00f3n(de(la(diversidad(en(los(anticuerpos(.....................................................................................(13!Activaci\u00f3n(de(linfocitos(B(.................................................................................................................................(16!Tipos(de(anticuerpos(en(respuesta(a(infecciones(virales(....................................................................(21!Dengue!......................................................................................................................................................................!23!El!virus!Dengue!(DENV)!....................................................................................................................................!25!Patolog\u00eda!del!Dengue!y!respuesta!de!anticuerpos!contra!el!DENV!................................................!27!Neutralizaci\u00f3n(mediada(por(anticuerpos(.................................................................................................(29!Potenciaci\u00f3n(mediada(por(anticuerpos(.....................................................................................................(33!Respuesta(celular(.................................................................................................................................................(35!Vacuna!contra!Dengue!.......................................................................................................................................!36!Antecedentes\"...........................................................................................................\"37!Justificaci\u00f3n\".............................................................................................................\"39!Pregunta\"de\"investigaci\u00f3n\"........................................................................................\"39!Hip\u00f3tesis\"..................................................................................................................\"39!Objetivos\".................................................................................................................\"40!Objetivo!principal!.................................................................................................................................................!40!Objetivos!espec\u00edficos!..........................................................................................................................................!40!Metodolog\u00eda\"y\"Resultados\"........................................................................................\"40!Reconstructing!and!mining!the!B!cell!repertoire!with!ImmunediveRsity.!..................................!41!Lower!IgG!Somatic!Hypermutation!(SHM)!Rates!during!acute!Dengue!virus!infection!indicate!a!TUIndependent!B!Cell!Response!associated!with!Disease!Enhancement!................!74!Discusi\u00f3n\"...............................................................................................................\"124!Perspectivas\"...........................................................................................................\"130!Congresos,\"estancias\"y\"ponencias\"...........................................................................\"132!Anexos\"...................................................................................................................\"133!Anexo!1.!Definiciones!operacionales!para!el!diagn\u00f3stico!de!Dengue!.........................................!133!Anexo!2.!Tabla!de!Anticuerpos!monoclonales!(mAbs)!descritos!en!la!literatura.!................!135!Anexo!3.!Art\u00edculos!de!coUautor\u00eda!................................................................................................................!138!HybridizationKbased(antibody(cDNA(recovery(for(the(production(of(recombinant(antibodies(identified(by(repertoire(sequencing.(...................................................................................(138!Differential(effect(of(preKpandemic(and(2009(pandemic(influenza(vaccination(in(the(peripheral(B(cell(repertoire.(..........................................................................................................................(138!Bibliograf\u00eda\"............................................................................................................\"152!!!\"!\n8\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Acr\u00f3nimos\"\"!Acr\u00f3nimo#Significado#ADE!Antibody!dependent!enhancement/!Potenciaci\u00f3n!mediada!por!anticuerpos!aicda(Gen!de!la!Desaminasa!de!citidina!inducida!por!activaci\u00f3n!(AID)!AID!Desaminasa!de!citidina!inducida!por!activaci\u00f3n!BCR!Receptor!de!ant\u00edgeno!del!linfocito!B!CDR!Regiones!determinantes!de!la!complementariedad!CDR1!Regi\u00f3n!determinante!de!la!complementariedad!1!CDR2!Regi\u00f3n!determinante!de!la!complementariedad!2!CDR3!Regi\u00f3n!determinante!de!la!complementariedad!3!CG!Centro!Germinal!CRS!Cambio!de!clase!C\u03b1!Cadena!constante!alfa!C\u03b3!Cadena!constante!gamma!C\u03b5!Cadena!constante!\u00e9psilon!C\u03bc!Cadena!constante!mu!D!Segmento!de!Diversidad!DENV!Dengue!virus!DNA!\u00c1cido!desoxirribonucle\u00edco!DWSU!Dengue!sin!signos!de!alarma!DWS+!Dengue!con!signos!de!alarma!E!Prote\u00edna!de!la!envoltura!del!DENV!EDE1!Ep\u00edtopo!del!d\u00edmero!de!la!prote\u00edna!de!envoltura!del!DENV!1!EDE2!Ep\u00edtopo!del!d\u00edmero!de!la!prote\u00edna!de!envoltura!del!DENV!2!EDI!Dominio!1!de!la!prote\u00edna!de!envoltura!del!DENV!EDII!Dominio!2!de!la!prote\u00edna!de!envoltura!del!DENV!EDIII!Dominio!3!de!la!prote\u00edna!de!envoltura!del!DENV!FACS!Fluorescence!Activated!Cell!Sorting!FLE!Ep\u00edtopo!del!asa!de!fusi\u00f3n!de!la!prote\u00edna!de!envoltura!del!DENV!FR!Regi\u00f3n!de!marco!o!Framework!en!Ingles!FR1!Regi\u00f3n!de!marco!1!o!Framework!1!FR2!Regi\u00f3n!de!marco!1!o!Framework!2!FR3!Regi\u00f3n!de!marco!1!o!Framework!3!FR4!Regi\u00f3n!de!marco!1!o!Framework!4!HCC!Clonotipo!de!cadena!pesada!Ig!Inmunoglobulina!IgH!Cadena!pesada!de!la!inmunoglobulina!IgL!Cadena!ligera!de!la!inmunoglobulina!Ig\u03ba!Cadena!ligera!lambda!Ig\u03bb!Cadena!ligera!kappa!J!Segmento!de!Uni\u00f3n!M!Prote\u00edna!de!membrana!del!DENV!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"9\"!#Instituto!Nacional!de!Salud!P\u00fablica!###mAbs!Anticuerpos!monoclonales!MAMPS!Patr\u00f3n!molecular!asociado!a!microorganismos!NFU\u03baB!Factor!nuclear!potenciador!de!las!cadenas!ligeras!kappa!de!los!Linfocitos!B!activados!NS1!Prote\u00edna!no!estructural!1!del!DENV!nt!Nucle\u00f3tidos!OMS!Organizaci\u00f3n!Mundial!de!la!Salud!!PCR!Reacci\u00f3n!en!cadena!de!la!polimerasa!PL!P\u00e9ptido!l\u00edder!preB!Linfocito!pre!B!prM!Prote\u00edna!precursora!de!la!membrana!del!DENV!proB!Linfocito!pro!B!Rag1!Recombinasa!1!(recombination!activating!gene!1)!Rag2!Recombinasa!2!(recombination!activating!gene!2)!RE!Ret\u00edculo!endopl\u00e1smico!RepUSeq!Secuenciaci\u00f3n!del!repertorio!de!linfocitos!RNA!\u00c1cido!ribonucle\u00edco!RNAss!RNA!de!cadena!sencilla!RSS!Se\u00f1ales!se\u00f1alizadoras!de!la!recombinaci\u00f3n!!S!Regi\u00f3n!de!cambio!o!\u201cswith\u201d!!SHM!Hipermutaci\u00f3n!som\u00e1tica!TCR!Receptor!de!ant\u00edgeno!del!linfocito!T!TdT!Enzima!desoxinucleotidil!transferasa!terminal!TFH!Linfocito!T!folicular!TLR!Receptor!tipo!Toll!UHC!Cadena!pesada!\u00fanica!V!Segmento!Variable!!!\"!\n10\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Introducci\u00f3n\"Biolog\u00eda\"de\"la\"producci\u00f3n\"de\"anticuerpos\"!La! respuesta! adaptativa! s\u00f3lo! est\u00e1! presente! en! vertebrados! y! depende!una!capacidad!de!reconocimiento!de!ant\u00edgenos!mediante!la!expresi\u00f3n!de!receptores!de!ant\u00edgenos!clonalmente!distribuidos!en!la!superficie!de!linfocitos!B!y!T!(BCR!para!linfocitos! B! y! TCR! para! linfocitos! T).! Una! de! las! caracter\u00edsticas! principales! de! la!inmunidad!adaptativa!es!la!generaci\u00f3n!de!memoria,!por!lo!que!si!el!individuo!llega!a! tener! una! segunda! infecci\u00f3n,! la! respuesta! ser\u00e1! mucho! m\u00e1s! r\u00e1pida! y! de! mayor!magnitud!(1,!2).!Particularmente,! la! respuesta! adaptativa! en! linfocitos! B,! la!afinidad! por! el! ant\u00edgeno! tiende! a! mejorar! con! retos! subsecuentes! con! el! mismo!ant\u00edgeno!(maduraci\u00f3n!de!afinidad).!!!La!teor\u00eda!de!la!Selecci\u00f3n!Clonal!propuesta!por!Frank!McFarlane!Burnet!durante!la!d\u00e9cada!de!1950,!es!una!de!las!teor\u00edas!que!engloba!varias!de!las!caracter\u00edsticas!de!la!inmunidad!adaptativa.!La!teor\u00eda!se!compone!de!cuatro!postulados!(3,!4):!!1. Cada!linfocito!tiene!un!tipo!\u00fanico!de!receptor!con!especificidad!\u00fanica.!2. La!interacci\u00f3n!entre!el!ant\u00edgeno!y!un!receptor!de!linfocito!capaz!de!unirse!a!esa!mol\u00e9cula!con!alta!afinidad!conduce!a!la!activaci\u00f3n!de!linfocitos.!3. Las!c\u00e9lulas!efectoras! diferenciadas! derivadas! de! un! linfocito! activado!portar\u00e1n!receptores!de!especificidad!id\u00e9ntica!a!la!c\u00e9lula!original!a!partir!de!la!cual!se!deriv\u00f3!ese!linfocito.!4. Los!linfocitos!que!portan!receptores!espec\u00edficos!para!las!mol\u00e9culas!propias!se!eliminan!en!una!etapa!temprana!del!desarrollo!de!las!c\u00e9lulas!linfoides!y!por!lo!tanto,!est\u00e1n!ausentes!del!repertorio!de!linfocitos!maduros.!!!Parte! importante! de!la! respuesta! inmune! adaptativa! est\u00e1! mediada! por! las!mol\u00e9culas! de! reconocimiento! de! ant\u00edgeno! de! los! linfocitos! B,! es! decir,! las!inmunoglobulinas!(Ig).!!Las!inmunoglobulinas!son!prote\u00ednas!heterodim\u00e9ricas!que!se! producen! por! los! linfocitos! B! en! una! gama! muy! amplia! de! especificidades! de!ant\u00edgeno;!cada!linfocito!B!produce!una!Ig!de!especificidad!\u00fanica.!La!Ig!unida!a!la!membrana!de!linfocitos!B!sirve!como!receptor!de!la!c\u00e9lula!para!el!ant\u00edgeno,!y!se!conoce! como! BCR.! La! Ig! de! la! misma! especificidad! de! ant\u00edgeno! se! secreta! como!anticuerpo!por!los!linfocitos!B!diferenciados!a!c\u00e9lulas!plasm\u00e1ticas!(5).!!Ontogenia\"de\"los\"linfocitos\"B\"!El! desarrollo! de! los! linfocitos! B! se! puede! dividir! en! dos! partes:! una! fase! de!ant\u00edgeno!independiente!y!una!fase!de!ant\u00edgeno!dependiente.!!La!primera!fase!est\u00e1!limitada! a! la! m\u00e9dula! \u00f3sea,! donde! el! precursor! de! linfocitos! B! con! la! ayuda! de!c\u00e9lulas!del!estroma!se!desarrolla!hasta!linfocito!B!inmaduro.!El!desarrollo!de!los!linfocitos!B!inmaduros!a!maduros!ocurre!en!los!\u00f3rganos!linfoides!perif\u00e9ricos!como!el!bazo.!Cuando!el!linfocito!B!se!encuentra!y!reconoce!un!ant\u00edgeno,!prolifera!y!se!diferencia!a!c\u00e9lulas!plasm\u00e1ticas!o!c\u00e9lulas!de!memoria!(6).!!!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"11\"!#Instituto!Nacional!de!Salud!P\u00fablica!###La!maduraci\u00f3n!de!los!linfocitos!B!comienza,!cuando!la!c\u00e9lula!progenitora!com\u00fan!se!diferencia!a!la!primera!etapa,!una!c\u00e9lula!progenitora!B!(proB).!La!c\u00e9lula!proB!inicia!los!rearreglos!de!IgH,!prolifera!y!se!diferencia!a!precursor!del!linfocito!B!(preB),!el!cual!expresa!un!preUBCR.!La!se\u00f1alizaci\u00f3n!del!preUBCR!selecciona!positivamente!a!linfocitos!preB,!los!cuales!inician!los!rearreglos!de!IgL,!lo!que!permite!la!expresi\u00f3n!de!IgM!en!superficie!(BCR),!lo!cual!define!al!linfocito!B!inmaduro.!Las!c\u00e9lulas!del!estroma! forman! contactos! adhesivos! espec\u00edficos! con! el! desarrollo! del! linaje! de!linfocitos!B!y!sus!ligandos.!Los!linfocitos!B!inmaduros!se!someten!a!procesos!de!selecci\u00f3n!para!autoUreactividad!y!la!capacidad!de!sobrevivir!en!los!tejidos!linfoides!perif\u00e9ricos!(6).!Los!linfocitos!B!inmaduros!dejan!la!m\u00e9dula!\u00f3sea!y!migran!al!bazo,!donde! finalizan! su! desarrollo! temprano! y! se! diferencian! a! linfocitos! B!v\u00edrgenes,!foliculares!y!de!zona!marginal!(7).!En!general!la!diferenciaci\u00f3n!hacia!linfocitos!B!se!compone! de! seis! fases:! progenitor! linfoide! com\u00fan,! proB! temprano,! proB! tard\u00edo,!preB,!linfocito!B!inmaduro,!y!linfocito!B!virgen.!El!rasgo!m\u00e1s!caracter\u00edstico!de!este!proceso! es! el! rearreglo! de!los!segmentos!g\u00e9nicos!que! codifican! al! BCR! y! la!expresi\u00f3n!de!prote\u00ednas!en!la!superficie!celular!caracter\u00edsticas!de!cada!etapa!(6,!7)!(Figura!1).!!!\n!!Figura#1.#Diferenciaci\u00f3n#de#las#subpoblaciones#de#linfocitos#B#(8,!9).!El!desarrollo!de!los!linfocitos!B!se!da!en! su! mayor! parte! en! la! m\u00e9dula! \u00f3sea,! posteriormente! los! linfocitos! B! inmaduros! migran! al! bazo,! donde! se!completa!la!maduraci\u00f3n.!!Los!diferentes!estados!se!definen!por!el!estado!de!la!recombinaci\u00f3n!VDJ!tanto!de!la!cadena!pesada!como!de!la!ligera!as\u00ed!como!de!la!expresi\u00f3n!de!marcadores!de!superficie.!Imagen!modificada!de!Martensson,!2010.!FEBS!Lett!584:!2572U9.!!Estructura\"del\"anticuerpo\"!Los!anticuerpos!est\u00e1n!compuestos!por!dos!cadenas!pesadas!(IgH)!id\u00e9nticas!y!dos!cadenas! ligeras! (IgL)! id\u00e9nticas! unidas! por! varias! interacciones! no! covalentes! y!mediante!enlaces!disulfuro.!De!las!IgL!se!pueden!distinguir!dos!tipos,!lambda!(Ig\u03bb)!y!kappa!(Ig\u03ba).!La!proporci\u00f3n!de!los!dos!tipos!de!IgL!var\u00eda!de!una!especie!a!otra,!en!el!humano!la!proporci\u00f3n!promedio!es!de!2:1!(\u03ba:\u03bb)!(5).!!proB pre-BIpre-BITranscisional pre-BIIGrandepre-BIIPeque\u00f1aB inmadura B inmadura B maduraPlasmablastoC\u00e9lulaPlasm\u00e1tica\nB de memoriaY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYY\nY\nYM\u00e9dula \u00d3seaBazo\nD-JHDJHVDJHVDJHGLLVJLIgL subrogadaRearreglosCadena PesadaCadena LigeraMarcadores de superficieB220+CD19+CD117+CD25+IgM+CD93+!\n12\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Los!anticuerpos!se!pueden!separar!funcionalmente!en!una!regi\u00f3n!variable,!que!se!encuentra!en!el!amino!terminal!y!es!capaz!de!reconocer!y!unirse!a!los!ant\u00edgenos,!y!una!regi\u00f3n!constante,!misma!que!determina!las!funciones!efectoras.!El!BCR!unido!al! linfocito! carece! de! estas! funciones! efectoras,! porque! la! regi\u00f3n! constante!permanece! insertada! en! la! membrana! celular.! El! isotipo! de! la! cadena! pesada!establece!las!propiedades!funcionales!del!anticuerpo!y!se!pueden!distinguir!cinco!tipos:!IgM,!IgD,!IgG,!IgA!e!IgE!(5).!!!\n!Figura#2.#Estructura#del#BCR#(5).#!La!inmunoglobulina!es!la!forma!soluble!del!BCR!y!est\u00e1!conformada!por!dos!cadenas!pesadas!(IgH)!y!dos!ligeras!(IgL)!id\u00e9nticas!unidas!por!puentes!disulfuro!(SUS).!!La!regi\u00f3n!variable!del!anticuerpo!se!conforma!de!3!CDRs!y!de!4!FWRs!de!IgH!!e!IgL.!La!regi\u00f3n!constante!est\u00e1!compuesta!por!dos!o!tres! dominios! constantes! de! ambas! cadenas! pesadas,! dependiendo! de! la! clase! del! anticuerpo.!Imagen!modificada!de!Schroeder,!2010.!J!Allergy!Clin!Immunol!125:!S41U52.#Tanto!la!cadena!pesada!como!la!ligera!contienen!una!regi\u00f3n!variable!codificada!por!m\u00e1s!de!un!segmento!g\u00e9nico.!En!el!caso!de!la!IgH,!la!regi\u00f3n!variable!es!codificada!por! tres! segmentos! g\u00e9nicos! V,! D!y! J,! mientras! que! en! IgL,! es!codificada! por! los!segmentos!V!y!J!(Figura!2).!!!A! nivel! de! amino\u00e1cidos,! la! variabilidad! de! la! regi\u00f3n! variable! no! se! encuentra!distribuida!de!modo!uniforme,!sino!que!se!concentra!en!ciertos!segmentos,!que!se!denominan!dominios!o!asas!hipervariables.!A!estos!dominios!se!les!denomina!con!mayor! frecuencia! como! Regiones! Determinantes! de! Complementariedad!(CDR).!Tanto!la!IgH,!como!la!IgL!tienen!tres!CDR!(CDR1,!CDR2!y!CDR3)!(Figura!3).!Cuando!CDR1CDR2CDR3FWR1FWR2FWR3FWR45'5'\n3'ssssssss\nCH2CH2CH3CH3CH1CH1\nCCCLCLCCNNNN\nCHO CHORegi\u00f3n constanteRegi\u00f3n VariableN-DH-NVHJHVLJLCadenas Ligeras (IgL)Cadenas Pesadas (IgH)!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"13\"!#Instituto!Nacional!de!Salud!P\u00fablica!###las! cadenas! IgL! y! IgH! est\u00e1n! pareadas,! las! asas! hipervariables! de! cada! cadena! se!unen!y!crean!un!sitio!hipervariable!\u00fanico,!el!sitio!de!uni\u00f3n!al!ant\u00edgeno!(5).!!!\n!Figura#3.# Dominios# variables# Ig#(10).#(A)! Representaci\u00f3n! en! listones! de! la! regi\u00f3n! variable! de! la! cadena!pesada.!(B)!La!regi\u00f3n!variable!de!IgH!esta!coloreada!en!azul!marino,!mientras!que!la!regi\u00f3n!variable!de!la!IgL!esta!coloreada!en!azul!cielo.!Los!CDRs!est\u00e1n!coloreados!en!amarillo!(CDR1),!naranja!(CDR2)!y!rojo!(CDR3).!Imagen!tomada!de!Almagro,!2012.!Front!Immunol.!15;3:342!La!contribuci\u00f3n! de! las! cadenas! ligeras! y! pesadas! en! la! especificidad! de!los!anticuerpos!se!estudi\u00f3! en! anticuerpos! antiUlisozima!(11),!en! donde! se! demostr\u00f3!que! las! interacciones! sutiles! entre! las! cadenas! ligeras! y! pesadas! de! uni\u00f3n!determinan!tanto!la!afinidad!y!especificidad.!En!general,!la!especificidad!de!uni\u00f3n!para!dos!haptenos!frente!a!lisozima!era!dependiente!absolutamente!de!la!cadena!pesada.!Se!realizaron! varias! combinaciones! de!cadenas! ligeras! con! pesadas! y!observaron!que!la!especificidad!global!es!atribuible!a!las!diferencias!en!el!CDR3!de!la! cadena! pesada,! lo! que! sugiere! un! uso! alternativo! de! cadenas! ligeras.!Como! se!mencion\u00f3! previamente! el!CDR3! de! IgH! tiene! el! segmento! D! por! lo! que! hay! m\u00e1s!variabilidad!y!m\u00e1s!posibilidad!de!uni\u00f3n!con!el!ant\u00edgeno.!!!Esta!misma!observaci\u00f3n!se!realiz\u00f3!en!nuestro!grupo!de!investigaci\u00f3n!en!donde!se!prob\u00f3! una! nueva! estrategia!para! la! generaci\u00f3n! de! anticuerpos! monoclonales!recombinantes!basada! en! el! an\u00e1lisis!de! repertorios! digitales.! En! este! trabajo! se!probaron! distintos! anticuerpos! monoclonales! cuyas! cadenas! pesadas! fueron!obtenidas!de!la!secuenciaci\u00f3n!masiva!de!ratones!inmunizados!contra!lisozima!y!se!combinaron! con! cadenas! ligeras! gen\u00e9ricas! antiUlisozima! ya! reportadas! en! la!literatura.! Los! anticuerpos! generados! tuvieron!la! capacidad! de! uni\u00f3n! con! el!ant\u00edgeno!a!pesar!de!que!la!cadena!ligera!no!era!la!cadena!nativa!(12)(Anexo!3).!Generaci\u00f3n\"de\"la\"diversidad\"en\"los\"anticuerpos\"!Los!mecanismos!de!generaci\u00f3n!de!la!diversidad!pueden!dividirse!en!dos,!los!que!son!independientes!de!ant\u00edgeno!y!los!que!son!dependientes!de!ant\u00edgeno.!!La!recombinaci\u00f3n! som\u00e1tica!de! los!segmentos!g\u00e9nicos!que! codifican! las! regiones!variables!de!las! cadenas!pesadas! y! ligeras!es! el! proceso! m\u00e1s! importante! en! la!creaci\u00f3n!de!la!diversidad!combinatoria!en!los!anticuerpos,!la!cual!ocurre!en!forma!\nAB!\n14\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###independiente!del!ant\u00edgeno.!Para!la!generaci\u00f3n!de!la!regi\u00f3n!variable!de!la!cadena!pesada,!el!genoma! humano!cuenta!con! 46!segmentos!V,! 23! segmentos!D!y! 6!segmentos!J!(codificados!en!la!regi\u00f3n!14q32.33)(13).!Mientras!que!para!la!regi\u00f3n!variable!de!cadena!ligera!kappa!se!cuenta!con!41!segmentos!V,!y!5!J,!(Codificados!en! 2p.11.2.);!y!para!la!cadena! ligera! lambda!se!cuenta! con! 74! segmentos! V,!y!7!segmentos!J!(codificados!en!22q.11.2).!Debido!a!que!los!eventos!de!recombinaci\u00f3n!parecen!ocurrir!al!azar,!cada!clona!genera!un!rearreglo!diferente!y!por!lo!tanto!un!receptor! de! especificidad! \u00fanica.! La! magnitud!potencial!del! repertorio! est\u00e1!parcialmente! determinada! por! el! n\u00famero! de! segmentos! codificados! en!l\u00ednea!germinal! (diversidad!combinatoria).!Por! esta! raz\u00f3n,! la! recombinaci\u00f3n! de! los!segmentos! V,! D! y! J! de! l\u00ednea! germinal!puede! generar! aproximadamente! 6,000!regiones!variables!distintas!para!las!cadenas!pesadas!humanas.!Esta!diversidad!se!hace! m\u00e1s! grande! cuando!agregamos!la! adici\u00f3n! o!eliminaci\u00f3n!de! nucle\u00f3tidos!durante!la! uni\u00f3n! de! los! segmentos! antes! mencionados,! proceso! denominado!diversidad!de!uni\u00f3n.!Adicionalmente,!el!apareamiento!de!la!cadena!pesada!con!la!ligera!aumenta!la!diversidad!del!repertorio!(14).!!!Entre!los!mecanismos!dependientes!del!ant\u00edgeno!se!encuentra!el!cambio!de!clase!(CSR)!y!la!hipermutacion!som\u00e1tica!(SHM).!El!CSR!!consiste!en!la!sustituci\u00f3n!de!la!regi\u00f3n!constante! de! clase! IgM! por!diferentes! isotipos! de! inmunoglobulinas!(IgA,!IgG,!e!IgE),! lo! cual! le! confiere! al! anticuerpo!diferentes! funciones! efectoras,!conservando!la! misma! especificidad!por! el! ant\u00edgeno.!Por! su! parte! la!SHM!es! un!proceso!de!mutag\u00e9nesis!de!la!regi\u00f3n!V!mediada!por!el!ant\u00edgeno!que!resulta!en!la!selecci\u00f3n!de!variantes!de!anticuerpos!con!mayor!afinidad!por!su!ant\u00edgeno!blanco.!(14,!15).!!!En!conjunto,! estos!procesos!contribuyen!a!la!generaci\u00f3n! de!diversidad!del!repertorio!de!anticuerpos!cuya!magnitud!potencial!se!ha!estimado!en!1x1011!(16).!!A! continuaci\u00f3n! se! da! una! explicaci\u00f3n! m\u00e1s! detallada! cada! uno! de! los! procesos!mencionados.!!!Recombinaci\u00f3n\"som\u00e1tica\"y\"diversidad\"de\"uni\u00f3n\"!El!resultado!de!la!recombinaci\u00f3n!V(D)J!es!el!ensamble!funcional!de!los!segmentos!V,!D!y!J!codificados!en!l\u00ednea!germinal!por!medio!de!las!recombinasas!Rag1/Rag2!(17).!Estas!recombinaciones!ocurren!en!los!segmentos!interg\u00e9nicos!formados!por!la!regla!12:23.!Las!secuencias!se\u00f1alizadoras!de!recombinaci\u00f3n!(RSS)!se!localizan!en! los! flancos! de! los! genes! que! ser\u00e1n! recombinados! y! est\u00e1n!formadas! por! las!siguientes! secuencias! en! n\u00fameros! de! bases:!U7U12U9Usecuencia! DNAU9U23U7.! En!donde!las!secuencias!de!siete!nucle\u00f3tidos!(hept\u00e1meros)!se\"emparejan\"entre\"s\u00ed\"y\"las\"de! nueve!tambi\u00e9n,! mientras!que! las!secuencias! de! 23!y! 12!nucle\u00f3tidos!emparejadas!son!el!sustrato!de!las!recombinasas,!y!determinan!el!sitio!donde% se%realizar\u00e1(el(corte(del(DNA.(5(\u0301UCACAGTGU12/23U!ACAAAAACCU3\"\u0301.!!!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"15\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\n!Figura#4.# Recombinaci\u00f3n# som\u00e1tica#(9).#Durante! el! desarrollo! de! los! linfocitos! B,! el! primer! evento! de!recombinaci\u00f3n!se!da!entre!los!segmentos!D!y!J!del!locus!de!la!IgH.!Se!elimina!el!fragmento!de!DNA!entre!los!segmentos!seleccionados.!Posteriormente!se!lleva!a!cabo!la!recombinaci\u00f3n!con!el!segmento!V,!para!dar!lugar!a!un!gen!V(D)J!reorganizado.!Se!genera!un!transcrito!primario!que!contiene!la!regi\u00f3n!VDJ!y!las!regiones!de!la!cadena! constante! C\u03bc!y! C\u03b4.! El! transcrito! primario! de! RNA! se! procesa! a\u00f1adiendo! una! cola! de! poliadenilaci\u00f3n!(polyUA)!posterior!a!la!cadena!C\u03bc.!La!traducci\u00f3n!de!este!mRNA!produce!la!cadena!pesada!de!la!Ig.!Las!cadenas!IgL!(\u03ba!y!\u03bb)!se!reorganizan!de!un!modo!similar,!con!la!excepci\u00f3n!de!que!las!cadenas!ligeras!carecen!de!segmento!D,.!Finalmente!se!lleva!acabo!el!ensamblaje!de!la!cadena!IgH!e!IgL,!que!da!lugar!a!una!Ig!unida!a!membrana!que!se! expresa! en! la! superficie! de! los! linfocitos! B! inmaduros! (IgM).!!PL! =P\u00e9ptido! l\u00edder.!Imagen! modificada! de!Martensson,!2010.!FEBS!Lett!584:!2572U9.!Las!recombinasas!Rag1/Rag2!cortan!en!un!sitio!que!siempre!ser\u00e1!el!mismo,\"lo\"cual\"generar\u00e1' extremos' libres' que' se' autoUcierran!formando!una!horquilla!transitoria!(\u201chairpin\u201d).! Esta! horquilla!es!cortada!aleatoriamente!por! una! exonucleasa!provocando! que! las! secuencias!se!realineen,! lo! cual! puede! generar!codones!diferentes!por!un!cambio!en!el!marco!de!lectura.!Si!este!cambio!en!los!marcos!de!lectura!ocurre!en! m\u00faltiplos!de! tres,! se!generan! diferentes! segmentos! D! sin!producir!prote\u00ednas!truncadas.!De!esta!manera,!la!uni\u00f3n!VUD!y!DUJ!contribuye!a!la!diversidad!de!los!anticuerpos!(17,!18)!(Figura!4).!!!!La! enzima!desoxinucleotidil! transferasa! terminal!(TdT)! une! nucle\u00f3tidos! en! los!extremos!libres! del! DNA! mediante! la! inserci\u00f3n! de! segmentos! N,! los! cuales! no! se!encontraban!en!la!secuencia!original.!Esta!enzima!genera!diversidad!de!uni\u00f3n,!al!recuperar! los! extremos! de! los!\u201chairpins\u201d!e! incluir! nucle\u00f3tidos! N,! si! \u00fanicamente!completa!esta!regi\u00f3n!sin!agregar!al!azar!nucle\u00f3tidos!se!denominan!nucle\u00f3tidos!P!(19)!(Figura!5).!!Traducci\u00f3n y ensamblajeVJDCH1CH2CH3PLSegmentos VSegmentos D Segmentos JRegi\u00f3n ConstanteL\u00ednea GerminalVHRecombinaci\u00f3n D-JRecombinaci\u00f3n V-DJTranscripci\u00f3n y splicingAAAA5'5'\n3'ssssssss\nCH2CH2CH3CH3CH1CH1\nCCCLCLCCNNN\nCHO CHOVLVHVLVHN!\n16\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\n!Figura#5.# Adici\u00f3n# de# Nucle\u00f3tidos# N# y#P#(20).##La! adici\u00f3n! de! nucle\u00f3tidos! P! ocurre! cuando! el! corte! de! la!horquilla!genera!extremos!con!una!porci\u00f3n!de!cadena!sencilla!(azul!claro)!que!ser\u00e1n!rellenadas!para!dar!lugar!a! una! secuencia! distinta! a! la! original,! generando! un! pal\u00edndromo.! La! adici\u00f3n! de! nucle\u00f3tidos! N! ocurre! por! la!acci\u00f3n! de! la! TdT,! enzima!que!a\u00f1ade! nucle\u00f3tidos! al! azar! (rojo).! Imagen! modificada! de! Kuby,! Kindt! et! al.,! 6\u00ba!Edici\u00f3n!McGraw!Hill,!2007.!!Activaci\u00f3n\"de\"linfocitos\"B\"!Dada!la!enorme!diversidad!potencial!del!BCR,!el!linfocito!B!es!capaz!de!reconocer!ant\u00edgenos! de! tipo!proteico,! glicoprote\u00ednas! y! polisac\u00e1ridos.! Actualmente,! se! han!descrito!dos!mecanismos!mediante!los!cuales!los!linfocitos!B!pueden!activarse.!El!primero!es!una!respuesta!timoUindependiente,!es!decir,!en!ausencia!de!linfocitos!T!y!que!se!caracteriza!por!ser!inducida!por!ant\u00edgenos!no!proteicos,!principalmente!polisac\u00e1ridos.! La! activaci\u00f3n! de! los! linfocitos! B! por! esta! v\u00eda!se! da! fuera! de! los!fol\u00edculos! linfoides,! no! genera!memoria! y! tampoco! se! asocia! con! maduraci\u00f3n! de!afinidad!por!SHM.!Las!respuestas!TUindependientes!ocurre!como!un!r\u00e1pido!foco!de!expansi\u00f3n!clonal,!alrededor!de!3!a!5!d\u00edas!postUinfecci\u00f3n!y!constituye!una!primera!l\u00ednea!de!defensa!en!contra!de!pat\u00f3genos!(21).!!El!otro!mecanismo!de!activaci\u00f3n!es!una!respuesta!timoUdependiente,!en!donde!los!linfocitos! T! CD4+! tienen! un! papel! crucial.! Esta! respuesta! se! ha! descrito!principalmente! para! ant\u00edgenos! de! naturaleza! proteica,! en! virtud! del!correconocimiento!de!p\u00e9ptidos!antig\u00e9nicos!por!parte!del!linfocito!T.!Los!linfocitos!B!que!reconocen!el!ant\u00edgeno!reciben!se\u00f1ales!coestimuladoras!del!linfocito!T!CD4+,!lo! cual! les! permite! su!ingreso!al!fol\u00edculo!para! formar! un!foco!proliferativo!denominado!centro!germinal!(CG).!Es!en!el!CG!donde!se!da!la!SHM!!y!la!selecci\u00f3n!de!variantes!de!mayor!afinidad(21U23).!Esta!respuesta!es!m\u00e1s!lenta!y!ocurre!en!el!interior! del! fol\u00edculo! linfoide,! tiene! una! duraci\u00f3n! de! una! semana! en! donde! se!generara!un!microambiente! en! donde! interact\u00faan! los! linfocitos! B! ant\u00edgenoUespec\u00edficos,! linfocitos! T! CD4+! foliculares! y! las! c\u00e9lulas! dendr\u00edticas! foliculares!(22,!23)(Figura!6).!!!\nDTGAGJTAAT\nDTGGAJATAT\nDJTGGAATATCTACTATA\nDTGAGJTAAT\nDTGGAJATAT\nDJTGGAATATCTACTATATCAAGTLa escisi\u00f3n de la horquillagenera sitios para la adici\u00f3n de nucle\u00f3tidos P (Palindromo)Las enzimas de reparaci\u00f3n a\u00f1aden nucle\u00f3tidos complementariosTdT a\u00f1ade nucle\u00f3tidos N. Las enzimas de reparaci\u00f3n a\u00f1aden nucle\u00f3tidos complementariosNucle\u00f3tdos PNucle\u00f3tdos N!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"17\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Respuesta\"TTdependiente\"!Los!linfocitos!T!son!cruciales!para!el!mantenimiento,!la!regulaci\u00f3n!de!la!eficacia!y!la!longevidad!de!la!respuesta!inmune!humoral.!En!la!periferia,!los!linfocitos!T!CD4+!interact\u00faan! con! los! linfocitos! B! v\u00edrgenes! para! su! activaci\u00f3n.!Dentro! de! los! CG!ocurre!la!expansi\u00f3n!clonal!de!los!linfocitos!B.!Este!proceso!promueve!la!expansi\u00f3n!de! varias! poblaciones! celulares.! Por! un! lado! la! maduraci\u00f3n! del! linfocito! B! a!plasmablastos!y! c\u00e9lulas! plasm\u00e1ticas! productoras! de! anticuerpos! y! por! otro! la!generaci\u00f3n! de! linfocitos! B! de! memoria! que! ser\u00e1n! activados! en! exposiciones!posteriores! al! mismo! ant\u00edgeno.! Dentro! de! los! centros! germinales! se! generan!linfocitos!B!mutados!por!medio!de!la!SHM!y!se!lleva!a!cabo!el!cambio!de!isotipo!por!medio!del!CSR!(24).!!Hipermutaci\u00f3n\"som\u00e1tica\"!La!SHM!es!dependiente!de!ant\u00edgenos!y!de!la!cooperaci\u00f3n!entre!los!linfocitos!B!y!T.!Este!mecanismo!ocurre!exclusivamente!en!centros!germinales,!es!dependiente!de!linfocitos!T!y!ocurre!predominantemente!contra!ant\u00edgenos!de!naturaleza!proteica!(Figura! 6).!Durante! la! SHM,! mutaciones! puntuales! y! en! ocasiones! delaciones!e!inserciones!son!introducidas!en!la!regi\u00f3n!variable!tanto!de!la!IgH!e!IgL!en!una!taza!alta! de! mutaci\u00f3n! (10U2!a! 10U3!por! base,! por! generaci\u00f3n)(25).! Este! mecanismo!ocurre!durante!la!expansi\u00f3n!clonal!y!t\u00edpicamente,!las!mutaciones!son!acumuladas!en! los! CDR\u2019s,! lo! que! permite! la! selecci\u00f3n! de! clonas! de! linfocitos! B! con! mayor!afinidad! por! el! ant\u00edgeno.! Con! los! retos! subsecuentes!con! el! ant\u00edgeno,! como! por!ejemplo,! una! infecci\u00f3n! secundaria! o! un! refuerzo! de! una! vacuna,!la! afinidad! del!anticuerpo!se!va!incrementando!(26).!!La!desaminasa!de!citidina!inducida!por!activaci\u00f3n!(AID)!causa!errores!de!copiado!en! la! regi\u00f3n! variable,! la! cual! se! utiliza! durante! el! CSR! y! durante! la! SHM,! este!mecanismo! imperfecto! ayuda! a! generar! mayor! variabilidad! de! los! anticuerpos!(27).!!La!AID!desamina!las!citidinas!a!uracilos!en!las!regiones!variables,!generalmente!en!\u201chotspots\u201d!definidos!por!el!motivo!RGYW.!La!actividad!de!reparaci\u00f3n!de!genes!y!de!reparaci\u00f3n! por! escisi\u00f3n! de! bases! de!prote\u00ednas!junto! con! la! replicaci\u00f3n! del!DNA!generan!mutaciones!de!transici\u00f3n!y!transversi\u00f3n!(28).!!!\n18\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\n!Figura#6.#Respuesta#T\\dependiente.(23).#(1)!Dentro!de!las!horas!siguientes!despu\u00e9s!de!la!uni\u00f3n!del!ant\u00edgeno!al!BCR!se!desencadena!un!movimiento!de!los!linfocitos!B!a!la!interfaz!entre!el!fol\u00edculo!y!la!zona!de!linfocitos!T!en!donde!los!linfocitos!B!presentan!ant\u00edgenos!pept\u00eddicos!a!los!linfocitos!T!CD4+.!En!este!punto,!los!linfocitos!B!y!T!integran!los!recursos!para!decidir!entre!la!muerte!celular!o!la!proliferaci\u00f3n.!Durante!los!pr\u00f3ximos!2U3!d\u00edas,!los!linfocitos!B!migran!activamente!y!forman!complejos!estables!con!los!linfocitos!TCD4+!y!proliferan!en!la!periferia!del!fol\u00edculo.!(2)!Tres!o!cuatro!d\u00edas!despu\u00e9s!de!la!exposici\u00f3n!al!ant\u00edgeno,!los!linfocitos!B!integran!los!recursos!para!decidir!la!diferenciaci\u00f3n!a!c\u00e9lulas!plasm\u00e1ticas,!linfocitos!B!de!centros!germinales!o!linfocitos!B!de!memoria.!Los!linfocitos!que!migran!a!centros!germinales!contin\u00faan!dividi\u00e9ndose!r\u00e1pidamente,!hipermutan!la!regi\u00f3n!variable!del!BCR!y/o!cambian!de!isotipo,!interactuando!con!los!linfocitos!T!cooperadoras!foliculares!(TFH).!(3)!Los!linfocitos!B!que!se!encuentran!en!centros!germinales!integran!los!recursos!para!decidir!entre!la!supervivencia!o!la!muerte!en!funci\u00f3n!de!la!afinidad!de!su!BCR!tanto!para!ant\u00edgenos!propios!como!for\u00e1neos.!Imagen!modificada!de!Goodnow,!2010.!Nat!Immunol!11:!681U8.!Cambio\"de\"clase\"(CSR)\"!La! recombinaci\u00f3n! V(D)J! genera! variaciones! en! los!extremos!NUterminal! de! las!regiones!variables,!proceso!com\u00fan!en!los!linfocito!B!y!T.!Sin!embargo,!los!linfocitos!B!contienen!mecanismos!adicionales!de!diversificaci\u00f3n.!El!primero!es!el!CSR!de!la!cadena!constante,!lo!cual!no!implica!un!cambio!de!la!especificidad!o!afinidad!por!el!ant\u00edgeno,!si!no!en!las!formas!efectoras!del!anticuerpo!(29).!El!cambio!de!clase!de!IgH! ocurre! r\u00e1pidamente! despu\u00e9s! de! la! activaci\u00f3n! de! los! linfocitos! B! maduros,!resultando!en!un!cambio!de!expresi\u00f3n!de!IgM!e!IgD!a!una!expresi\u00f3n!de!IgG,!IgE!o!IgA.!Este!cambio!mejora!la!habilidad!de!los!anticuerpos!para!remover!al!pat\u00f3geno!que!est\u00e1!estimulando!la!respuesta!(30).!!!La!cadena!pesada!de!la!Ig!intercambia!los!exones!predeterminados!C\u03bc!por!un!ex\u00f3n!alternativo!rio!abajo!en!la!cadena!constante,!ya!sea!C\u03b3,!C\u03b5!o!C\u03b1.!!De!esta!manera!el!linfocito!B!deja!de!expresar!IgM!y!expresa!un!isotipo!diferente!como!IgG,!IgE!o!IgA.!Cada! isotipo! tiene! una! funci\u00f3n! efectora! diferente.! Para! el! CSR,! son!necesarios!secuencias!de!elementos!repetitivos!en!el!DNA!denominados!regiones!de!\u201cswitch\u201d!o! regiones! S,! que! preceden! a! cada! gen! de! cadena! constante.! La! transcripci\u00f3n! a!trav\u00e9s!de!las!regiones!S!permite!la!generaci\u00f3n!de!un!h\u00edbrido!de!DNA:RNA,!lo!que!permite! ser!el! sustrato! para! la! AID.! Subsecuentemente,! la! AID! desaminar\u00e1!las!citidinas! para! convertirlas! en! uracilos,! lo! que! permite! un! corte! en! el! DNA! y! que!entre!la!maquinaria!de!reparaci\u00f3n!de!extremos!no!hom\u00f3logos!(Figura!7)!(28).!!!\n!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"19\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\n!Figura#7.#Cambio#de#clase#(CSR)#(30).!Durante!el!CSR!a!IgE,!la!AID!desamina!la!regi\u00f3n!S\u03bc!y!de!S\u03b5,!generando!la!formaci\u00f3n!de!un!circulo!de!escisi\u00f3n.!Las!regiones!de!S\u03bc!y!S\u03b5!se!recombinan!provocando!que!se!exprese!la!regi\u00f3n!VDJ!asociada!a!una!regi\u00f3n!constante!C\u03b5.!Imagen!modificada!de!Stavnezer,!J!Immunol!193:!5370U8!.!Respuesta\"TTindependiente\"!Los!receptores!tipo!Toll!(TLR)!junto!con!los!linfocitos!B!inducen!el!CSR!de!manera!TUindependiente! por! medio! del! entrecruzamiento! del! BCR! por! un! lado;!por! otra!parte! los! TLRs! promueven! la! proliferaci\u00f3n! de! linfocitos! B.! La! sinergia! del!entrecruzamiento! del! BCR! junto! con! los! TLR! promueven!el!CSR! a! todos! los!isotipos,! dependiendo! del! perfil! de! citocinas! que! se! expresen.!La!integraci\u00f3n! del!BCR!y!la!se\u00f1alizaci\u00f3n!por!los!TLRs!resulta!en!la!activaci\u00f3n!de!v\u00edas!tanto!can\u00f3nicas!como! no! can\u00f3nicas! del! NFU\u03baB,! promoviendo! la! inducci\u00f3n! de! la! AID! y! la!transcripci\u00f3n!de!la!regi\u00f3n!de!\u201cswich\u201d!(S)!del!locus!de!IgH!(Figura!8)(31).!!!Las! respuestas! TUindependientes! se! inducen! por! los! ant\u00edgenos! asociados! con!bacterias!o!virus!que!provocan!una!respuesta!de!linfocitos!T!d\u00e9bil!o!en!donde!no!hay!respuesta!de!linfocitos!T.!De!estos!ant\u00edgenos!se!pueden!reconocer!dos!tipos,!el!primero!es!esencialmente!un!patr\u00f3n!molecular!asociado!a!microorganismos,!mejor!conocido! como! MAMPS,! que! puede! activar! policlonalmente! los! linfocitos! B;!y! el!segundo! tipo! de! ant\u00edgeno! consiste! de! ep\u00edtopos! repetidos! de! baja! complejidad,!como!lo!son!las!capsulas!bacterianas!compuestas!por!polisac\u00e1ridos!(31).!!!!!SVDJC\u03b33C\u03b5C\u03bc C\u03b4C\u03b31C\u03b32bC\u03b32aC\u03b1SSSSSS\nVDJC\u03b33C\u03b5C\u03bc C\u03b4C\u03b31C\u03b32bC\u03b32aC\u03b1\nVDJC\u03b5C\u03b1\n\u03bc mRNA \u03b4 mRNAAID\n\u03b5 mRNATranscrito no codificante de l\u00ednea Germinal\nC\u03b33\nC\u03bc C\u03b4C\u03b31C\u03b32bC\u03b32a\nAID\nCambio de Clase!\n20\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\n!Figura#8.#Cambio#de#clase#T\\independiente#a#trav\u00e9s#de#NF\\\u03baB#(32).#(A)!El!entrecruzamiento!del!BCR!activa!la! v\u00eda! noUcan\u00f3nica! de! NFU\u03baB.! Los! ligandos! de! TLR! localizados! en! la! superficie! de! los! microorganismos! se!reconocen!por!TLRs!extracelulares!(se!ejemplifica!la!v\u00eda!de!reconocimiento!del!l\u00edpido!A!por!TLR4),!mientras!que!los!ligandos!de!TLR!como!los!\u00e1cidos!nucle\u00edcos!son!reconocidos!por!TLRs!en!el!endosoma.!La!se\u00f1alizaci\u00f3n!de!los!TLRs!activa!de!manera!can\u00f3nica!la!v\u00eda!del!NFU\u03baB,!dando!como!resultado!la!expresi\u00f3n!del!gen!de!AID!y!un!CSR!marginal.!La!se\u00f1alizaci\u00f3n!del!BCR!potencia!la!v\u00eda!de!NFUkB!dependiente!de!TLRs,!a!su!vez!la!se\u00f1alizaci\u00f3n!de! los! TLRs! potencia! la! v\u00eda! noUcan\u00f3nica! de! NFU\u03baB,! provocando! un! la! inducci\u00f3n! de! AID! y! el! CSR.! ! (B)! Los!polisac\u00e1ridos! reconocidos! por! los! BCR! aunado! a! el! reconocimiento! de! TLRs! extracelulares! (TLR4)!desencadenan! la! se\u00f1alizaci\u00f3n! de! las! v\u00edas! tanto! can\u00f3nica! como! no! can\u00f3nica! de! NFU\u03baB! induciendo! AID!provocando! el! CSR.!(C)!CSR! TUdependiente.!La! mol\u00e9cula!CD40!de! los! linfocitos! B!activada! por! el! CD154!(CD40L)!en!los!linfocitos!T!!induce!las!v\u00edas!can\u00f3nicas!y!no!can\u00f3nicas!de!NFU\u03baB!y!la!inducci\u00f3n!alta!de!AID!y!el!CSR,!particularmente!en!presencia!de!ILU4.!Imagen!tomada!de!Pone,!2012.!Nat!Commun!3:!767.!!El!cambio! de! clase! TUindependiente! puede! generar! anticuerpos! policlonales! no!mutados.!En!modelos!murinos! se! han! descrito! isotipos! IgG3! e! IgA,! que! se! ven!involucrados!en!el!control!de!bacterias!comensales!as\u00ed!como!en!el!mantenimiento!de! los! anticuerpos! naturales! y! en! el! mantenimiento! de! la! memoria! serol\u00f3gica.!Tambi\u00e9n!se!han!descrito!anticuerpos!ant\u00edgenoUespec\u00edfico!de!isotipos!IgG3,!IgG2b,!IgG2a,! IgG1,! IgE! e! IgA! en! respuesta! a! ant\u00edgenos! TUindependientes,! que! pueden!ayudar!a!controlar!la!infecci\u00f3n!en!etapas!tempranas!de!la!enfermedad.!En!cambio!los! anticuerpos! generados! por! una! respuesta! TUdependiente,! son! ant\u00edgenoUespec\u00edfico,! hipermutados,! de! isotipos! ! IgG3,! IgG2b,! IgG2a,! IgG1,! IgE! e! IgA! que! su!principal! funci\u00f3n! es! la! erradicaci\u00f3n! de! la! infecci\u00f3n! y! la! generaci\u00f3n!de! memoria!inmunol\u00f3gica!(31,!32)!(Figura!9).!!!\n!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"21\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\n!Figura#9.# Generaci\u00f3n# de# anticuerpos# v\u00eda#T\\independiente# y# T\\dependiente#(31).#(A)! Producci\u00f3n! de!anticuerpos! IgG! no! mutados! por! la! activaci\u00f3n!del! BCR! y! TLRs! en! el! endosoma! v\u00eda! TUindependiente.!(B)!Producci\u00f3n! de! anticuerpos! mutados! y! no! mutados! IgG! por! medio! de! la!activaci\u00f3n!de! TLRs! y! BCRs!en! el!endosoma!v\u00eda!TUindependiente!(C)!Producci\u00f3n!de!anticuerpos!IgG!hipermutados!por!la!activaci\u00f3n!de!BCR!y!TLRs!en!el!endosoma!v\u00eda!TUdependiente.!Imagen!tomada!de!Pone!2012.!Front!Biosci!(Landmark!Ed)!17:!2594U615.!!!Tipos\"de\"anticuerpos\"en\"respuesta\"a\"infecciones\"virales\"Las! respuestas!antiUvirales! se! han! estudiado!ampliamente! para! la! generaci\u00f3n! de!mejores!vacunas.! Las! infecciones! virales! producen! una! variedad! de! diferentes!clases! de! anticuerpos! que! pueden! influenciar! la! eficacia! de! las! respuestas! antiUvirales!(33).!A!continuaci\u00f3n!de!describen!una!serie!de!anticuerpos!producidos!en!respuesta!a!infecciones!virales.!!!Anticuerpos\"naturales\"Los! anticuerpos! naturales! se! producen! por! linfocitos! B! que! no! han! sido!seleccionados! por! la! infecci\u00f3n! o! vacunaci\u00f3n.!Estos! anticuerpos! tienen! la!caracter\u00edstica!de!que!su!afinidad!no!ha!madurado,!en!consecuencia!tienen!una!baja!tasa! de! SHM.! En! ausencia! de! selecci\u00f3n! en! la! periferia,! estos! anticuerpos! son!capaces!de!reaccionar!contra!los!pat\u00f3genos,!unirse!a!ellos!y!neutralizar!la!infecci\u00f3n!(34).! La! mayor\u00eda! de! los! anticuerpos! naturales! murinos! son! producidos! por!linfocitos! B1,! una! subpoblaci\u00f3n! de! linfocitos! B!abundante! en! el! peritoneo! y!generalmente!son!del!isotipo! IgM!(35).! Sin! embargo,!tambi\u00e9n! se! han! descrito!anticuerpos!naturales!de!tipo!IgG!en!ratones.!En!humanos!esta!subpoblaci\u00f3n!se!ha!reportado!que!se!localiza!en!cord\u00f3n!umbilical!y!en!sangre!perif\u00e9rica!(36)!y!son!de!isotipo!IgM,!IgG!e!IgA!y!han!sido!implicados!en!la!activaci\u00f3n!del!complemento!y!en!fagocitosis!as\u00ed!como!en!citotoxicidad!mediada!por!anticuerpos!(37).!!!Anticuerpos\"polireactivos\"El! termino! polireactividad! en! los! anticuerpos! se! refiere! a! la! capacidad! del!anticuerpo! a! reaccionar! con! diferentes! pat\u00f3genos.! Por! ejemplo,!se! han! descrito!\n!\n22\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###anticuerpos!antiUvirus!del!Dengue!(DENV)!que!tienen!la!capacidad!de!reconocer!al!virus! de! la! Polio!(38).!Una! de! las! caracter\u00edsticas! de! los! anticuerpos! polireactivos!son!las!altas!tasas!de!SHM!que!tienen,!adem\u00e1s!de!que!se!ha!reportado!que!tienen!un!uso!preferencial!del!los!segmentos!de!la!familia!IGHV1!(35,!39).!Largos!CDR3!se!han!asociados!a!estos!anticuerpos,!sin!embargo,!esta!caracter\u00edstica!tambi\u00e9n!se!ha!encontrado! en! autoanticuerpos! y! en! anticuerpos! monoUespec\u00edficos!(40).!El!mantenimiento!de!los!anticuerpo!polireactivos!se!debe!a!la!SHM!de!los!linfocitos!B.!Un! incremento! en! la! maduraci\u00f3n! de! la! afinidad! se! activa! con! la! infecci\u00f3n! y! la!formaci\u00f3n!de!los!centros!germinales!provocando!la!producci\u00f3n!de!linfocitos!B!de!memoria! que! persistir\u00e1n! en! circulaci\u00f3n.! Y! para! infecciones! cr\u00f3nicas,! la! selecci\u00f3n!positiva!de!estos!anticuerpos!deber\u00eda!de!ser!un!proceso!continuo,!sin!embargo!en!infecciones!agudas,!la!nueva!generaci\u00f3n!de!los!centros!germinales!se!dar\u00eda!con!las!reinfecciones!y!la!activaci\u00f3n!de!los!linfocitos!B!de!memoria!(35).!!Anticuerpos\"altamente\"neutralizantes\"Los! anticuerpos! altamente! neutralizantes! se! han! descrito! en! infecciones! con!Influenza!y!VIH.!Estos!anticuerpos!tienen!la!capacidad!de!neutralizar!la!infecci\u00f3n!de! varias! cepas! virales! y! que! las! tasas! de! SHM! son! altas!(41U43).! Se! detalla! m\u00e1s!adelante!en!el!contexto!del!DENV.!!Anticuerpos\"de\"reactividad\"cruzada\"Los!anticuerpos!de! reactividad! cruzada! son! aquellos! anticuerpos! que! fueron!generados! en! una! infecci\u00f3n! primaria! contra! un! ant\u00edgeno! y! que! en! un! reto!subsecuente!con!un!ant\u00edgeno!similar;!como!por!ejemplo:!las!diferentes!cepas!del!virus!de!Influenza!o!los!serotipos!del!DENV!(35).!Estos!anticuerpos!se!han!descrito!ampliamente!en!infecciones!virales!y!ser\u00e1n!descritos!m\u00e1s!adelante!en!el!contexto!del!DENV.!!!!\"!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"23\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Dengue\"!El!Dengue!es!una!enfermedad!viral!que!en!las!\u00faltimas!d\u00e9cadas!se!ha!convertido!en!uno!de!los!problemas!m\u00e1s!graves!de!salud!p\u00fablica!a!nivel!mundial,!principalmente!en!pa\u00edses!tropicales!y!subtropicales!(Figura!10).!El!Dengue!es!end\u00e9mico!en!m\u00e1s!de!100!pa\u00edses!en!el!sureste!Asi\u00e1tico,!de!Am\u00e9rica,!del!Pac\u00edfico!Occidental,!\u00c1frica!y!las!regiones!del!Mediterr\u00e1neo!oriental,!y!su!incidencia!a!aumentado!30!veces!en!los!\u00faltimos!50!a\u00f1os!(44).!De!acuerdo!con!las!cifras!de!la!Organizaci\u00f3n!Mundial!de!la!Salud!(OMS)!anualmente!ocurren!50!millones!de!casos!nuevos!con!m\u00e1s!de!500,000!hospitalizaciones!y!entre!25,000!y!50,000!muertes!(45U47).!!\n!Figura#10.#Distribuci\u00f3n#del#Dengue#a#nivel#mundial#(48).#En#el#mapa,#los!pa\u00edses!con!una!alta!presencia!del!Dengue!se!encuentran!resaltados!en!rojo!fuerte,!los!que!tienen!una!presencia!media!en!rojo!medio!y!los!que!tienen!una!baja!presencia!en!rojo!claro.!El!mapa!se!integro!a!partir!de!los!datos!obtenidos!de!Healtmap!del!CDC!y!del!mapa!interactivo!de!viajes!internacionales!y!la!salud!de!la!OMS;!ambos!consultados!el!19!de!Junio!2014.!!Imagen!tomada!de!Guzman,!2014.!Lancet.!!La! transmisi\u00f3n! del! Dengue! es! resultado! de! la! interacci\u00f3n! entre! las! personas,!mosquitos,! virus! y! factores! ambientales.! Los! movimientos! de! las! personas! son!clave! para! determinar! la! din\u00e1mica! espacioUtemporal! de! la! transmisi\u00f3n! del! virus!Dengue!(DENV),!tanto!de!su!amplificaci\u00f3n!como!de!su!propagaci\u00f3n!(49).!!El!Dengue! es! causado! por! cuatro! serotipos! virales! (DENVU1,! DENVU2,! DENVU3! Y!DENVU4)! pertenecientes! a! la! familia!Flaviviridae.!Los! cuatro!serotipos! virales!tienen! un! 65%! de!identidad!entre! sus! genomas.!A!pesar! de! las! diferencias,!cada!serotipo!causa!una!sintomatolog\u00eda!id\u00e9ntica!en!los!seres!humanos!y!circulan!en!las!mismas!regiones!(50).!Un!serotipo!es!una!subpoblaci\u00f3n!del!DENV!que!se!diferencia!de!otras!subpoblaciones!del!DENV!por!medio!de!pruebas!serol\u00f3gicas.!!!El!virus!tiene!un!periodo!de!incubaci\u00f3n!de!3!a!14!d\u00edas!(en!promedio!de!4!a!7!d\u00edas),!despu\u00e9s! del! cual!aparece! un! cuadro!caracterizado! por! fiebre!(mayor! a! 38\u00b0C),!cefalea,!artralgias!y!mialgias,!inflamaci\u00f3n!de!los!ganglios!linf\u00e1ticos!y!petequias,!que!suelen! aparecer! en! las! extremidades! inferiores! y! el! t\u00f3rax,!desde! donde! se!extienden!para!abarcar!la!mayor!parte!del!cuerpo!(51,!52).!!El! modelo!de!clasificaci\u00f3n! del!Dengue!de!la! OMS,!basada!en! la! gravedad!de! la!enfermedad,!fue!sugerido!por!un!grupo!de!expertos!en!Ginebra,!Suiza!en!el!2008.!\n!\n24\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Esta! clasificaci\u00f3n! tiene!gran!potencial! para! su! uso! pr\u00e1ctico! por! los! m\u00e9dicos!tratantes,!para!decidir!d\u00f3nde!y!cu\u00e1n!intensivamente!se!debe!observar!y!tratar!al!paciente,! para! una! notificaci\u00f3n! de! casos! m\u00e1s! acorde! con! el! sistema! de! vigilancia!epidemiol\u00f3gica!nacional!e!internacional!(Figura!11)(53,!54).!!!!Despu\u00e9s!del!periodo!de!incubaci\u00f3n,!la!infecci\u00f3n!puede!producir!un!amplio!espectro!de!enfermedad,!donde!50%!de!las!infecciones!cursan!de!manera!asintom\u00e1ticas!o!subcl\u00ednica.!Los!pacientes!se!recuperan!despu\u00e9s!de!una!enfermedad!auto!limitada!(Dengue! sin! signos! de! alarma;! DWSU),! mientras! que! un! peque\u00f1o! grupo! de!pacientes!progresa!a!una!enfermedad!m\u00e1s!grave,!la!mayor\u00eda!se!caracteriza!por!la!p\u00e9rdida!de!plasma!con!o!sin!sangrado!(Dengue!con!signos!de!alarma;!DWS+).!La!enfermedad!comienza!abruptamente,!seguida!de!tres!fases:!fase!aguda!en!donde!el!paciente! se! encuentra!febril,! la! fase! cr\u00edtica! y! la! fase! de! recuperaci\u00f3n! o!convalecencia.!El!per\u00edodo!cr\u00edtico!se!produce!alrededor!de!desaparici\u00f3n!de!la!fiebre,!cuando!un!aumento!de!la!permeabilidad!capilar!acompa\u00f1ada!de!un!aumento!en!el!hematocrito!pueden!ocurrir,!lo!que!lleva!a!un!shock!hipovol\u00e9mico!que!pueden!dar!lugar! al! deterioro! de! \u00f3rganos,! acidosis! metab\u00f3lica,! coagulaci\u00f3n! intravascular!diseminada!y!hemorragia!severa.!El!Dengue!grave!tambi\u00e9n!incluye!a!los!pacientes!con!hepatitis,!trastornos!neurol\u00f3gicos,!miocarditis!o!hemorragia!grave!sin!p\u00e9rdida!de!plasma!o!una!descarga!(48,!55).!!!En!M\u00e9xico,!la!clasificaci\u00f3n!se!basa!en!la!Norma!Oficial!Mexicana!NOMU032USSA2U2002! para! la! Vigilancia! Epidemiol\u00f3gica,! Prevenci\u00f3n! y! Control! de! Enfermedades!Transmitidas! por!vector! y! los! lineamientos! para! el! diagn\u00f3stico! que! actualmente!establece! el! Instituto! de! Referencia! y! Diagn\u00f3stico! Epidemiol\u00f3gicos! (InDRE)!(56).!Para! prop\u00f3sitos! de! la! vigilancia! epidemiol\u00f3gica! se! han! elaborado! definiciones!operacionales! de! caso,! a! efecto! de! unificar! los! criterios! para! la! detecci\u00f3n,!notificaci\u00f3n!y!clasificaci\u00f3n!de!los!casos!de!Dengue!(Anexo!1).!!#\n!Figura#11.#Clasificaci\u00f3n#del#Dengue#definido#por#la#OMS#(57).#Criterios!para!la!clasificaci\u00f3n!del!Dengue!con!y!sin!signos!de!alarma!y!criterios!para!Dengue!grave.!Imagen!modificada!de!WHO,!2009.!!!\"Dengue +/- signos de Alarma1. Extravasaci\u00f3n de plasma2. Hemorragia Grave3. Compromiso grave de \u00f3rganosDengue GraveCon signos de alarmaSin signosde alarmaDengue Probable* Vivir en \u00e1reas end\u00e9micas de dengue/  Viajar a ella* Fiebre y dos o m\u00e1s de los    siguientes s\u00edntomas:   - Na\u00faseas, v\u00f3mito   - Erupci\u00f3n cut\u00e1nea   - Molestias o dolores   - Prueba de torniquete positiva   - Leucopenia   - Cualquier signo de alarma Dengue confirmado por laboratorio. Importante cuando no hay signos de extravasaci\u00f3n de plasma.Signos de Alarma:* Dolor abdominal intenso o abdomen  doloroso a la palpaci\u00f3n.* V\u00f3mitos persistentes* Acumulaci\u00f3n cl\u00ednia de l\u00edquidos* Sangrado de mucosas* Letargia, agitaci\u00f3n* Hepatomegalia >2cm* Laboratorio:  - Aumento del hematocrito concurrente   con r\u00e1pida disminuci\u00f3n del n\u00famero de     plaquetas. Todos los signos de alarma requieren de observaci\u00f3n e intervenci\u00f3n m\u00e9dica* Extravasaci\u00f3n grave de plasma  que conduce a:  - Choque (SCD)  - Acumulaci\u00f3n de l\u00edquidos con     insuficiencia respiratoria* Sangrado intenso* Compromiso org\u00e1nico grave:   - H\u00edgado: AST o ALT -> 1000   - Sistema nervioso central: Alteraci\u00f3n      de la conciencia   - Coraz\u00f3n y otros \u00f3rganos!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"25\"!#Instituto!Nacional!de!Salud!P\u00fablica!###El\"virus\"Dengue\"(DENV)\"!El!virus!Dengue!posee!un!genoma!lineal!de!RNA!de!cadena!sencilla!con!polaridad!positiva,!de! aproximadamente! 10,700! bases.! El! genoma!viral!contiene!un! solo!marco!de!lectura,!que!codifica!una!poliprote\u00edna,!que!en!su!extremo!amino!terminal!contiene!tres!prote\u00ednas! estructurales! [C\u00e1pside! (C),! preUmembrana! (prM)! y!Envoltura!(E)],!que!constituyen!la!part\u00edcula!viral.!El!resto!del!genoma!codifica!siete!prote\u00ednas!no!estructurales!(NS1,!NS2a,!NS2b,!NS3,!NS4a,!NS4b,!NS5),!encargadas!de!la!replicaci\u00f3n!viral!(Tabla!1!y!Figura!12)(58,!59).!!!Figura#12.#Genoma#del#DENV#(60).#El!genoma!del!virus!!Dengue!presenta!una!regi\u00f3n!codificante!flanqueada!en!los!extremos!5!'y!3'!por!regiones!no!traducidas!(UTR).#El!marco!de!lectura!abierto!codifica!tres!prote\u00ednas!estructurales!(la!c\u00e1pside!(C),!de!membrana!(M)!y!la!de!envoltura!(E))!y!siete!prote\u00ednas!no!estructurales!(NS1,!NS2A,!NS2B,!NS3,!NS4A,!NS4B!y!N55).!Imagen!tomada!de!Guzman,!2010.!Nat!Rev!Microbiol!8:!S7U16#Tabla#1.#Funciones#de#las#prote\u00ednas#del#DENV#(61)#Prote\u00edna\"Funci\u00f3n'C'Encapsulaci\u00f3n'del'RNA'prM'Precursor'de'la'membrana.'Chaperona'del'plegado'de'la'prote\u00edna'E.'E'Uni\u00f3n'a'la'c\u00e9lula'y'fusi\u00f3n'de'las'membranas.'NS1'Cofactor'para'la'replicaci\u00f3n'del'RNA'viral'NS2A'Inhibici\u00f3n'de'la'se\u00f1alizaci\u00f3n'del'interfer\u00f3n'NS2B'Proteasas'de'serina.'NS3'Helicasa.'Trifosfatasa'RNA'NS4A'Inhibici\u00f3n'de'la'se\u00f1alizaci\u00f3n'del'interfer\u00f3n'NS4B'NS5'RNA'polimerasa.'Metiltransferasa.'Inducci\u00f3n'de'ILP8.'Actividad'de'localizaci\u00f3n'nuclear'!El!DENV!es! transmitido! por! mosquitos! del! g\u00e9nero!Aedes,! principalmente!Aedes(aegypti.!Sin!embargo,!tambi\u00e9n!puede!ser!transmitido!por!A.(albopictus!y!A.(polinesis((55).!!!El!ciclo!de!transmisi\u00f3n!del!DENV!inicia!cuando!un!mosquito!hembra!infectado!con!el!virus!se!alimenta!de!una!persona!sana.!Los!viriones!se!adhieren!a!la!membrana!celular!y!posteriormente!entran!a!la!c\u00e9lula!por!endocitosis!mediada!por!receptor.!En! las! c\u00e9lulas! del! hospedero!se! han! identificado!varios! receptores! primarios! y!correceptores! de! baja! afinidad!para!Flavivirus(como!DCUSIGN,! GRP78/BiP,! y!\n!\n26\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###mol\u00e9culas!asociadas!a!CD14!(62).!El!blanco!del!DENV!son!las!c\u00e9lulas!dendr\u00edticas,!principalmente!las!c\u00e9lulas!de!Langerhans,!que!se!activan!y!presentan!el!virus!a!los!linfocitos!T.!Cuando!el!virus!entra!en!circulaci\u00f3n!es!identificado!por!los!monocitos!y!c\u00e9lulas!endoteliales!(63U65).!!!La!acidificaci\u00f3n!de!las!ves\u00edculas!endos\u00f3micas!provoca!cambios!conformacionales!en!el!viri\u00f3n!y!permite!la!fusi\u00f3n!con!la!membrana!celular,!que!a!su!vez!promueve!que!las!part\u00edculas!virales!se!desensamblen!y!se!libere!el!material!gen\u00e9tico.!Una!vez!que!el!genoma!se!encuentra!en!el!citoplasma,!el!RNA!de!sentido!positivo!se!traduce!en! una! \u00fanica! poliprote\u00edna!por! ribosomas! en! la! membrana! del! RE! rugoso.! La!poliprote\u00edna!se!procesa! tanto! cotraduccionalmente! como! postraduccionalmente!por!proteasas!virales!y!del!hospedero!en!tres!prote\u00ednas!estructurales!(C,!prM!y!E)!y!siete!no!estructurales!(NS1,!NS2A,!NS2B,!NS3,!NS4A,!NS4B!y!NS5).!Las!prote\u00ednas!no!estructurales!junto!con!otras!prote\u00ednas!del!hospedero!inducen!una!invaginaci\u00f3n!en!el! lumen! del! RE! que! sirve! como! uni\u00f3n! al!citoplasma!(66).!La! replicaci\u00f3n! del!genoma!se!produce!en!las!membranas!intracelulares!(65).!!!!El!ensamblaje! del! virus! ocurre!en! la! superficie! del! ret\u00edculo! endopl\u00e1smico! (RE)!cuando!las! prote\u00ednas! estructurales! y!el!RNA!reci\u00e9n! sintetizados!se! unen! en! el!lumen! del! RE,!gener\u00e1ndose!part\u00edculas! virales! inmaduras!no! infecciosas!que!son!transportadas! en! la! red! de! transUGolgi.!Las! part\u00edculas! de! viriones! inmaduros! se!escinden!del! hospedero!por! la!furin! proteasa,! dando! como! resultado! part\u00edculas!maduras! infecciosas.!Las! part\u00edculas! subvirales! tambi\u00e9n! se! escinden!por! la!furin!proteasa.!Finalmente,!los! viriones! maduros! y!las!part\u00edculas! subvirales! son!liberados! por! exocitosis! y! son! capaces! de! unirse! a! otras! c\u00e9lulas! e! infectarlas!(Figura!13)(67).!!!\n!Figura#13.# Ciclo# infectivo# del# DENV#(62).#El! virus! se! une! a! los! receptores! de! la! superficie! celular! y! se!transporta!en!la!c\u00e9lula!por!endocitosis.!La!fusi\u00f3n!de!la!envoltura!viral!con!la!membrana!del!endosoma!libera!la!nucleocapside/RNA! viral! al! citoplasma.! !Una! sola! poliprote\u00edna! viral! se! genera! por!la! traducci\u00f3n! del! ARN!gen\u00f3mico.! Esta! poliprote\u00edna! se! escinde! en! tres! prote\u00ednas! estructurales! (! C,!prM,! y! E! )! y! siete! prote\u00ednas! no!\n!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"27\"!#Instituto!Nacional!de!Salud!P\u00fablica!###estructurales!(!NS1!,!NS2A!,!NS2B!,!NS3!,!NS4A!,!NS4B!,!y!NS5!)!por!proteasas!virales!y!celulares!.!La!replicaci\u00f3n!viral!se!lleva!a!cabo!en!ves\u00edculas!de!membrana!derivadas!del!RE.!Los!viriones!inmaduros!son!ricos!en!prUM!y!son!liberados!de!la!c\u00e9lula!por!medio!de!transporte!a!trav\u00e9s!de!la!v\u00eda!secretora.!La!maduraci\u00f3n!del!virus!se!lleva!a! cabo! en! la! red! transUGolgi! como! resultado! del! procesamiento! proteol\u00edtico! de!prM!por!una!furin!proteasa.!Finalmente,! part\u00edculas! de! virus! maduro! se! secretan! en! el! medio! extracelular.!Imagen! tomada! de!Mukhopadhyay!2005.!Nat!Rev!Microbiol!3:!13U22.#Patolog\u00eda\"del\"Dengue\"y\"respuesta\"de\"anticuerpos\"contra\"el\"DENV\"!Los! mecanismos! de! la! patog\u00e9nesis! de! DENV! no! est\u00e1n! bien! entendidos.! Los!s\u00edntomas!s\u00f3lo!los!desarrollan!los!humanos,!es!por!esto!que!la!investigaci\u00f3n!de!\u00e9ste!fen\u00f3meno!se!ha!basado!principalmente!en!estudios!que!involucran!a!los!pacientes.!!!El!desarrollo!de!modelos!animales!en!la!infecci\u00f3n!por!DENV!ha!sido!un!reto!debido!a! que!DENV! no! infecta! de! manera! natural! a! especies! noUhumanas.! Primates! noUhumanos!pueden!sostener!una!replicaci\u00f3n!viral!en!los!tipos!de!c\u00e9lulas!relevantes!y!desarrollar! una! respuesta! inmune! robusta,! sin! embargo,! no! desarrollan! los!s\u00edntomas!de!la!enfermedad.!En!contraste,!modelos!de!ratones!inmunodeficientes!infectados! con! cepas! de! DENV! adaptadas! muestran! signos! de! la! enfermedad!severa,! similar! a! la! fuga! vascular!(68).! Los! modelos! de! ratones! humanizados!pueden!mantener!una!replicaci\u00f3n!viral!y!mostrar!signos!de!la!enfermedad,!pero!se!necesita!de!un!mayor!desarrollo!para!validar!la!respuesta!inmune.!En!general,!cada!modelo! tiene!sus! ventajas! y! desventajas! y! son!adecuados!diferencialmente! para!estudios!de!la!patogenia!del!DENV,!de!la!inmunopatog\u00e9nesis;!as\u00ed!como!de!pruebas!de!ensayos!precl\u00ednicos!de!medicamentos!antivirales!y!vacunas!(69)!(Tabla!2).!!!La! patog\u00e9nesis! del! DENV! parece! ser! determinada! por! numerosos! factores! que!interact\u00faan! como! son! la! virulencia! del! DENV!y!el!estado! inmunol\u00f3gico! del!hospedero,!as\u00ed! como! factores! gen\u00e9ticos! del! mismo! o! incluso! otros! como! por!ejemplo! enfermedades! preexistentes!o! posibles! contactos! previos! con! el! DENV!(70)!(Figura!14).!!!\n!Figura#14.#Patog\u00e9nesis#del#DENV#de#acuerdo#a#la#fase#de#la#enfermedad#(48).#Los!posibles!mecanismos!de!la!patog\u00e9nesis!del!DENV!incluyen!la!existencia!previa!de!anticuerpos!que!podr\u00edan!potenciar!la!infecci\u00f3n!(ADE);!infecci\u00f3n! y! activaci\u00f3n! de! c\u00e9lulas! de! la!respuesta! inmune! innata;! activaci\u00f3n! del! sistema! de! complemento,!linfocitos! T! y! B;!y!la! producci\u00f3n! de! autoanticuerpos.!Las! citocinas! proinflamatorias! se! secretan! como!consecuencia! de! la! activaci\u00f3n! de! diferentes! c\u00e9lulas! del! sistema! inmune! y! juegan! un! papel! importante! en! la!patog\u00e9nesis!de!la!enfermedad,!se!ven!involucradas!en!la!fuga!de!plasma!del!endotelio!vascular.!DENV!=!virus!Dengue.!Abs!=!anticuerpos.!ADE!=!Potenciaci\u00f3n!mediada!por!anticuerpos.!Ics!=!inmunocomplejos.!DC!=!c\u00e9lulas!dendr\u00edticas.!Mo!=!monocitos!/!macr\u00f3fagos.!NS1!=!Prote\u00edna!NS1.!mT!=!Linfocito!T!de!memoria.!Tn!=!Linfocito!T!\n!\n28\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###virgen.! Treg! =!Linfocitos!T! reguladores.! mB! =!Linfocito! B! de! memoria.! Bn! =!Linfocito! B!virgen.!DIC!=!coagulaci\u00f3n!intravascular!diseminada.!Imagen!tomada!de!Guzman,!2014.!Lancet.!!!Tabla#2.#Modelos#murinos#para#el#estudio#del#DENV.#Tabla#modificada#de#Guabiraba,#2014.#Immunology.#141(2):143\\56.#(68)#Cepa#de#rat\u00f3n#Virus#Signos#y#S\u00edntomas#Ventajas#Desventajas#Referencia#Ratones#Humanizados#SCIDUhuUPBL!!DENV1!Bajos!t\u00edtulos!de!viremia!o!viremia!moderada,!fiebre,!salpullido,!hemoconcentraci\u00f3n,!trombocitopenia!y!una!producci\u00f3n!de!TNFU\u03b1!menor.!Los!ratones!desarrollan!funciones!del!sistema!inmune!humano,!incluyendo!la!inmunidad!adaptativa,!infecci\u00f3n!de!c\u00e9lulas!humanas!lo!que!permiten!el!estudio!de!una!respuesta!\"humana\"!a!la!infecci\u00f3n.!Permiten!el!estudio!de!la!patog\u00e9nesis!de!la!fiebre!por!Dengue,!la!respuesta!celular!en!contra!del!tropismo!del!virus;!detecci\u00f3n!de!factores!de!virulencia!de!los!diferentes!genotipos!virales!as\u00ed!como!el!estudio!de!vacunas!in!vivo.!Solo!presentan!las!manifestaciones!de!la!enfermedad!no!grave!y!no!hay!manifestaci\u00f3n!de!la!tormenta!de!citocinas!o!de!signos!y!s\u00edntomas!de!choque!como!los!observados!en!la!enfermedad!grave!en!humanos!(71)!SCIDUK562!!DENV2!(72)!SCIDUHepG2!!DENV2!(73)!SCIDUHuHU7!!DENV4!(74)!NOD/SCIDUhuman!CD34+!DENV2!(75)!RAG2U/U!\u03b3cU/U!human!CD34+!DENV2!(76)!\nRatones#inmunodeficientes#AG129!DENV1;!DENV2!Bajos!t\u00edtulos!de!viremia!o!altos!t\u00edtulos!de!viremia!asociados!con!encefalitis!letal!tard\u00eda!y!elevaci\u00f3n!del!hematocrito;!fuga!de!plasma!en!etapas!tempranas!(producci\u00f3n!de!TNFU\u03b1).!Replicaci\u00f3n!viral!de!aislados!cl\u00ednicos!relevantes;!desarrollo!de!viremia;!desarrollo!de!potenciaci\u00f3n!mediada!por!anticuerpos.!Permite!la!investigaci\u00f3n!de!tejidos!y!del!tropismo!celular!del!DENV;!ideal!para!hacer!un!escaneo!de!antivirales.!!Ausencia!de!componentes!importantes!en!la!respuesta!antiviral!del!hospedero;!estudio!inapropiado!de!la!inmunopatog\u00e9nesis!del!DENV;!desarrollo!de!par\u00e1lisis!y!encefalitis!letal.!!(77U79)!A/J!DENV2!(80,!81)!STAT1U/U!DENV2!(82)!Ratones#inmunocompetentes#C57BL/6!DENV2;!DENV3!Hemorragias,!tormenta!de!citocinas,!da\u00f1o!de!h\u00edgado,!hemoconcentraci\u00f3n,!trombocitopenia.!No!hay!desarrollo!de!anticuerpos!o!linfocitos!T!DENV!espec\u00edfico.!El!rat\u00f3n!desarrolla!la!mayor\u00eda!de!las!manifestaciones!cl\u00ednicas!de!la!enfermedad!severa.!Las!cepas!virales!han!sido!adaptadas!para!m\u00faltiples!pases!en!el!rat\u00f3n;!por!lo!que!la!modificaci\u00f3n!del!virus!puede!implicar!diferentes!mecanismos!patol\u00f3gicos!a!los!que!se!generar\u00edan!en!humanos;!la!enfermedad!severa!ocurre!en!infecciones!primarias.!(83U89)!BALB/c!DENV2!(90U92)!\n!Muchas! de! las! manifestaciones! cl\u00ednicas! se! deben! a! la! respuesta! inmune! del!hospedero.! El! incremento! en! la! permeabilidad! vascular! visto!en!pacientes! con!Dengue!est\u00e1!asociado! con! los! altos! niveles! de!citocinas,!incluidas! el! factor! de!necrosis!tumoral!alpha!(TNFU\u03b1),!interfer\u00f3n!gamma!(INFU\u03b3),!interleucina!6!(ILU6),!e!interleucina!2!(ILU2)!(93).!!La!respuesta!inmune!adaptativa!inducida!por!DENV!contribuye!a!la!resoluci\u00f3n!de!la!infecci\u00f3n! y! a! generar! protecci\u00f3n!contra! posibles! reinfecciones.!Controversialmente,!tambi\u00e9n!se!ha!descrito!el!papel!de!la!inmunidad!adaptativa,!tanto!de!linfocitos!B!como!T,!en!el!potenciamiento!de!la!infecci\u00f3n!dando!lugar!a!las!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"29\"!#Instituto!Nacional!de!Salud!P\u00fablica!###formas!severas!del!Dengue.!Para!los!linfocitos!B,!esta!observaci\u00f3n!se!hizo!a!trav\u00e9s!de! estudios! epidemiol\u00f3gicos!en! donde! se! ha!mostrado! que! la! severidad! de! la!enfermedad!es!m\u00e1s!com\u00fan!en!infecciones!secundarias!(94).!Este!fen\u00f3meno!podr\u00eda!ser!la!explicaci\u00f3n!a!la!severidad!de!la!enfermedad!observada!en!ni\u00f1os!de!entre!6!y!9! meses! de! edad,! en! donde! los! bajos!niveles!de! anticuerpos! no! neutralizantes!derivados!de!la!madre!podr\u00edan!promover!un!cuadro!severo!de!la!enfermedad!(93),!sin!embargo,!no!hay!estudios!que!lo!comprueben!en!su!totalidad.!!Despu\u00e9s! de! la! infecci\u00f3n! por!DENV!se! desarrolla! una! respuesta! robusta! de!anticuerpos!neutralizantes,!sobre!todo!contra!la!prote\u00edna!E.!Esta!respuesta!adem\u00e1s!de!proveer!protecci\u00f3n!homot\u00edpica!de!largo!plazo!en!la!primera!infecci\u00f3n,!es!decir,!contra!el!serotipo!infectante,!confiere!protecci\u00f3n!heterot\u00edpica!contra!los!otros!tres!serotipos!(95,!96).!!!Uno!de!los!estudios!previos!sobre!la!duraci\u00f3n!de!la!respuesta!inmune!contra!DENV!fue!realizado!por!Sabin!en!1952.!En!\u00e9ste!estudio!infectaron!con!DENV1!y!DENV2!a!voluntarios! que! no! hab\u00edan! tenido! contacto! previo! con! DENV.! Estos! individuos!tuvieron!un!segundo!reto!con!el!virus!hom\u00f3logo!a!diferentes!tiempos!despu\u00e9s!de!la!primera!infecci\u00f3n.!Los!sujetos!presentaron!una!protecci\u00f3n!de!18!meses!(el!\u00faltimo!periodo!de!tiempo!que!se!midi\u00f3!en!el!estudio)!desde!la!reinfecci\u00f3n!con!el!mismo!serotipo.!Sin!embargo,!cuando!el!reto!posterior!fue!con!un!serotipo!heter\u00f3logo,!la!protecci\u00f3n!cruzada!s\u00f3lo!dur\u00f3!de!dos!a!tres!meses!despu\u00e9s!de!la!primera!infecci\u00f3n!(97).!Estudios!m\u00e1s!recientes!sugieren!que!este!tiempo!puede!ser!m\u00e1s!extenso,!para!pacientes!con!fiebre!por!Dengue!oscila!entre!1.9!a\u00f1os!y!para!pacientes!con!Dengue!severo!de! 2.6! a\u00f1os,! entre! una! infecci\u00f3n! y! otra! subsecuente!(98).!Otros! estudios!sugieren!un!tiempo!menor!de!1.2!a\u00f1os!(99).!!Neutralizaci\u00f3n\"mediada\"por\"anticuerpos\"!La!producci\u00f3n!de!anticuerpos!neutralizantes!representa!la!base!de!la!inmunidad!adaptativa!contra!varios!pat\u00f3genos!virales!y!el!\u00e9xito!de!algunas!vacunas!como!la!del! sarampi\u00f3n,!rub\u00e9ola!y! viruela! por! mencionar! algunas.!Sin! embargo,!algunos!pat\u00f3genos! virales! como!Influenza! o!VIH! han! desarrollado! mecanismos! que! les!permite!evadir!la!capacidad!neutralizante.!Este!fen\u00f3meno!se!debe,!en!gran!medida,!a!la!alta!tasa!de!mutaci\u00f3n!viral.!Cabe!mencionar!que!no!todos!los!anticuerpos!que!se!producen!durante!la!infecci\u00f3n!tienen!capacidad!neutralizante!(95,!100)(Figura!15).!!!La! prote\u00edna! de! la! envoltura! (E)! es! el! blanco! principal! de! anticuerpos!neutralizantes.!Sin! embargo,! tambi\u00e9n! se! han! descrito! anticuerpos!neutralizantes!contra!la!prote\u00edna!prM,!M!y!algunas!de!las!prote\u00ednas!no!estructurales!como!NS1,!NS3!y!NS5.!NS3!y!NS5!se!localizan!exclusivamente!dentro!de!las!c\u00e9lulas!infectadas!por!el!virus!pero!debido!a!la!lisis!celular,!estas!prote\u00ednas!quedan!accesibles!a!los!anticuerpos!(101).!!!!\n30\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\n!Figura#15.# Respuesta# de# anticuerpos# a# las# prote\u00ednas# del# DENV# y# su# funci\u00f3n#(101).#El!ciclo!de!vida!del!DENV!y!las!fuentes!de!ant\u00edgenos!se!muestran!en!la!imagen.!Los!viriones!de!DENV!se!unen!a!la!superficie!de!la!c\u00e9lula!por!medio!de!receptores!y!los!viriones!se!internalizan!por!medio!de!endocitosis!mediada!por!receptor.!La!acidificaci\u00f3n!de!las!ves\u00edculas!endocitadas!induce!un!reUarreglo!de!la!prote\u00edna!E!en!la!superficie!del!virion,!,!este!proceso!permite!la!fusi\u00f3n!de!la!membrana!viral!y!la!membrana!ves\u00edcular,logrando!de!esta!manera!que!se!libera!el!RNA!viral!en!el!citoplasma.!EL!RNA!viral!se!traduce!y!se!producen!las!prote\u00ednas!virales!en!el!RE,!las!prote\u00ednas!virales!y!el!nuevo!RNA!sintetizado!se!ensamblan!en!viriones!inmaduros!dentro!del!lumen!del!RE.!El!corte! de! la! prote\u00edna! preUM! por! medio! de! furin!proteasa!del! hospedero! permite! la! formaci\u00f3n! de! viriones!maduros,!que!son!secretados!de!la!c\u00e9lula.!Adem\u00e1s,!algunas!prote\u00ednas!sintetizadas!como!NS1!son!expresadas!en!la!membrana!plasm\u00e1tica!de!las!c\u00e9lulas!del!hospedero!y!algunos!viriones!son!secretados!de!forma!inmadura.!La!producci\u00f3n! de! viriones! maduros! e! inmaduros! induce! la! producci\u00f3n! de! anticuerpos! antiUE! y! antiUprM,! estos!anticuerpos!se!involucran!en!la!neutralizaci\u00f3n!o!en!la!potenciaci\u00f3n!de!la!enfermedad.!Los!anticuerpos!antiUNS1!pueden!interactuar!con!la!uni\u00f3n!a!la!membrana!de!NS1!y!causar!la!lisis!dependiente!de!complemento!de!la!c\u00e9lula!infectada.!Imagen!modificada!de!Rothman!AL.!2011.!Nat!Rev!Immunol!11:!532U43.##La! prote\u00edna! E! es! una!glicoprote\u00edna! multifuncional!involucrada! en!la! entrada! del!DENV! a! la! c\u00e9lula! hospedera,!por! medio!de! la! uni\u00f3n! con! el! receptor! celular!y! la!posterior!fusi\u00f3n! con! la! membrana! celular.! Las! subunidades! de! la! prote\u00edna! E!consisten! de! tres! dominios! de! barrilUbeta! designados! como! dominio! I! (EDI),! II!(EDII)!y!III!(EDIII).!!EDII!y!EDIII!forman!parte!del!p\u00e9ptido!de!fusi\u00f3n!(100)!(Figura!16).!!!\n!Figura#16.#Estructura#de#la#prote\u00edna#E#del#DENV#(97).#Esquema!tridimensional!de!un!d\u00edmero!de!la!prote\u00edna!E.!El!mon\u00f3mero!de!la!prote\u00edna!E!se!conforma!del!dominio!I!(amarillo),!dominio!II!(rojo)!y!dominio!III!(azul).!Cada!part\u00edcula!viral!contiene!180!mon\u00f3meros!de!prote\u00edna!E!que!son!organizados!en!90!d\u00edmeros!apretados!que!se! mantienen! planos! sobre! la! superficie! de! la! membrana! viral.!Imagen! tomada!de!Wahala,!2011.!Viruses!3:!2374U95#La!prote\u00edna!E!es!el!principal!componente!de!la!superficie!del!viri\u00f3n!y!es!el!blanco!dominante!de!los!anticuerpos!con!capacidad!neutralizante.!El!dominio!EDIII!se!ha!descrito!como!el!dominio!inmunodominante!(102,!103).!Mediante!experimentos!in(vitro!con! anticuerpos! monoclonales!y! el! uso! de! modelos! animales!(ratones!humanizados)!se! han! logrado! identificar! al! menos! 12!ep\u00edtopos!distintos! en! la!superficie! de! la! prote\u00edna! E! que! unen! anticuerpos! con! distinta! capacidad!ViralProteins\nERVirionEndocitosisAcidificaci\u00f3ndel endosomaTraducci\u00f3n delRNA viral\nY\nY\nYY\nY\nYLiberaci\u00f3n deviriones madurosSecreci\u00f3n de viriones inmadurosProte\u00ednaEnvoltura (E)Virion maduroVirion inmaduroProte\u00ednaPrMAb anti-PrMAb anti-E\nProte\u00edna NS1Ab anti-NS1Y\nY\nYDC-SIGN, GRP78/BiP, moleculas asociadas a CD14Formaci\u00f3n deviriones madurosEnsamblajede virionesN\u00facleoCitoplasma* Neutralizaci\u00f3n* Potenciaci\u00f3n mediada   por anticuerpos* Potenciaci\u00f3n mediada   por anticuerpos* Lisis dependiente de  Complemento\nPeptido!de!fusi\u00f3n \nEDII \nEDI \nEDIII !\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"31\"!#Instituto!Nacional!de!Salud!P\u00fablica!###neutralizante.! Varios! de! estos! anticuerpos,! particularmente! los! que! presentan!mayor!capacidad!neutralizante,!se!unen!al!EDIII!(104U106).!!!Recientemente! se! describi\u00f3! un! modelo! din\u00e1mico! de! las! interacciones! entre!residuos!espec\u00edficos!de!la!prote\u00edna!E!que!median!la!infectividad!del!DENV!(107).!Este! modelo! ofrece! nuevos! objetivos! funcionales! para! usarse! en! vacunas! o! en!terapias!contra!el!DENV!(Figura!17).!!El! an\u00e1lisis! del! suero! y! de!linfocitos! B! de! memoria! recuperados! de! pacientes! con!infecci\u00f3n! con! DENV! indican! que! la! inmunidad! a! largo! plazo! serotipo! espec\u00edfica!involucra!a!anticuerpos!que!se!unen!a!los!dominios!EDI,!EDII!y!EDIII!(102,!108).!!Beltramelo! y! colaboradores! en! el! 2010!(108),!aislaron! clonas! de! linfocitos! B!de!cultivos!independientes!y!caracterizaron!70!anticuerpos!antiUDENV.!Ellos!pudieron!determinar!que!los!donadores,!pacientes!con!Dengue,!tienen!un!gran!repertorio!de!linfocitos!B!de!memoria,!incluso!si!han!pasado!a\u00f1os!despu\u00e9s!de!la!infecci\u00f3n.!Los!anticuerpos! monoclonales! aislados! espec\u00edficos!contra!E! y! prM! muestran!reactividad! cruzada! para! los! cuatro!serotipos! DENV!y! observaron! que! los!anticuerpos!monoclonales!con!mayor!grado!de!neutralizaci\u00f3n!son!los!espec\u00edficos!para!el!EDIII.!El!an\u00e1lisis!realizado!en!un!gran!n\u00famero!de!anticuerpos!monoclonales!mostr\u00f3!que!la!fracci\u00f3n!de!anticuerpos!antiUEDIII!y!EDI/EDII!de!reacci\u00f3n!cruzada!fue!considerablemente!mayor!en!las!infecciones!secundarias.!!\n!Figura#17.# Modelo#de# residuos# cr\u00edticos# para# la# infectividad# en# la# prote\u00edna# E#(107).#(A)!Los! residuos!cr\u00edticos!de!DENV3!para!la!infectividad!mostrados!en!el!d\u00edmero!de!DENV3!agrupados!de!acuerdo!a!su!rol!en!la!\n!\n32\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###infecci\u00f3n:! El! asa! de! fusi\u00f3n! (naranja),! tallo/M! cerrojo! (morado)! y! la! bisagra! (verde).! (B)!El! modelo! para! los!residuos!cr\u00edticos!en!la!medicaci\u00f3n!de!los!cambios!estructurales!que!inician!la!fusi\u00f3n!de!las!membranas.!1)!En!el!viri\u00f3n!maduro,!los!residuos!cr\u00edticos!importantes!para!la!funcionalidad!del!cerrojo!mantienen!interacciones!con!el!DII/prote\u00edna!M,!mientras!que!los!residuos!de!apoyo!al!asa!de!fusi\u00f3n!atan!y!posicionan!el!asa!de!fusi\u00f3n!para!retener!a!E!en!una!conformaci\u00f3n!de!d\u00edmero!hasta!que!la!captaci\u00f3n!por!las!c\u00e9lulas!!y!el!transporte!al!endosoma!se!lleve!a!cabo.!2)!Durante!el!bajo!pH!de!los!endosomas,!los!residuos!de!histidina!se!protonan!para!interrumpir!las!interacciones!entre!EUM!y!que!los!residuos!de!soporte!del!asa!de!fusi\u00f3n!disocien!el!d\u00edmero!de!E.!!Esto!es!seguido!por!los!cambios!en!las!posiciones!relativas!de!DI,!DII!y!DIII,!facilitado!por!los!residuos!cr\u00edticos!de!la!bisagra.!3)!Los!residuos!del!asa!de!fusi\u00f3n!se!insertan!en!la!membrana!del!endosoma!como!mon\u00f3meros!de!E!del!tr\u00edmero! de! fusi\u00f3n.! Las! membranas! del! endosoma! y! del! virus! se! jalan! juntas! por! el! tallo! de! E!entre! los!intersticios!de!DI,!facilitados!por!los!residuos!cr\u00edticos!del!tallo!y!del!cerrojo.!Imagen!tomada!de!Christian,!2013.!Proc!Natl!Acad!Sci!U!S!A!110:!18662U7.!La! prote\u00edna! no! estructural! 1! (NS1)! es! sintetizada! en! el! RE! rugoso! como! una!glicoprote\u00edna!monom\u00e9rica!e!hidrof\u00edlica.!Posteriormente,!se!forman!d\u00edmeros!de!la!prote\u00edna! que! pasaran! al! aparato! de! Golgi.!NS1! se! expresa! en! la! superficie! de! las!c\u00e9lulas! infectadas! por! el! virus! y! se! secreta! en! la! circulaci\u00f3n! como! mult\u00edmero!soluble.!!Durante!la!infecci\u00f3n!de!la!c\u00e9lula!del!hospedero!in(vitro,!NS1!se!encuentra!asociada! con! organelos! intracelulares! como! requisito! para! su! papel! en! la!replicaci\u00f3n!viral!(109).!NS1!es!un!blanco!importante!de!los!anticuerpos!antiUDENV.!Los! anticuerpos!contra! NS1! pueden! provocar! lisis! mediada! por!complemento! de!las!c\u00e9lulas!infectadas!in(vitro!y!proteger!a!los!ratones!neonatos!infectados!por!v\u00eda!intraUcerebral! a! un!reto! con! DENV.!Al! mismo! tiempo,! estos! anticuerpos! pueden!provocar! reactividad! a! c\u00e9lulas! endoteliales,! dando! lugar! a! su! activaci\u00f3n! y! la!expresi\u00f3n!de!citocinas,!quimiocinas!y!mol\u00e9culas!de!adhesi\u00f3n!a!da\u00f1o!celular,!lo!que!se!ha!asociado!con!la!generaci\u00f3n!de!la!forma!severa!de!la!enfermedad!(110,!111).!!Esto!podr\u00eda!desencadenar!efectos!locales!o!sist\u00e9micos!implicados!en!la!coagulaci\u00f3n!intravascular!(112).!!!Algunos! estudios! correlacionan! la! producci\u00f3n! de! anticuerpos! antiUNS1! con! la!severidad!de!la!enfermedad,!as\u00ed!como!los!anticuerpos!antiUNS1!tienen!reactividad!cruzada!con!h\u00edgado,!c\u00e9lulas!endoteliales!y!plaquetas;!este!mecanismo!es!llamado!mimetismo! molecular.!Se! ha! propuesto! que! estas! c\u00e9lulas! pueden! producir! oxido!n\u00edtrico!y!generar!apoptosis!(113).!!!Neutralizaci\u00f3n\"de\"amplio\"espectro\"Uno!de!los!objetivos!de!varios!en!la!investigaci\u00f3n!en!Dengue!es!encontrar!ep\u00edtopos!que!induzcan!la!generaci\u00f3n!de!anticuerpos!altamente!neutralizantes!de!reactividad!cruzada! y! que! tengan! una! actividad! de! potenciaci\u00f3n! m\u00ednima! en! contra! de! los! 4!serotipos!del!DENV.!Recientemente!el!grupo!de!Dejnirattisai!a!principios!del!2015!caracterizo! a! 145! mAbs! altamente! neutralizantes,! aislados! de! plasmablastos! de!pacientes!Vitmanitas,!la!mayor\u00eda!cursaban!con!infecciones!secundarias!de!DENV.!112! mAbs! se! pudieron! mapear! en! part\u00edculas! similares! a! virus! (VLPs)! y! se!determinaron! tres!clases! de!ep\u00edtopos:!aquellos! dirigidos! contra! dos! ep\u00edtopos!relacionados!en!el!d\u00edmero!de!la!prote\u00edna!E!!(EDE1!y!EDE2)!y!otro!ep\u00edtopo!dirigido!contra!el!asa!de!fusi\u00f3n!(FLE).!!Los!EDE!abarcan!dos!mon\u00f3meros!de!la!prote\u00edna!E!adyacentes! dentro! de! un! solo! d\u00edmero! y! tienen! puntos! de! contacto! en! los! tres!dominios! de! la! prote\u00edna! E.! Se! probaron! los! t\u00edtulos! de! neutralizaci\u00f3n! y! de!potenciaci\u00f3n!entre!estos!mABs!y!se!observo!que!los!mAbs!dirigidos!contra!EDE!se!unieron!y!neutralizaron!tanto!a!part\u00edculas!maduras!como!part\u00edculas!inmaduras!del!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"33\"!#Instituto!Nacional!de!Salud!P\u00fablica!###viri\u00f3n! de! DENV.! Los! mAbs! contra! EDE! son! de! cuatro! a! ocho! veces! menos!potenciadores!de!la!infecci\u00f3n!que!los!mAbs!dirigidos!contra!FLE!(114U116).!!Potenciaci\u00f3n\"mediada\"por\"anticuerpos\"!Como! se! hab\u00eda! mencionado! anteriormente,!los! anticuerpos! antiUDENV!se! han!implicado!en! la! generaci\u00f3n! de! las! formas! graves.!Una! de! las! hip\u00f3tesis! es! la!conocida!como!Potenciaci\u00f3n!mediada!por!anticuerpos!o!ADE!(antibody(dependent(enhancement,(por! sus! siglas! en! ingles).! Esta!se! ha! documentado! en! estudios!seroepidemiol\u00f3gicos! principalmente,! y! m\u00e1s! recientemente!en! estudios! con!modelos!animales!(117).!En!estos!estudios!se!document\u00f3!que!la!enfermedad!grave!ocurr\u00eda!m\u00e1s!frecuentemente!en!pacientes!que!cursaban!por!una!segunda!infecci\u00f3n!causada! por! un! serotipo! distinto! al! responsable!de!la! infecci\u00f3n! primaria.!Esta!misma!observaci\u00f3n!se!hizo!en!ni\u00f1os!mayores!de!6!meses!con!altos!t\u00edtulos!de!IgG!materna!y!menores!de!un!a\u00f1o!en!donde!la!madre!ten\u00eda!antecedentes!de!infecci\u00f3n!de!DENV!con!un!diferente!serotipo!(52,!94,!118).!!!La! hip\u00f3tesis! fue! descrita! en! primera! instancia! en! los! a\u00f1os! 60! por! Hawkes! y!colaboradores!para!arbovirus!(virus!de!la!encefalitis!del!Valle!de!Murray,!virus!del!Oeste! del! Nilo! y! el! virus! de! la! encefalitis! japonesa! entre! otros)!(119,!120).!Esta!hip\u00f3tesis!fue!retomada!por!Scott!Halstead!en!la!d\u00e9cada!de!1970,!y!propone!que!en!una! infecci\u00f3n! primaria! se! producen! anticuerpos!DENV!serotipo! espec\u00edficos! que!generan!protecci\u00f3n!homot\u00edpica!a!largo!plazo.!Si!el!individuo!se!reUinfecta!por!un!serotipo!distinto!al!de!la!infecci\u00f3n!primaria,!los!anticuerpos!de!memoria!contra!el!serotipo! de! la! primera! infecci\u00f3n! reaccionan! con! ep\u00edtopos! compartidos! en! el!serotipo!de!la!segunda!infecci\u00f3n.!En!este!caso,!estos!anticuerpos!no!neutralizantes!al!interaccionar! con! el!virus! forman! complejos! virusUanticuerpos,! que! se!pueden!unir!a!los!receptores!tipo!Fc\u03b3!presentes!en!monocitos!y!macr\u00f3fagos,!lo!que!permite!la!internalizaci\u00f3n!del!virus!por!fagocitosis,!aumentando!la!carga!viral!celular!y!por!lo! tanto,!la! severidad!de! la! infecci\u00f3n.! Los! sistemas! de! coagulaci\u00f3n,! fibrin\u00f3lisis! y!complemento!se! activan,! y! consecuentemente,! el! da\u00f1o! al! endotelio! vascular,! que!favorecer\u00e1!los!fen\u00f3menos!hemorr\u00e1gicos,!con!fuga!de!l\u00edquidos!al!espacio!intersticial!y!descompensaci\u00f3n!hemodin\u00e1mica!desde!leves!hasta!el!choque!profundo!(Figura!18)(121U124).!Este! fen\u00f3meno!no! es! una! forma! de! entrada! a! la! c\u00e9lula! que! use! el!DENV.!La!entrada!del!DENV!a!la!c\u00e9lula!es!por!endocitosis!mediada!por!receptor.!!!\n!Figura#18.#Potenciaci\u00f3n#mediada#por#anticuerpos#(95).#Este!fen\u00f3meno!ocurre!cuando!los!anticuerpos!no!neutralizantes!heterot\u00edpicos! presentes! en! el! hospedero,!que! se! produjeron! a!consecuencia! de! una! infecci\u00f3n!primaria,!se!unen!a!un!virus!durante!una!infecci\u00f3n!secundaria!heterot\u00edpica!pero!no!pueden!neutralizarlo.!En!\n!\n34\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###cambio,!se! forman!complejos! de! virusUanticuerpo!que!se! unen! a! los! receptores! Fc\u03b3!(Fc\u03b3R)! de! monocitos! o!macr\u00f3fagos! en! circulaci\u00f3n!(c\u00e9lulas! que! no! necesariamente! son! la! c\u00e9lula! blanco!principal!del! virus).! Este!fen\u00f3meno! provoca! un! incremento! en! la! replicaci\u00f3n! global! del! virus,! lo! que! conduce! a! la! posibilidad! de! una!enfermedad!m\u00e1s!grave!(95).!Imagen!tomada!de!Whitehead,!2007.!Nat!Rev!Microbiol!5:!518U28.#!EL! ADE! es! una! hip\u00f3tesis! que! tiene! similitud! con! el! pecado! antig\u00e9nico!original,!descrito! por! primera! vez! en!1953!por! Thomas! Francis,! Jr.!en! infecciones! con! el!virus!de!influenza!(125).!El!pecado!antig\u00e9nico!original!se!refiere!a!la!tendencia!del!sistema! inmune! a! utilizar!preferentemente! la! memoria! inmune! generada! en!infecciones!anteriores!cuando!el!individuo!se!encuentra!en!una!segunda!infecci\u00f3n!con!un!pat\u00f3geno!similar!o!con!una!variaci\u00f3n!muy!peque\u00f1a,!como!ser\u00eda!el!caso!de!las! diferentes! cepas! del! virus! de!Influenza! o! para! este! caso! en! particular,!los!serotipos!de!DENV.!!Los! mecanismos! que! definen! al! fen\u00f3meno! del! pecado! antig\u00e9nico! original! se!desconocen.! Uno! de! varios! modelos! propone! que! factores! como! la! frecuencia! de!linfocitos!B!de!memoria!y!la!carga!antig\u00e9nica!pueden!definir!la!competencia!entre!linfocitos!B!de!memoria!con!reactividad!cruzada!y!linfocitos!B!v\u00edrgenes!espec\u00edficos!de!serotipo,!haciendo! que! el! hospedero!sea!incapaz!!de! montar! una! respuesta!eficaz!a!la!segunda!infecci\u00f3n!(15,!101).!!En!donde,!los!linfocitos!B!de!memoria!se!activaran! con! mayor! rapidez! y! con! una! intensidad! mayor! que! los! linfocitos! B!v\u00edrgenes!seleccionados!por!el!segundo!serotipo,!causante!de!la!infecci\u00f3n!en!curso!(126).!Interesantemente,! se! han! descrito! que! infecciones! secundarias! con! un!nuevo!serotipo!tambi\u00e9n!hacen!que!proliferen!linfocitos!T!de!reactividad!cruzada,!de!baja!afinidad!que!compiten!con!los!linfocitos!T!v\u00edrgenes!de!baja!avidez!que!se!activan!por!la!infecci\u00f3n!en!curso!(127,!128).! !La!prM,!prote\u00edna!antig\u00e9nica!importante!del!virus,!es!precursora!de!la!prote\u00edna!de!membrana! y! funciona! como! chaperona! para! el! plegamiento! de! la! prote\u00edna! E,!adem\u00e1s!de!que!evita!la!fusi\u00f3n!prematura!de!las!membranas!del!virus!dentro!de!la!c\u00e9lula.! Esta! prote\u00edna! se! encuentra! asociada! con! 166! amino\u00e1cidos! al! EDII.! La!porci\u00f3n!CUterminal!de!prM!contiene!un!dominio!transmembranal!que!permanece!asociada!a!la!part\u00edcula!del!virus!y!en!su!porci\u00f3n!NUterminal!de!91!amino\u00e1cidos!se!encuentra!el!fragmento!precursor!(pr),!que!se!disocia!tras!la!liberaci\u00f3n!de!los!virus!de!la!infecci\u00f3n!celular,!formando!el!viri\u00f3n!maduro!(129,!130).!!!Dejnirattisai! y! colaboradores!en! el!2010!(67,!131,!132)!observaron! que! los!anticuerpos!antiUprM!potencian!la!infecci\u00f3n!de!10!hasta!800!veces!m\u00e1s!y!muestran!una! capacidad! limitada! de! neutralizaci\u00f3n! menor! del! 80%.! Ellos! proponen! que! la!combinaci\u00f3n!de!la!escisi\u00f3n!parcial!de!prM,!junto!con!una!reacci\u00f3n!cruzada!entre!los!serotipos,!hace!que!la!respuesta!antiUprM!potencie!la!infecci\u00f3n,!por!lo!que!\u00e9sta!respuesta! podr\u00eda! interpretarse! como! una! evasi\u00f3n! del! sistema! inmune! o! incluso!como! una! estrategia! de! mejora! inmunol\u00f3gica! del! virus.!Dejnirattisai! y!colaboradores!proponen!que!puede!haber!tres!poblaciones!de!DENV,!de!acuerdo!a!la!pobre!capacidad!de!neutralizaci\u00f3n!que!presentan!estos!anticuerpos:!!1. Virus!no!infecciosos!con!niveles!relativamente!altos!de!prM!en!la!superficie,!pero! que! puede! volverse! infecciosos! en! la! presencia! de! anticuerpos!antiUprM!y!potenciar!la!infecci\u00f3n.!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"35\"!#Instituto!Nacional!de!Salud!P\u00fablica!###2. Virus!con!densidad!intermedia!de!prM!en!la!superficie!que!puede!infectar,!y!son!susceptibles!a!la!neutralizaci\u00f3n!en!un!t\u00edtulo!alto!de!anticuerpos.!3. Virus! con!niveles! bajos! de!prM!o! ausentes! en! la! superficie!y!que!normalmente!no!ser\u00edan!susceptibles!de!neutralizaci\u00f3n.!!Con!base!en! los! puntos! anteriores,!ellos! proponen! que! los! individuos! con! las!formas!severas!de!la!enfermedad!podr\u00edan!tener!una!poblaci\u00f3n!de!virus!que!tiene!niveles!altos!de!prM!en!la!superficie!del!viri\u00f3n!y!que!en!presencia!de!anticuerpos!antiUprM!pueden!potenciar!la!infecci\u00f3n.!Esta!diferencias!pueden!observarse!en!el!repertorio!de!anticuerpos.!!!Wrammert! y! colaboradores!en! 2012!(133)!observaron! una! inducci\u00f3n! masiva! de!plasmablastos!en!sangre!perif\u00e9rica,!t\u00edpicamente!al!d\u00eda!6U7!despu\u00e9s!del!inicio!de!la!fiebre,!en!respuesta!a!una!infecci\u00f3n!por!DENV!en!pacientes!agudos!de!DH!y!DC.!En!algunos! casos! corresponden! al! 30%! del! total! de! linfocitos! circulantes! en! sangre!perif\u00e9rica!y!que!hay!un!incremento!de!los!plasmablastos!(1!X!106!plasmablastos!por! ml! de! sangre),! en! comparaci\u00f3n!con! sujetos! sanos.! Al! mes! del! inicio! de!la!infecci\u00f3n,! los! plasmablastos! regresan! a! niveles! basales.! Esta! respuesta! es! muy!similar! a! la! generada!contra! las!vacunas!de!la! Influenza! al! d\u00eda! 7! y!de! la!fiebre!amarilla!atenuada!al!d\u00eda!11U14!(56).!!Ellos!pudieron!determinar!que!alrededor!del!80%!de!los!plasmablastos!son!IgG!DENV!espec\u00edfico.!Y!que!en!la!respuesta!no!existe!diferencia!a!nivel!se!serotipo!ni!en!infecciones!secundarias!y!primarias.!!!!Esta! observaci\u00f3n! tambi\u00e9n! la! corroboraron! Balakrishnan!y! colaboradores! en!el!2011!(38).! Ellos,!estudiando!una! cohorte! de! pacientes! con!Dengue! en! Singapur,!observaron!que!durante!la!fase!aguda!de!la!enfermedad!(4U7d\u00edas!posteriores!a!la!fiebre)! circulan! altas! cantidades! de! plasmablastos! en! sangre! perif\u00e9rica! que!coinciden! con! la! aparici\u00f3n! de! anticuerpos! IgG! DENV! espec\u00edficos.! El! n\u00famero! de!plasmablastos!cae!a!niveles!basales!dentro!de!las!dos!o!tres!semanas!posteriores!a!la!aparici\u00f3n!de!la!enfermedad!(134).!Adicionalmente!ya!se!ha!demostrado!que!los!anticuerpos! antiUDENV!provenientes! de! plasmablastos! se! unen! de! manera!dominante! a! la! prote\u00edna! E! del! virus! y! que! tienen! una! alta!capacidad! de!neutralizaci\u00f3n!contra!los!cuatro!serotipos!(39).!!Respuesta\"celular\"!Durante! la! respuesta! primaria! a! la! infecci\u00f3n! se! generan! linfocitos! B! serotipoUespec\u00edficos! y! linfocitos! T! de! memoria! de! reactividad! cruzada.! En! infecciones!secundarias!los!linfocitos!T!memoria!de!reactividad!cruzada!se!activan!y!proliferan!desencadenando! la! producci\u00f3n! de! citocinas! proUinflamatorias! que! dan! como!resultado! la! fuga! de! plasma!en! el! endotelio! vascular!(48).! Los! mecanismos! de!eliminaci\u00f3n!del!virus!se!vuelven!no!\u00f3ptimos!!debido!a!que!los!linfocitos!T!de!baja!afinidad!son!menos!capaces!de!eliminar!a!las!c\u00e9lulas!infectadas.!La!activaci\u00f3n!de!linfocitos! T! de! memoria! con! baja! afinidad! para! el! serotipo! infectante! pero! alta!afinidad!contra!el!serotipo!de!la!infecci\u00f3n!previa!han!sido!reportada!previamente!y!se!ha!correlacionado!con!la!severidad!de!la!enfermedad!(101,!135).!!!\n36\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\"Tormenta\"de\"citocinas\"y\"fuga\"vascular\"!La!producci\u00f3n!de!citocinas!se!ha!observado!en!pacientes!con!la!enfermedad!severa!y!pacientes!con!s\u00edndrome!de!choque!por!Dengue.!La!infecci\u00f3n!viral!de!las!c\u00e9lulas!endoteliales!directamente!no!aparenta!ser!la!mayor!causa!de!la!perdida!de!plasma;!sin! embargo,! productos! solubles! producidos! por! los! linfocitos! T,! monocitos,!macr\u00f3fagos! y! mastocitos,! se! han! propuesto! que! incrementan! la! permeabilidad!vascular!en!c\u00e9lulas!del!endotelio!primario.!Estos!factores!incluyen!TNF\u03b1,!ILU6,!ILU8,!ILU10,!e!IL12,!as\u00ed!como!el!factor!inhibidor!de!la!migraci\u00f3n!de!macr\u00f3fagos,!HMGB1,!MCPU1!y!metaloproteasas!de!la!matriz!(48,!136).!!La!permeabilidad!endotelial!tambi\u00e9n!puede!ser!afectada!por!prote\u00ednas!del!virus.!Se!ha!visto!que!la!maduraci\u00f3n!de!NS4B!puede!modular!la!producci\u00f3n!de!citocinas!en!l\u00edneas! celulares! de! monocitos!(137).! La! prote\u00edna! NS1! secretada! junto! con!anticuerpos! antiUNS1,! que! activan! el! complemento,! se! han! involucrado!directamente!en!la!inducci\u00f3n!de!la!fuga!vascular!(138).!!!!!!!!Vacuna\"contra\"Dengue\"!Actualmente! existen! varios! candidatos! de! la! vacuna! contra! DENV! en! diferentes!estados!de!desarrollo.!De!estos!candidatos!,!la!vacuna!m\u00e1s!avanzada!es!la!conocida!como! ChimeriVaxTM,! una! quimera! de! flavivirus! con! prote\u00ednas! E! y!prM!de!los!DENV1U4! que! fueron! reemplazadas! en! una! cepa! de! virus! de! fiebre! amarilla! 17D!(139).! Es! una! vacuna! tetravalente,! conteniendo! cuatro! cepas! modificadas.! Esta!vacuna! se! encuentra! en! fase! III!y! se! ha! probado! en! zonas!no! end\u00e9micas!y!end\u00e9micas!de!Asia!y!Am\u00e9rica!Latina!(incluido!M\u00e9xico)!(48).!!!Los! estudios! precl\u00ednicos!in( vitro!e!in( vivo!muestran! que! la! vacuna! tetravalente!induce! una! estimulaci\u00f3n! controlada! de! c\u00e9lulas! dendr\u00edticas! humanas! y! una!respuesta! inmune! significativa! en! monos.! Tres! dosis! de! la! vacuna! induce! una!respuesta! inmune! en! contra! de! los! 4! serotipos.! La! inmunidad! preUexistente!de!flavivirus! favorece! una! respuesta! inmune! mayor! y! m\u00e1s! r\u00e1pida! a! la! vacuna,! sin!incrementar!la!viremia!de!la!vacuna!o!afectar!negativamente!la!seguridad!cl\u00ednica.!Sin! embargo,!y! de! manera! desafortunada,! la! eficacia! global! de! la! vacuna! fue! del!30%!y!difer\u00eda!por!serotipo.!La!mayor\u00eda!de!las!infecciones!despu\u00e9s!de!la!aplicaci\u00f3n!de! la! vacuna! fueron! del! serotipo! DENV2,! este! serotipo! fue! el! que! mostr\u00f3! una!eficacia! m\u00e1s! baja! (9%).! La! eficacia! m\u00e1s! alta! fue! del! serotipo! DENV4! (100%),!seguido!del!DENV3!(75%)!y!el!DENV1!(56%)!(140).!!!Los! resultados! en! Am\u00e9rica! Latina! mostraron! que! los! ni\u00f1os! vacunados! ten\u00edan! un!79.4%! de! inmunogenicidad! para! uno! o! mas! serotipos! de! DENV! previos!a! la!vacunaci\u00f3n.!Una!vez!aplicada!la!vacuna,!se!encontr\u00f3!una!eficacia!global!del!60.8%!para!el!grupo!control!y!para!la!poblaci\u00f3n!que!se!intenta!tratar!fue!del!64.7%.!Una!vez!m\u00e1s!se!mostr\u00f3!que!la!eficacia!contra!el!serotipo!DENV2!fue!la!menor!(42.3%),!seguida! del! DENV1! (50.3%),! DENV3! (74.0%)! y! DENV4! (77.7%).! La! vacuna!logr\u00f3!reducir!la!cantidad!de!hospitalizaciones!en!los!pa\u00edses!evaluados!(141).!!!!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"37\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Antecedentes\"!En!el! 2005,!nuestro! grupo! de!trabajo!inici\u00f3!una! l\u00ednea! de! investigaci\u00f3n! con! la!finalidad! de! desarrollar! un! m\u00e9todo! de! an\u00e1lisis! semiUcuantitativo! y!cualitativo!de!muestras! del!repertorio! de! linfocitos! B! en! humanos.!Hasta! la! fecha! se! ha!desarrollado!una!estrategia!basada!en!secuenciaci\u00f3n!masiva!de!cDNA!de!la!regi\u00f3n!variable! de! Ig.!Esta! estrategia! se!valid\u00f3!en! linfocitos! B! de! sangre! perif\u00e9rica! de!individuos!sanos!(T\u00e9llezUSosa!y!colaboradores,!2015;!en!preparaci\u00f3n).!El!resultado!de! la! secuenciaci\u00f3n! masiva! genera!un! repertorio! digital! que! permite! la!caracterizaci\u00f3n! tanto! cualitativa! como! cuantitativa! a! nivel! de! diversidad! clonal! y!frecuencia!clonal,!respectivamente.!El!an\u00e1lisis!bioinform\u00e1tico!nos!permite!generar!perfiles!de!clonalidad!de!diferentes!individuos!en!distintas!condiciones!asociados!a!un!determinado!estado!inmunol\u00f3gico!(vacunaci\u00f3n!contra!el!virus!de!la!Influenza,!o!infecci\u00f3n! por! DENV).!Si! se! tiene! la! informaci\u00f3n! de! los! pacientes! en! estado!convaleciente,!nos!puede!dar!indicio!del!estado!basal!previo!a!estas!condiciones.!Estos!perfiles!se!comparan!y!pueden!ser!utilizados!para!la!identificaci\u00f3n!de!clonas!espec\u00edficas!contra!las!condiciones!que!estemos!estudiando.!Finalmente,!gracias!a!que!se!obtiene!la!informaci\u00f3n!de!la!secuencia!de!las!regiones!variables!podemos!producir!los!anticuerpos!de!manera!recombinante!para!posteriormente!validar!su!reactividad!y!grado!de!neutralizaci\u00f3n.!!Tradicionalmente,!el!estudio!del!repertorio!inmunol\u00f3gico!se!basaba!en!la!clonaci\u00f3n!de!linfocitos!\u00fanicos!mediantes!FACS!(Fluorescence!Activated!Cell!Sorting),!seguido!de! PCR! con! oligonucle\u00f3tidos! gen\u00e9ricos! que! amplifican! las! regiones! variables,!clonaci\u00f3n!de!productos!de!PCR!y!secuenciaci\u00f3n!(142U144).!En!el!anexo!2!se!pueden!encontrar! algunos! ejemplos! de! estudios! realizados! para! la! generaci\u00f3n! de!anticuerpos!monoclonales.!!!Los!recientes!avances!en!la!secuenciaci\u00f3n!masiva!del!DNA!han!revolucionado!los!campos! en! la! gen\u00f3mica! haciendo! posible! generar!grandes! cantidades! de!secuencias! (miles)! r\u00e1pidamente! y! a! bajo! costo.! La! aplicaci\u00f3n! de! tecnolog\u00edas! de!secuenciaci\u00f3n!de!la!siguiente!generaci\u00f3n!(nextUgeneration)!tanto!de!DNA!como!de!RNA! impacta! en! la! manera! de! abordar! el! estudio! de! m\u00faltiples! aspectos! en! la!investigaci\u00f3n!gen\u00f3mica!(145).!!!La!plataforma!de!secuenciaci\u00f3n!GS!FLX!Titanium!454!de!Roche!es!de!las!primeras!en! el! mercado! y! se! basa! en! la! pirosecuenciaci\u00f3n.! La! tasa! de! error! de! esta!plataforma! oscila! en! un! rango! de! 10U3U10U4!y! el! tama\u00f1o! de! lectura! se! encuentra!entre!400!y!500!nucle\u00f3tidos!(146).!!El!uso!de!la!secuenciaci\u00f3n!masiva!en!el!estudio!del!repertorio!inmunol\u00f3gico!inicio!en!el!2009!y!desde!entonces!su!uso!se!ha!incrementado.!En!los!\u00faltimos!a\u00f1os,!se!han!descrito! varios! estudios! sobre! la! estimaci\u00f3n! de! la! diversidad! del! repertorio! de!linfocitos!T!y!B!en!diferentes!estadios!de!maduraci\u00f3n!o!en!respuesta!a!pat\u00f3genos.!En!estos!estudios!se!usa!ampliamente!la!secuenciaci\u00f3n!masiva!como!herramienta!para!el!estudio!de!los!repertorios!(147U151).!!!!\n38\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Debido!a!la!gran!cantidad!de!informaci\u00f3n!que!estas!plataformas!pueden!aportar,!muchas! de! las! caracter\u00edsticas! estructurales! pueden! ser! estudiadas! desde! un!aspecto! m\u00e1s! fino,! y! as\u00ed! pueden! ayudar! a! comprender! mejor! la! din\u00e1mica! de! la!respuesta!inmune!en!diferentes!situaciones!o!enfermedades.!La!secuenciaci\u00f3n!del!repertorio!de! linfocitos!(RepUSeq)!en! combinaci\u00f3n! con! el! uso! de! herramientas!computacionales!provee! un! enfoque!de! Biolog\u00eda! de!Sistemas! en! el! campo! de! la!inmunolog\u00eda!(145)!(Figura!19).!!!\n!#Figura#19.# Esquema# de# secuenciaci\u00f3n#del# repertorio#(145).#Se!comienza!con!una!muestra!relevante,!en!donde!se!puede!o!no!aislar!linfocitos!T!y!B.!Se!a\u00edslan!las!regiones!variables!de!T!o!B!de!acuerdo!a!un!m\u00e9todo!espec\u00edfico!(RACE!5\u2019!PCR,!PCR!multiprimers,!etc.).!Posteriormente,!las!librer\u00edas!amplificadas!se!secuencian!en!una! plataforma! de! secuenciaci\u00f3n! masiva.! Con! las! secuencias! obtenidas! se! hace! la! caracterizaci\u00f3n! del!repertorio! de! acuerdo! con! la! pregunta! que! tenga! la! investigaci\u00f3n.!Imagen! tomada! de!Benichou,!2012.!Immunology!135:!183U91.!As\u00ed,!con!estas!nuevas!tecnolog\u00edas!de!secuenciaci\u00f3n!se!posibilita!el!estudio!a!mayor!detalle! de! aspectos! fundamentales! de! la! selecci\u00f3n! clonal! de! linfocitos! y! de! una!mejor! comprensi\u00f3n!de! la! manera! en! que!el! sistema! inmune! elimina! infecciones.!Este!conocimiento!podr\u00e1!ser!utilizado!en!contextos!terap\u00e9uticos,!particularmente!en!el!dise\u00f1o!de!vacunas.!En!t\u00e9rminos!de!eventos!de!selecci\u00f3n!clonal,!en!trabajos!recientes! se! ha! observado! que! poblaciones! de! clonas! est\u00e1n! dominadas! por! la!abundancia! de! clonas! espec\u00edficas,! lo! que! sugiere! que!la!selecci\u00f3n! no! es! un!mecanismo! azaroso.! Las! frecuencias! de! combinaci\u00f3n! VUJ! en!linfocitos!T,! por!ejemplo,!var\u00edan!fuertemente!entre!repertorios!de!linfocitos!v\u00edrgenes!y!de!memoria!en!un!individuo,!pero!se!observa!un!comportamiento!consistente!entre!individuos,!lo!que!sugiere!selecci\u00f3n!de!un!repertorio!sesgado.!Es!decir,!idiotipos!que!se!pueden!\n!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"39\"!#Instituto!Nacional!de!Salud!P\u00fablica!###encontrar! no! s\u00f3lo! en! un! individuo! si! no! en! varios,! idiotipos! p\u00fablicos.!Otros!aspectos! que! el! estudio! del! repertorio! est\u00e1! arrojando! es,! por! ejemplo,! que! en!t\u00e9rminos! del! CDR3,! se! ha! observado! que! una! mayor! frecuencia! de!ciertos! CDR3!correlaciona!negativamente!con!la!cantidad!de!inserciones!en!las!uniones!VUD!y!DUJ(151).!!Justificaci\u00f3n\"!El!Dengue!es!una!enfermedad!viral!emergente!de!importancia!en!la!salud!p\u00fablica!a!nivel!mundial!que!afecta!a!zonas!tropicales!y!subtropicales.!La!infecci\u00f3n!con!DENV!produce! en! humanos! una! enfermedad! febril! leve! y! autolimitada,!sin! embargo,!tambi\u00e9n!puede!producir!un!cuadro!hemorr\u00e1gico!grave!que!puede!llevar!al!choque!hipovol\u00e9mico!y!la!muerte.!!Por!el!momento!solo!se!ha!descrito!la!convergencia!de!CDR3!(152)!en!dengue!sin!embargo!no!se!ha!profundizado!en!una!asociaci\u00f3n!de!patrones!estructurales!y!de!diversidad!en!los!diferentes!cuadros!cl\u00ednicos!de!la!enfermedad!y!el!repertorio!de!anticuerpos.!Como!ya!fue!mencionado!previamente,!el!papel!de!los!anticuerpos!en!dengue!juega!un!rol!importante!tanto!en!la!resoluci\u00f3n!de!la!infecci\u00f3n!as\u00ed!como!en!la! patog\u00e9nesis! de!la! enfermedad.!Por! un! lado! se! han! descrito! anticuerpos!neutralizantes!que!reconocen!a!la!prote\u00edna!E!del!DENV,!ya!sea!que!reaccionen!de!manera!espec\u00edfica!(antiUEDI,!EDII!o!EDIII)!o!que!sean!capaces!de!reconocer!a!varios!serotipos! (antiUEDE).!Sin! embargo,! por! el! otro! lado! se! han! descrito! anticuerpos!capaces!de!potenciar!la!infecci\u00f3n!del!DENV!y!de!neutralizaci\u00f3n!pobre!(antiUprM).!!Por!lo!que!el!estudio!del!repertorio!de!anticuerpos!de!linfocitos!B!en!pacientes!con!esta!enfermedad!nos!dar\u00e1!una!perspectiva!de!las!bases!estructurales!que!podr\u00edan!distinguirse!en!las! diferentes! formas! cl\u00ednicas!y! su! asociaci\u00f3n! al! desarrollo! de! las!formas! graves.!Este!conocimiento!puede!ser! de! utilidad! en! el! desarrollo! de!estrategias!de!contenci\u00f3n!del!dengue!as\u00ed!como!el!mejoramiento!de!vacunas.!Pregunta\"de\"investigaci\u00f3n\"!\u00bfExisten! diferencias! estructurales! en! el! repertorio! de! anticuerpos! generado! en!pacientes!que!cursan!con!una!infecci\u00f3n!por!Dengue!con!signos!(DWS+)!y!sin!signos!de!alarma!(DWSU)?!Hip\u00f3tesis\"!Durante! la! infecci\u00f3n! aguda,!el! repertorio! de! linfocitos! B! es! modificado! por! la!selecci\u00f3n!clonal!y!se\u00f1ales!coUestimulatorias.!Durante!la!fase!aguda!(estado!febril)!de! la! enfermedad! se! ha! reportado! una! expansi\u00f3n! masiva! de! plasmablastos! que!miran! a! sangre! perif\u00e9rica,! la! mayor\u00eda! reportados! como! DENV! espec\u00edficos.! La!circulaci\u00f3n!en!sangre!perif\u00e9rica!de!los!plasmablastos!permite!tomar!una!muestra!del!repertorio!de!anticuerpos!contra!DENV.!Por!lo!que!planteamos!que!durante!la!fase! aguda! existir\u00e1n!diferencias! clonales! en! el! repertorio! de! linfocitos! B! que!!\n40\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###correlacionan!en!el!patr\u00f3n!de!diversidad!clonal!e!intraclonal!con!las!formas!cl\u00ednicas!de!la!enfermedad!(Figura!20).!!!Objetivos\"Objetivo\"principal\"Comparar! la! estructura!y! diversidad!clonal!del! repertorio! de! linfocitos! B! en!pacientes!con!Dengue!con!signos!(DWS+)!y!sin!signos!de!alarma!(DWSU).!!!!Objetivos\"espec\u00edficos\"1. Descripci\u00f3n!del!repertorio!de!anticuerpos!en!DWSU!y!DWS+.#2. Comparaci\u00f3n!del!repertorio!de!individuos!que!tuvieron!DWSU!y!DWS+.#3. Correlaci\u00f3n!de!los! patrones! estructurales! y! de! diversidad! clona!del!repertorio!de!anticuerpos!en!DWSU!y!DWS+.!##\n!Figura#20.#Hip\u00f3tesis.#Esquema!de!la!hip\u00f3tesis!planteada!en!el!proyecto.!Metodolog\u00eda\"y\"Resultados\"!Mi!proyecto!de!doctorado!consisti\u00f3!en!realizar!la!caracterizaci\u00f3n!molecularUdigital!detallada!del!repertorio!de!linfocitos!B!de!pacientes!con!DWSU!y!con!DWS+!(Figura!21).! Para!abordar! los! objetivos! espec\u00edficos!se! tomaron! muestra! de! sangre!perif\u00e9rica!de!pacientes!que!asistieron!a!los!servicios!estatales!de!salud!del!Estado!de!Veracruz,!en!donde!se!conto!con!la!colaboraci\u00f3n!del!Dr.!H\u00e9ctor!Vivanco!Cid!para!la! recolecci\u00f3n! de! las! muestras! y! el! llenado! de! las! cartas! de! consentimiento!informado.!!!Las!muestras!fueron!tomadas!durante!el!periodo!inmediato!a!la!infecci\u00f3n!(hasta!10!d\u00edas!de!inicio!del!cuadro!febril,!fase!aguda)!y!su!retorno!al!estado!basal!3!a!6!meses!despu\u00e9s,!durante!la!\u00e9poca!de!baja!transmisi\u00f3n!(Fase!de!postUconvalecencia).!!!De!las!muestras!de!sangre!perif\u00e9rica!se!colecto!el!suero!y!se!aisl\u00f3!el!RNA.!El!suero!se!utiliz\u00f3!para!caracterizar!la!capacidad!de!neutralizaci\u00f3n!y!reactividad!cruzada!de!los! 4! serotipos! del! DENV! por! medio! de! part\u00edculas! reporteras! virales! en!colaboraci\u00f3n! con! la! compa\u00f1\u00eda! Integral! Molecular! presidida! por! el! Dr.! Benjam\u00edn!Doranz! en! Filadelf\u00eda,! USA.! El! RNA! se! utiliz\u00f3!para! la! generaci\u00f3n! de!repertorios!\n!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"41\"!#Instituto!Nacional!de!Salud!P\u00fablica!###digitales!de! la! regi\u00f3n! variable! de! cadena! pesada! de! IgG!mediante!secuenciaci\u00f3n!masiva!por!medio!de!la!plataforma!454!FLX!titanium!de!ROCHE.!!!Alrededor! de! 2! millones! de! secuencias! fueron! utilizadas! para! caracterizar!el!repertorio! de! anticuerpos! contra! DENV.! Para! lo! cual! se! utiliz\u00f3! la! tuber\u00eda! de!programas!inform\u00e1ticos!ImmunediveRsity.!Esta!herramienta!fue!desarrollada!en!el!laboratorio.!ImmunediveRsity!permiti\u00f3!relacionar!las!secuencias!a!una!estructura!clonal! e! idiotipica! en! particular! as\u00ed! como! el! uso! de! segmentos! IGHV.!Adicionalmente! ImmunediveRsity! permiti\u00f3! realizar! la! caracterizaci\u00f3n! de! la!diversidad! en! las! diferentes! formas! cl\u00ednicas! de! la! enfermedad.!Por! otro! lado,! se!realiz\u00f3!un!an\u00e1lisis!de!las!mutaciones!en!la!regi\u00f3n!variable!de!IgG.!Con!estos!an\u00e1lisis!conseguimos!cumplir!los!objetivos!espec\u00edficos!planteados.!!\n!Figura#21.#Metodolog\u00eda.#Resumen!de!la!metodolog\u00eda!para!abordar!el!estudio!del!repertorio!de!linfocitos!B!en!pacientes!con!DWS+!y!DWSU.!!A! continuaci\u00f3n! se! presentan! dos! manuscritos! que! abordan! la! metodolog\u00eda! y! los!resultados!obtenidos!en!mi!Doctorado.!!!Reconstructing\"and\"mining\"the\"B\"cell\"repertoire\"with\"ImmunediveRsity.\"!En!el!primer!manuscrito!se!incluye!parte!del!an\u00e1lisis!bioinform\u00e1tico.!Se!hace!una!descripci\u00f3n! de!ImmunediveRsity,!una!herramienta!que! desarrollamos! en! el!laboratorio!y!una!aplicaci\u00f3n!para!el!an\u00e1lisis!del!RepUSeq.!!!ImmunediveRsity! es! una! tuber\u00eda! de! programas! inform\u00e1ticos,! escrita! casi! en! su!totalidad!en!lenguaje!R,!que!permite!al!usuario!analizar!la!gran!cantidad!de!datos!generada! por! la! RepUSeq.! ImmunediveRsity! asigna! cada! secuencia! a! un! grupo!clonal!y!a!un!idiot\u00edpo!en!particular,!dependiendo!de!la!estructura!de!su!CDR3!y!de!la!composici\u00f3n!de!la!regi\u00f3n!variable,!tipo!de!segmento!VUJ,!as\u00ed!como!el!grado!de!SHM.!!!!!!\n \n42#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!Reconstructing and mining the B cell repertoire with 1 ImmunediveRsity 2 Bernardo Cortina-Ceballos1&, Elizabeth Ernestina Godoy-Lozano1&, Hugo S\u00e1mano-S\u00e1nchez1&, 3 Andr\u00e9s Aguilar-Salgado1, Mart\u00edn Del Castillo Velasco-Herrera2, Carlos Vargas-Ch\u00e1vez2, Daniel 4 Vel\u00e1zquez-Ram\u00edrez1,3, Guillermo Romero1, Jos\u00e9 Moreno1,4, Juan T\u00e9llez-Sosa1 and Jes\u00fas Mart\u00ednez-5 Barnetche1* 6 1 Centro de Investigaci\u00f3n Sobre Enfermedades Infecciosas, Instituto Nacional de Salud P\u00fablica 7 (CISEI-INSP). Cuernavaca, Morelos. M\u00e9xico. 8 2 Winter Genomics, D.F., M\u00e9xico. 9 3 Present Address: Universidad del Istmo, Juchit\u00e1n de Zaragoza, Oaxaca, 70000, M\u00e9xico. 10 4 Present Address: Direcci\u00f3n de Investigaci\u00f3n, Hospital Ju\u00e1rez de M\u00e9xico, Mexico City, D.F., 11 M\u00e9xico 12  13 * To whom correspondence should be addressed. Phone: (+52) 777 329 3000 Ext.: 2364; Fax: 14 (+52) 777 3175485; Email: jmbarnet@insp.mx. 15 & These authors contributed equally. 16 Keywords: High-throughput sequencing Ig repertoire CDR3 data mining 17 Abbreviations:  18 HEL: Hen Egg Lysozyme 19 CDRH3: Heavy Chain Complementarity Determining Region 3 20 Rep-Seq: Repertoire sequencing 21 SHM: Somatic hypermutation 22 Running title: 23 Rep-Seq mining with ImmunediveRsity  24  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#43# !Instituto(Nacional(de(Salud(P\u00fablica(!!!ABSTRACT 25 The B cell antigen receptor repertoire is highly diverse and constantly modified by clonal selection. 26 High-throughput DNA sequencing (HTS) of the lymphocyte repertoire (Rep-Seq) represents a 27 promising technology to explore such diversity ex-vivo and assist in the identification of antigen-28 specific antibodies based on molecular signatures of clonal selection. Therefore, integrative tools 29 for repertoire reconstruction and analysis from antibody sequences are needed. We developed 30 ImmunediveRity, a stand-alone pipeline primarily based in R programming for the integral analysis 31 of B cell repertoire data generated by HTS. The pipeline integrates GNU software and in house 32 scripts to perform quality filtering, sequencing noise correction and repertoire reconstruction based 33 on V, D and J segment assignment, clonal origin and unique heavy chain identification. Post-34 analysis scripts generate a wealth of repertoire metrics that in conjunction with a rich graphical 35 output facilitates sample comparison and repertoire mining. Its performance was tested with raw 36 and curated human and mouse 454-Roche sequencing benchmarks providing good approximations 37 of repertoire structure. Furthermore, ImmunediveRsity was used to mine the B cell repertoire of 38 immunized mice with a model antigen, allowing the identification of previously validated antigen-39 specific antibodies, and revealing different and unexpected clonal diversity patterns in the post-40 immunization IgM and IgG compartments. Although ImmunediveRsity is similar to other recently 41 developed tools, it offers significant advantages that facilitate repertoire analysis and repertoire 42 mining. ImmunediveRsity is open source and free for academic purposes and it runs on 64 bit 43 GNU/Linux and MacOS. Available at: https://bitbucket.org/ImmunediveRsity/immunediversity/ 44   45  \n44#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!INTRODUCTION 46  Adaptive immunity relies on a highly diverse lymphocyte antigen receptor repertoire, which 47 is dynamically shaped by endogenous and exogenous antigens by means of clonal selection. T and 48 B lymphocyte receptor repertoires are generated by somatic recombination of germline V, D and J 49 segments in an antigen-independent manner 1. Each lymphocyte bears a unique antigen receptor 50 that can be clonally selected. In the case of B lymphocytes, antigen receptors can be further 51 diversified in an antigen-dependent manner by somatic hypermutation of clonally expanded 52 lymphocytes 2, 3. Thus, the basic unit of the B cell repertoire is the idiotype, which refers to a unique 53 antigen receptor structure (H and L chain pair) with unique epitope specificity. One or more 54 idiotypes derived from the same VDJ recombination event and H+L pairing represents a clonotype. 55 The degree of idiotypic diversification within a clonotype is indicative of antigen-mediated selection. 56  High-throughput DNA sequencing of lymphocyte antigen receptor repertoire (Rep-Seq) 4 57 provides a technological solution to measure repertoire diversity, both to track the clonal responses 58 to antigenic challenge and to infer antigen receptor specificity (repertoire mining), that in conjunction 59 with other high-throughput approaches could impact our view of immunity to infection, vaccine 60 efficacy, lympho-hematological malignancies, among others 5. Consequently, there is an increasing 61 demand for automated data processing tools from raw data to a full virtual repertoire reconstruction 62 and its comparative analysis within different experimental conditions. There are a number of 63 excellent tools such as iHMMune-align6, JoinSolver 7 and IgBLAST 8 for primary structural analysis 64 of Ig sequences, as well as tools that provide detailed structural features of lymphocyte receptor 65 sequences in massive datasets such as High-V_Quest9 and VDJfasta 10. However none of them 66 integrate raw data processing, reconstruction of the ontogenic relations in terms of clonal origin and 67 diversification by somatic hypermutation to a full qualitative and quantitative representation of the 68 sampled repertoire. 69  Accurate characterization of the B cell repertoire faces the challenge of correctly identifying 70 sequences belonging to a common clonal origin, as well as the identification of the structural 71 relationships of idiotypes within each clonal linage, accounting for sequencing errors. Clonal 72  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#45# !Instituto(Nacional(de(Salud(P\u00fablica(!!!structure metrics, together with mutation analysis indicative of selection, represent the basis for a 73 quantitative statistical description of repertoire diversity and could provide the means for 74 comparative analysis between different immunological conditions, as well as for the identification of 75 putative antigen-specific antibodies by repertoire mining 11, 12. 76 RESULTS 77 ImmunediveRsity is a flexible standalone pipeline based primarily in R programming language 13, 78 originally designed for 454-Roche unpaired IgH sequence data derived from libraries prepared from 79 total RNA by 5\u2019 RACE-PCR 14, thus H and L chain paring information is lost during the process. 80 Different scripts and functions (R, Python and Perl) bundled with GNU software provide a full 81 automated analysis per sequencing library. It uses Acacia 15 for noise correction; IgBLAST 8 for V 82 and J segment assignment; HMMER3 (http://hmmer.janelia.org/) for complementarity-determining 83 region 3 (CDRH3) Junction identification and USEARCH 16 for clustering sequences into Heavy 84 Chain Clonotypes, hereafter referred to as clonotypes, and their corresponding clonally related 85 Heavy Chain lineages, referred hereafter as lineages (Figure S1). The overall algorithm used by 86 ImmunediveRsity is depicted in Figure 1 and described in detail in Figure S2. For Illumina MiSeq 87 users, a pre-processing algorithm for paired end reads assembly using PANDAseq 17 (Figure S3) is 88 provided (imm-Illumina). 89 Output: ImmunediveRsity generates four types of output: 1) Fasta files: containing the CDRH3 90 sequences for each read and clonotype, as well as the sequence for each lineage consensus. 2) 91 Text files, describing V, D and J assignments for each read and the relation of each read to a given 92 clonotype and lineage. 3) Metrics files: metrics of repertoire structure based on frequency, degree 93 of diversification and somatic hypermutation that can aid the exploration of the effects of antigen-94 driven selection or repertoire alterations in a given disease. Such metrics include normalized clonal 95 and lineages frequencies, global entropy measurements such as Shannon-Weaver index 18 and 96 Gini coefficient 19,20 (Figure 1 and Figure S2). Such metrics can be calculated according to IGHV 97 usage, potentially revealing hidden trends in antigen-driven clonal diversification that otherwise 98 would not be detected only by a relative frequency analysis. Also, entropy is calculated to reveal the 99  \n46#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!degree of idiotypic diversification within each clonotype, irrespectively of their IGHV segment usage 100 (Figure S2). Finally, the number of synonymous (Ks) and non-synonymous mutations (Ka) per 101 lineage is calculated to indicate potential lineages under antigen-driven selection. 4) Repertoire 102 visualization (Figures S4-12): A series of predefined vectorized graphics providing frequency of V, 103 D and J segment usage (Figures S4-6), CDRH3 digital-spectratyping (Figure S7), amino-acid 104 composition at given CDRH3 length (Figure S8), a heat-map of hierarchical clustering of V family 105 usage (Figure S5), rarefaction curves describing clonotype and lineage richness at a standardized 106 sampling effort 21, 22 (Figures S9 and S10) and read quality before and after filtering (Figure S11). In 107 an attempt to capture the B cell repertoire complexity, an integrative graph representing a network 108 of clonotype with their respective lineages is generated in the context of a previously described 109 HEL-immunizantion experiment in mice 12 using iGraph 23 (Figure 2A). These graphs can be 110 customized to plot parameters other than hypermutation, such as diversity indices (see Methods 111 and Figure S12) or CDRH3 physicochemical properties. Finally, ImmunediveRsity provides a 112 collection of scripts (Post-processing multi-library analysis toolbox) aimed to aid with comparisons 113 within multiple library experiments (Figures 1, 4, Supplementary Figure S2). A tool for sampling 114 equal number of reads or clonotypes is particularly useful for such task. A tool for searching 115 convergent CDRH3 in different individuals22, 24, 25 is also provided (find_CDR3). 116 Performance of ImmunediveRsity: To test ImmunediveRsity we used three benchmark datasets: 117 1) A mouse benchmark composed by 5,359 reads generated by sequencing a PCR amplicon library 118 generated from a cloned 5\u2019 RACE-PCR product derived from the spleen of a MD4 transgenic 119 mouse (see Supplementary material), which bears a monoclonal (IGHV6-3*01-IGHD4-1*01-120 IGHJ2*01) B cell compartment 26. This benchmark was also used to assess ImmunediveRsity\u2019s 121 clonotype and lineage assignment performance, such that the identification of a single clonotype 122 and a single lineage was expected. The MD4 amplicon contains one G homopentamer and one A 123 homotetramer within the CDRH3 region, and 3 additional homotetramers in FWR2, 3 and 4, 124 respectively, providing a means to assess homopolymeric sequencing errors and Acacia correction 125 performance. 2) A human benchmark composed by 1,044 sequences of a single clonotype (IGHV1-126 3*01-IGHD3-10*01-IGHJ3*02) manually identified from a human library (see Supplementary 127  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#47# !Instituto(Nacional(de(Salud(P\u00fablica(!!!material). To construct a reference dataset, sequences were aligned, indels were manually 128 corrected and 10 lineages were identified according to their mutation patterns and based on the 129 error pattern observed in the MD4 sequence data. As for the mouse benchmark, the manually 130 curated human dataset was used to evaluate ImmunediveRsity\u2019s lineage assignment accuracy 131 using the corresponding human raw sequences as input. 3) The previously described Stanford 22 132 dataset 27, 28 was used to assess ImmunediveRsity\u2019s clonotype assignment capacity. It consists of 133 13,141 human IgH sequences referred to as being derived from independent V(D)J recombination 134 events (non- identical V, D, and J segments and non-identical V-D and D-J junction sequences). 135 Although, absolute certainty regarding the independence of a V(D)J recombination event cannot be 136 ascertained, the Stanford 22 dataset was used as a proxy of non-clonaly related sequences. 137  Using the MD4 mouse dataset as a proxy for sequence error calibrator, a major clonotype 138 containing 99.5% of the reads was obtained. A second clonotype with 10 reads (0.18%) was found. 139 Closer examination of the sequences in this clonotype determined that a G insertion in the G 140 homopentamer located in the CDRH3 anchor created this artifact. The remaining 14 reads (0.26%) 141 generated 8 clonotypes with low frequency and singletons (Table 1). At the lineage level, 142 ImmunediveRsity identified 21 lineages, with a single lineage containing 99.3% reads, and the 143 remaining were composed of \u22645 reads. Thus, based on the errors identified in the MD4 mouse 144 dataset, a minimum of 6 reads was defined as threshold to consider a true lineage (well supported). 145 This corresponds roughly to 1 read per 1000 reads of coverage. The MD4 or other amplicons 146 should be used as guides for calibration in terms of homopolymer content, but it does not represent 147 all the possible sources of sequencing errors. Therefore, users are encouraged to optimize their 148 own amplicons and means to calibrate sequencing runs. 149  Using this threshold, results for each dataset are shown in Table 1. For the human dataset 150 of 1,044 human immunoglobulin raw sequences from a single clonal origin with 10 lineages, 151 ImmunediveRsity identified correctly a single clonotype. However, it identified 469 lineages as well, 152 most of them singletons. Using the \u22656 read threshold, the number of lineages identified was 7. 153 Therefore, if the experimental aim is to describe the clonal structure of the repertoire, we 154  \n48#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!recommend not to use coverage filters. However, if the goal is to identify and analyze structural 155 properties of an antibody subset, one should choose a minimal coverage to call a true lineage. For 156 the Stanford22 dataset, after removal of one read with a duplicated identifier and 11 with duplicated 157 sequences, ImmunediveRsity identified 11,779 different clonotypes and 12,421 lineages (Table 1), 158 indicating that either the Stanford 22 dataset contains clonally related sequences or that the 159 CDRH3 clustering identity threshold is too low, allowing to merge non-clonally related sequences 160 into clonotypes. 161  As IgBLAST is time consuming and must be executed twice, ImmunediveRsity allows 162 parallelization according to the number of cores, which can also be customized by the user. 163 Processing of a raw dataset of 48,350 reads described in figure 3 (HEL-immunized mice) takes 136 164 minutes or 92 minutes in 1/8 or 7/8 Intel core i7 CPU\u2019s of a 3.8 GHz and 8 Gb RAM PC computer; 165 and 173 min in 4/4 Intel core i5 CPU\u2019s of a 2.3 GHz and 4 Gb RAM MacBook computer. 166  To test ImmunediveRsity performance with data derived from MiSeq Illumina sequencing, 167 we used the human dataset described by Schanz et al.29. The whole dataset contained 2.88 x 106 168 paired reads, and was processed with the imm-Illumina script, which uses PANDAseq 17 for paired 169 read assembly. Random subsampling of 1 x 104 and 1 x 105 assembled pairs were used as input 170 for ImmunediveRsity taking 18 and 280 minutes, respectively, in a 7/8 Intel core i7 CPU\u2019s of a 3.8 171 GHz 8 Gb RAM PC computer. 172 Critical parameters for optimization according to user needs and data type: As described in 173 the previous sections, it is highly recommended that users include as reference a monoclonal 174 amplicon to optimize ImmunediveRsity. Critical parameters that may require tweaking by the user 175 are CDRH3 identity (specified by the id parameter. Default =0.97), low frequency reads cutoff for 176 clonotypes (specified by the CGfreq_cut parameter. Default = 6) and lineages (specified by the 177 Ifreq_cut parameter. Default = 6). These filters are applied by default and the output is directed to 178 different directories (WellSupportedCGs and WellSupportedIs, respectively), however unfiltered 179 results are still available in the library output directory. 180  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#49# !Instituto(Nacional(de(Salud(P\u00fablica(!!!Differences in the B cell repertoire after an immune challenge: Immunization with protein 181 antigens induces the germinal center reaction characterized for an extensive antigen-specific B cell 182 proliferative response, somatic hypermutation and class switching 30. In mice, the germinal center 183 reaction induced by immunization peaks after 10-12 days 31. As a proof of principle of 184 ImmunediveRsity performance to digitally reconstruct the antibody repertoire with experimental 185 data, we used our previously described IGHV sequence data derived from libraries (IgM and IgG 186 class) from two BALB/c mice spleens at 3, 7 and 15 days post-immunization with Hen Egg 187 Lysozyme (HEL) and one mouse inoculated with PBS in each time point as controls 12. The 188 sequencing metrics of the 18 sequenced libraries are shown on Supplementary Table S1. As 189 expected, the proportion of somatic hypermutation was higher in the IgG than in the IgM 190 compartment (Figure 2B-C). 191  Fifteen days after immunization, two HEL-specific IGHV B cell clones, functionally validated 192 in a previous work 12, were identified as clones with high relative frequency, but lower Gini 193 coefficients as compared to the corresponding high relative frequency clones from control mice, 194 (Figure 3), suggesting that within the higher frequency range (y axis), antigen-specific clones are 195 the ones having lower Gini coefficient values. Lower Gini coefficients make biological sense based 196 on the assumption that affinity maturation would allow the selection of different lineages leading to a 197 more even distribution than in the non-selected clonotypes. Further research is needed to clarify if 198 Gini coefficient per clonotype is a useful measure to identify clonotypes undergoing antigen-199 mediated selection. 200  The germinal center reaction is initiated by a small number (1-8) of antigen-selected IgM 201 expressing-B cells31, 32. Due to the extensive oligoclonal proliferation of founder cells and their 202 concomitant differentiation to IgG switched high affinity antibody secreting cells, a reduction in 203 clonal diversity would be expected after immunization. We used ImmunediveRsity to sample a fixed 204 number of reads per library (5,700) and to track clonal and idiotypic diversity induced by HEL 205 immunization 3, 7 and 15 days post-immunization in the IgM and IgG compartment. Sampling was 206 necessary to compare equal numbers of reads. The number of reads was based on the library with 207  \n50#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!the lowest number of reads (Supplementary Table1. Library m04). No changes in clonal and 208 idiotypic entropy (Shannon-Weaver index), or in clonal and idiotypic inequality (Gini coefficient) 209 were detected at day 3 and 15 post-immunization (Figure 4). However, a reduction in clonal and 210 idiotypic diversity was observed in the IgM compartment at day 7 post-immunization. In contrast, 211 clonal and idiotypic diversity was markedly increased in the IgG compartment (Figure 4a). 212 Consistently but in opposite direction, clonal and idiotypic inequality in the IgM compartment 213 increased at day 7 post-immunization, whereas in the IgG compartment decreased (Figure 4b). The 214 entropy measures suggest an increase in the circulation of non-clonally related IgG+ B cells at day 215 7. 216 DISCUSSION AND CONCLUSIONS 217 The lymphocyte antigen receptor repertoire is a fascinating biological system that represents the 218 basis for acquired immunity. Hence, its analysis is critical to understand responses to vaccination 219 and autoimmune diseases. Antibody repertoire diversity is generated by antigen-independent 220 somatic rearrangements of germline V(D)J segments and antigen-dependent somatic 221 hypermutation 33, 34. Potentially, the repertoire diversity can reach astronomical proportions. 222 However, it is clear that structural and functional constraints, as well as clonal selection operating at 223 different developmental stages influence its ultimate size and shape 35. Owing to the capacity to 224 screen a larger sample of the lymphocyte repertoire, High-throughput DNA sequencing is offering 225 the possibility to approach its complexity, and how it is affected during normal and pathological 226 immune response 5. Additionally, the information generated by HTS on antibody repertoires can be 227 exploited to address higher order statistical properties of biological structures in general 36. 228  Aiming toward a faithful digital reconstruction of clonal and idiotypic diversification as a 229 result of somatic hypermutation, repertoire sequencing imposes particular challenges regarding 230 data analysis. 1) All HTS platforms possess certain degree of quality to throughput trade off that 231 can potentially overestimate true diversity 37. To minimize the impact of sequencing errors, 232 ImmunediveRsity attempts to correct or discard noisy reads. However, this process is not 233 exhaustive as exemplified by the MD4 experiment (Table 1). Thus it is important that users tweak 234  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#51# !Instituto(Nacional(de(Salud(P\u00fablica(!!!clustering parameters in order to obtain a reliable repertoire reconstruction. 2) Clonal relations for 235 large datasets are difficult to assign due to the nature of V(D)J recombination process, which can 236 be confounded by CDRH3 somatic hypermutation. 3) Incomplete knowledge of germline structure 237 and population diversity at immunoglobulin loci, including allelic copy number variation 38, 39. 4) The 238 influence of sample size sequencing depth and BCR transcript expression variation in entropy 239 measurements, particularly in the case of cDNA library sequencing. 240  The development of ImmunediveRsity was motivated by the need of a standalone tool for 241 digital reconstruction of the B cell repertoire and measurement of clonal diversity parameters 242 describing functional aspects of clonal selection and to facilitate repertoire mining. There are open 243 source tools which allow B cell repertoire analysis from HTS datasets, including clonotype 244 reconstruction and somatic hypermutation analysis such as IgAT 40, AbMining ToolBox 41 and 245 Michaeli\u2019s algorithm 42 (Supplementary Table S2). IgAT is a basic and friendly tool that does not 246 provide clonal assignments and runs only in Windows. AbMining ToolBox is a fast powerful tool 247 optimized for selection of phage displayed antibodies avoiding panning steps and increasing the 248 yield of relevant recombinant antibodies. In many ways, the most similar tool to ImmunediveRsity is 249 the Michaeli\u2019s algorithm, which also integrates a sequencing error correction step and allows 250 lineage identification. However Michaeli\u2019s algorithm is designed to run in 32 bit computers, limiting 251 its use. Additional contributions of ImmunediveRsity are the calculation of different entropy 252 measurements such as the Gini and Shannon-Weaver indexes per clonotype and lineage and their 253 corresponding partitions according to IGHV gene usage. Its utilization in the analysis of the B cell 254 repertoire in response to immunization suggests a potential application of the Gini coefficient in 255 repertoire mining and in silico identification of antigen-specific clones (Figure 3), but further 256 experimentation is required. Moreover, entropy measurements provided the observation that clonal 257 and somatic diversity in the IgG compartment increases at day 7 post-immunization instead of 258 decreasing (Figure 4), supporting the notion that germinal centers are open structures that can be 259 colonized by unrelated B cells 43-46. The inverse relationship between Shannon entropy and Gini 260 coefficient indicate that both measures are redundant. However, we have explored such correlation 261 at the clonotype level in human peripheral blood of patients infected with dengue virus and found 262  \n52#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!very weak correlation (Godoy-Lozano, unpublished). The significance of the correlation between 263 both measures warrants further research. 264  An additional feature that contributes to an integrative analysis of the B cell repertoire is 265 ImmunediveRsity\u2019s rich output in terms of a diverse and informative graphical output and a detailed 266 description per clonotype sequence and structure. In conclusion, ImmunediveRsity is a highly 267 modular and customizable tool for B cell repertoire analysis that can accelerate data integration and 268 discovery of biologically relevant processes, as well as the identification of antibodies with potential 269 biotechnological applications. 270 METHODS 271 Input: ImmunediveRsity accepts *.fastq files in reverse complement, thus in principle is suitable for 272 most HTS platforms. Currently, it can only process VH libraries from human and mouse. It should 273 be noted that somatic hypermutation can occur along the whole variable region, which is 400 bp on 274 average. Platforms that generate longer reads lengths can offer better representation of somatic 275 diversity (Figure 1). 276 Pre-processing: As an initial step, IgBLAST 8 is performed for each individual read to map the 277 V(D)J region and to trim the 5\u2019 and 3\u2019 flanks. This step is particularly important for the analysis of 278 libraries generated by 5\u2019 RACE-PCR to exclude germ-line transcripts (sterile transcripts) that may 279 be present in libraries derived from total RNA i.e. when using 5\u2019 RACE-PCR (unpublished 280 observations), and to trim the 5\u2019 UTR and signal peptide sequences and possible IGHC nucleotides, 281 which are irrelevant for antigen binding and thus for clonal selection. Moreover, the distal flank to 282 the sequencing primer usually will have the lowest quality. As 454-Roche and Ion Torrent 283 sequencing platforms are prone to indels in homopolymeric regions 47, ImmunediveRsity can call 284 Acacia 48, an error-correction tool. Sequences below a mean read quality of Q28 or below 200 bp 285 long are discarded. These parameters can be easily customized (Figure 1). 286 CDRH3 Junction identification: The CDRH3 Junction region is delimited by the 3\u2019 end of the V 287 gene and the 5\u2019 end of the J gene, including the D gene and the N and P-nucleotides 49. The 288  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#53# !Instituto(Nacional(de(Salud(P\u00fablica(!!!CDRH3 region is the most variable and defines the clonal origin. The CDRH3 region has conserved 289 regions (anchors) in both flanks, hence ImmunediveRsity uses HMMER3 with a HMMER DNA 290 profile trained to match either human or mouse CDRH3-coding sequence for each read. HMMER3 291 retrieves the CDRH3 by means of two anchors, which are trimmed on the basis of the conserved 292 motifs Tyr-Phe/Tyr/His-Cys or Phe-Phe-Cys in the 3\u2019 end of the IGHV segment (IMGT positions 293 102-104) and the motif Trp-Gly in the IGHJ segment. Additionally, it considers the potential 294 presence of indels due to homopolymeric errors in the sequence coding for Tyr-Phe-Cys. The 295 presence of D segments in tandem, previously described 50, 51, are also considered since our 296 second step returns the largest CDRH3 with the different possible motifs. Reads without an 297 identifiable CDRH3 are discarded (Figure 1). 298 V(D)J assignment: A critical step toward clonal origin identification is the determination of V, D and 299 J segment usage. Different tools are publicly available to achieve this task. The main challenge 300 relies on correctly identifying the D segment, because of its usually short length (from 11 to 37 nt) 52 301 and mutations content by exonuclease activity during the recombination process. To assign the V, 302 D and J segments, ImmunediveRsity uses IgBLAST 8 by aligning each read to the current set of 303 functional germ line sequences from ImMunoGeneTics database (50 V genes and 239 alleles, 23 D 304 genes and 30 alleles, and 6 J genes and 13 alleles for human) 53 (Figure 1). However, this 305 database can be upgraded as new genes and alleles are described39. 306 Heavy Chain Clonotype (clonotype) identification: Although biologically a B cell clonotype 307 corresponds to a group of B cells sharing a unique antigen receptor originated by a unique VDJ and 308 VJ recombinatorial event leading to the respective H and L chain pair, ImmunediveRsity interprets 309 the clonotypes as single chained (in this case IGHV) objects. The clonotypes are defined by 310 CDRH3 clustering with USEARCH 54. USEARCH is fast, exhaustive and offers simplicity in setting 311 the desired parameters. As the human D gene sequences can be as small as 11 bp 52, as in the 312 case of IGHD7-27, accurate D gene assignation in mature B-lymphocytes is difficult to achieve 28. 313 For that reason, we define that two reads belong to the same clonotype if the following is true: i. 314 The V and J gene assignment is the same in both sequences. ii. Junction regions of the two 315  \n54#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!sequences have a nucleotide identity \u2265 97%. This parameter (id) can be adjusted according to the 316 user needs and calibration results. iii. The trimmed length of the shorter Junction sequence \u2265 97% 317 of the length of the larger Junction sequence (Figure 1). CDRH3 length identity and length 318 parameters used for clustering were determined by estimating the accuracy obtained by 319 sequencing an IgH amplicon derived form an anti-HEL transgenic mouse (MD4) which is virtually 320 monoclonal 26 and a manually-curated human immunoglobulin set (IGHV1-3) (see Results. 321 Performance of ImmunediveRsity. Table 1), but can be easily customized. 322 Unique Heavy Chain (lineage) identification. As for clonotypes, ImmunediveRsity obviates L 323 chain pairing and interprets a lineage as an object derived from a unique VDJ recombinatorial event 324 and a unique SHM pattern. Lineages are identified on a second iterative clustering step with 325 USEARCH, using the complete VDJ region of each read within each clonotype 54. Reads 326 corresponding to the same clonotype may have different lengths due to the sequence quality decay 327 during the sequencing process. Shorter reads generated by early sequencing termination or 328 shortened by quality filters would be still retained in the analysis. Two reads belong to the same 329 lineage if: i. Both reads have the same clonotype assignment. ii. The V(D)J regions of the two 330 sequences have a nucleotide identity \u2265 99.5%. iii. The length of the shorter V(D)J region is \u2265 60% of 331 the larger read length (Figure 1). These criteria are based on the mouse MD4 and the human 332 IGHV1-3 sets (see 3.4 datasets, Table 1). 333 Entropy and Gini coefficient measurement: The Shannon-Weiner index was calculated by the 334 following formula: !!=\u2212!\"!!\"(!\")!! , where p is the proportion of i elements (clonotypes or 335 lineages). The Gini coefficient was calculated according to the following formula: 336 !=!!![(!!!)!!\"]!!!!\"!!\u2212(!+!) where n is the number of elements (lineages per clonotype), xi is the 337 sorted proportion of each lineage within clonotype. 338 Post-processing multi-library analysis toolbox: ImmunediveRsity provides a collection of scripts 339 aimed to aid comparisons within multiple library experiments (Figures 1, 4, Supplementary Figure 340 S1). A tool for sampling equal number of reads or clonotypes is particularly useful for such task. A 341  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#55# !Instituto(Nacional(de(Salud(P\u00fablica(!!!search tool for convergent CDRH3 in different individuals22, 24, 25 is also provided. 342 ACKNOWLEDGEMENTS 343 We would like to thank Rosa Elena G\u00f3mez Barreto for support on 454-Roche sequencing and 344 Humberto Valdovinos Torres for support with animal immunization and library preparation. The 345 input of Robert Edgar in improving this manuscript is greatly acknowledged. 346 Funding: This work was funded by FOSISS-CONACyT grant # 142120 to JMB and SEP-CONACyT 347 grant # 133765 to JTS. 348 REFERENCES 349 1. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302:575-81. 350 2. Cohn M, Mitchison NA, Paul WE, Silverstein AM, Talmage DW, Weigert M. Reflections on 351 the clonal-selection theory. Nature reviews Immunology 2007; 7:823-30. 352 3. Jackson KJ, Kidd MJ, Wang Y, Collins AM. The shape of the lymphocyte receptor 353 repertoire: lessons from the B cell receptor. Frontiers in immunology 2013; 4:263. 354 4. Benichou J, Ben-Hamo R, Louzoun Y, Efroni S. Rep-Seq: uncovering the immunological 355 repertoire through next-generation sequencing. Immunology 2012; 135:183-91. 356 5. Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR. The promise 357 and challenge of high-throughput sequencing of the antibody repertoire. Nature biotechnology 358 2014; 32:158-68. 359 6. Gaeta BA, Malming HR, Jackson KJ, Bain ME, Wilson P, Collins AM. iHMMune-align: 360 hidden Markov model-based alignment and identification of germline genes in rearranged 361 immunoglobulin gene sequences. Bioinformatics 2007; 23:1580-7. 362 7. Souto-Carneiro MM, Longo NS, Russ DE, Sun HW, Lipsky PE. Characterization of the 363 human Ig heavy chain antigen binding complementarity determining region 3 using a newly 364 developed software algorithm, JOINSOLVER. J Immunol 2004; 172:6790-802. 365 8. Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain 366 sequence analysis tool. Nucleic acids research 2013; 41:W34-40. 367  \n56#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!9. Alamyar E, Duroux P, Lefranc MP, Giudicelli V. IMGT((R)) tools for the nucleotide analysis 368 of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG 369 mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. Methods Mol Biol 2012; 882:569-370 604. 371 10. Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, Ni I, Mei L, Sundar PD, Day 372 GM, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into 373 the human immunoglobulin repertoire. Proceedings of the National Academy of Sciences of the 374 United States of America 2009; 106:20216-21. 375 11. Saggy I, Wine Y, Shefet-Carasso L, Nahary L, Georgiou G, Benhar I. Antibody isolation 376 from immunized animals: comparison of phage display and antibody discovery via V gene 377 repertoire mining. Protein engineering, design & selection : PEDS 2012; 25:539-49. 378 12. Valdes-Aleman J, Tellez-Sosa J, Ovilla-Munoz M, Godoy-Lozano E, Velazquez-Ramirez D, 379 Valdovinos-Torres H, Gomez-Barreto RE, Martinez-Barnetche J. Hybridization-based antibody 380 cDNA recovery for the production of recombinant antibodies identified by repertoire sequencing. 381 MAbs 2014; 6:493-501. 382 13. Zhao JH, Tan Q. Integrated analysis of genetic data with R. Hum Genomics 2006; 2:258-383 65. 384 14. Matz M, Shagin D, Bogdanova E, Britanova O, Lukyanov S, Diatchenko L, Chenchik A. 385 Amplification of cDNA ends based on template-switching effect and step-out PCR. Nucleic acids 386 research 1999; 27:1558-60. 387 15. Bragg L, Stone G, Imelfort M, Hugenholtz P, Tyson GW. Fast, accurate error-correction of 388 amplicon pyrosequences using Acacia. Nature methods 2012; 9:425-6. 389 16. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 390 2010; 26:2460-1. 391 17. Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD. PANDAseq: paired-end 392 assembler for illumina sequences. BMC bioinformatics 2012; 13:31. 393 18. Shannon CE. The mathematical theory of communication. 1963. MD computing : computers 394 in medical practice 1997; 14:306-17. 395  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#57# !Instituto(Nacional(de(Salud(P\u00fablica(!!!19. Ceriani L, Verme P. The origins of the Gini index: extracts from Variabilit\u00e0 e Mutabilit\u00e0 396 (1912) by Corrado Gini. The Journal of Economic Inequality 2012; 10:421-43. 397 20. Bashford-Rogers RJ, Palser AL, Huntly BJ, Rance R, Vassiliou GS, Follows GA, Kellam P. 398 Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-399 cell populations. Genome Res 2013; 23:1874-84. 400 21. Hughes JB, Hellmann JJ. The application of rarefaction techniques to molecular inventories 401 of microbial diversity. Methods in enzymology 2005; 397:292-308. 402 22. Weinstein JA, Jiang N, White RA, 3rd, Fisher DS, Quake SR. High-throughput sequencing 403 of the zebrafish antibody repertoire. Science 2009; 324:807-10. 404 23. Csardi G, Nepusz T. The igraph software package for complex network research. 405 InterJournal, Complex Systems 2006; 1695. 406 24. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe 407 JE, Jr. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal 408 sequence divergence and interclonal convergence. J Immunol 2011; 187:3704-11. 409 25. Jackson KJ, Liu Y, Roskin KM, Glanville J, Hoh RA, Seo K, Marshall EL, Gurley TC, Moody 410 MA, Haynes BF, et al. Human responses to influenza vaccination show seroconversion signatures 411 and convergent antibody rearrangements. Cell host & microbe 2014; 16:105-14. 412 26. Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, Pritchard-Briscoe 413 H, Wotherspoon JS, Loblay RH, Raphael K, et al. Altered immunoglobulin expression and 414 functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988; 334:676-82. 415 27. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, Jones CD, Simen BB, 416 Hanczaruk B, Nguyen KD, et al. Measurement and Clinical Monitoring of Human Lymphocyte 417 Clonality by Massively Parallel V-D-J Pyrosequencing. Science translational medicine 2009; 418 1:12ra23-12ra23. 419 28. Jackson KJ, Boyd S, Gaeta BA, Collins AM. Benchmarking the performance of human 420 antibody gene alignment utilities using a 454 sequence dataset. Bioinformatics 2010; 26:3129-30. 421 29. Schanz M, Liechti T, Zagordi O, Miho E, Reddy ST, Gunthard HF, Trkola A, Huber M. High-422 throughput sequencing of human immunoglobulin variable regions with subtype identification. PloS 423  \n58#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!one 2014; 9:e111726. 424 30. Victora GD, Nussenzweig MC. Germinal centers. Annual review of immunology 2012; 425 30:429-57. 426 31. Kelsoe G. Life and death in germinal centers (redux). Immunity 1996; 4:107-11. 427 32. Hermans MH, Wubbena A, Kroese FG, Hunt SV, Cowan R, Opstelten D. The extent of 428 clonal structure in different lymphoid organs. The Journal of experimental medicine 1992; 175:1255-429 69. 430 33. Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. 431 Nature reviews Immunology 2011; 11:251-63. 432 34. Maul RW, Gearhart PJ. AID and somatic hypermutation. Advances in immunology 2010; 433 105:159-91. 434 35. Schroeder HW, Jr., Zemlin M, Khass M, Nguyen HH, Schelonka RL. Genetic control of DH 435 reading frame and its effect on B-cell development and antigen-specifc antibody production. Critical 436 reviews in immunology 2010; 30:327-44. 437 36. Mora T, Walczak AM, Bialek W, Callan CG, Jr. Maximum entropy models for antibody 438 diversity. Proceedings of the National Academy of Sciences of the United States of America 2010; 439 107:5405-10. 440 37. Kircher M, Kelso J. High-throughput DNA sequencing--concepts and limitations. 441 BioEssays : news and reviews in molecular, cellular and developmental biology 2010; 32:524-36. 442 38. Kidd MJ, Chen Z, Wang Y, Jackson KJ, Zhang L, Boyd SD, Fire AZ, Tanaka MM, Gaeta 443 BA, Collins AM. The inference of phased haplotypes for the immunoglobulin H chain V region gene 444 loci by analysis of VDJ gene rearrangements. J Immunol 2012; 188:1333-40. 445 39. Watson CT, Steinberg KM, Huddleston J, Warren RL, Malig M, Schein J, Willsey AJ, Joy 446 JB, Scott JK, Graves TA, et al. Complete haplotype sequence of the human immunoglobulin heavy-447 chain variable, diversity, and joining genes and characterization of allelic and copy-number 448 variation. American journal of human genetics 2013; 92:530-46. 449 40. Rogosch T, Kerzel S, Hoi KH, Zhang Z, Maier RF, Ippolito GC, Zemlin M. Immunoglobulin 450 Analysis Tool: A Novel Tool for the Analysis of Human and Mouse Heavy and Light Chain 451  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#59# !Instituto(Nacional(de(Salud(P\u00fablica(!!!Transcripts. Frontiers in immunology 2012; 3:176. 452 41. D'Angelo S, Glanville J, Ferrara F, Naranjo L, Gleasner CD, Shen X, Bradbury AR, Kiss C. 453 The antibody mining toolbox: an open source tool for the rapid analysis of antibody repertoires. 454 MAbs 2014; 6:160-72. 455 42. Michaeli M, Barak M, Hazanov L, Noga H, Mehr R. Automated analysis of immunoglobulin 456 genes from high-throughput sequencing: life without a template. Journal of clinical bioinformatics 457 2013; 3:15. 458 43. Schwickert TA, Lindquist RL, Shakhar G, Livshits G, Skokos D, Kosco-Vilbois MH, Dustin 459 ML, Nussenzweig MC. In vivo imaging of germinal centres reveals a dynamic open structure. 460 Nature 2007; 446:83-7. 461 44. Bende RJ, van Maldegem F, Triesscheijn M, Wormhoudt TA, Guijt R, van Noesel CJ. 462 Germinal centers in human lymph nodes contain reactivated memory B cells. The Journal of 463 experimental medicine 2007; 204:2655-65. 464 45. Schwickert TA, Alabyev B, Manser T, Nussenzweig MC. Germinal center reutilization by 465 newly activated B cells. The Journal of experimental medicine 2009; 206:2907-14. 466 46. Bergqvist P, Stensson A, Hazanov L, Holmberg A, Mattsson J, Mehr R, Bemark M, Lycke 467 NY. Re-utilization of germinal centers in multiple Peyer's patches results in highly synchronized, 468 oligoclonal, and affinity-matured gut IgA responses. Mucosal immunology 2013; 6:122-35. 469 47. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman 470 MS, Chen YJ, Chen Z, et al. Genome sequencing in microfabricated high-density picolitre reactors. 471 Nature 2005; 437:376-80. 472 48. Bragg L, Stone G, Imelfort M, Hugenholtz P, Tyson GW. Fast, accurate error-correction of 473 amplicon pyrosequences using Acacia. Nature methods 2012; 9:425-6. 474 49. Yousfi Monod M, Giudicelli V, Chaume D, Lefranc MP. IMGT/JunctionAnalysis: the first tool 475 for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. 476 Bioinformatics 2004; 20 Suppl 1:i379-85. 477 50. Sanz I. Multiple mechanisms participate in the generation of diversity of human H chain 478 CDR3 regions. J Immunol 1991; 147:1720-9. 479  \n60#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!51. Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH 480 repertoires revealed by deep sequencing. J Immunol 2012; 189:3221-30. 481 52. Lefranc MP. The Immunoglobulin FactsBook. Academic Press, 2001. 482 53. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, Wu Y, 483 Gemrot E, Brochet X, Lane J, et al. IMGT, the international ImMunoGeneTics information system. 484 Nucleic acids research 2009; 37:D1006-12. 485 54. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 486 2010; 25:2460-1. 487 55. Miqueu P, Guillet M, Degauque N, Dore JC, Soulillou JP, Brouard S. Statistical analysis of 488 CDR3 length distributions for the assessment of T and B cell repertoire biases. Molecular 489 immunology 2007; 44:1057-64. 490 Figure legends: 491 Figure 1. The overall algorithm used by ImmunediveRsity. Input file is a *.fastq. Pre-processing 492 consists on VDJ assignment and non-VDJ sequence trimming (5\u2019 UTR, signal sequence and 493 IGHC), homo-polymer correction (particularly required for 454-Roche or Ion Torrent reads), quality, 494 size and IGH germ line transcript filters (GLT). Processing: ImmunediveRsity first identifies the 495 CDRH3 with HMMER3 and the V and J segment rearrangement with IgBLAST. The CDRH3 reads 496 belonging to the same V and J assignment are clustered iteratively according to sequence identity 497 and length to define clonotypes. A second clustering step according to sequence identity is 498 performed within the full V region of reads belonging to each clonotype to identify the lineages with 499 different somatic hypermutation patterns. The output consists 1) Fasta files: containing the CDRH3 500 sequences for each read and clonotype, as well as the sequence for each consensus lineage with a 501 unique identifier. 2) Text files, describing V, D and J assignments for each read and the relation of 502 each read to a given clonotype and lineage. 3) Metrics files: for each clonotype is given frequency, 503 the number of synonymous (Ks) and non-synonymous mutations (Ka) mutations, diversity indices, 504 CDRH3 physico-chemical characteristics (P.Q.) and 4) Repertoire visualization: A series of 505 predefined vectorized graphics: 1) Rarefaction curves, 2) Aminoacid composition per specific length 506  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#61# !Instituto(Nacional(de(Salud(P\u00fablica(!!!of CDRH3, 3) Heat-map of VJ rearrengment frequencies, 4) CDRH3 spectratyping, 5) 3D cloud VDJ 507 rearrangement frequency and 6) Network representation of the overall structure of the antibody 508 repertoire. clonotypes (CG), lineages (Id). 509 Figure 2. iGraph network representation of the sampled antibody repertoire in mouse spleen 15 510 days after immunization with HEL. A) Left: IgM compartment. Right: IgG compartment. Each 511 clonotype is represented by the agglomeration of lineages (nodes; represented by circles), the 512 diameter of the circle represents the relative frequency and the color code according to the number 513 of non-synonymous mutations. The CDRH3 sequence (*3G1 ARGEGNYGY) of recombinant HEL-514 specific antibody as described 12 is shown. Fading of certain clonotypes allows visualization of other 515 clonotypes in the background. B) Quantitative analysis of SHM in the IgM vs. IgG compartment in 516 the same dataset as in A. C) Statistical analysis of SHM in the IgM vs. IgG compartment. Median for 517 each compartment is shown (dotted line). U-Mann-Whitney test. Frame shifted sequences were 518 removed before the analysis. 519 Figure 3. Comparison of clonotype intra-clonal inequality (Gini coefficient) between control (PBS) 520 and two HEL-immunized mice 15 days post-immunization. clonotypes derived from control mice are 521 shown as green dots. Clonotypes from HEL-immunized mice are shown in red (m8) and purple (m9) 522 dots. x axis; Gini coefficient per clonotype, y axis; clonotype relative frequency. The CDRH3 523 sequences of anti-HEL recombinant antibodies as described12 are shown. Fading dots allow the 524 visualization of overlapping dots. 525 Figure 4. Clonal diversity and somatic diversification after immunization. A change in clonal (closed 526 symbols) and lineage (open symbols) diversity measured by the average Shannon-Weaver index of 527 HEL-immunized (n=2) minus PBS-injected mouse (n=1) at day 3, 7 and 15 post-immunization for 528 the IgM (upper panel) and IgG (lower panel) compartments. B) The corresponding change in clonal 529 (closed symbols) and lineage (open symbols) inequality measured by the average Gini coefficient. 530 For A and B, 5,700 reads per library were randomly sampled using the post-processing multi-library 531 analysis toolbox. Sequencing metrics of the libraries used to estimate diversity measurements are 532 described in Supplementary Table 1.  533  \n62#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!Table 1. Overview of the reference sequencing sets 534 Set Sequenced reads After filters1 Observed clonotypes Expected clonotypes Well supported clonotypes2 Observed lineages (without singletons) Expected lineages Well supported lineages3 MD4 5,359 99.6% 10 1 1 21(7) 1 1 IGHV1-3 1,044 95.2% 1 1 1 469 (52) 10 7 Stanford224 13,141 100% 11,779 13,141 NA 12,421 13,141 NA  535 1 Percent of reads that pass the pre-processing filters. 536 2 Number of clonotypes whose corresponding lineages are composed \u2265 6 reads. 537 3 Lineages composed of \u2265 6 reads. 538 4 The publicly available Stanford22 set was published as a set of non-clonally related 539 immunoglobulin sequences 28; we removed one read with a duplicated identifier and 11 with 540 duplicated sequences. 541 NA, not applicable. 542 - Heavy Chain Clonotypes identification- Unique Heavy Chain (lineages) identificationClonotypes & lineagesNo. of ClonotypesNo. of lineagesFigure 1\nFigure 2\nFigure 3Figure 4\u0394HEL-PBS-1012\n-1012\n-0.2-0.10.00.10.2\n-0.2-0.10.00.10.2\n\u0394HEL-PBS-1012\n-1012\n-0.2-0.10.00.10.2\n-0.2-0.10.00.10.2\n \n64#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!SUPPLEMENTARY MATERIAL 1 1.1 Generation of human VH amplicon libraries: 2 To generate a human single clonal group benchmark, a sample of 2.5 mL of peripheral blood was taken 3 from a healthy donor into a PAXgene blood tube to preserve RNA integrity. Total RNA was purified from 4 these samples and cDNA was synthesized and used to generate IgGH amplicons by a 5\u2019 RACE-PCR 5 approach as described12 using the TBIgGHu antisense primer (5\u2019-{454adaptorB}CTA TGC GCC TTG 6 CCA GCC CGC{454key}TCAG{IGHCG}ACC GAT GGG CCC TTG GTG-3\u2019) that is complementary to 7 positions 5-24 of exon I of IGHCG. These amplicons were sequenced with the GS FLX Titanium platform 8 (454-Roche). The raw data in format *.sff was converted to *.fna and *.qual with SFFTools. After running 9 earlier versions of ImmunediveRsity, a single Heavy Chain Clonotype of 1,044 reads was selected and 10 subjected to manual curation by multiple sequence alignment and frame-shift editing. A Unique Heavy 11 Chain lineage was called when a mutation was present in at least six reads. Under these criteria, 10 12 lineages were identified (Table 1). 13  14 1.2 Generation of MD4 mouse VH amplicon library: 15 To generate a monoclonal VH amplicon, total RNA from a MD4 mouse26 spleen was obtained using 16 TRIzol reagent (Invitrogen). VH amplicons were prepared as described12, with the exception that primer 17 Igh-6-B (5\u2019-{454adaptorB}CTA TGC GCC TTG CCA GCC CGC{454key}TCAG{IGHCM} ACA TTT GGG 18 AAG GAC T-3\u2019) was used as antisense primer for 5\u2019 RACE-PCR. The 5\u2019 RACE-PCR product was cloned 19 in pCR2.1TOPO, Sanger sequenced and used as template for PCR amplification. The PCR amplicon was 20 purified from agarose gel, quantified and used for sequencing in a 1:100 ratio with experimental libraries. 21   22  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#65# !Instituto(Nacional(de(Salud(P\u00fablica(!!!\n23 Supplementary figure 1: Detailed structural analysis of a single HEL-specific clonotype shown in figure 24 2A and previously described in Vald\u00e9s-Alem\u00e1n et al.12. The clonotype is defined by a unique CDRH3 25 sequence (Cluster of circles connected to a virtual center, *3G1_ARGEGNYGY), but it can be further 26 subdivided in unique Heavy chain lineages (individual circles). A) Clonotype decomposed into 12 lineages 27 with \u22652 reads, the first one (m09HEL_1) reacted with HEL12. The remaining (m09HEL_2-12) were not 28 tested. As in Figure 2 A, circle color of are based on the number of non-synonymous mutations (ka). B) 29 Multiple protein sequence alignment of each of the 12 lineages and the corresponding IGHV1-9*01 30 germline sequence (GL). C) Corresponding multiple sequence alignment at the nucleotide level. AA*, 31 number of aminoacid changes. n, number of reads in each lineage. Seed alignment was performed with 32 IMGT/V-QUEST9, edited and completed manually. Lineage sequences Genbank accession numbers (XX-33 XX). Ks, synonymous mutation. 34   35 \n \n66#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!\n 36 Supplementary figure 2. ImmunediveRsity pipeline diagram. R functions (Inside grey box); files written 37 by fullAnalysis.R (green); file written by its corresponding R function (red); and R objects (blue). WSCG: 38 Well Supported clonotypes, WSId: Well Supported lineages. 39 \n 40 Supplementary figure 3: The imm-illumina script suggested for pre-processing MiSeq Illumina Ig reads 41 prior ImmunediveRsity processing (https://bitbucket.org/ImmunediveRsity/imm-illumina). Both paired end 42 Fastq files are used for PANDASeq assembly17. Pairs are transformed to reverse complement with Seqtk 43 package (https://github.com/lh3/seqtk). Once assembled, an optional subsampling script generates the 44 subsets to be processed with ImmunediveRsity. 45 \n \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#67# !Instituto(Nacional(de(Salud(P\u00fablica(!!!\n 46 Supplementary figure 4: V, D and J segment utilization frequency. In x axis, the VDJ segment and y 47 axis, their relative abundance (Frequency). This kind of plot can facilitate the identification of usage 48 biases of particular segments due to clonal expansions or abundance of plasma cells. Data derived from 49 library m09 (see Table S1). 50 \n  51 Supplementary figure 5: Heat map representation of hierarchical clustering of the relative abundance of 52 IGHV and IGHJ segment usage. Poorly represented IGHV clusters were eliminated for clarity. Alleles 53 were not included. As for figure S4, this kind of plot can facilitate the identification of usage biases of 54 particular segments due to clonal expansions or abundance of plasma cells. Data as in figure S4. 55   56 \n \n68#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!! 57 Supplementary figure 6: 3-D plot of V(D)J rearrangements 58 according to relative size (diameter) based on the proportion of 59 reads for each rearrangements. IGHD segments (x axis), IGHV 60 (y axis), IGHJ segment (z axis). As for figure S4 and S5, this 61 kind of plot can facilitate the identification of usage biases of 62 particular segments due to clonal expansions or abundance of 63 plasma cells Data as in figure S4. 64  65 \n 66  67 Supplementary figure 7: Distribution of CDRH3 nucleotide lengths in terms of their relative number of 68 reads indicated for the full library and for the consensus CDRH3 clonotypes. This kind of plot can be used 69 to assess the clonal complexity of a sample, as well as to detect clonal expansion. A robust statistical 70 framework for CDRH3 length distribution was described by Miqueu et al.56 . Data as in figure S4. 71  72 \n \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#69# !Instituto(Nacional(de(Salud(P\u00fablica(!!!\n 73 Supplementary figure 8: Amino acid frequency distribution per position in the CDRH3 for all 14 residue-74 long CDRH3\u2019s in the IgG compartment of a 15 day post-immunized mouse with HEL. This plot may be 75 particularly useful to identify CDRH3 convergence.  76 \n 77 Supplementary figure 9: Rarefaction curve points of clonotypes obtained (y axis) at different number of 78 sampled reads (x axis). Rarefaction analysis is used to estimate sample diversity by estimating unique 79 species (in this case clonotypes) at different random read sampling depths. No replacement is done. The 80 curve will reach a plateau when all the diversity in the sample has been characterized (saturation). Data 81 as in figure S4. 82   83 \n \n70#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!\n 84 Supplementary figure 10: Rarefaction curve points of lineages obtained (y axis) at different number of 85 sampled reads (x axis). Note the differences in the curve between lineages and clonotypes (figure S9). 86 Data as in figure S4. 87  88 \n 89 Supplementary figure 11: Median Quality (Q) distribution before (left) and after filtering according to pre-90 processing described in figure S2. Data as in figure S4. 91 92 \n \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#71# !Instituto(Nacional(de(Salud(P\u00fablica(!!!\n 93 Supplementary figure 12. Network representation of the sampled antibody repertoire in mouse spleen. 94 Left: Day 15 after intraperitoneal inoculation with PBS (control, library m07). Right: Day 15 post-95 immunization with Hen Egg Lysozyme (HEL) in incomplete Freund\u2019s adjuvant (library m09). Each 96 clonotype is represented by the agglomeration of lineages (nodes; represented by circles). The diameter 97 of the circle represents the relative frequency and the color code represents de Gini coefficient. Frame 98 shifted sequences were not removed before the analysis. 99  100   101 \n \n72#An\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico# !Instituto(Nacional(de(Salud(P\u00fablica(!!!Supplementary Table 1. Sequencing metrics of mouse spleen libraries. 102  mouse  group  day  isotype  sequenced reads  reads after preprocessing  No. of clonotypes  No. of lineages  No. of sampled reads  No. of clonotypes sampled  No. of lineages sampled  m01  CTL  3  IgG  15,227  13,744  1,604  5,198  5,700  1,123  2,629    IgM 22,773 21,220 9,041 13,298 5,700 3,541 4,358 m02 HEL 3 IgG 19,671 18,375 2,075 6,450 5,700 1,252 2,677    IgM 25,538 23,713 9,730 14,870 5,700 3,499 4,329 m03 HEL 3 IgG 22,910 21,509 2,267 7,490 5,700 1,262 2,783    IgM 42,445 40,859 13,627 19,078 5,700 3,420 3,936  m04  CTL  7  IgG  6,086  5,777  783  1,896  5,700  777  1,870    IgM 37,551 35,982 11,614 17,685 5,700 3,437 4,049 m05 HEL 7 IgG 101,293 95,323 5,354 26,339 5,700 1,277 2,630    IgM 33,854 31,981 8,039 12,686 5,700 2,602 3,256 m06 HEL 7 IgG 35,464 33,312 2,381 7,645 5,700 1,215 2,198    IgM 41,750 39,744 7,292 13,462 5,700 2,376 3,181  m07  CTL  15  IgG  48,350  44,593  2,984  17,086  5,700  1,095  2,973    IgM 44,321 39,785 10,666 20,857 5,700 3,314 4,286 m08 HEL 15 IgG 46,062 43,089 3,101 17,169 5,700 994 2,954    IgM 59,439 56,195 9,724 21,700 5,700 2,909 3,810 m09 HEL 15 IgG 36,562 33,800 2,967 15,395 5,700 1,229 3,383    IgM 76,194 73,142 9,267 21,979 5,700 2,742 3,579     Total  715,490  672,143  112,516  260,283  102,600  38,064  58,881 Sequence metrics for each library, defined experimentally as HEL (Hen Egg Lysozyme), under either 103 antigen exposure or PBS, CTL (control) at the day the spleen sample was processed. Despite the 104 different number of reads per library, these were randomly sampled with reference to the lowest one 105 (5,700). (NCBI-SRA accession: XXX). 106  107   108  \nAn\u00e1lisis#estructural#y#funcional#del#repertorio#de#anticuerpos#en#pacientes#con#Dengue#Cl\u00e1sico#y#Dengue#Hemorr\u00e1gico#73# !Instituto(Nacional(de(Salud(P\u00fablica(!!!Supplementary Table 2. Comparative characteristics among similar software used for Rep-Seq data. 109 Characteristics ImmunediveRsity IMGT/HighV-QUEST9 AbMining Toolbox41 IgAT40 Michaeli\u2019s algorithm42 Quality filtering Yes No Yes No Yes Sequencing noise correction Yes No No No Yes Size filter Yes No No No Yes VDJ Assignment IgBLAST IMGT No IMGT SoDA Clonotype identification# Yes No Yes Yes Yes Clonotype assignment& Yes No No No Yes Lineage identification# Yes No No No Yes Lineage assignment& Yes No No No Yes Diversity characterization$ Yes No No Yes Yes Intraclonal graphical representation Yes No No No Yes SHM analysis Yes Yes No Yes Yes CDR-H3 physicochemical properties Yes Yes Yes Yes No VH replacement footprints identification No No No Yes No Platform architecture x64 WebServer x32, x64 x32, x64 x32 Programming language mainly in R C/Java Python VisualBasicScript Java/C++ Operative system Linux/Mac WebServer Linux/Mac/Win Win Linux/Mac  110 # Clonotype or lineages identification is whether the tool provides the number of clonotypes or lineages in 111 the sample. 112 & Clonotypes or lineages assignment is whether the tool assigns each read a specific clonotype or 113 lineage. 114 $ Diversity characterization is whether the tool provides parameters to measure clonotype or lineage 115 richness. SHM, Somatic hypermutation. 116 !\n74\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Lower\" IgG\" Somatic\" Hypermutation\" (SHM)\" Rates\" during\" acute\" Dengue\" virus\"infection\" indicate\" a\" TTIndependent\" B\" Cell\" Response\" associated\" with\" Disease\"Enhancement\"!El!segundo!manuscrito,!hace!referencia!al!an\u00e1lisis!del!RepUSeq!de!anticuerpos!de!IgG!en!infecci\u00f3n!aguda!por!DENV.!A!lo!largo!del!manuscrito!describimos!el!hallazgo!de!una!mayor!diversidad!clonal!e!idiotipica!en!pacientes!que!se!tienen!la!infecci\u00f3n!aguda,! en! comparaci\u00f3n! con! la! fase! de! postUconvalecencia.! Describimos! el! uso!preferencial! de! familias! y! segmentos! IGHV! que! correlacionan! con! la! condici\u00f3n!cl\u00ednica!de!la!enfermedad!y!de!manera!sorprendente!reportamos!una!baja!tasa!de!SHM! en! infecciones! agudas,! tanto! de! pacientes! que! cursan! con! una! infecci\u00f3n!primaria!como!en!infecciones!secundarias.!\"\"\"\"PLOS Pathogens\n \nLower IgG Somatic Hypermutation (SHM) Rates during acute Dengue virus infection\nindicate a T-Independent B Cell Response associated with Disease Enhancement\n--Manuscript Draft--\n \nManuscript Number:\nFull Title: Lower IgG Somatic Hypermutation (SHM) Rates during acute Dengue virus infection\nindicate a T-Independent B Cell Response associated with Disease Enhancement\nShort Title: Lower IgG SHM rates in acute DENV infection\nArticle Type: Research Article\nSection/Category: Virology\nKeywords: Dengue;  neutralizing antibodies;  B cell repertoire;  somatic hypermutation;  antibody-\ndependent enhancement\nCorresponding Author: Jes\u00fas Mart\u00ednez-Barnetche\nINSP\nCuernavaca, Morelos MEXICO\nCorresponding Author Secondary\nInformation:\nCorresponding Author's Institution: INSP\nCorresponding Author's Secondary\nInstitution:\nFirst Author: Elizabeth Ernestina Godoy-Lozano\nFirst Author Secondary Information:\nOrder of Authors: Elizabeth Ernestina Godoy-Lozano\nJuan T\u00e9llez-Sosa\nHugo S\u00e1mano-S\u00e1nchez\nAndr\u00e9s Aguilar\nAar\u00f3n Salinas-Rodr\u00edguez\nBernardo Cortina-Ceballos\nHector Vivanco-Cid\nKarina Hern\u00e1ndez-Flores\nJennifer M Pfaff\nKristen M Kahle\nBenjamin J Doranz\nRosa E G\u00f3mez-Barreto\nIrma Lopez-Martinez\nMario Henry Rodr\u00edguez\nJes\u00fas Mart\u00ednez-Barnetche\nOrder of Authors Secondary Information:\nAbstract: The study of human B cell response to DENV infection is critical to understand\nserotype-specific protection and cross-reactive sub-neutralizing response. Whereas\nthe first is beneficial and thus represents the ultimate goal of vaccination, the latter has\nbeen implicated in the development of severe disease, which occurs in a small, albeit\nsignificant fraction of secondary DENV infections. Both primary and secondary\ninfections are associated with the production of poly and cross-reactive IgG antibodies.\nPowered by Editorial Manager\u00ae and ProduXion Manager\u00ae from Aries Systems CorporationTo gain insight into the impact of DENV infection on the B cell repertoire, we used VH\nregion high throughput sequencing (Rep-Seq) of the peripheral blood IgG B cell\ncompartment of 19 individuals during the acute phase of infection. For 11 individuals, a\nsecond sample obtained six months later was also analyzed. We found that in acute\ndisease there is an increase in IgG B cell diversity and changes in the relative use of\nsegments IGHV1-2, IGHV1-18 and IGHV1-69. Somewhat unexpectedly, an overall low\nproportion of somatic hypermutated antibody genes was observed during the acute\nphase, particularly in secondary infections and those cases with more severe disease.\nOur data is consistent with an innate-like antiviral recognition system mediated by B\ncells using defined germ-line coded B cell receptors, which provides a rapid extra-\nfollicular T-independent antibody response during the early phase of infection. A model\ndescribing the T-dependent and T-independent B cell responses in the context of\nDENV infection is proposed, incorporating the selection of B cells using hypomutated\nIGHV segments, their role in poly/cross-reactivity and potential implication in antibody-\ndependent enhancement. Its formal demonstration may contribute to rational vaccine\ndevelopment efforts.\nSuggested Reviewers: David Tarlinton\nWalter and Eliza Hall Institute of Medical Research\ntarlinton@wehi.edu.au\nThomas MacCarthy\nStony Brook University\nmaccarth@ams.sunysb.edu\nkatja Fink\nSingapore ImmunologyNetwork,AgencyforScience,Technologyand Research\nA\u2217STAR,Singapore\nkatja_fink@immunol.a-star.edu.sg\nAravinda M de Silva\nUniversity of North Carolina at Chapel Hill\naravinda_desilva@med.unc.edu\nOpposed Reviewers: Eva Harris\nUniversity of California Berkeley\nPotential confilict of interest.\nScott D Boyd\nStanford University School of Medicine\nsboyd1@stanford.edu\nHe has kind to review our manuscript draft prior submission.\nAdditional Information:\nQuestion Response\nData Availability\nPLOS journals require authors to make all\ndata underlying the findings described in\ntheir manuscript fully available, without\nrestriction and from the time of\npublication, with only rare exceptions to\naddress legal and ethical concerns (see\nthe PLOS Data Policy  and FAQ for further\ndetails). When submitting a manuscript,\nauthors must provide a Data Availability\nStatement that describes where the data\nunderlying their manuscript can be found.\nYour answers to the following constitute\nyour statement about data availability and\nwill be included with the article in the\nevent of publication. Please note that\nsimply stating \u2018data available on request\nfrom the author\u2019 is not acceptable. If,Yes - all data are fully available without restriction\nPowered by Editorial Manager\u00ae and ProduXion Manager\u00ae from Aries Systems Corporationhowever, your data are only available\nupon request from the author(s), you must\nanswer \u201cNo\u201d to the first question below,\nand explain your exceptional situation in\nthe text box provided.\nDo the authors confirm that all data\nunderlying the findings described in their\nmanuscript are fully available without\nrestriction?\nPlease describe where your data may be\nfound, writing in full sentences. Your\nanswers should be entered into the box\nbelow and will be published in the form\nyou provide them, if your manuscript is\naccepted. If you are copying our sample\ntext below, please ensure you replace any\ninstances of XXX with the appropriate\ndetails.\nIf your data are all contained within the\npaper and/or Supporting Information files,\nplease state this in your answer below.\nFor example, \u201cAll relevant data are within\nthe paper and its Supporting Information\nfiles.\u201d\nIf your data are held or will be held in a\npublic repository, include URLs,\naccession numbers or DOIs. For example,\n\u201cAll XXX files are available from the XXX\ndatabase (accession number(s) XXX,\nXXX).\" If this information will only be\navailable after acceptance, please\nindicate this by ticking the box below.\nIf neither of these applies but you are able\nto provide details of access elsewhere,\nwith or without limitations, please do so in\nthe box below. For example:\n\u201cData are available from the XXX\nInstitutional Data Access / Ethics\nCommittee for researchers who meet the\ncriteria for access to confidential data.\u201d\n\u201cData are from the XXX study whose\nauthors may be contacted at XXX.\u201d\n* typesetAll IgG sequencing data files will be available from the Sequence Read Archive\nhttp://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi\nAdditional data availability information: Tick here if the URLs/accession numbers/DOIs will be available only after acceptance\nof the manuscript for publication so that we can ensure their inclusion before\npublication.\nPowered by Editorial Manager\u00ae and ProduXion Manager\u00ae from Aries Systems CorporationLower IgG Somatic Hypermutation (SHM) Rates during acute Dengue 1 \nvirus infection indicate a T -Independent B Cell Response associated 2 \nwith  Disease Enhancement  3 \n 4 \nElizabeth Ernestina Godoy -Lozano1, Juan T\u00e9llez -Sosa1\u00b6, Hugo S\u00e1mano -S\u00e1nchez1, Andr\u00e9s 5 \nAguilar1, Aar\u00f3n Salinas -Rodr\u00edguez2, Bernardo Cortina -Ceballos1, Hector Vivanco -Cid3, Karina 6 \nHern\u00e1ndez -Flores3, Jennifer M. Pfaff4, Kristen M. Kahle4, Ben jamin  J. Doranz4, Rosa Elena 7 \nG\u00f3mez -Barreto1, Irma Lopez Martinez5, Mario H . Rodriguez1, Jes\u00fas Mart\u00ednez -Barnetche1\u00b6 8 \n 9 \n1 Centro de Investigaci\u00f3n Sobre Enfermedades Infecciosas. Instituto Nacional de Salud P\u00fablica.  10 \nCuernavaca, Morelos. M\u00e9xico.  11 \n2 Centro de Investigaci\u00f3n en Evaluaci\u00f3n y Encuestas. Instituto Nacional de Salud P\u00fablica.  12 \nCuernavaca, Morelos. M\u00e9xico.  13 \n3 Instituto  de Investigaciones Medico -Biol\u00f3gicas. Universidad Veracruzana. Veracruz, M\u00e9xico.  14 \n4 Integral Molecular. Philadelphia, United States of America.  15 \n5 Instituto de Diagn\u00f3stico y Referencia Epidemiol\u00f3gicos. M\u00e9xico, DF. M\u00e9xico.  16 \n 17 \n* Corresponding author s 18 \nEmail: jmbarnet@insp.mx  (JMB)  19 \n 20 \n\u00b6 These authors contributed equally to this work.  21 \n 22 \nShort Title: Lower IgG SHM rates i n acute DENV infection  23 \n  24 Manuscript\nClick here to download Manuscript: dengue_manuscrito_final_30_dic.docx Abstract  25 \nThe study of human B cell response to DENV infection is critical to understand  serotype -26 \nspecific protection and cross -reactive sub -neutralizing response. Whereas the first is beneficial 27 \nand thus represents the ultimate goal of vaccination, the latter has been implicated in the 28 \ndevelopment of severe disease, which occurs in  a small, albeit significant fraction of secondary 29 \nDENV infections. Both primary and secondary infections are associated with the production of 30 \npoly and cross -reactive IgG antibodies. To gain insight into the impact of DENV infection on 31 \nthe B cell repertoi re, we used VH region high throughput sequencing ( Rep-Seq) of the 32 \nperipheral blood IgG B cell compartment of 19 individuals during the acute phase  of infection . 33 \nFor 11 individuals, a second sample obtained six months later was also analyzed. We found that 34 \nin acute disease there is an increase in IgG B cell diversity and changes in the relative use of 35 \nsegments IGHV1 -2, IGHV1 -18 and IGHV1 -69. Somewhat unexpectedly, an overall low 36 \nproportion  of somatic hypermutated  antibody genes  was observed during the acute phase, 37 \nparticularly in secondary infections and those cases with more severe disease . Our data is 38 \nconsistent with an innate -like antiviral recognition system mediated by B cells using defined 39 \ngerm -line coded B cell receptors , which  provides a rapid extra -follicular T -independent 40 \nantibody respons e during the early phase of infection. A model describing the T -dependent and 41 \nT-independent B cell responses in the context of DENV infection is proposed, incorporating the 42 \nselection of B cells using hypomutated IGHV segments, their role in poly /cross -reactivity and 43 \npotential implication in  antibody -dependent enhancement . Its formal demonstration may 44 \ncontribute to rational vaccine development efforts.  45 \n  46 Author summary  47 \nDengue is a vector -borne acute febrile illness  of global health importance  caused by Dengue 48 \nvirus (DENV) infection. There is neither approved specific treatment nor vaccines. Although 49 \nthe majority of cases evolve as uncomplicated self -limited disease, some cases develop  a severe 50 \nlife-threatening disease, which  is more common in secondary than in primary infections. A 51 \nprimary DENV infection induces immunity to the infecting serotype, which i s mediated in part 52 \nby the production of serotype -specific neutralizing antibodies. However, primary infection is 53 \nalso accompanied by the production of cross -reactive antibodies capable of binding, but not 54 \nneutralizing multiple DENV serotypes other than the  primary infecting serotype. These cross -55 \nreactive antibodies are implicated in facilitating DENV infection in host cells  and consequently 56 \nin the development of severe Dengue disease.  During acute disease, a high proportion of 57 \ncirculating B cells is DENV -specific. Thus, using high -throughput sequencing , we analyzed the 58 \nstructure of antibody genes obtained from peripheral B cells during acute infection  in 59 \ncomparison with post -convalescence. We found that during acute disease , there  are structural 60 \nfeatures  in antibody genes indicating that DENV infection  triggers a T -independent B cell 61 \nproduction of poly/cross -reactive antibodies that may be implicated in severe disease  that 62 \nshould be avoided for safe  vaccine development . 63 \nIntroduction  64 \nDengue , the most important mosquito borne -viral disease in humans  is caused by four closely 65 \nrelated serotypes of Dengue virus (DENV)  of the flaviviridae  family . The infection can be 66 \nasymptomatic, a mild self-limited febrile disease lasting up to 7 -10 days  (Dengue  fever  without 67 \nwarning signs, DWS -), or a severe disease with hemostatic  and hemodynamic dysfunction 68 \n(Dengue with warning signs , DWS +, and Dengue shock syndrome ) [1,2]. According to recent 69 \nestimates, 390 million dengue infections occur each year, of which only 96 millio n reach the 70 \npublic health surveillance system [3]. 71  DENV primarily infects dendritic cells and monocytes [4-6]. During the early stages of 72 \ninfection , a rapid, strong i nnate immune response is elicited, result ing in a systemic 73 \ninflammatory immune response that explains the majority of symptoms of uncomplicated 74 \nillness. Shortly after, an adaptive immune response manifests as  the production of  low affinity 75 \nIgM anti-DENV  antibodies , and later, high affinity anti-DENV IgG neutralizing antibodies that 76 \nconfer long -term protection to the infecting serotype (homotypic protection) . However, primary 77 \ninfection s are also associated with the production of low affinity , non-neutraliz ing or sub -78 \nneutralizing cross -reactive anti-DENV antibodies against multiple  DENV -serotypes  that only 79 \nconfer partial short -term protection  [7]. 80 \n An almost paradigmatic  feature of Dengue infection is the epidemiological observation 81 \nthat severe illness is associated with  a previous infection with a different DENV serotype [8]. 82 \nNon-neutralizing, cross -reactive antibodies induced during primary infection s have been 83 \nimplicated in potentiating viral replication, systemic immunopathology and severe disease  by 84 \nFcJR-mediated antibody -depend ent enhancement (ADE), offering a plausible explanation of the 85 \nincreased disease severity after multiple reinfections  [9]. 86 \n Antibody production is the result of B cell clonal selection , expansion  and 87 \ndifferentiation into antibody secreting plasma cells . In the case of protein antigens, antigen -88 \nspecific B cells are clonally selected and  form germinal centers  (GC)  depend ing on T cell  help. 89 \nWithin the GC , selected B cells undergo somatic hypermutation ( SHM ) and class switch 90 \nrecombination ( CSR ) [10,11], which are two mechanistically coupled processes result ing in 91 \nhigh affinit y, IgG switched memory B cells and  antibody secreting plasma cells  [12]. However, 92 \nit has become increasingly clear that B cell memory is heterogeneous in terms of their origin 93 \nand function [13]. In the context of DENV infection, t he generation of long -lived anti -DENV 94 \nIgG+ memory cells selected by  a primary infection has been implicated in the predominance of 95 \nneutralizing antibodies against the primary infecting serotype over neutralizing antibod ies 96 \nspecific for a different serotype causing a secondary infection [14]. Presumably, this so called 97 \n\u201coriginal antigenic sin\u201d could also favor ADE by outcompeting secondary serotype anti -DENV 98 \nhigh affinity B cell clones. Consistently, poly -reactive and serotype cross -reactive IgG\u2019s are 99 presen t at high titers in early primary and secondary DENV infections [15-19]. Thus, 100 \nunderstanding B cell responses to DENV infection as well as antibody -mediated immune 101 \nprotection and enhance ment requires the integrative analysis of the clonal selection process 102 \nwithin the actual conceptual framework of pathway  heterogeneity of effector B cell 103 \ndifferentiation [13]. 104 \n Acute DENV infection is also associated with a massive CD19+ CD20- CD38+ CD27+ 105 \nIgG+ DENV -specific plasmablast (PB) mobilization to peripheral blood , representing nearly 106 \nhalf of total circulating B cells  [20]. Given the central role of antibodies and their affinity in the 107 \nprotection against DENV, as well as their implication in severe disease, we hypothesized that 108 \nthe B cell clonal selection process and diversification may be different between Dengue primary 109 \nand secondary infections and in DENV infection s without clinical warning signs and D engue  110 \ninfections  with clinical warning signs  (referr ed hereafter as DWS \u2013 and DWS +, respectively) . 111 \nTo identify these differences, we used high -throughput sequencin g (HTS) of  peripheral blood  112 \nIgG antibody repertoires (reviewed in [21,22]) to compare clonal diversity, IGHV usage and 113 \nSHM rates between acute DWS \u2013 and DWS + patients and their corresponding post -114 \nconvalescent blood sa mple s (six months).  115 \n Consistent with increased plasmablast circulation in peripheral blood, we found an 116 \nincrease in clonal diversity during the acute phase of the disease compared to the convalescent 117 \nphase, regardless of severity. Differential changes in IGHV1 -2, IGHV1 -18 and IGHV1 -69 usage 118 \nfrequency  and transcription were also detected.  Paradoxically, we found overall lower SHM  119 \nrates during acute illness, particularly  in DWS + and  in lymphocytes using IGHV1 -2, suggesting 120 \ntheir implication in  cross -reactiv e, low -affinity IgG antibodies. Our results also indicate that in 121 \nhumans infected with DENV, an alternative, T -independent effector B cell differentiation 122 \npathway may take place, in which CSR to IgG is decoupled from SHM . 123 \n  124 Results  125 \nDonor s, samples, demographic data and sequencing metrics.  126 \nIn order to  characterize the impact of acute DENV infection in the human B cell repertoire in 127 \nterms of clinical status ( DWS - and DWS +) and immunological status (primary and secondary 128 \ninfection), w e sampled peripheral blood from 19 patients with laboratory confirmed DENV 129 \ninfection during their febrile stage ( DWS \u2013 n = 10, DWS +  n = 9). As a reference, a second 130 \nsample was obtained  from some individuals  six months after the first sample (post -131 \nconvales cence)  (DWS - Pc n = 7, DWS + Pc = 4), coinciding with the low Dengue transmission 132 \ndry season , minimizing the possibility of a concurrent asymptomatic DENV infection  (Figure 133 \n1A-B). Socio -demographic and clinical data is summarized in Table 1.  Of all acute patients, 134 \nonly three  patients had a primary infection (15.8%) and the rest were  secondary infection s 135 \n(84.2%). All primary cases  were classified as DWS -. No differences in the number of days after 136 \nsymptoms onset were found regarding clinical (DWS \u2013 and DWS  +) and immunological status 137 \n(Figure S1 ). The predominant infecting serotype was DENV2 ( 10/19; 52.6 %), followed by  138 \nDENV1 ( 7/19; 36.8%). We could not determine the serotype in four patients  (21.0%) (Table 1) . 139 \nSera of fifteen individuals (78.9%) presented high titers of cross -neutralizing antibodies to  the 140 \nfour DENV serotypes,  as measured by DENV reporter particle neutralization assay  [23], only 141 \none individual showed cross -reactive titers to three DENV serotypes, whereas as expected , the 142 \nthree primary infections showed homotypic neutral ization  (Figure 1C, Supplementary Table 143 \nS1). 144 \nThirty VH region IgG+ cDNA libraries of peripheral blood B cells were generated using 145 \na generic IGHG CH1 -coding  exon -specific antisense oligonucleotide for 5\u2019 RACE 146 \namplification. A  total of 2,364,822 raw  and 2,044,447  pass-filter  454-ROCHE sequences were 147 \ngenerated  [24]. Pass filter reads were the input for our in -house developed pipeline 148 \nImmunediveRsity (Cortina -Ceballos, et al. 2014 . Submitted) , which reconstructed 385,206 149 \nunique heavy chains ( UHC ) derived from 146,565  heavy chain clonotypes ( HCC). The average 150 \nnumber of UHC and HCC per patient was 11,553 (\u00b1 6,587 ) and 4,420 (\u00b1 2,961 ), respectively 151 (Table 2. Supplementary Table S2 ). Assuming that every blood mL has 1 x106 PBMC\u2019s and 10 152 \n% corresponds to B cells, the average number of UHC correspond s roughly to  at least  4% of the 153 \nexpected B cells in a PAX Gene tube  (2.5 mL) . Since the source of the sequenced material  was 154 \nRNA , these results imply that sequenced UHC are those  with either higher IgG expression (i.e. 155 \nplasma cells and plasmablasts ) or clonally expanded B cells, but using this approach , it is 156 \nimpossible to discriminate between them . 157 \nHigh clonal diversity during acute  Dengue infection  158 \nAs a general approach to generate quantitative measures of B cell clonal diversity 159 \nsuitable for comp arison  among clinical and immunological status , ImmunediveRsity performs 160 \nrarefaction  analysis  for HCC  and UHC  [25], where the increasing read sub -samples  (x) are 161 \nplotted against its respective  cumulative number of novel HCC  or UHC  (y). Although the 162 \nobserved curves do not reach saturation  (Figure 2A -D), consistently higher clonal diversity 163 \n(HCC) was observed during the  acute phase  than in the post -convalescent phase, regardless of 164 \nclinical (Figure 2A-B) and immunological status (Figure 2C-D). As a complementary approach  165 \nto estimate clonal diversity , entropy  measurement  (or uncertainty to predict a HCC identity in a 166 \nrandom draw)  for each sample was estimated with the Shannon index [26]. As observed in the 167 \nrarefaction analysis, the Shannon index was higher in  the acute phase than in the post -168 \nconvalescent phase for HCC (Figure 2E -F) and UHC (Figure 2G -H), regardless  of clinical and 169 \nimmunological status , although the difference was not stat istically significant (Figure 2 E-H). 170 \nMoreover, n o differences were found  between acute DWS+ and acute DWS - (Figure S 2A), 171 \nbetween acute primary vs. secondary dengue infection  (Figure S2B) and between DENV 172 \nserotype  (Figure S 2C). Flow cytometric analysis of PBMCs in an independent group of acute 173 \nDENV infected patients revealed a h igher proportion of circulating CD19+ B cells (Figure S2D). 174 \nTaken  together, rarefaction analysis and entropy measurement s and flow cytometric data 175 \nindicate that higher numbers of  non-clonally related  B cells are sampled during acute DENV 176 \ninfection than in the post -convalescent phase , and that clinical status, immunological status and 177 \nDENV serotype have no effect in the diversity  of sampled B cells . 178 Given that no replicate blood samples were taken, it is difficult to discriminate between 179 \nhigh Ig G transcription levels in a  single cell (i.e. plasma cell) or a clonally expanded group of 180 \nlow-expressing Ig G B cells (i.e. memory  B cells) . However, SHM can produce different 181 \nclonally related B cells , providing a means for gross discrimination of the cellu lar composition 182 \nwithin a HCC . The Gini coefficient is used to calculate  population  inequity . Equal distributions 183 \namong entities have  a low (close to 0) Gini coefficient, whereas highly unequally distributed 184 \nentities have a Gini coefficient near 1.0  [27]. Size is a measure of HCC and UHC transcription 185 \nbased on normalized read counts , thus , we used the Gini coefficient t o estimate equity  of HCC 186 \nand UHC size distribution per library. Acute DENV infection was associated with lower  HCC  187 \nGini coefficients than the post -convalescent phase, regardless clinical status  (Figure 3A) . The 188 \nGini coefficient was also  used to estimate equity of UHC\u2019s size within each clonal group.  We 189 \nobserved that in acute phase of DENV infection HCC Gini coefficients were lower than in the 190 \npost-convalescent phase, regardless of clinical status (Figure 3B). The median UHC size was 191 \nlower in the acute pha se of  both DWS \u2013 and DWS +  compared  to the post -convalescent phase  192 \n(Figure S3) . A graphical reconstruction of 1,280  random ly sample d UHC linked by their clonal 193 \norigin  performed using iGraph for  each clinical condition  [28] is shown in Figure 3C. More 194 \neven distribution of UHC size could be expected if there is an enrichment of the B cell 195 \npopulation with a subpopulation expressing IgG at a similar rate (i.e. plasmablasts) . Smaller 196 \nUHC \u2019s relative  size during acute DENV infection  could indicate that the sequencing throughput 197 \nis more evenly distributed due to the massive plasmablasts influx . In conjunction with  changes 198 \nin diversity  (Figure 2), Gini coefficient is compatible  with the increase of plasmablast  in 199 \nperipheral bl ood during the acute phases of DENV infection . 200 \nDifferential usage of IGHV families and segments in acute phases  201 \n A predominant use of certain IGHV families and segments in plasmablast -derived anti-202 \nDENV antibodies has been  described [16]. As described previously, relative frequencies are 203 \nheavily influenced by Ig G transcription levels according to B cell functional stage. Thus, to 204 \ncompare relative IGHV family and segment usage we analyz ed IGHV family and segment 205 \nusage per UHC  (Figure 4A -B), per HCC (Figure S4C) , as well as IGHV family and segment 206 relative transcription  (based on read count) (Figure 4SA -B). To identify a potential bias in 207 \nIGHV use during acute DENV infection, w e measured the difference between the relative 208 \nfrequencies  of each IGHV famil y or segment  during the acute phase minus the  corresponding  209 \npost-convalescent phase  ('A-Pc). Interestingly, hierarchical clustering of 'A-Pc IGHV usage  210 \nper UHC revealed two patient clusters : one that showed  increased IGHV3 and decreased 211 \nIGHV1 fam ily usage , containing  all patients with primary infection s and two DWS \u2013 with 212 \nsecondary infections ; and the other w hich showed  increased IGHV1 and decreased IGHV3 213 \nfamily usage, containing  the rest of secondary infections including  all DWS +  patients  (Figure 214 \n4A). IGHV1  and IGHV3 usage was significantly different between DWS \u2013 and DWS + (Two 215 \nWay ANOVA. p < 0.0 1 and p < 0.0 01, respectively ). 216 \n To identify the IGHV segments responsible for such differences, comparison  of 'A-Pc 217 \nIGHV segment  usage  revealed a significant increase  IGHV1 -2 (2-way ANOVA. p < 0. 01) and 218 \nIGHV1 -69 (2-way ANOVA. p < 0.0 01) usage frequency  in acute DWS +  (Figure 4B. Table 3) . 219 \nFurther analysis of differential IGHV family or segment usage according to HCC\u2019s c onsistently  220 \nrevealed that  IGHV1 -69 was significantly increased during acute DWS + ( 2-way ANOVA. p < 221 \n0.001). One additional segment belonging to the IGHV1 family, IGHV1 -18, was also 222 \nsignificantly increased during acute DWS \u2013, but not DWS + ( 2-way ANOVA. p < 0.05) ( Table 223 \n3. Figure S4 C). 224 \n Table 3 summarizes the analysis of differential IGHV family/ segment  usage in terms of  225 \nthe level of aggregation (UHC, HCC and relative expression) and in terms of  differences 226 \nbetween clinical and immunological status. Because this analysis was performe d using u nsorted 227 \nB cell populations, it is impossible to know the exact number of B cells involved. However , 228 \nthese results suggest a potential  selection bias by DENV of B cells using segments  of the 229 \nIGHV1 family, particularly IGHV1 -2, IGHV1 -18 and IGHV1 -69. Although IGHV1 -2 raw 230 \nexpression was significantly increased in acute DWS +  (Figure S4B. 2-way ANOVA.  p < 0.05) , 231 \nno differences were found at the HCC frequency level  (Figure S4C). Such differences may 232 \nimply different proportions in cells with high IgG vs. low IgG transcription. In addition, a bias 233 for IGHV segment usage may imply a polyclonal selection of B cells using that particular 234 \nIGHV segment. Indeed, digital CDRH3 \u201cspectra -typing\u201d confirmed that is the case (Figure S5). 235 \nLower SHM in the acute phase  236 \n A hallmark of the adaptive humoral immune response is affinity maturation as a result 237 \nof antigen re -exposure. Affinity maturation occurs by SHM and affects mainly class -switched B 238 \ncells. Given that the majority of the samples analyzed in this study focused  on the IgG 239 \ncompartment from secondary infections, higher levels of somatic hypermutation in B cells 240 \nwould be expected. In order to detect whether higher levels of somatic hypermutation had 241 \nindeed occurred, the percent age of mutations in the IGHV  using the germ -line as reference 242 \nsegments was calculated for each consensus of UHC [29]. We observed  that acute DENV 243 \ninfection  had overall lower proportion of SHM than the corresponding level during post -244 \nconvalescence , regardless clinical status (Figure 5A) or immunologic status (Figure 5B) . This 245 \neffect appeared  to be restricted to  acute DENV infection , as the proportion of SHM at seven 246 \ndays post vaccination with the 2008 -2009 trivalent influenza vaccine (Figure 5A)  was increased . 247 \nInterestingly, SHM levels were significantly lower in DWS+ than in DWS - and in secondary 248 \nthan in primary DENV infection (Figure 5 A -B). Moreover, among secondary cases, lower 249 \nSHM levels were found in acute DWS + than in acute DWS \u2013 (Figure S6A). 250 \n Somatic hypermutation is the basis for selection of high affinity antibodies , 251 \nnevertheless, calculation of non -synonymous mutations yielded  the same results as overall 252 \nmutation rates (Figure S7A). Lower Gini coefficients described in the previous section could 253 \nalso be the result of low hypermutation rates, as a HCC to UHC ratio near 1 would be expected 254 \nto result in maximal equity (Gini  coefficient = 0). We then calculated the proportion of HCC 255 \nthat had  a Gini coefficient = 0 for each individual according to clinical status. As shown in 256 \nFigure S7B, higher proportion of HCC with Gini coefficient = 0 were observed during the acute 257 \nphase of  DENV infection.  258 \nIn mice,  marginal zone B cell subsets are less dependent on T cell help,  can be class -259 \nswitched to IgG,  have lower SHM rates , and have a differential IGHV usage  [30], thus 260 \nsuggesting  that in human DENV infection, the participation of a particular  IgG+ B cell subset 261 using unmutated  or poorly mutated IGHV segments may take place . To determine if the 262 \nreduction of SHM affected particularly certain IGHV segments during acute DENV infection, 263 \nwe calculated SMH rates according to IGHV segment. Significantly lower levels of SHM 264 \nduring acute  DENV infection  than in post -convalescence  were observed for IGHV1 -2, IGHV1 -265 \n18 and IGHV1 -69 (p < 0.001) (Figure 5C-H). As for the total repertoire, significantly lower 266 \nlevels of SHM of IGHV1 -2 were observed in acute DWS + compared to acute DWS - (p < 267 \n0.001)  (Figure 5C) , in acute secondary vs. acute primary infections  (Figure 5C -D), and among 268 \nsecondary cases, in DWS + vs. DWS  \u2013 (Figure S6B). In the case of IGHV1 -18 and IGHV1 -69, 269 \nacute secondary infection had significantly lower SHM levels than acute primary infection 270 \n(Figure 5F, H), however, no significant differences between acute DWS+ and DWS \u2013 were 271 \nobserved (Figure 5E, G  and S 6C-D). 272 \nAs shown in Figure 5A, global SHM rates are lower in acute DENV infection, 273 \nsuggesting that this effect is not only re stricted to IGHV1 -2, IGHV1 -18 and IGHV1 -69. 274 \nCalculation of SHM rates for all IGHV segments  during  acute and post -convalescent  DENV 275 \ninfection  and controls (subjected to h ierarchical clustering according to IGHV segment ) 276 \nrevealed significantly higher SHM rates in controls and post -convalescent individuals than in 277 \nacute DENV infection (U -Mann -Whitney test. p < 0.001) (Figure S8). 278 \nSince the number of UHC belonging to a given B cell clonotype is the result of SHM, a 279 \nstraightforward pr ediction derived from lower SHM rates is that the number of UHC per heavy 280 \nchain clonotype during the acute phase of DENV infection will also be low. Consistent with our 281 \nobservations , the clonotype per UHC ratio (1/UHC\u2019s)  was significantly reduced during the 282 \nacute phase  DENV infection in  both DWS + and DWS - (p < 0.001Kruskal -Wallis test, Dunn\u2019s 283 \ncorrection ). 284 \n Finally , we performed a multivariate analysis based on  Mutilevel  Principal Component 285 \nAnalysis (PCA), to search for association patterns between SHM rates and clinical condition. 286 \nWe used the mean proportion (%) of all  mutations , non -synonymous and synonymous 287 \nmutations in the IGHV segment, as well as the  mean  relative frequency of 1,280 randomly 288 \nchosen UHC as variables f or the analysis . Two components, PC1 and PC2 explain ed 76.3% and 289 22.6% of the variance, respectively, with a cumulative p roportion  of 98.9%. Mean PC1 score 290 \nwas significantly different between acute DWS + and post-convalescence  (p<0.01) (Figure 6A). 291 \nAlthough PC1 was lower in acute DWS - than in post-convalescence , no significant differences 292 \nwere found. However,  component 1 (PC1) was  significantly lower in DWS \u2013 and DWS + than 293 \nin healthy control group ( p < 0.05 and p < 0.01, respectively). Biplots  of PC1 and PC2 showed 294 \nfour major clusters , one  containing the majority of  the healthy  control samples , a second 295 \ncontaining DWS +, a third containing most of the DWS \u2013 and a fourth containing most of the 296 \npost-convalescent patients , regardless clinical stat us during acute disease (Figure 6B). Taken 297 \ntogether, mutation analysis  using supervised and non -supervised approaches robustly support 298 \nthat circulating IgG+ B cells during acute DENV infection were less hypermutated than their 299 \ncounterparts in the post -conv alescent phase or in healthy controls.  300 \nDiscussion  301 \nThe understanding of the immune response to DENV infection has been hampered by the lack 302 \nof adequate experimental models [31], but represents an urgent goal in order to develop safe 303 \nvaccination st rategies and as the basis for understanding the role of population immunity in 304 \ndisease transmission dynamics [32]. Following a  Rep-Seq approach,  we have shown that the 305 \ncourse of an acute DENV infection is associated with an increase in B cell clonal diversity in 306 \nperipheral blood . We also documented  differenc es in the relative frequencies of B cells using 307 \ncertain IGHV segments belonging to the IGHV1 family  according to clinical status,  and more 308 \nimportantly,  a paradoxically low SHM frequency  in the acute phase , as compared to the 309 \ncorresponding post -convalescen ce. Also paradoxical is the fact that SHM frequency was even 310 \nlower in secondary  and DWS +  than in primary and DWS \u2013 DENV infections . For some IGHV 311 \nsegments  such as IGHV1 -2, the SHM rates were lower in DWS +  compared to DWS -. 312 \n HTS of the B cell repertoire has been applied to explore higher order structural 313 \nproperties of the antibody repertoire [25,33], track leukemia re sidual disease [34], uncover  314 \nclonal linages and patterns of SHM profiles in broadly neutralizing antibodies in HIV [35], as 315 \nwell as to analy ze the antibody response in influenza  virus infection [36] and vaccination 316 [37,38](Cortina -Ceballos et al. 2014 . Manuscript in preparation ) and , particularly relevant for 317 \nthe work presented here, to explore convergent antibody signatures  in DENV infection [39]. 318 \nBeing a relatively recently developed approach, there are substantial methodological and 319 \nanalytical differences in which the research groups involved have coped with the challenge of 320 \nmining the lymphocyte repertoire complexity. An important methodological  difference is 321 \nwhether the starting material for Ig sequencing is DNA or RNA. Sequencing DNA has the 322 \nadvantage of providing a single copy per B cell as template for PCR amplification, thus the 323 \nclonal size is the reflection of the number of clonally related  B cells in a given clone. An 324 \nimportant advantage of using RNA derived libraries for sequencing, particularly those generated 325 \nby 5\u2019 RACE , is that less PCR amplification bias is expected due to the use of a single primer 326 \npair based on invariant amplicon fla nks [21]. However, in contrast to DNA sequencing, 327 \ndifferences in BCR expression related to differentiation stage hamper  an accurate estimation of 328 \nclonal composition and  size. 329 \n In the context of DENV infection, we used rarefaction analysis and Shannon -Weaver 330 \nindex (entropy) as an approximation to estimate diversity in a subsample B cell repertoire  331 \n(Figure 2) . Both analyses suggest that during acute DENV infection there is an increase in B 332 \ncell diversity. An increase in B cell clonality due to clonal expansion using P[collision] was 333 \nrecently described [39]. We argue that our results are not in contradiction : P[collision] is 334 \nestimated by replicate sampling and measures the probability of finding clonally related B cells 335 \nin the replicates. Thus, clonal expansions can be readily assessed and proved during the acute 336 \nphase of DENV infection [39]. Here, as we used RNA as the starting material and sequenced a 337 \nunique sample, we cannot evaluate clonal expansion directly (as clonally related sequences may 338 \nbe clustered during the reconstruction of HCC and UHC). Nevertheless , we interpret the  higher 339 \nspecies richness in rarefaction analysis and increased Shannon -Weaver index as the result of 340 \nhigher numbers of circulating B cells , which  could be explained, at least partially, by the 341 \nmassive plasmablast  migration that occurs during the acute phase of the disease [15,19,20]. 342 \nFlow cytometric analysis  in an independent group of patients further supported the increase of B 343 \ncell diversity (Figure S2D).  344 Preferential IGHV usage has been described in antigen -specific B cells in models of 345 \ncytopathic viral infection. In the vesicular stomatitis virus (VSV) in fection in mice, a rapid 346 \ninitial IgG neutralizing response of defined germ line, unmutated IGHV segments ( VHQ52 ) 347 \nconfers protection. Secondary challenge is associated with a shift in the use of other segments 348 \n(VH7183  and VHJ558 ) and the occurrence of SHM [40,41]. 349 \nThe generation of unmutated IgG+ switched memory B cells beyond the VSV model has 350 \nbeen described  in a mice model of polyoma virus infection [42] and Bcl6-deficient mice , which 351 \nare devoid of T FH cells and thus lack germinal center reaction [43,44]. Strikingly similar results 352 \nhave been obtained in human rotavirus infection, where the response to VP6 is mediated in part 353 \nby class -switched memory B cells  exhibiting low hypermutation rates  that pr edominantly use 354 \nIGHV1 -46 [45]. These observations have been generalized as part of the concept of \u201cnatural 355 \nantibodies\u201d, which can be IgM, IgG and IgA, are encoded by unmutated germ line antibod y 356 \ngenes , are produced as a rapid T cell -independent response against a variety of viruses with 357 \nrelatively high affinity, and recognize repetitive structures such as viral capsids, but are 358 \nintrinsically poly -reactive  [46]. A notable example of this type of antibodies are IGHV1 -69-359 \ncoded antibodies that have been recurrently implicated in recogn ition against influenza A, 360 \nhepatitis C and human immunodeficiency viruses [47-52]. 361 \nIn accordance with a  \u201cnatural\u201d antibody response , DENV a ctivates poly-reactive, 362 \nnatural IgG B cells after primary and secondary infection [15]. Studies with human anti -DENV 363 \nmonoclonal antibodies have revealed that  a large proportion of DENV -reactive human 364 \nantibodies are highly cross -reactive  [17,18] and recognize quaternary epitopes present only  on 365 \nthe viral particle, but not in monomeric E protein [53]. Here we have found low levels of SHM 366 \nand differential usage of IGHV1 -2, IGHV1 -18 and IGHV1 -69 in acute DWS - and D WS + , 367 \nsuggesting their potential implication in \u201cnatural\u201d DENV recognition , cross -reactivity  and 368 \nantibody -dependent enhancement . Lower mutation rates did not seem to be associated with time 369 \n(days)  after the onset of the first symptoms, as no differences were observed between primary 370 \nand secondary infection s, nor between  DWS \u2013 and DWS +. Moreover, by using a  5\u2019RACE 371 \napproach for VH library generation , a bias for amplification of unmutated sequences is ruled 372 out. We propose that during acute primary and secondary DENV infection s, at least two effector 373 \nB cell differentiation pathways  co-occur , one consist ing in natural unmutated antibody IgG 374 \nresponse , (similar to that occurring in  VSV infection model and  polyomavirus infection s in 375 \nmice and rotavirus infections in humans) , along  with the classical secondary T -cell and 376 \ngerminal center dependent B cell respon se pathway  (Figure 7). 377 \nInterestingly , lower IgG SHM rates were found in acute disease, and appeared to be 378 \nmore accentuated in DWS + than in DWS -, and in secondary more than in primary acute 379 \ninfection . This effect was particularly accentuated in IGHV1 -2 expressing  IgG B cells.  380 \nConsistent with its role in \u201cnatural\u201d antibody recognition, IGHV1 -2 is frequently used by 381 \nneonatal cord blood IgM+ lymphocytes  [54] and in marginal zone B cell lymphomas  [55,56], 382 \nwhich are thought to derive from chronic pathogen -mediated selection  [57]. Marginal zone 383 \n(MZ) B cells are capable of mounting class -switched and unclass -switched  T-independent as 384 \nwell as T -dependent antibody responses [30]. Normal Marginal zone B cells produce rapid 385 \nresponses to blood -borne pathogens and could be the source of natural IgM and IgG responses 386 \nagainst DENV. However, no modification in MZ B cells was observed in pediatric acute DENV 387 \ninfected children  [19], and human MZ B cells are usually hypermutated  [30], thus suggesting 388 \nthat during acute DENV infection, MZ B cells are not the source of circulating unmutated IgG+ 389 \nB cells . Additionally, a subset of human IgG+ memory B cells expressing  a low frequency of 390 \nsomatic m utations and the lack of CD27 expression has been described [58]. Further research is 391 \nneeded to clarify if the source of B cells with low SHM rates found during acute DENV 392 \ninfection derives from MZ or CD27 - IgG+ B cells.  393 \nAmong other  limitation s of the HTS approach we followed is that our VH libraries 394 \nderive d from total peripheral blood IgG expressing B cells ; as such , we have no information 395 \nregarding the relative contribution of different B cell subsets  or their antigen specificity . 396 \nHowever, in support of our results, a preferential use of IG HV1 family in PB, but no memory B 397 \ncells has been described in acute D ENV infection  [16]. Moreover, the high proportion of 398 \nDENV -specific plasmablasts occurring during acute infection [20] provide s further support to 399 \nthe claim that the observed repertoire differences may be DENV -specific as well.  400  The molecular basis for T -independent CSR  to IgG  is starting to be elucidated. In mice, 401 \nTLR7 and TLR9 synergize with BCR signaling to promote activation -induced cytidine 402 \ndeaminase (AID) expression, which is required for CSR  and SHM  [59]. Although both 403 \nprocesses are functionally coupled , it is not clear how SHM is prevented in B cel ls undergoing 404 \nT-independent CSR . DENV signals through  TLR3 [60,61], but being an ssRNA virus, it may 405 \nalso activate s ignaling through TLR7 leading to  the activation of type I IFN response. Both 406 \nsignaling pathways are implicated in promoting T -independent CSR [59] and T-independent 407 \nIgG responses against polyomavirus require MyD88  [62]. Among  peripheral blood 408 \nmononuclear cells, higher  levels of DENV RNA are found in B cells, although no significant 409 \nviral replication occurs  [63]. Therefore, i t is likely that anti-DENV cross -reactive B cells may 410 \nbe infected by BCR -mediated endocytosis . Endosomal DENV recognition by TLR7 could 411 \nprovid e a synergic signal  with the BCR  for T -independent CSR anti-DENV cross -reactive B 412 \ncells (Figure 7). This model is analogous  to, and is further supported by the induction of a rapid 413 \nclass -switched extra -follicular B cell response  to CpG -conjugated protein antigen (a TLR -9 414 \nagonist) immunization [64]. 415 \nIf correct, the present model  of extra -follicular B cell responses offers a potential 416 \nexplanation for the production of low affinity sub-neutralizing and cross -reactive IgG antibodies 417 \nthat may promote disease enhancement. Thus, in the case of DENV vaccination  and 418 \nanalogously to observations in polyomavirus immunized mice [42], strategies that promote T-419 \nindependent  B cell responses (i.e. TLR7 agonist) such as live attenuated chimeric yellow 420 \nfever/Dengue viruses , could be associated with a higher risk of severe disease upon reinfection 421 \nthan vaccines that do not promote TLR7 activation  (e.g. protein subunit  and virus-like particles)  422 \n[65,66]. 423 \n  424 Materials and Methods  425 \nEthics Statement  426 \nThis study was conducted according to the principles expressed  in the Declaration of Helsinki 427 \nand in strict accordance with the recommendations  of the Research, Ethics and Biosafety 428 \nCommittees of the National Institute of Public Health (INSP)  (CI:1023/1100) , Universidad 429 \nVeracruzana (UV) , Integral Molecular  and Instituto de Diagn\u00f3stico y Referencia 430 \nEpidemiol\u00f3gicos (InDRE).  Written informed consent of all participants was obtained.  431 \nPatients, donors  and samples.  432 \n During Dengue season 2010 and 2011 , 19 adult patients with clinical and laboratory 433 \nconfirmed DENV infection  living in Veracruz, a DENV endemic zone in Mexico  [67], were 434 \nenrolled  after written informed consent . Patients were classified as DWS + if they required 435 \nhospitalization, hematocrit > 40, platelet cou nt < 100 x103 and at least one of the following 436 \nsigns: abdominal pain or tenderness, p ersistent vomiting , clinical fl uid accumulation , mucosal 437 \nbleed ing, l ethargy, restlessness  or liver enlarg ement (>2 cm ). After signing informed consent, 438 \npatients donate d two peripheral blood samples  to obtain RNA and serum : one during the febrile 439 \nstage (acute sample) and the other six months after recovery (post -convalescent sample) , 440 \ncoinciding with the low transmission season to minimize the possibility of asymptomatic re -441 \ninfection . For some data analyses, a n additional control group of 10 healthy volunteers enrolled 442 \nin an influenza vaccination study (Cortina -Ceballos et al., 2014 . Manuscript in preparation ), was 443 \nincluded . Peripheral blood was collected to obtain serum and total RNA.  For RNA isolation , 2.5 444 \nml of peripheral blood in PaxGene RNA tubes (QIAGEN GmbH, Hilden, Germany) was used 445 \naccording to manufacturer\u2019s instructions and store d at -70qC until use.  446 \nFlow cytometry analysis o f CD19+ cells 447 \n An independent group of ac ute Dengue patients (n= 17) and healthy volunteers (n= 12) 448 \nwas included for flow cytometric analysis. Blood samples were obtained during the 2014 449 season. PBMC s were purified by density centrifugation  and cryopreserved  at -80\u00b0C for up to 3 450 \nmonths. Staining was performed with anti -CD19 -FITC (Biolegend) and analyzed in a BD 451 \nAccuri TM C6 cytometer  (BD Biosciences) . 452 \nDengue virus genotyping  453 \nViral RNA was isolated from the ser a during  the acute  febrile  phase (QIAamp Viral 454 \nRNA mini kit, Q iagen) and used to determinate DENV serotype by RT -qPCR according to the 455 \nprotocol of the Epidemiological Diagnosis and Reference Institute in Mexico (InDRE) 456 \n(http://www.epidemiologia.salud.gob.mx/doctos/sinave/ve_lab/LINEAMIENTOS_DENGUE_2457 \n012.pdf ) and the Official Mexican Nor m: NOM -032-SSA-2002 ( http://www.salud.gob.mx/  458 \nunidades/cdi/nom/032ssa202.html ). 459 \nDENV Reporter Virus Particles  Neutralization assay  460 \n DENV Reporter Virus Particles (RVPs)  [23] were pre -incubated with an equal volume 461 \nof serially diluted sera (1:10 to 1:10,240; all dilutions a re pre -incubation with RVPs) in 462 \ncomplete DMEM for 1 hour at room temperature with slow agitation. Following incubation, 463 \nBHK DC -SIGN cells were added to each well at a density of 30,000 cells per well followed by 464 \nincubation at 37\u00b0C in 5% CO 2 for 72 hours. C ells were subsequently lysed and analyzed for 465 \nluciferase luminescent reporter expression. The percent infection for each concentration of 466 \nserum was calculated using Prism software 5.0  and raw data expressed as percent infection 467 \nversus log 10 of the reciproc al serum dilution. A sigmoidal dose response curve with a variable 468 \nslope was applied to determine the titer of antibody that achieved a 50% reduction in infection 469 \n(50% neutralization titer, NT 50). Maximum infection was determined by using a no serum 470 \ncontro l. A NT 50 \u22651:50 was defined as a positive neutralization test . 471 \nVH libraries and High throughput sequencing  472 \nRNA concentration and integrity was analyzed through capillary electrophoresis in a n 473 \nAgilent  2100 BioAnalyzer, with the RNA 6000 Pico kit. cDNA  was generated for V H region of 474 \nIgG through RACE 5\u2019 PCR a proto col modified from Clontech kit (Clontech Laboratories, Inc. 475 PT 3269 -1. 2008). Forward primer (FpAmpTA) is a modification from the UPM primer to 476 \nwhich we added in 5' end an A adapter from the pl atform GS FLX Titanium 45 4 of Roche. The 477 \nreverse primer TBIgGHu (5\u2019-{454adaptorB}CTA TGC GCC TTG CCA GCC CGC  {454key}  478 \nTCAG{IGHCG}ACC GAT GGG CCC TTG GTG -3\u2019) primes  in Exon I of the IGHCG gene and 479 \nhas the B adapter for the  454-Roche sequencing  [24]. 500-600bp 5\u2019RACE PC R products we re 480 \nanalyzed by 1.5% agarose gel electrophoresis and purified with Qiagen MiniElute PCR 481 \npurification kit. The concentration and integrity was analyzed through capillary electrophoresis 482 \nin a 2100 BioA nalyzer, using the Agilent Hig h Sensitivity DNA 2100 LabChip.  483 \nWe used 100ng of each library for the emulsion PCR (GS emPCR Kit, Roche). High 484 \nthroughput sequencing was performed using Genome Sequencer FLX Titanium System 454 485 \nRoche with the kit GS LR70 Seque ncing according to the manufacturer\u2019s instructions. This 486 \nplatform allows sequences with an average length of 450 -500bp. We performed the sequencing 487 \nwith the B adapter (3\u2019 \u00c65\u2019) so that  the CDR H3 region is proximal and the 5\u2019 UTR is to the 488 \nsequencing primer a llowing higher sequencing quality in the majority of the IGHV coding 489 \nregion.  490 \nBioinformatic s analysis  491 \nPre-processing and repertoire reconstruction  492 \nWe have developed a  pipeline named ImmunediveRsity (Cortina -Ceballos  et al. , 493 \nSubmitted. 2014). ImmunediveRsity  is written in R language [68] and automates Ig sequencing 494 \nanalysis from pre -processing, error correction and quality filtering, V(D)J segment assignment, 495 \nCDRH3 -based sequence clustering for Heavy Chain Clonotype (HCC ) and Unique Heavy 496 \nChain (UHC) identification . Raw sequences with an average  \u2265 Q28 value and reads \u2265250bp 497 \npassed the quality filter. In order to exclude non -VH sequences , ImmunediveRsity assigns 498 \nIGHV and IGHJ segments use to each read using IgBLAST  [69]. A HCC is composed by reads 499 \nthat share the same V  and J segment  and their CDRH3  has the same length and is 97% identical.  500 \nReads belonging to a  HCC  are further clustered  along the whole coding region, excluding signal 501 \npeptide, so that UHC is the consensus of reads sharing  99.5% identity.  502 Estimation of sample B cell diversity  503 \nImmunediveRsity calculates  HCC  and UHC  entropy values (Shannon I ndex ) [26,70] 504 \nand rarefaction analysis [25] as indirect measures of lympho cyte diversity . The number of reads 505 \nper HCC  and UHC  obtained for each sample ( acute or post-convalescent phase) was used to 506 \ncalculate the Shannon Index . Rarefaction curves were calculated with the number of HCC  in 507 \ngrowing subsamples of 1,000 reads. Immuned iveRsity also calculates the Gini coefficient 508 \n[27,71] to measure HCC relative size evenness, as well as the degree of diversification and 509 \nevenness of UHC size within each HCC.  510 \nIGHV segment overrepresentation analysis  511 \nWe took two approaches to identify overrepresented IGHV segments during acute 512 \nDENV infection. The first approach aims to reflect plasmablast IGHV use based on the 513 \nestimation on IGHV segment relative transcription levels,  and was calculate d based on the 514 \nproportion of reads for each IGHV family and segments normalized to the  total number of reads 515 \nper library , regardless of clonal diversity within each segment . When both acute and post -516 \nconvalescent samples were available, th e proportion of reads for each segment during the acute  517 \nphase was subtracted to its corresponding value during the post -convalescent phase ( 'A-Pc). 518 \nThe second approach aims to estimate IGHV usage per clone, where the number of HCC using 519 \na particular IGHV s egment is expressed as the proportion of all HCC in the corresponding 520 \nlibrary. Similarly to the first approach, changes of IGHV usage are expressed as the difference 521 \nof the acute phase frequency  minus its corresponding post -convalescent frequency ( 'A-Pc). 522 \nStatistical evaluation was done with two -way ANOVA with Bonferroni correction for multiple 523 \ntesting using Graph Pad Prism v5.0. Differences were considered statistically significant if p-524 \nvalues  <0.05.  525 \nVH Mutation analysis  526 \nThe number of n on-synonymous and synonymous mutation s were obtained with 527 \nIMGT/High VQuest [29] for each UHC  consens us. To compare the proportion of mutation s, 528 \nonly productive UHC\u2019s were subjected to random sub -sampling (1,280 UHC per library).  The 529 proportion of mutation s (pM-VH), proportion of non -synonymous (pNSM -VH) and 530 \nsynonymous mutatio ns (pSM -VH) was calculated as the percentage of  total of mutations in VH 531 \nregion divided by its length.  To identify differences in the proportion of mutations per IGHV 532 \nsegment, t he mean global mutation  proportion  was subtracted from each individual IGHV mean 533 \nmutation proportion. The difference was subjected to unsupervised hi erarchical clustering  534 \naccording to IGHV segment using a correlation -uncentered metric for clustering with software 535 \nCLUSTER 3.0 [72]. For multi variate comparisons among control, DWS - A, DWS + A , DWS - 536 \nPc and DWS + P c consensus of UHC based on the mean of mutation proportion (pMVH, 537 \npMNS -VH, pMS -VH) and the mean of frequency of UHC , multilevel principal component 538 \nanalysis (PCA) [73] was applied in a sample of  1280 consensus of UHC  chosen randomly for 539 \neach individual, and graphically visualized  using biplot graph, which is a graphical 540 \nrepresentation of Component 1 (PC1) versus Component 2 ( PC2), selected by the criteria of 541 \nproportion of explained variance (t hat is, accounts for as much of the variability in the data as 542 \npossible) . This analysis was conducted using R software [74]. For visualiz ation of graphical 543 \nreconstructions of the B cell repertoire for each condition, 1,280  UHC were randomly sampled 544 \nto make a network representation of HCC  with their respective UHC with iGraph [28]. The 545 \ncolor scale represents the numb er of non -synonymous mutations. Non -parametric analysis 546 \n(Kruskal -Wallis test) with Dunn\u2019s correction for multiple testing were performed for 547 \ncomparisons among the different groups with R software  [75]. Differences were considered 548 \nstatistically significant if p-values  <0.05.  549 \nAcknowledgements  550 \nWe would like to thank Mauricio Vazquez Pichardo for support with DENV genotyping , 551 \nMarbella Ovilla Mu\u00f1oz and Helena Kuri for labora tory assistance . Special thanks to Scott D . 552 \nBoyd and Jos\u00e9 Ramos Casta\u00f1eda for critically reviewing the manuscript.  553 \n 554 \nAcronyms  555 \nADE   Antibody -Dependent Enhancement  556 BCR   B Cell Receptor  557 \nCDRH3  Complementarity Determining Region Heavy 3  558 \nCSR   Class Switch Recombination  559 \nDENV   Dengue virus  560 \nDWS -   Dengue without Warning Sings . 561 \nDWS +  Dengue with  Warning Sings . 562 \nHCC   Heavy Chain Clonotype  563 \nHTS   High-Throughput Sequencing  564 \nNSM   Non-Synonymous Mutations  565 \nRep-Seq Repertoire sequencing  566 \nRVPs   Reporter Virus Particles  567 \nSHM   Somatic Hyper Mutation  568 \nSM  Synonymous Mutations  569 \nUHC   Unique Heavy Chain  570 \n  571 References  572 \n1. Halstead SB (2007) Dengue. The Lancet 370: 1644 -1652.  573 \n2. WHO (2009) Dengue: guidelines for diagnosis, treatment, prevention and control.  574 \n3. Bhatt  S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. (2013) The global 575 \ndistribution and burden of dengue. Nature 496: 504 -507. 576 \n4. Wu SJ, Grouard -Vogel G, Sun W, Mascola JR, Brachtel E, et al. (2000) Human skin 577 \nLangerhans cells are targets of dengue viru s infection. Nat Med 6: 816 -820. 578 \n5. Durbin AP, Vargas MJ, Wanionek K, Hammond SN, Gordon A, et al. (2008) 579 \nPhenotyping of peripheral blood mononuclear cells during acute dengue illness 580 \ndemonstrates infection and increased activation of monocytes in severe c ases 581 \ncompared to classic dengue fever. Virology 376: 429 -435. 582 \n6. Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, et al. (2001) Infection of human 583 \ndendritic cells by dengue virus causes cell maturation and cytokine production. J 584 \nImmunol 166: 1499 -1506.  585 \n7. Wahal a WM, Silva AM (2011) The human antibody response to dengue virus 586 \ninfection. Viruses 3: 2374 -2395.  587 \n8. Guzman MG, Alvarez M, Halstead SB (2013) Secondary infection as a risk factor for 588 \ndengue hemorrhagic fever/dengue shock syndrome: an historical perspectiv e and 589 \nrole of antibody -dependent enhancement of infection. Arch Virol 158: 1445 -590 \n1459.  591 \n9. Halstead SB (2009) Antibodies determine virulence in dengue. Ann N Y Acad Sci 592 \n1171 Suppl 1: E48 -56. 593 \n10. Maul RW, Gearhart PJ (2010) Controlling somatic hypermutation i n 594 \nimmunoglobulin variable and switch regions. Immunol Res 47: 113 -122. 595 \n11. Xu Z, Zan H, Pone EJ, Mai T, Casali P (2012) Immunoglobulin class -switch DNA 596 \nrecombination: induction, targeting and beyond. Nat Rev Immunol 12: 517 -531. 597 \n12. Victora GD, Nussenzweig  MC (2012) Germinal centers. Annu Rev Immunol 30: 598 \n429-457. 599 \n13. Tarlinton D, Good -Jacobson K (2013) Diversity among memory B cells: origin, 600 \nconsequences, and utility. Science 341: 1205 -1211.  601 \n14. Midgley CM, Bajwa -Joseph M, Vasanawathana S, Limpitikul W, Wil ls B, et al. 602 \n(2011) An in -depth analysis of original antigenic sin in dengue virus infection. J 603 \nVirol 85: 410 -421. 604 \n15. Balakrishnan T, Bela -Ong DB, Toh YX, Flamand M, Devi S, et al. (2011) Dengue 605 \nvirus activates polyreactive, natural IgG B cells after prim ary and secondary 606 \ninfection. PLoS One 6: e29430.  607 \n16. Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, et al. (2012) Plasmablasts 608 \ngenerated during repeated dengue infection are virus glycoprotein -specific and 609 \nbind to multiple virus serotypes. J Immunol 189:  5877 -5885.  610 \n17. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. (2010) 611 \nThe human immune response to Dengue virus is dominated by highly cross -612 \nreactive antibodies endowed with neutralizing and enhancing activity. Cell Host 613 \nMicrobe 8: 271-283. 614 \n18. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, et al. (2012) 615 \nPersistence of circulating memory B cell clones with potential for dengue virus 616 \ndisease enhancement for decades following infection. J Virol 86: 2665 -2675.  617 19. Zompi S, M ontoya M, Pohl MO, Balmaseda A, Harris E (2012) Dominant cross -618 \nreactive B cell response during secondary acute dengue virus infection in 619 \nhumans. PLoS Negl Trop Dis 6: e1568.  620 \n20. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, et al. (2012) Rapid 621 \nand massive virus -specific plasmablast responses during acute dengue virus 622 \ninfection in humans. J Virol 86: 2911 -2918.  623 \n21. Benichou J, Ben -Hamo R, Louzoun Y, Efroni S (2012) Rep -Seq: uncovering the 624 \nimmunological repertoire through next -generation sequencing. Immunology 625 \n135: 183 -191. 626 \n22. Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, et al. (2014) The 627 \npromise and challenge of high -throughput sequencing of the antibody repertoire. 628 \nNat Biotechnol 32: 158 -168. 629 \n23. Mattia K, Puffer BA, Will iams KL, Gonzalez R, Murray M, et al. (2011) Dengue 630 \nreporter virus particles for measuring neutralizing antibodies against each of the 631 \nfour dengue serotypes. PLoS One 6: e27252.  632 \n24. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, et al. (2005) Genome  633 \nsequencing in microfabricated high -density picolitre reactors. Nature 437: 376 -634 \n380. 635 \n25. Weinstein JA, Jiang N, White RA, 3rd, Fisher DS, Quake SR (2009) High -636 \nthroughput sequencing of the zebrafish antibody repertoire. Science 324: 807 -637 \n810. 638 \n26. Robert L, T soi J, Wang X, Emerson R, Homet B, et al. (2014) CTLA4 blockade 639 \nbroadens the peripheral T -cell receptor repertoire. Clin Cancer Res 20: 2424 -640 \n2432.  641 \n27. Ceriani L, Verme P (2012) The origins of the Gini index: extracts from Variabilit\u00e0 e 642 \nMutabilit\u00e0 (1912) by  Corrado Gini. The Journal of Economic Inequality 10: 643 \n421-443. 644 \n28. Csardi G, Nepusz T (2006) The igraph software package for complex network 645 \nresearch. InterJournal, Complex Systems 1695.  646 \n29. Li S, Lefranc MP, Miles JJ, Alamyar E, Giudicelli V, et al. (2013 ) IMGT/HighV 647 \nQUEST paradigm for T cell receptor IMGT clonotype diversity and next 648 \ngeneration repertoire immunoprofiling. Nat Commun 4: 2333.  649 \n30. Cerutti A, Cols M, Puga I (2013) Marginal zone B cells: virtues of innate -like 650 \nantibody -producing lymphocytes. Nat Rev Immunol 13: 118 -132. 651 \n31. Zompi S, Harris E (2012) Animal models of dengue virus infection. Viruses 4: 62 -652 \n82. 653 \n32. Andraud M, Hens N, Marais C, Beutels P (2012) Dynamic epidemiological models 654 \nfor dengue transmission: a systematic review of structural  approaches. PLoS 655 \nOne 7: e49085.  656 \n33. Mora T, Walczak AM, Bialek W, Callan CG, Jr. (2010) Maximum entropy models 657 \nfor antibody diversity. Proc Natl Acad Sci U S A 107: 5405 -5410.  658 \n34. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, et al. (2009) 659 \nMeasure ment and Clinical Monitoring of Human Lymphocyte Clonality by 660 \nMassively Parallel V -D-J Pyrosequencing. Sci Transl Med 1: 12ra23 -12ra23.  661 \n35. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. (2011) Focused evolution of HIV -662 \n1 neutralizing antibodies revealed by structures and deep sequencing. Science 663 \n333: 1593 -1602.  664 \n36. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, et al. (2011) Epitope -665 \nspecific human influenza antibody repertoires diversify by B cell intraclonal 666 \nsequence divergence and interclonal c onvergence. J Immunol 187: 3704 -3711.  667 37. Jiang N, He J, Weinstein JA, Penland L, Sasaki S, et al. (2013) Lineage structure of 668 \nthe human antibody repertoire in response to influenza vaccination. Sci Transl 669 \nMed 5: 171ra119.  670 \n38. Jackson KJ, Liu Y, Roskin KM,  Glanville J, Hoh RA, et al. (2014) Human 671 \nresponses to influenza vaccination show seroconversion signatures and 672 \nconvergent antibody rearrangements. Cell Host Microbe 16: 105 -114. 673 \n39. Parameswaran P, Liu Y, Roskin KM, Jackson KK, Dixit VP, et al. (2013) 674 \nConvergent antibody signatures in human dengue. Cell Host Microbe 13: 691 -675 \n700. 676 \n40. Kalinke U, Bucher EM, Ernst B, Oxenius A, Roost HP, et al. (1996) The role of 677 \nsomatic mutation in the generation of the protective humoral immune response 678 \nagainst vesicular stomatitis virus. Immunity 5: 639 -652. 679 \n41. Kalinke U, Oxenius A, Lopez -Macias C, Zinkernagel RM, Hengartner H (2000) 680 \nVirus neutralization by germ -line vs. hypermutated antibodies. Proc Natl Acad 681 \nSci U S A 97: 10126 -10131.  682 \n42. Szomolanyi -Tsuda E, Le QP, Gar cea RL, Welsh RM (1998) T -Cell-independent 683 \nimmunoglobulin G responses in vivo are elicited by live -virus infection but not 684 \nby immunization with viral proteins or virus -like particles. J Virol 72: 6665 -685 \n6670.  686 \n43. Toyama H, Okada S, Hatano M, Takahashi Y, Tak eda N, et al. (2002) Memory B 687 \ncells without somatic hypermutation are generated from Bcl6 -deficient B cells. 688 \nImmunity 17: 329 -339. 689 \n44. Kaji T, Ishige A, Hikida M, Taka J, Hijikata A, et al. (2012) Distinct cellular 690 \npathways select germline -encoded and soma tically mutated antibodies into 691 \nimmunological memory. J Exp Med 209: 2079 -2097.  692 \n45. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, et al. (2008) 693 \nImmunodominance of the VH1 -46 antibody gene segment in the primary 694 \nrepertoire of human rotavirus -specific B cells is reduced in the memory 695 \ncompartment through somatic mutation of nondominant clones. J Immunol 180: 696 \n3279 -3288.  697 \n46. Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: 698 \nthe two extremes of a wide spectrum. Nat Re v Immunol 6: 231 -243. 699 \n47. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) 700 \nAntibody recognition of a highly conserved influenza virus epitope. Science 701 \n324: 246 -251. 702 \n48. Lingwood D, McTamney PM, Yassine HM, Whittle JR, Guo X, et al . (2012) 703 \nStructural and genetic basis for development of broadly neutralizing influenza 704 \nantibodies. Nature.  705 \n49. Sasso EH, Ghillani P, Musset L, Piette JC, Cacoub P (2001) Effect of 51p1 -related 706 \ngene copy number (V1 -69 locus) on production of hepatitis C-associated 707 \ncryoglobulins. Clin Exp Immunol 123: 88 -93. 708 \n50. Breden F, Lepik C, Longo NS, Montero M, Lipsky PE, et al. (2011) Comparison of 709 \nantibody repertoires produced by HIV -1 infection, other chronic and acute 710 \ninfections, and systemic autoimmune diseas e. PLoS One 6: e16857.  711 \n51. Warter L, Appanna R, Fink K (2012) Human poly - and cross -reactive anti -viral 712 \nantibodies and their impact on protection and pathology. Immunol Res 53: 148 -713 \n161. 714 \n52. Lerner RA (2011) Rare antibodies from combinatorial libraries sugg ests an S.O.S. 715 \ncomponent of the human immunological repertoire. Mol Biosyst 7: 1004 -1012.  716 53. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, et al. (2012) 717 \nIdentification of human neutralizing antibodies that bind to complex epitopes on 718 \ndengue viri ons. Proc Natl Acad Sci U S A 109: 7439 -7444.  719 \n54. Prabakaran P, Chen W, Singarayan MG, Stewart CC, Streaker E, et al. (2011) 720 \nExpressed antibody repertoires in human cord blood cells: 454 sequencing and 721 \nIMGT/HighV -QUEST analysis of germline gene usage, junc tional diversity, and 722 \nsomatic mutations. Immunogenetics.  723 \n55. Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, et al. (2012) Over 724 \n30% of patients with splenic marginal zone lymphoma express the same 725 \nimmunoglobulin heavy variable gene: ontogenetic  implications. Leukemia 26: 726 \n1638 -1646.  727 \n56. Warsame AA, Aasheim HC, Nustad K, Troen G, Tierens A, et al. (2011) Splenic 728 \nmarginal zone lymphoma with VH1 -02 gene rearrangement expresses poly - and 729 \nself-reactive antibodies with similar reactivity. Blood 118: 33 31-3339.  730 \n57. Bikos V, Stalika E, Baliakas P, Darzentas N, Davis Z, et al. (2012) Selection of 731 \nantigen receptors in splenic marginal -zone lymphoma: further support from the 732 \nanalysis of the immunoglobulin light -chain gene repertoire. Leukemia 26: 2567 -733 \n2569.  734 \n58. Fecteau JF, Cote G, Neron S (2006) A new memory CD27 -IgG+ B cell population 735 \nin peripheral blood expressing VH genes with low frequency of somatic 736 \nmutation. J Immunol 177: 3728 -3736.  737 \n59. Pone EJ, Zhang J, Mai T, White CA, Li G, et al. (2012) BCR -signall ing synergizes 738 \nwith TLR -signalling for induction of AID and immunoglobulin class -switching 739 \nthrough the non -canonical NF -kappaB pathway. Nat Commun 3: 767.  740 \n60. Nasirudeen AM, Wong HH, Thien P, Xu S, Lam KP, et al. (2011) RIG -I, MDA5 741 \nand TLR3 synergistically  play an important role in restriction of dengue virus 742 \ninfection. PLoS Negl Trop Dis 5: e926.  743 \n61. Tsai YT, Chang SY, Lee CN, Kao CL (2009) Human TLR3 recognizes dengue 744 \nvirus and modulates viral replication in vitro. Cell Microbiol 11: 604 -615. 745 \n62. Raval FM , Mishra R, Garcea RL, Welsh RM, Szomolanyi -Tsuda E (2013) Long -746 \nlasting T cell -independent IgG responses require MyD88 -mediated pathways 747 \nand are maintained by high levels of virus persistence. MBio 4: e00812 -00813.  748 \n63. Srikiatkhachorn A, Wichit S, Gibbons RV, Green S, Libraty DH, et al. (2012) 749 \nDengue viral RNA levels in peripheral blood mononuclear cells are associated 750 \nwith disease severity and preexisting dengue immune status. PLoS One 7: 751 \ne51335.  752 \n64. Eckl -Dorna J, Batista FD (2009) BCR -mediated uptake of a ntigen linked to TLR9 753 \nligand stimulates B -cell proliferation and antigen -specific plasma cell formation. 754 \nBlood 113: 3969 -3977.  755 \n65. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH (2011) The 756 \ndevelopment of recombinant subunit envelope -based vaccine s to protect against 757 \ndengue virus induced disease. Vaccine 29: 7267 -7275.  758 \n66. Zhang S, Liang M, Gu W, Li C, Miao F, et al. (2011) Vaccination with dengue 759 \nvirus -like particles induces humoral and cellular immune responses in mice. 760 \nVirol J 8: 333.  761 \n67. Hurtado -Diaz M, Riojas -Rodriguez H, Rothenberg SJ, Gomez -Dantes H, Cifuentes 762 \nE (2007) Short communication: impact of climate variability on the incidence of 763 \ndengue in Mexico. Trop Med Int Health 12: 1327 -1337.  764 \n68. Team RC (2013) R: A language and environme nt for statistical computing. 3.0.2 ed. 765 \nVienna, Austria: R Foundation for Statistical Computing.  766 69. Ye J, Ma N, Madden TL, Ostell JM (2013) IgBLAST: an immunoglobulin variable 767 \ndomain sequence analysis tool. Nucleic Acids Res 41: W34 -40. 768 \n70. Jost L (2006) Entropy and diversity. Oikos 113: 363 -375. 769 \n71. Bashford -Rogers RJ, Palser AL, Huntly BJ, Rance R, Vassiliou GS, et al. (2013) 770 \nNetwork properties derived from deep sequencing of human B -cell receptor 771 \nrepertoires delineate B -cell populations. Genome Res 23: 1874 -1884.  772 \n72. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display 773 \nof genome -wide expression patterns. Proc Natl Acad Sci U S A 95: 14863 -774 \n14868.  775 \n73. Zipunnikov V, Caffo B, Yousem DM, Davatzikos C, Schwartz BS, et al. (2011) 776 \nFunc tional principal component model for high -dimensional brain imaging. 777 \nNeuroimage 58: 772 -784. 778 \n74. Francois Husson JJ, Sebastien Le and Jeremy Mazet (2014) FactoMineR: 779 \nMultivariate Exploratory Data Analysis and Data Mining with R. R package 780 \nversion. 1.27 ed.  781 \n75. Dinno A (2014) dunn.test: Dunn's test of multiple comparisons using rank sums. R 782 \npackage version.  783 \n 784 \n 785 \n  786 Figure legends  787 \nFigure 1. Clinical specimen  sampling design and DENV cross -neutralization. A) Graphical 788 \nrepresentation of peripheral blood samples  taken for the study in relation to the onset of 789 \nsymptoms . B) Clinical and immunological status of patients included in the study. The number 790 \nof patients in each category during the acute phase is shown . Number of post -convalescent 791 \nsamples is shown in pare ntheses. C) Cross -reactivity of acute DENV infection sera to four 792 \nserotypes using the DENV reporter virus particle neutralization test. Each bar represents the 793 \nnumber of individuals having NT 50> 1:50 to x number of serotypes.  794 \nFigure 2. Rarefaction analysis  and entropy measurements reveal higher clonal diversity 795 \nduring acute phase than in the post -convalescent phase, regardless clinical classification  796 \nRarefaction analysis of acute vs . post-convalescent samples  according to clinical status,  (A) 797 \nDWS - and (B) DWS +; and immunologic status, (C) primary and (D) secondary infection.  (2-798 \nway ANOVA with Bonferroni correction. * p < 0.05; ** p <0.01). Shannon -Weaver entropy 799 \nvalues for Heavy chain clonotypes according to (E) clinical status  and (F) immunological status  800 \nand for unique Heavy chains ( UHC \u2019s) according to (G) clinical status and (H) immunological 801 \nstatus . (For E-H, one-way ANOVA with Bonferroni correction. * p < 0.05; ** p < 0.01).  802 \nFigure 3.  Lower Gini coefficient in acute phase of infection in both  DWS \u2013 and DWS + 803 \nindicate a more equitable UHC size distribution.  A) Scatter plot representing individual Gini 804 \ncoefficients  based on HCC size distributions.  B) Scatter plots representing the Gini coefficient 805 \nof pooled UHC\u2019s subsamples (n  = 1,280) per individual in each clinical status group. The mean 806 \nper group is represented as a red bar. Kruskal -Wallis test. Dunn\u2019s correction for multiple testing. 807 \n***p <0.001). C) Network graph representing equal numbers of HCC\u2019s (n=1,280) linked to 808 \ntheir c orresponding UHC. Diameters represent UHC relative frequency. Color code according 809 \nto Gini coefficient. Note lower  Gini coefficients (dark blue) in acute DWS \u2013 and DWS +.  810 \nFigure 4. Preferential  IGHV  usage  during acute DENV infection. A). Heat map of 811 \nhierarchical clustering of the difference between acute minus post -convalescent UHC  frequency 812 \n('A\u2013 Pc) per IGHV family. Over -representation of IGHV family usage during acute phase is 813 indicated in Yellow  tones, whereas blue tones indicate unde r-representation . Upper rows classify 814 \npatients according to clinical status (DWS -, green  and DWS +, blue) and immunologic status 815 \n(primary, orange  and secondary, purple ). (2-way ANOVA. Bonferroni correction for multiple 816 \ntesting.  *p <0.05).  B) Difference  between acute minus post -convalescent ( 'A \u2013 Pc) according to 817 \nIGHV segment , clinical and immune status.  IGHV1 -2 and IGHV1 -69 are over -represented  in 818 \nacute DWS  +. (columns . DWS -, green  and DWS +, blue) and immunologic status (primary, 819 \norange  and secondary, purple ). Higher frequency of UHC  using  IGHV1 -18 and IGHV1 -69 in 820 \nDWS+  is shown in red tones . 821 \nFigure 5. IgG B cell repertoire during acute DENV infection is associated with low SHM 822 \nrates.  SHM rates are shown according to clinical status (A, C, E and G) and according to 823 \nimmunologic status (B, D, F and H).  A) Global somatic hypermutation  rate during acute phase 824 \nis significantly lower in acute DENV infection, but not as a result of 2008 -2009 seasonal 825 \ntrivalent influenza vaccination. B) Global SHM rates are lowe r in acute phase of DENV 826 \ninfection and  significantly lower  in acute secondary infection than in acute primary infection. 827 \nC) SHM rates of IGHV1 -2 regarding clinical status and  D) immunologic status. E) SHM rates 828 \nof IGHV1 -18 regarding clinical status and F) immunologic status. G) SHM rates of IGHV1 -69 829 \nregarding clinical status and H) immunologic status.  (Kruskal -Wallis test. Dunn\u2019s correction for 830 \nmultiple testing. ** p <0.01, *** p <0.001).  831 \nFigure 6. Multilevel Principal Component A nalysis of mutational parameters in acute 832 \nDENV infection . A) Single Principal Component plot of PC1, which represents number of 833 \ntotal, non -synonymous and synonymous mutations in IGHV segments of controls, acute D WS- 834 \n(DWS \u2013A), post -convalescent DWS - (DWS - Pc), acute DWS +  (DWS  + A) and post -835 \nconvalescent ( DWS + Pc ). Lower scores for PC1 are observed during acute phase of DENV 836 \ninfection. D WS - A and DWS -Pc were significantly different (Kruskal -Wallis test. **p < 0.01). 837 \nB) Biplot showing clustering of patient samples according to  clinical status.  838 \nFigure 7. Proposed model for B cell responses in secondary lymphoid organs during a 839 \nprimary and a secondary DENV infection.  DENV recognition by na\u00efve B cells and during 840 \nearly primary infection occurs in extra -follicular regions and induces a rapid differentiation to Ig 841 switched plasmablast/plasma cell secreting unmutated poly /cross -reactive IgG. This pathway 842 \nmay be initiated b y DENV low affinity interactions with B cells using an \u201cinnate\u201d or SOS 843 \nIGHV segment such as IGHV1 -69 [52] that promote receptor -mediated endocytosis and TLR7 844 \nrecognition. Both signals promote T -independent activation and CSR. Later, the cl assical 845 \ngerminal center T -dependent response develops peaking at 1 -2 weeks after symptoms onset. A 846 \nsecondary infection with a different serotype triggers the same \u201cnatural\u201d B cell response derived 847 \nfrom na\u00efve B cells that temporally overlaps with a more rap id secondary T -dependent B cell 848 \nresponse.  849 \nSupplementary Figure legends  850 \nFigure S1.  Days after onset of clinical illness for blood sampling  according to clinical 851 \nstatus . (One -way ANOVA. p > 0.05. Not significant) . 852 \nFigure S2. Rarefaction analysis and entropy measurements for acute DENF infection 853 \naccording to clinical and immunologic status. A) Comparative rarefaction analysis between 854 \nacute DWS - vs. DWS +, B) acute primary vs. acute secondary infection; C) Shannon -Weaver 855 \nentropy  according to DENV serotype and ( D) Proportion of CD19+ B cells in PBMC of acute 856 \nDENV infection according to clinical status (one -way ANOVA with Bonferroni correction. * p 857 \n< 0.05; ** p < 0.01).  858 \nFigure S3. Unique Heavy chain size in acute and post -convalescent DENV infection 859 \naccording to clinical status.  860 \nFigure S4 . Preferential  IGHV  transcription and usage  during acute DENV infection. A). 861 \nHeat map of hierarchical clustering of the difference between acute minus post -convalescent 862 \nread relative frequency ( 'A \u2013 Pc) per IGHV family. Over -transcription of IGHV family during 863 \nacute phase is indicated in Yellow  tones, whereas blue tones indicate under -transcription. Upper 864 \nrows classify patients according to clinical status (DWS -, green  and DWS +, blue) and 865 \nimmunologic status (primary, orange  and secondary, purple ). (2-way ANOVA. Bonferroni 866 \ncorrection for multiple testing.  *p <0.05). B) Relative transcription difference  between acute 867 \nminus post -convalescent ( 'A \u2013 Pc) according to IGHV segment and clinical status. IGHV1 -2 868 and IGHV1 -69 are overexpressed in acute DWS  + (2-way ANOVA. Bonferroni correction for 869 \nmultiple testing.  *p <0.05).  C) Difference  between the relative IGHV segment use per HCC  870 \n(rows ) in acute minus post -convalescent ( 'A \u2013 Pc) according to clinical status ( columns . DWS -, 871 \ngreen  and DWS +, blue) and immunologic status (primary, orange  and secondary,  purple ). 872 \nHigher frequency of HCC using  IGHV1 -18 and IGHV1 -69 in DWS+ is shown in red tones (2-873 \nway ANOVA. Bonferroni  correction for multiple testing.  *p <0.05).  874 \nFigure S5. Digital CDR H3 \u201cspectratyping\u201d of  acute phase DENV infection of  all sampled 875 \nB cells and according to IGHV1 -2, IGHV1 -18 and IGHV1 -69 segments . Clinical and 876 \nimmunological status is shown in upper bars. CDR H3 length (bp) is shown in x axis and relative 877 \nfrequency is shown in y axis. 878 \nFigure S 6. Somatic hypermutation rates in secondary cases. A)  Global mutation rates; B) 879 \nIGHV1 -2; C) IGHV1 -18; and D) IGHV1 -69. 880 \nFigure S7. Graphical reconstruction of the peripheral blood sampled B cell repertoire.  A) 881 \nQuantitative analysis of non -synonymous somatic hypermutation based on the repertoire graphs 882 \nshown in B (Kruskal -Wallis test for non -parametric data with Dunn\u2019s multiple comparison test. 883 \n*p< 0.001). B) Proportion of HCC having a Gini coefficient = 0.0.  884 \n 885 \nFigure S 8. Heat map  representation of  SHM according to IGHV segment (rows) and 886 \nclinical status (columns).  Acute DENV infection had significantly lower levels of SHM than 887 \npost-convalescent and control sa mples.  888 \n  889 Table 1. Demographic data and clinical parameters . 890   DWS-A DWS-PC DWS+A DWS+PC Number, n   10 7 9 4 Male, n (%)  3 (30%) 2 (28.6%) 4 (44.4%) 1 (25%) Age, median (range)  33 (18-50) 27 (18-50) 30 (16-47) 18 (16-46) Days of symptoms, median (range)  4 (1-8) 294.5 (133-323) 6 (3-9) 268 (128-309) Type of infection, n (%) Primary 3 (30%) 3 (42.9%) 0 (0%) 0 (0%)  Secondary 7 (70%) 4 (57.1%) 9 (100%) 4 (100%) Serotype, n (%)  DENV1 2 (20%) NA 3 (33.3%) NA  DENV2 5 (50%) NA 5 (55.6%) NA  Unknown 3 (30%) NA 1 (11.1%) NA Hemoglobin, mean (SD)  14.2 (1.5) UD 13.55 (2.0) UD Platelets, mean (SD)  125.5 (78.0) UD 68.8 (34.7) UD Hematocrit, mean (SD)  41.3 (1.6) UD 40.42 (1.7) UD SD. Standard Deviation; UD. Undetermined; NA. Not Applicable . Percentages (%) are calculated based on n per 891 \ncolumn.892 Table 2. Sequencing summary . 893   DWS-A (SD) DWS-PC (SD) DWS+A (SD) DWS+PC (SD) Raw Sequences 731,977 (25,500) 460,685 (23,151) 594,743 (27,433) 260,066 (47,798) Pass filters Sequences 659,621 (23,636) 395,217 (22,634) 499,483 (25,926) 227,017 (44,401) Heavy Chain Clonotypes (unique) 49,616 (2,590) 19,260 (858) 53,573 (4,027) 10,144 (806) Unique Heavy Chains 125,631 (5,334) 60,708 (5,687) 129,040 (8,620) 31,213 (2,534) SD. Standard Deviation  894 \n  895 Table 3. IGHV differential ( 'A-Pc) usage summary  896 Family/Segment Relative transcription HCC Frequency UHC Frequency Clinical Status Immune Status Clinical Status Immune Status Clinical Status Immune Status IGHV1 * * ** NS ** NS IGHV3 * * *** NS *** * IGHV1-2 * NS NS NS ** NS IGHV1-18 NS NS * NS NS NS IGHV1-69 *** NS *** * *** NS p values * < 0.05; ** < 0.01; *** <0.001 ; NS N ot significant ; Two-way ANOVA with Bonferroni correction  897 \n 898 A\n123 405101520\nDWS-\nDWS+\nNumber of serotypes\nIndividualsDWS- DWS+\nPrimary\nSecondaryImmune status3 (3) 0 (0)\n9 (4) 7 (4)\n9 (4) 10 (7) TotalClinical statusFigure 1\nAP c A Pc681012\nShannon Index\nPrimaryUHC\nAP c A Pc681012\nShannon Index\nDWS -\nDWS +UHC\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n220100020003000400050006000\nA\nPc\n***\nSampling (Number of sequences x 103)\nHCC (n)\nDWS +1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n220100020003000400050006000\nA\nPc\n***\nSampling (Number of sequences x 103)\nHCC (n)\nDWS -1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n220100020003000400050006000\nA\nPc\n***\nSampling (Number of sequences x 103)\nHCC (n)\nPrimary\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n220100020003000400050006000\nA\nPc\n***\nSampling (Number of sequences x 103)\nHCC (n)\nSecondaryA B\nD C\nAP c A Pc681012\nPrimary\nShannon IndexHCC\nAP c A Pc681012\nShannon Index\nDWS -\nDWS +HCCE\nGF\nHSecondary\nSecondaryFigure 2\nBOnset Dengue\nsymptoms\n0 days 4-7 days > 6 monthsPost-Convalescent \nPhaseAcute\nPhase\nC0.1\n0.2\n0.3\n0.4\n0.5\n0.6\n0.7\n0.8\n>0.9DWS-A DWS+A\nDWS-Pc DWS+PcGini coefficientA\nBC\nA Pc A Pc0.50.60.70.80.9\nDWS -\nDWS +\nGini coefficient\nA Pc A Pc0.00.20.40.60.81.0\n***\n***\nGini coefficient\nDWS -\nDWS +Figure 3\nClick here to download Figure: FIG3.pdf A\nDWS -\nDWS + \nPrimary\nSecondary\nDWS - \nDWS + \nPrimary\nSecondary-0.010\n-0.007\n-0.003\n0.000\n0.003\n0.007\n0.010\nIGHV1\nIGHV2\nIGHV4\nIGHV5\nIGHV6IGHV3\nIGHV7**\n***Clinical Status\nImmune Statusi07 i17 i03 i25 i20 i27 i28 i01 i08 i10 i18\nB\nClinical Status\nImmune Statusi07 i01 i27 i28 i03 i20 i17 i25 i08 i10 i18\nIGHV1-2 **\nIGHV1-46\nIGHV3-23\nIGHV3-72\nIGHV1-18\nIGHV3-30-3\nIGHV4-30-2\nIGHV3-15\nIGHV3-13\nIGHV3-7\nIGHV3-53\nIGHV2-70\nIGHV1-24\nIGHV6-1\nIGHV1-8\nIGHV4-30-4\nIGHV3-20\nIGHV3-33\nIGHV3-9\nIGHV3-49\nIGHV3-64\nIGHV7-4-1\nIGHV1-3\nIGHV2-26\nIGHV3-73\nIGHV4-39\nIGHV3-66\nIGHV3-43\nIGHV3-11\nIGHV4-4\nIGHV3-74\nIGHV4-59\nIGHV2-5\nIGHV1-69 ***\nIGHV3-21\nIGHV3-30\nIGHV4-31\nIGHV3-48\nIGHV4-34\nIGHV5-51\nIGHV1-58\nIGHV5-a\nIGHV4-61\nIGHV4-b\n-0.05-0.03-0.020.000.020.030.05Figure 4\nClick here to download Figure: FIG4.pdf A Pc A Pc01020304050\n***\n***\n***\nPrimary\nA Pc A Pc01020304050\n***\n***\n***\nDWS -\nDWS +\nIGHV1-2\nd0 d7 A Pc A Pc01020304050\n***\n***\n***\n***\nDWS -\nDWS +\nTVIA B\nC\nA Pc A Pc01020304050\n***\n***\n***\nIGHV1-2\nPrimaryD\nA Pc A Pc01020304050\n***\n***\nDWS -\nDWS +\nIGHV1-18\nA Pc A Pc01020304050\n***\n***\nDWS -\nDWS +\nIGHV1-69\nA Pc A Pc01020304050\n**\n***\n***\nIGHV1-18\nPrimary\nA Pc A Pc01020304050\n***\n***\n***\nIGHV1-69\nPrimaryF\nH GE\npM-VH (%) pM-VH (%)\npM-VH (%) pM-VH (%) pM-VH (%)pM-VH (%)\npM-VH (%)pM-VH (%)SecondarySecondary\nSecondary\nSecondaryFigure 5\nClick here to download Figure: FIG5.pdf Healthy A Pc A Pc-4-2024\n*\n**\n***\nPC1\nControl\nDWS -\nDWS +\n\u22124 \u221220 24\u221210 1 23PC2 (22.63%)\nPC1 (76.28%)\nqControlDWS - ADWS - PcDWS + ADWS + PcA B\nPrimary Infection Secondary Infection\nTh Cell\nB naive CellGCTFh CellCDFPlasmablastPlasma Cell\nMemory \nIgG+ Cell\nHipermutatedMantle Zone\nTLR7/8ssRNA\nYY\nBCR \nCrosslinkingYY\nYY?IgG+ B cells\nUnmutatedLow SHM\nCross-reactivity\nADE ?PlasmablastHigh SHM\nNautralizing Ab\nDENV serotype specific Ab\nDENVDENVEarly\nAcuteLate\nConvalescent\nTh Cell\nB naive CellGCTFh CellCDFPlasmablastPlasma Cell\nMemory \nIgG+ Cell\nHipermutatedMantle Zone\nTLR7/8ssRNA\nYY\nBCR \nCrosslinkingYY\nYY?IgG+ B cells\nUnmutatedLow SHM\nCross-reactivity\nADE ?PlasmablastHigh SHM\nNautralizing Ab\nDENV serotype specific Ab\nDENVEarly\nDENVAcuteFigura 7Figura 6Table S1. Neutralization Summary of DENV RVPs by human sera. The 50% neutralization titers (NT50) are shown as reciprocal serum dilutions.  Sample Diagnostic DENV-1 NT50 DENV-2 NT50 DENV-3 NT50 DENV-4 NT50 den-01 DWS+A >10240 >10240 >10240 4564 den-05 DWS+A >10240 >10240 >10240 >10240 den-08 DWS+A 2717 2393 >10240 1200 den-10 DWS+A >10240 >10240 >10240 >10240 den-18 DWS+A >10240 8390 >10240 >10240 den-21 DWS+A 3450 7889 >10240 >10240 den-22 DWS+A >10240 >10240 >10240 >10240 den-23 DWS+A >10240 >10240 >10240 >10240 den-29 DWS+A >10240 >10240 >10240 >10240 den-03 DWS-A 749 34 413 952 den-04 DWS-A >10240 >10240 >10240 >10240 den-07 DWS-A 678 266 1149 241 den-13 DWS-A >10240 >10240 >10240 >10240 den-15 DWS-A >10240 >10240 >10240 >10240 den-17 DWS-A 42 NN 15 143 den-20 DWS-A NN 11 NN 180 den-25 DWS-A NN 66 25 33 den-27 DWS-A 4660 7493 >10240 >10240 den-28 DWS-A 2046 5630 4965 >10240 NN. No appreciable neutralization at the maximum amount of serum tested.    Table S2. Reads, clonal groups and Idiotypes numbers per individual and condition ID Diagnostic Condition Serotype Total reads Pass filters reads Heavy Chain Clonotypes Unique Heavy Chains den-i03 DWS- Acute Unknown 116,670 105,559 5,349 12,568 den-i03 DWS- Post-convalescent NA 103,995 91,804 2,834 8,331 den-i04 DWS- Acute DENV-2 37,407 31,147 8,327 20,524 den-i07 DWS- Acute Unknown 53,555 48,331 2,024 6,324 den-i07 DWS- Post-convalescent NA 34,823 21,344 3,737 10,896 den-i13 DWS- Acute DENV-2 78,178 70,533 3,590 10,643 den-i15 DWS- Acute DENV-2 80,783 74,156 6,134 16,053 den-i17 DWS- Acute Unknown 62,564 55,757 4,929 11,796 den-i17 DWS- Post-convalescent NA 66,787 58,242 4,031 20,476 den-i20 DWS- Acute DENV-2 73,251 65,896 9,801 18,868 den-i20 DWS- Post-convalescent NA 77,428 65,346 2,031 5,099 den-i25 DWS- Acute DENV-1 54,476 49,214 2,306 4,578 den-i25 DWS- Post-convalescent NA 60,130 53,982 2,652 5,440 den-i27 DWS- Acute DENV-1 61,684 56,093 4,743 16,230 den-i27 DWS- Post-convalescent NA 42,482 36,956 1,758 4,050 den-i28 DWS- Acute DENV-2 113,409 102,935 2,413 8,047 den-i28 DWS- Post-convalescent NA 75,040 67,543 2,217 6,416 den-i01 DWS+ Acute DENV-1 118,864 99,682 4,678 13,003 den-i01 DWS+ Post-convalescent NA 134,520 122,211 3,185 8,980 den-i05 DWS+ Acute DENV-1 42,552 34,036 8,052 15,689 den-i08 DWS+ Acute Unknown 30,834 23,106 3,318 10,176 den-i08 DWS+ Post-convalescent NA 39,239 35,390 1,406 4,290 den-i10 DWS+ Acute DENV-2 38,722 21,733 4,311 10,519 den-i10 DWS+ Post-convalescent NA 28,965 24,675 2,517 7,787 den-i18 DWS+ Acute DENV-1 65,871 61,288 7,766 23,161 den-i18 DWS+ Post-convalescent NA 57,342 44,741 3,036 10,156 den-i21 DWS+ Acute DENV-2 79,255 70,765 5,639 11,700 den-i22 DWS+ Acute DENV-2 84,812 76,075 3,010 8,018 den-i23 DWS+ Acute DENV-2 57,857 49,945 1,689 4,220 den-i29 DWS+ Acute DENV-2 75,976 62,853 15,110 32,554 NA. Not applicable   048 1 2 100 200 300 400DWS - ADWS - PcDWS + ADWS + Pc\nDays\nDENV1 DENV2 DENV1 DENV256789\nShannon Index\nDWS-A\nDWS+A1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n220100020003000400050006000\nDWS - A\nDWS + A\nSampling (Number of sequences x 103)\nHCC (n)\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\n16\n17\n18\n19\n20\n21\n220100020003000400050006000\nPrimary Acute\nSecondary Acute\nSampling (Number of sequences x 103)\nHCC (n)A B\nControl DWS-A DWS+A0102030\n*\n*\n% CD19 + of LymphocytesC D\nAP cA Pc-4-3-2-101\nDWS -\nDWS +\n***\n***\n***\nDiameter (log10)Figura S1 Figura S2\nFigura S3A B\n-0.2 0.0 0.2 0.4 0.6IGHV1-18IGHV1-2IGHV1-24IGHV1-3IGHV1-46IGHV1-58IGHV1-69IGHV1-8IGHV2-26IGHV2-5IGHV2-70IGHV3-11IGHV3-13IGHV3-15IGHV3-20IGHV3-21IGHV3-23IGHV3-30IGHV3-30-3IGHV3-33IGHV3-43IGHV3-48IGHV3-49IGHV3-53IGHV3-64IGHV3-66IGHV3-7IGHV3-72IGHV3-73IGHV3-74IGHV3-9IGHV4-30-2IGHV4-30-4IGHV4-31IGHV4-34IGHV4-39IGHV4-4IGHV4-59IGHV4-61IGHV4-bIGHV5-51IGHV5-aIGHV6-1IGHV7-4-1\nDWS -\nDWS +\n***\n*\n\u0394Relative Frequency (A-P )c\nIGHV Segments\nDWS -\nDWS + \nPrimary\nSecondary\nDWS - \nDWS + \nPrimary\nSecondaryFigura S4\nIGHV1IGHV2IGHV4IGHV5IGHV6IGHV3IGHV7P.i17P.i25P.i20S.i03S.i08S.i07\nS.i01S.i18S.i28S.i10S.i27*\n*Clinical StatusImmune Status\nIGHV5-51\nIGHV3-48\nIGHV4-34\nIGHV2-5\nIGHV3-23\nIGHV3-74\nIGHV3-72\nIGHV4-59\nIGHV3-9\nIGHV3-33\nIGHV3-53\nIGHV3-15\nIGHV1-8\nIGHV3-43\nIGHV3-49\nIGHV6-1\nIGHV4-31\nIGHV3-73\nIGHV3-20\nIGHV3-NL1\nIGHV1-68\nIGHV3-d\nIGHV4-28\nIGHV1-45\nIGHV4-30-4\nIGHV2-26IGHV3-64\nIGHV1-f\nIGHV3-66\nIGHV3-13\nIGHV4-30-2\nIGHV7-4-1\nIGHV1-3\nIGHV1-24\nIGHV4-4\nIGHV2-70\nIGHV5-a\nIGHV4-61\nIGHV1-58\nIGHV3-11\nIGHV4-39\nIGHV3-7\nIGHV4-b\nIGHV3-30\nIGHV3-30-3\nIGHV3-21\nIGHV1-18 *\nIGHV1-2\nIGHV1-46\nIGHV1-69 ***\nClinical Status\nImmune Statusi01 i10 i27 i07 i28 i20 i18 i25 i17 i08 i03\n-0.010\n-0.007\n-0.003\n0.000\n0.003\n0.007\n0.010i20 i17 i25 i03 i07 i08 i27 i28 i01 i10 i18\nC\n-0.10\n-0.05\n0.00\n-0.05\n-0.10\n0.15Relative FrequencyImmune Status\nCDR3 LengthRelative FrequencyCDR3 Length\nImmune StatusClinical Status DWS - A\nDWS + A\nPrimary\nSecondaryClinical Status\ni28 i27 i20 i25 i17 i15 i13 i07 i04 i03\nAll IGHV1-2 IGHV1-18 IGHV1-69\ni29\ni23\ni22\ni21\ni18\ni10\ni08\ni05 i01\nAll IGHV1-2 IGHV1-18 IGHV1-69\nFigura S5AP c A Pc01020304050\nDWS-\nDWS+\npMV (%)\n***\n***\nIGHV1-18\nAP c A Pc01020304050\nDWS-\nDWS+\npMV (%)\n***\nIGHV1-2\nAP c A Pc01020304050\nDWS-\nDWS+\npMV (%)\n***\n***\nIGHV1-69\nAP c A Pc01020304050\nDWS-\nDWS+\npMV (%)\n***\n**A B\nD C\nA B\nAP A Pc60708090100\nDWS -\nDWS +\nProportion Gini value 0 (%)\nc\nAP A Pc020406080100120\nNon-synonymous mutations (n)\nDWS -\nDWS +\n***\n***\n***\ncFigura S6\nFigura S7IGHV1.58\nIGHV3-13\nIGHV3-43\nIGHV2-26\nIGHV2-70\nIGHV2-5\nIGHV3-33\nIGHV3-49\nIGHV3-7\nIGHV3-74\nIGHV3-73\nIGHV4-61\nIGHV1-46\nIGHV3-20\nIGHV3-72\nIGHV1-24\nIGHV3-15\nIGHV1-18\nIGHV1-69\nIGHV3-23\nIGHV3-53\nIGHV3-66\nIGHV3-64\nIGHV3-11\nIGHV3-48\nIGHV4-4\nIGHV1-3\nIGHV4-30\nIGHV4-39\nIGHV3-30\nIGHV1-2\nIGHV3-30\nIGHV4-59\nIGHV4-34\nIGHV4-b\nIGHV1-8\nIGHV3-9\nIGHV4-30\nIGHV3-21\nIGHV4-313.0\n2.0\n1.0\n0.0\n-1.0\n-2.0\n-3.0***\nMissing\nvaluesPrimary Secondary DWS + A DWS + Pc DWS - A DWS - Pc Healthy Control\nClinical Status\nImmune Status\ni17 i15i27i28 i13 i07 i04 i03 i25 i20 i01 i05 i08 i10 i18 i21 i22 i23 i29 i17i20 i25 i03 i07 i27i28 i01 i08 i10 i18 c06 c07 c08 c09 c10 c11 c12 c13c14c15Figura S8!\n124\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Discusi\u00f3n\"\"!La!carencia!de!modelos!experimentales!adecuados!ha!limitado!el!entendimiento!de!la! respuesta! inmune! a! la! infecci\u00f3n! por! el! DENV!(69).!En! este! sentido,! el! Dengue!sigue! representando! un! reto!pensando! en! el!desarrollo! de!estrategias! de!vacunaci\u00f3n!seguras!que!tengan!como!base!la!comprensi\u00f3n!tanto!de!la!din\u00e1mica!de!transmisi\u00f3n!as\u00ed!como!de!la!comprensi\u00f3n!de!la!inmunopatolog\u00eda!de!la!enfermedad!(153).!!!Siguiendo!un!enfoque!de!secuenciaci\u00f3n!del!repertorio,!hemos!demostrado!que!la!fase!aguda!de!la!enfermedad!correlaciona!con!un!aumento!en!la!diversidad!clonal!de! los! linfocitos! B! de! sangre! perif\u00e9rica.!Tambi\u00e9n!hemos! documentado! que! las!frecuencias! relativas! de! los! linfocitos! B!que!usan! segmentos! g\u00e9nicos! IGHV!pertenecientes! a! la! familia! IGHV1!correlacionan! con! el! estado! cl\u00ednico! de! la!enfermedad.!Sorprendentemente,!hemos!encontrado!una!baja!frecuencia!de!SHM!durante! la! fase! aguda! de! la! enfermedad,! en! comparaci\u00f3n! con! la! fase! de! postUconvalecencia,! un! hecho! parad\u00f3jico,! debido! a! que! la! mayor\u00eda! de! los! pacientes! se!encontraban! cursando! una! infecci\u00f3n! secundaria!y! proven\u00edan!de! una! zona!end\u00e9mica!de!DENV.!A\u00fan!m\u00e1s,!fue!el!hecho!de!que!se!encontr\u00f3!una!menor!SHM!en!aquellos! individuos! que! cursaban!con!una! infecci\u00f3n! secundaria! y! con!DWS+!comparados! con! pacientes! en! infecci\u00f3n! primaria! y! DWSU.! Para! algunos! de! los!segmentos! de! la! familia! IGHV1,! como! el! segmento! IGHV1U2,! las! tasas! de!SHM!fueron!menores!en!pacientes!con!DWS+!que!en!pacientes!con!DWSU.!!!La! diversidad! del! repertorio! de! anticuerpos!la! generan! diferentes! procesos,!algunos! como! la! recombinaci\u00f3n! som\u00e1tica! de! los! genes! V(D)J! son! ant\u00edgeno!independiente!y!se!llevan!a!cabo!durante!la!maduraci\u00f3n!del!linfocito!B!dentro!de!la!m\u00e9dula!\u00f3sea!(26).!Otros!procesos!que!se!involucran!en!aumentar!la!diversidad!son!la!SHM!y!el!CSR,!que!necesariamente!necesitan!de!un!ant\u00edgeno!para!que!se!lleven!a!cabo!(154).!!La! diversidad! del! repertorio! de! linfocitos! B! es! muy! grande! sin!embargo,!hay!restricciones!estructurales,!funcionales!y!procesos!como!la!selecci\u00f3n!clonal!que!influyen!en!el!tama\u00f1o!y!la!forma!del!repertorio!real!(145).!Las!nuevas!tecnolog\u00edas!en! la! secuenciaci\u00f3n! del! DNA! ofrecen! una! posibilidad! de! estudiar! la!complejidad! del! repertorio! en! distintas! situaciones.!Se! ha! aplicado! a! explorar!altamente!las!propiedades!estructurales!del!repertorio!de!anticuerpos!(155,!156),!de! la! enfermedad! residual! en! leucemias!(157),!en! determinar! patrones! y!linajes!clonales! en! anticuerpos! neutralizantes! de! amplio! espectro! en! pacientes! con!infecci\u00f3n! por! HIV!(158),! adem\u00e1s! de! analizar!la! respuesta! inmune! contra!infecciones!(159)!y! vacunaci\u00f3n! por! virus!de! la!Influenza!(160,!161),! as\u00ed! como!explorar!la!firma!de!anticuerpos!convergentes!en!infecciones!por!DENV!(152).!!!Debido! a! este! hecho! cada! grupo! de! investigaci\u00f3n! se! ha! visto! en! la! necesidad! de!generar! herramientas! inform\u00e1ticas! que! les! ayuden! a! contestar! las! preguntas! de!investigaci\u00f3n!que!les!ata\u00f1en.!La!motivaci\u00f3n!en!nuestro!grupo!de!investigaci\u00f3n!nace!por!la!necesidad!de!generar!una!herramienta!independiente!para!la!reconstrucci\u00f3n!digital! del! repertorio! de! anticuerpos! y! la! medici\u00f3n! de! par\u00e1metros! de! diversidad!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"125\"!#Instituto!Nacional!de!Salud!P\u00fablica!###clonal! que! describieran! aspectos! funcionales! de! la! selecci\u00f3n! clonal! as\u00ed! como! la!facilitaci\u00f3n!de!la!miner\u00eda!del!repertorio.!!!La!reconstrucci\u00f3n!digital!del!repertorio!de!anticuerpos!debido!a!la!diversificaci\u00f3n!clonal!e!idiotipica!como!resultado!de!la!SHM!y!los!procesos!mismos!de!la!selecci\u00f3n!del!ant\u00edgeno!debe!ser!lo!m\u00e1s!fiel!que!se!pueda.!Por!lo!que!un!punto!importante!es!tomar!en!consideraci\u00f3n!los!errores!de!secuenciaci\u00f3n!de!la!plataforma!que!se!utilice!para! la! secuenciaci\u00f3n! masiva! para! que! no! sobreestimemos! la! diversidad! de! las!muestras!analizadas!(145).!Debido!a!eso!ImmunediveRsity!incluye!un!paso!previo!de!correcci\u00f3n!de!\u201cruido\u201d!de!secuenciaci\u00f3n.!Este!paso!se!completa!con!una!serie!de!par\u00e1metros! que! el! usuario! puede! adecuar! en! base! a! la! estructura! de! c\u00f3mo! se!realizaron! las! genotecas! y! de! sus! propias! necesidades.! Entre! los! par\u00e1metro! se!incluye!un! filtro! de! calidad,! un! filtro! de! tama\u00f1o! de! secuencia! y! un! filtro! de!secuencias!que!contienen!nucle\u00f3tidos!no!asignados!(\u201cN\u201d).!!La!asignaci\u00f3n!clonal!e!idiot\u00edpica!por!parte!de!Immunediversity!no!se!desliga!de!la!biolog\u00eda! de! los! anticuerpos,! al! contrario! se! hace! uso! de! ella! para! definir!operacionalmente!con!m\u00e1s!precisi\u00f3n!dicha!asignaci\u00f3n.!Dentro!de!la!herramienta!se!describen! operacionalmente! como!grupos! clonales!de! cadena! pesada!(HCC)!aquellas!secuencias!que!pertenecen!al!mismo!rearreglo!VUJ!y!tienen!un!porcentaje!de! identidad! en! el! CDR3! del! 97%.! !Dentro! del! grupo! clonal!se! genera! otra!agrupaci\u00f3n!de!aquellas!secuencias!que!tengan!un!99%!de!identidad!a!lo!largo!de!toda! la! regi\u00f3n! variable,! defini\u00e9ndose! como! idiotipos! o! cadenas! pesadas! \u00fanicas!(UHC).!!!La! asignaci\u00f3n! clonal! no! toma! en! cuenta! el! segmento! D,! debido! a! que! es! muy!peque\u00f1o!(entre!11!a!37!nt)!(162)!y!podr\u00edamos!estar!sobreestimando!la!diversidad!del!repertorio,!es!por!eso!que!solo!nos!basamos!en!la!asignaci\u00f3n!de!los!segmentos!J!y!V.!!Una! contribuci\u00f3n! adicional! de! ImmunediveRsity! y! que! no! tienen! otras!herramientas! con! el! mismo! fin!(163U165),!es! que! calcula! diferentes! medidas! de!diversidad!como!el!\u00edndice!de!ShannonUWeaver!y!el!coeficiente!de!Gini,!as\u00ed!como!la!generaci\u00f3n!de!gr\u00e1ficas!de!rarefacci\u00f3n!que!permiten!un!an\u00e1lisis!m\u00e1s!detallado!de!la!diversidad!del!repertorio!de!anticuerpos!(166).!!El!\u00edndice!de!ShannonUWeaver!no!solo! integra! el! n\u00famero! de! especies! diferentes! (clonotipos! e! idiotipos),! si! no! que!tambi\u00e9n! considera! la! proporci\u00f3n! relativa! de! cada! especie.!Recientemente! se! ha!utilizado! el! coeficiente! de! Gini! para! medir!la! inequidad! de! las! distribuciones! en!clonas! de! linfocitos! T! y! se! utiliz\u00f3! para! comparar! los! repertorios! de! linfocitos!v\u00edrgenes!y!de!memoria!(167).!!!Finalmente!ImmunediveRsity! ofrece!una! serie! de! gr\u00e1ficos! que! nos! dan! una!perspectiva!global!del! repertorio! de! anticuerpos!y! una! serie! de! tablas! que! nos!ayudan! a! generar! un! an\u00e1lisis! m\u00e1s! detallado! que! comprender\u00e1! de! la! pregunta! de!investigaci\u00f3n.!!!Debido!al!hecho!de!que!el!enfoque!utilizado!lleva!relativamente!poco!tiempo,!este!se!ha!desarrollado!poco!y!entre!las!diferentes!investigaciones!que!lo!han!utilizado!se! encuentran!diferentes! enfoques!metodol\u00f3gicos! y! anal\u00edticos! sustanciales,! que!!\n126\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###han! hecho! que! la! miner\u00eda! de! los! datos! sea! todo! un! desaf\u00edo! para! el! an\u00e1lisis! del!repertorio!de!linfocitos!B!y!T.!!!Entre!las! diferencias! metodol\u00f3gicas! que! se! presentan,! una! importante! es! el!material!gen\u00e9tico!del!cual!se!parte!para!realizar!las!genotecas!de!secuenciaci\u00f3n.!En!algunos!casos!se!usa! DNA! y! en! otros,! como! en! nuestro! trabajo,! se! usa! RNA! para!generar! los! amplicones! de! las! Ig.! La! secuenciaci\u00f3n! del! DNA! tiene!la!ventaja!de!proporcionar!una!sola!copia!por!linfocito!B!como!molde!para!su!amplificaci\u00f3n!por!PCR,! por! lo! que! se! obtendr\u00eda! una! secuencia! por! linfocito! B.! Esta! ventaja! nos!permite!medir!el!tama\u00f1o!clonal!como!el!reflejo!del!n\u00famero!de!c\u00e9lulas!clonalmente!relacionadas.! En! cambio,! cuando! se! usa! RNA! como! material! gen\u00e9tico,! se! puede!medir!la!expresi\u00f3n!relativa!del!RNA!mensajero,!lo!que!obstaculiza!una!estimaci\u00f3n!precisa!de!la!composici\u00f3n!y!tama\u00f1o!clonal.!Otra!diferencia!es!el!m\u00e9todo!utilizado!para!la!generaci\u00f3n!de!las!genotecas.!En!muchos!trabajos!se!usa!la!amplificaci\u00f3n!por!PCR!con!multiprimers,!lo!que!puede!generar!un!sesgo!en!las!genotecas.!En!nuestro!trabajo!se!uso!el!m\u00e9todo!de!5\u2019RACEUPCR,!que!provee!un!sesgo!menor!debido!a!que!solo!se!usan!dos!primers!para!su!amplificaci\u00f3n!(145).!!En!el!contexto!de!la!infecci\u00f3n!por!DENV,!para!estimar!la!diversidad!utilizamos!un!an\u00e1lisis!de!rarefacci\u00f3n!y!un!an\u00e1lisis!del!\u00edndice!se!ShannonUWeaver!(entrop\u00eda),!en!una! submuestra! del! repertorio! de! linfocitos! B.! Ambos! an\u00e1lisis! sugieren! un!incremento!en!la!diversidad!clonal!del!repertorio!de!linfocitos!B.!Previamente!se!describi\u00f3!un!aumento!en!la!clonalidad!de!linfocitos!B!debido!a!la!expansi\u00f3n!clonal!usando! el! P[collision]!(152).!Estos! resultados! no! se! contraponen! con! lo! descrito!por!nosotros,!debido!a!que!el!P[collision]!es!la!probabilidad!de!encontrar!clonas!de!linfocitos! B!relacionadas! en! diferentes! muestras.! Por! lo! tanto,! las! expansiones!clonales! se! pueden! evaluar! durante! la! fase! aguda! de! la! enfermedad!(152).! En!nuestro! estudio,!utilizamos! RNA! como! material! gen\u00e9tico! para! la! generaci\u00f3n! de!genotecas!de!la!regi\u00f3n!variable!de!la!cadena!pesada!de!IgG,!por!lo!que!no!podemos!evaluar! directamente! la! expansi\u00f3n! clonal,! sin! embargo,!pudimos! reconstruir! el!repertorio! agrupando! secuencias! relacionadas! clonalmente! por! medio! de!clonotipos!de!cadenas!pesadas!(HCC)!y!de!cadenas!pesada!\u00fanicas!(UHC).!!!Con! el! an\u00e1lisis! de! rarefacci\u00f3n! interpretamos! la! riqueza! de! especies! y! un!incremento!del!\u00edndice!de!ShannonUWeaver!como!resultado!de!un!alto!n\u00famero!de!linfocitos!B!circulantes,!que!a!su!vez,!podr\u00edan!explicarse!de!manera!parcial,!debido!a! la! migraci\u00f3n! de! plasmablastos! a! sangre! perif\u00e9rica! durante! la! fase! aguda! de! la!enfermedad!(38,!133,!168).!!Realizamos! un! an\u00e1lisis! de! citometr\u00eda! de! flujo! en! un!grupo!de!pacientes!independientes!y!demostramos!que!hay!un!incremento!en!la!diversidad! de! linfocitos! B!en! pacientes! con! una! infecci\u00f3n! aguda! por! DENV.! En!estudios! recientes! se! han! investigado! las! subpoblaciones! de! linfocitos! B! en!infecciones! primarias! y! secundarias,! y! se! ha! demostrado! un! aumento! en! la!cantidad! de!plasmablastos! en! sangre! perif\u00e9rica! sobre! todo! en! infecciones!secundarias!(169),!como!es!el!caso!de!los!pacientes!analizados!en!este!estudio.!!!El!uso!preferencial!de!segmentos!IGHV!ya!se!ha!descrito!previamente!en!modelos!de! linfocitos! B! ant\u00edgeno! espec\u00edfico! como! en! la! infecci\u00f3n! viral! citop\u00e1tica.! La!infecci\u00f3n!por!el!virus!de!la!estomatitis!vesicular!(VSV),!en!un!modelo!murino,!se!monta!una!respuesta!neutralizante!que!confiere!protecci\u00f3n!a!la!infecci\u00f3n!por!parte!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"127\"!#Instituto!Nacional!de!Salud!P\u00fablica!###de!anticuerpos!IgG+!de!l\u00ednea!germinal,!no!mutados!del!segmento!VHQ52.!Un!reto!secundario! se!asoci\u00f3!con! un! cambio! en! el! uso! de! otros! segmentos! como! son! el!VH7183!y!el!VHJ558,!as\u00ed!como!la!generaci\u00f3n!de!SHM!(170,!171).!!!!La!generaci\u00f3n!de!linfocitos!B!de!memoria!IgG+!no!mutados!tambi\u00e9n!se!ha!descrito!en!otro!modelo!murino!pero!\u00e9sta!vez!por!la!infecci\u00f3n!del!Poliomavirus!(172)!y!en!ratones!deficientes!de!Bcl6,!que!carecen!de!linfocitos!T!y!por!lo!tanto!no!generan!reacci\u00f3n! de! centro! germinal!(173,!174).!!Adicionalmente,! usando! secuenciaci\u00f3n!masiva! del! repertorio! en! muestras! de! ratones! sanos! se! determino! un! uso!preferencial! de! segmentos! VH! preferencial! en! subpoblaciones! de! linfocitos! B,!siendo!la!familia!VH1!la!que!mostraba!mayores!diferencias!en!los!diferentes!grados!de!maduraci\u00f3n!de!los!linfocitos!B!(175).!!!!!En!humanos!que!cursan!una!infecci\u00f3n!por!Rotavirus,!se!encontr\u00f3!que!la!respuesta!de!VP6!est\u00e1!mediada!por!linfocitos!B!de!memoria!que!cambiaron!de!clase!y!que!exhiben! bajas! tasas! de! SHM! y! adem\u00e1s! utilizan! predominantemente! el! segmento!IGHV1U46.! Estas! observaciones! ha! sido! generalizadas! como! parte! del! concepto!\u201canticuerpos!naturales\u201d.!Estos!anticuerpos!!pueden!ser!de!isotipo!IgM,!IgG!o!IgA!y!son!codificados! por! genes! de! l\u00ednea! germinal,! por! definici\u00f3n! no! mutados,!se!producen! r\u00e1pidamente! por! una! respuesta!extrafolicular!en! contra! de! una! gran!variedad! de! virus! con! una! afinidad!relativamente!alta! y! suelen! reconocer!estructuras!repetidas!como!las!c\u00e1psides!virales,!sin!embargo,!son!intr\u00ednsecamente!poliUreactivos!(176).! Un! ejemplo! de! estos!anticuerpos!son! los! que! codifica! el!segmento! IGHV1U69! que! ha! sido! implicado! de! manera! recurrente! en! el!reconocimiento!contra!diversos!virus!como!por!ejemplo!Influenza!A,!Hepatitis!C!y!VIH!(35,!177U181).!!!De!acuerdo!con!una!respuesta!de!\u201canticuerpos!naturales\u201d,!el!DENV!activa!linfocitos!B! poliUreactivos! naturales! de! isotipo! IgG! despu\u00e9s! de! una! infecci\u00f3n! primaria! y!secundaria!(35).!En! estudios! previos,! se! ha! reportado! que! la! respuesta! de!anticuerpos! monoclonales! antiUDENV! espec\u00edficos! es! de! reactividad! cruzada!(108,!182)(Anexo! 2)! y! que! reconocen! ep\u00edtopos! cuaternarios! presentes! solo! en! la!part\u00edcula!viral,!pero!no!en!la!prote\u00edna!monom\u00e9rica!E!(104).!!!!En!nuestro!estudio!hemos!encontrado!bajos!niveles!de!SHM!y!un!uso!diferencial!de!IGHV1U2,! IGHV1U18! y! de! IGHV1U69! en! pacientes! que! cursan! con! una! infecci\u00f3n!aguda! de! DWSU!y! de! DWS+,! sugiriendo! su! implicaci\u00f3n! potencial! en! el!reconocimiento!\u201cnatural\u201d! de!DENV,!en!la! reactividad! cruzada! as\u00ed! como! en! la!potenciaci\u00f3n!mediada!por!anticuerpos.!!!No! hubo! diferencias! significativa! entre! los! d\u00edas! en! que! se! tomo! la! muestra! de!sangre!entre!los!pacientes!con!DWSU!y!los!pacientes!con!DWS+.!Por!lo!que!las!bajas!tasas! de!SHM!encontradas!no! se!vieron!asociadas!a!los! d\u00edas! en! que! se!tom\u00f3!la!muestra! de! sangre.!Con! esto! descartamos! que! hubi\u00e9ramos! podido! tomar! la!muestra!en!etapas!distintas!de!la!enfermedad.!As\u00ed!como!tampoco!se!observ\u00f3!una!diferencia! entre! las! infecciones! primarias! y! secundarias! o! diferencias! entre! la!sintomatolog\u00eda!cl\u00ednica!de!los!pacientes!con!DWSU!y!DWS+.!!!!!\n128\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Como! se! menciono! previamente,! el!m\u00e9todo!utilizado! para! la! generaci\u00f3n! de! las!genotecas! de! IgG! fue! el!5\u2019RACEUPCR.! Con! este! enfoque! al! no! haber! una! serie! de!varios! primers! espec\u00edficos! de! cada! familia! IGHV,!podemos! descartar! un! sesgo! de!amplificaci\u00f3n!de!secuencias!no!mutadas.!!!Considerando!todo!lo!anterior,! proponemos! que! durante! las! infecciones! agudas!tanto!primarias!como!secundarias!en!la!infecci\u00f3n!por!DENV,!al!menos!dos!v\u00edas!de!diferenciaci\u00f3n!de!linfocitos!B!pueden!ocurrir.!La!primera!consiste!en!una!respuesta!\u201cnatural\u201d!extrafolicular!de!anticuerpos!IgG!no!mutados!similar!a!la!mostrada!con!el!VSV! y!Poliomavirus! en! ratones! y! por! infecciones! por!Rotavirus! en! humanos.! La!segunda! v\u00eda! consistir\u00eda! en! una! respuesta! secundaria! cl\u00e1sica! dependiente! de!linfocitos!T!que!pasar\u00eda!por!centro!germinal!en!la!que!se!generar\u00edan!anticuerpos!de!clase!IgG!mutados!(Figura!7!del!manuscrito!GodoyULozano!et!al,!2014).!!!De!manera!interesante,!se!encontraron!bajas!tasas!de!SHM!en!la!fase!aguda!de!la!enfermedad,! y! aparentemente! m\u00e1s! acentuadas! en! pacientes! con! DWS+! que! en!pacientes! con! DWSU,! y! en! infecciones! secundarias! m\u00e1s! que! en! infecciones!primarias.! Este! efecto! se! vio! reflejado! particularmente!en! el! segmento! IGHV1U2.!Consistentemente! con! el! papel! de! un! reconocimiento! \u201cnatural\u201d,! el! segmento!IGHV1U2! es! frecuentemente! usado! en! linfocitos! B! de! isotipo! IgM! en! sangre! del!cord\u00f3n!neonatal!(183)!y!en!linfomas!de!linfocitos!B!de!zona!marginal!(184,!185),!que!son!aquellos!que!probablemente!son!seleccionados!de!una!exposici\u00f3n!cr\u00f3nica!al!pat\u00f3geno!(186).!Los!linfocitos!B!de!zona!marginal!en!ratones!sanos!usan!m\u00e1s!el!segmento!VH1!que!los!linfocitos!B!foliculares!y!linfocitos!inmaduros.!Haciendo!un!mapeo! de! epitopos! en! las! estructuras! cristalizadas! de! estos! anticuerpos,! se!identifico! que! el! patr\u00f3n! del! uso! preferencial! de! segmentos! espec\u00edficos! VH! se!encontraba! en! el! FR1! y! que! contribu\u00eda! a!la! uni\u00f3n! entre! el! segmento! VH! y! al!dominio! CH1! de! la! regi\u00f3n! constante.! Experimentos! en! donde! se! sustituyeron!amino\u00e1cidos!en!estas!posiciones!demostraron!que!un!cambio!puede!disminuir!la!se\u00f1alizaci\u00f3n!del!BCR!y!por!lo!tanto!una!correcta!activaci\u00f3n!del!linfocito!B!(175).!!!Los!linfocitos!B!de!zona!marginal!son!capases!de!cambiar!de!clase!tanto!de!manera!TUindependiente! como! de! manera! TUdependiente!(187).! Los! linfocitos! B! de! zona!marginal! podr\u00edan! responder!r\u00e1pidamente! a! pat\u00f3genos!trasmitidos! por! sangre! y!podr\u00edan!ser!la!fuente!de!respuestas!de!\u201canticuerpos!naturales\u201d!de!isotipo!IgM!e!IgG!en! contra! del! DENV.! Sin! embargo,! ya! se! han!estudiado! los! linfocitos! B! de! zona!marginal!en!la!infecci\u00f3n!aguda!por!DENV!en!pacientes!pedi\u00e1tricos!(168)!y!no!se!ha!observado!modificaci\u00f3n!en!esta!subpoblaci\u00f3n.!Adicionalmente,!los!linfocitos!B!de!zona!marginal!son!subpoblaciones!que!est\u00e1n!usualmente!hipermutadas!(187).!Lo!anterior!sugiere!que!\u00e9sta! subpoblaci\u00f3n! no! es! responsable! de! la! circulaci\u00f3n! de!linfocitos!IgG+!no!mutados!en!la!infecci\u00f3n!aguda!por!DENV.!!!En!humanos!alrededor!del!40%!de!los!linfocitos!B!de!sangre!perif\u00e9rica!expresan!CD27! y! las! regiones! variables! de! estos! linfocitos! han! sido!hipermutadas.! La!mol\u00e9cula!CD27,!es!la!mol\u00e9cula!que!distingue!principalmente!a!los!linfocitos!B!de!memoria.! Sin! embargo,! se! ha! descrito! otra! subpoblaci\u00f3n! de! linfocitos! B! de!memoria! pero! que! no! expresan! CD27.! Esta! subpoblaci\u00f3n! en! personas! sanas!representa!alrededor!del!1U4%!de!los!linfocitos!B!de!sangre!perif\u00e9rica!y!el!25%!de!los!linfocitos!IgG+.!Esta!subpoblaci\u00f3n!tiene!la!particularidad!de!tener!una!baja!tasa!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"129\"!#Instituto!Nacional!de!Salud!P\u00fablica!###de! SHM! en! comparaci\u00f3n! con! su! contraparte,! linfocitos! B! CD19+CD27+IgG+.(188,!189).!Esta! subpoblaci\u00f3n! de! linfocitos! B! CD27UIgG+! se! ha! estudiado! en!enfermedades!autoinmunes!como!el!Lupus!Eritematoso,!encontr\u00e1ndose!una!mayor!cantidad!de!esta!subpoblaci\u00f3n!en!comparaci\u00f3n!con!linfocitos!B!CD27+IgG+.!Al!igual!que!lo!descrito!antes,!esta!subpoblaci\u00f3n!tiene!bajas!tasas!de!SHM!(190).!!!!Las! bases! moleculares! para! el! cambio! de! isotipo!extrafolicular!a! IgG! est\u00e1n!comenzando!a!ser!elucidadas.!En!modelos!murinos,!la!activaci\u00f3n!de!elementos!de!la!respuesta!inmune!innata!como!TLR7!y!TLR9!en!conjunto!con!la!se\u00f1alizaci\u00f3n!del!BCR! promueve! una! activaci\u00f3n! de! la! expresi\u00f3n! de! AID,! enzima! requerida! para! el!CSR!y!para!la!SHM!(32).!Aunque!ambos!procesos!est\u00e1n!acoplados!funcionalmente,!no! esta! claro! como!se! evita! la! SHM! en! linfocitos! B! que! se! someten! a! un! CSR! de!manera!extrafolicular.!!!El!DENV!es!reconocido!por!TLR3!(191,!192),!pero!siendo!un!virus!de!RNAss,!podr\u00eda!tambi\u00e9n!activar!las!v\u00edas!de!se\u00f1alizaci\u00f3n!de!TLR7!que!conducir\u00eda!a!la!activaci\u00f3n!de!la!respuesta!del!IFN!tipo!I.!Ambas!v\u00edas!de!se\u00f1alizaci\u00f3n!se!han!implicado!en!el!CSR!TUindependiente!(32)!y! en! respuestas! TUindependientes! en! infecciones! por!Poliomavirus!en!donde!se!requiere!de!MyD88!(193).!!!Entre!las!c\u00e9lulas!mononucleares!de!sangre!perif\u00e9rica,!los!niveles!m\u00e1s!altos!de!RNA!viral!se!encuentran!el!linfocitos!B,!sin!embargo,!no!hay!replicaci\u00f3n!viral!(194).!Por!lo! tanto,! es! probable! que! los! linfocitos! B! antiUDENV! con! reactividad! cruzada!puedan!infectarse!por!endocitosis!mediada!v\u00eda!BCR.!Por!lo!que!el!reconocimiento!en!el!endosoma!por!parte!de!TLR7!podr\u00eda!proporcionar!una!se\u00f1al!en!sinergia!con!el! se\u00f1alamiento! del! BCR! para! un! CSR!extrafolicular!en! aquellos! linfocitos! B! de!reactividad! cruzada.! Este! modelo! es! an\u00e1logo! y! se! apoya! de! lo! observado! por! la!r\u00e1pida!inducci\u00f3n!de!linfocitos!B!extrafoliculares!que!cambian!de!clase!en!respuesta!a!la!inmunizaci\u00f3n!de!la!prote\u00edna!conjugada!de!CpG,!un!agonista!del!TLR9!(195).!!#El! modelo! que! proponemos!(Figura!20),! si!es! correcto,! ofrece! un! potencial!explicaci\u00f3n!de!la!producci\u00f3n!de!anticuerpos!subUneutralizantes!de!baja!afinidad!y!de!anticuerpos!IgG+!de!reactividad!cruzada!que!podr\u00edan!promover!la!potenciaci\u00f3n!de!la!enfermedad.!!!!Por! lo! tanto,! en! el! caso! de! la! vacunaci\u00f3n! contra! DENV,! las! estrategias! de! que! se!promueva!una!respuesta!extrafolicular!de!linfocito!B!como!la!vacuna!quim\u00e9rica!de!DENV/Virus!de!la!fiebre!amarilla,!de!virus!atenuados,!podr\u00eda!estar!asociada!a!un!alto! riesgo! de! enfermedad! severa! en! aquellos! casos! de!una! reinfecci\u00f3n! que!aquellas! vacunas! dise\u00f1adas! para! no! promover! la! activaci\u00f3n! de! TLR7,! como! por!ejemplo!una!vacuna!basada!en!subunidades!proteicas!y!o!de!part\u00edculas!similares!a!virus!(virusUlike!particles)!(196,!197).!!!!\n130\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###\n!Figura#22.# Modelo# propuesto#en# respuesta# a# la# infecci\u00f3n# por# DENV.#Se! propone! un! cambio! de! clase!extrafolicular!en!la!infecci\u00f3n!por!DENV!que!podr\u00eda!activarse!por!el!entrecruzamiento!de!BCR!y!por!a!activaci\u00f3n!de! TLRs,! adicional! al! CSR! cl\u00e1sico! que! pasa! por! centro! germinal! en! donde,! adem\u00e1s! del! cambio! de! clase! los!anticuerpos! adquieren! maduraci\u00f3n! de! afinidad! por! la! SHM.! !Imagen! modificada! de!Goodnow,! 2010.!Nat!Immunol!11:!681U8.!Perspectivas\"!La! secuenciaci\u00f3n! masiva! cada! d\u00eda! tiene! m\u00e1s! auge! y! m\u00e1s! aplicaciones! en! el!!entendimiento! no! solo! de! la! respuesta! inmune! si! no! en! el! entendimiento! de! la!biolog\u00eda! en! general,! por! lo! que! las!nuevas! tecnolog\u00edas! est\u00e1n! en! cambio! y!crecimiento! constantemente.! Tal! es! el! caso! de! la! plataforma! 454! que! con! m\u00e1s!frecuencia! se! esta! dejando! de! utilizar! para! migrar! a! plataformas! con! una!secuenciaci\u00f3n!m\u00e1s!profunda!a!un!precio!m\u00e1s!accesible,!como!es!el!caso!de!Miseq.!Miseq! genera! millones! de! secuencias! a! un! bajo! costo! sin! embargo! tiene! el!inconveniente! del! tama\u00f1o! de! las!secuencias!que! genera.! Hasta! el! momento! el!mayor! tama\u00f1o! es!el! de! 250,! que! tiene! la! ventaja! de! que! si! se! realiza! la!secuenciaci\u00f3n!por!ambos!flancos!obtienes!secuencias!de!mayor!longitud!(198).!Sin!embargo,! esto! genera! la! necesidad! de! buscar! herramientas! que! nos! permitan! el!ensamblaje! correcto! de! las! secuencias.! Para! este! fin! recomendamos! el! uso! de!PANDAseq!Assembler!!(199),!ya!que!es!una!herramienta!muy!r\u00e1pida.!!!ImmunediveRsity!esta!inicialmente!dise\u00f1ada!para!el!an\u00e1lisis!de!secuencias!de!454,!sin! embargo! entre! las! perspectivas! propuestas!es! mejorarla! y! que! pueda! correr!datos! de! otras! plataformas.! Una! de! las! ventajas! de! ImmunediveRsity! es! que! la!entrada!de!los!datos!es!en!un!archivo!FASTQ!(archivo!que!contiene!la!informaci\u00f3n!tanto!de!secuencia!como!de!calidad)!por!lo!que!podr\u00eda!aceptar!cualquier!archivo!proveniente!de!otras!plataformas.!Lo!que!se!propone!para!analizar!datos!de!Miseq,!es! que! el! archivo! FASTQ! se! cambia! al! reverso! complementario! utilizando! la!herramienta!Seqtk!(200)!y!un!submuestreo!que!sea!representativo!de!los!millones!de!secuencias!que!se!generan.!!!\n!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"131\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Esta!claro!que!el!estudio!del!repertorio!de!anticuerpos!en!infecciones!por!DENV!es!importante,!debido!a!las!implicaciones!que!tienen!tanto!a!nivel!de!neutralizaci\u00f3n!de!la!infecci\u00f3n!como!en!la!patog\u00e9nesis!de!la!enfermedad.!!!Entre! las! perspectivas! que! genera! este! trabajo,! se! encuentra! la! de! validar! de!manera! experimental! anticuerpos! monoclonales! (mAbs)! encontrados! por! la!miner\u00eda!de!los!datos!de!secuenciaci\u00f3n.!Se!pretende!generar!mAbs!de!los!segmentos!IGHV1U2,! IGHV1U18,! e! IGHV1U69! y! estudiar! tanto! sus! niveles! de! neutralizaci\u00f3n! y!potenciaci\u00f3n!as\u00ed!como!correlacionarla!con!las!tasas!de!SHM!y!las!formas!cl\u00ednicas!de!la!enfermedad.!!!Una!de!las!limitaciones!del!estudio!es!que!las!genotecas!de!la!regi\u00f3n!variable!de!IgG!que!se!generaron!provienen!de!sangre!perif\u00e9rica,!por!lo!que!no!tenemos!manera!de!saber!que!subpoblaciones!son!las!que!est\u00e1n!contribuyendo!a!la!respuesta!contra!la!infecci\u00f3n.! Sin! embargo,! y! en! soporte! con! las! observaciones! obtenidas! en! este!estudio,!ya!se!ha!descrito!un!uso!preferencial!de!la!familia!IGHV1!en!plasmablastos,!pero!no!en!linfocitos!B!de!memoria,!en!infecciones!agudas!por!DENV!(39).!Por!otro!lado,! la! alta! proporci\u00f3n! de! plasmablastos! DENV! espec\u00edfica! que! migran! a! sangre!perif\u00e9rica! durante! la! fase! aguda!(133)!proporciona! un! apoyo! adicional! a! la!afirmaci\u00f3n!de!que!las!diferencias!en!el!repertorio!en!este!estudio!pueden!ser!DENV!espec\u00edficas.!!!Este! trabajo!adem\u00e1s,!senta! las! bases! para! que! se! abra! una! nueva! l\u00ednea! de!investigaci\u00f3n!a!subpoblaciones!que!no!se!han!estudiado!en!la!infecci\u00f3n!por!DENV,!en!pacientes!que!cursen!una!infecci\u00f3n!aguda.!El!experimento!consistir\u00eda!en!aislar!las!diferentes!subpoblaciones!de!linfocitos!B!y!extraer!el!RNA!y!el!DNA.!Generar!genotecas!de!las!IgG!de!estas!subpoblaciones!(no!solo!CD27UIgG+!y!linfocitos!B!de!zona!Marginal,!si!no!tambi\u00e9n!de!las!subpoblaciones!de!memoria!cl\u00e1sica!as\u00ed!como!de!plasmablastos).!Y!hacer!secuenciaci\u00f3n!masiva,!tanto!de!DNA!como!de!RNA.!Esta!informaci\u00f3n!arrojar\u00eda!un!estudio!del!repertorio!de!anticuerpos!en!Dengue!mucho!m\u00e1s! fino!y!datos! sobre! la! subpoblaci\u00f3n! responsable! de! las! bajas! tasas! de! SHM!encontradas!en!el!Dengue.!!!Otra! limitaci\u00f3n! del! estudio! es! que! solo! se! secuencio! la! cadena! pesada! de! los!anticuerpos! IgG! antiUDENV,! debido! a! eso! se! hace! la! distinci\u00f3n! de! clonotipos! de!cadenas!pesadas!debido!a!que!un!clonotipo!se!compone!tanto!de!IgH!como!de!IgL,!sin!embargo!no!podemos!asignar!una!IgL!con!su!IgH!nativa!por!que!adem\u00e1s!de!que!solo! se! secuencio! la! IgH,! las! genotecas! de! IgL! se! generan! en! amplicones!independientes.!La!secuenciaci\u00f3n!de!las!IgL!aportar\u00eda!m\u00e1s!datos!sobre!la!respuesta!inmune!a!la!infecci\u00f3n!por!DENV.!!#!Como! hemos! visto,! los! mecanismos! de! inmunopatog\u00e9nesis! del! DENV! son!multifactoriales! y! se! involucran! no! solo! poblaciones! del! sistema! inmune!adaptativo,!sino!tambi\u00e9n!del!sistema!inmune!innato.!Las!interconecciones!entre!un!sistema!y!otro!podr\u00edan!ser!la!clave!de!la!generaci\u00f3n!de!informaci\u00f3n!que!finalmente!nos!ayude!a!comprender!mejor!estos!mecanismos.!No!solo!para!su!entendimiento,!si!no!para!que!el!conocimiento!generado!ayude!a!la!formulaci\u00f3n!de!vacunas!m\u00e1s!eficaces!y!de!tratamientos!antivirales!que!ayuden!a!combatir!esta!enfermedad.!!!!!\n132\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Congresos,\"estancias\"y\"ponencias\"Este!trabajo!me!permiti\u00f3!asistir!a!diversos!congresos!y!dar!ponencias!sobre!los!resultados!del!trabajo.!!!Congreso#Lugar#Fecha#Modalidad#Notas#Estancia#Acad\u00e9mica#en#Integral#Molecular#Filadelfia,!USA!01UnovU11!al!29UfebU12!Estancia!Durante!la!estancia!aprend\u00ed!la!t\u00e9cnica!para!la!generaci\u00f3n!de!mAbs!XX#Congreso#Nacional#de#Inmunolog\u00eda#M\u00e9rida,!Yuc.!17UabrU12!al!21UabrU12!Poster!!4to#Foro#Estudiantil#de#la#Sociedad#Mexicana#de#Inmunolog\u00eda#M\u00e9xico,!DF.!23UagoU12!al!24UagoU12!Ponencia!!15vo#Congreso#de#Investigaci\u00f3n#en#Salud#P\u00fablica#Cuernavaca,!Mor.!05UmarU13!al!08UmarU13!Poster!!Mini#Simposio#de#Linfocitos#B#M\u00e9xico,!DF.!21UmarU13!al!22UmarU13!Ponencia!!Curso#Avanzado#de#Inmunolog\u00eda#Zacatecas,!Zac.!04UsepU13!al!06UsepU13!Ponencia!!Keystone#symposia#meeting#on#Advancing#Vaccines#in#the#Genomics#Era#Barra!de!Tijuca,!Brasil!31UoctU13!al!04UnovU13!Poster!y!Ponencia!Acreedora!de!la!beca!Keystone!Symposia!Future!of!Science!Fund!Scholarship!15a#Feria#de#Posgrados#CONACyT#M\u00e9xico,!DF.!04UabrU14!al!05UabrU14!Poster!!XXI#Congreso#Nacional#de#Inmunolog\u00eda#y#1er#Simposio#Internacional#con#la#ALAI#Quer\u00e9taro,!Qto.!06UmayU14!al!10UmayU14!Poster!y!Ponencia!Parte!del!comit\u00e9!organizador!del!congreso!2da#Feria#de#Posgrados#CISEI#Cuernavaca,!Mor.!16UeneU15!!!Poster!!!#!\"!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"133\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Anexos\"Anexo\"1.\"Definiciones\"operacionales\"para\"el\"diagn\u00f3stico\"de\"Dengue\"!Las!definiciones!se!caracterizan!por!tener!elevada!sensibilidad,!es!decir,!permiten!detectar!la!mayor\u00eda!de!los!casos\"a\"trav\u00e9s\"de\"los\"signos\"y\"s\u00edntomas\"m\u00e1s\"frecuentes\"de# la# enfermedad# y# de# las# pruebas# de# tamizaje.# La# especificidad# del# diagn\u00f3stico#est\u00e1%dada%por%los%estudios%de%laboratorio,%por%lo%que%es%fundamental%contar%con%los%resultados! virol\u00f3gicos,! serol\u00f3gicos! y! de!gabinete! correspondientes,! para! el!adecuado!seguimiento!del!caso!hasta!su!clasificaci\u00f3n!final.!!Caso'sospechoso'de'Dengue'cl\u00e1sico'o'fiebre'por'Dengue'Toda!persona!de!cualquier!edad!que!resida!o!proceda!de!una!regi\u00f3n!en!la!que!haya!transmisi\u00f3n! de! la! enfermedad! y! que! presente! cuadro! febril! inespec\u00edfico! o!compatible!con!infecci\u00f3n!viral!y!que!se!encuentre!en!situaci\u00f3n!de!brote.!!Caso'probable'de'Dengue'cl\u00e1sico'o'fiebre'por'Dengue'Todo! caso! sospechoso! que! presente! fiebre! y! dos! o! m\u00e1s! de! las! siguientes!caracter\u00edsticas:!cefalea,!mialgias,!artralgias!y!exantema.!Caso'confirmado'de'Dengue'cl\u00e1sico'o'fiebre'por'Dengue'Todo$caso$probable$en$el$que$se$confirme$infecci\u00f3n$reciente$por$DENV$mediante$t\u00e9cnicas( de( laboratorio.( Est\u00e9( asociado( epidemiol\u00f3gicamente( a( otro( caso(confirmado!o!NO!se!disponga!de!resultado!de!laboratorio.!!Una! variante! de! Dengue! cl\u00e1sico! puede! presentar! datos! de! fragilidad! capilar!(petequias,!equimosis,!hematomas)!o!hemorragias!espont\u00e1neas!ligeras!(epistaxis!o!gingivorragias)! pero! sin! datos! de! hemoconcentraci\u00f3n! ni! trombocitopenia! menor!de! 100! mil! plaquetas! por! ml3.! Esta! forma! se! denomina! \u201cFiebre! por! Dengue! con!Manifestaciones!Hemorr\u00e1gicas\u201d!y!deben!ser!registrados!en!la!casu\u00edstica!final!como!casos!de!Dengue.!Es!importante!enfatizar!que!\u00e9sta!constituye!una!clasificaci\u00f3n)final)y\" no\" es\" una\" definici\u00f3n\" operacional,\" ya\" que\" todo\" caso\" con\" este\" tipo\" de\" signos\" y\"s\u00edntomas,) debe) ser) considerado) como) probable) Fiebre) Hemorr\u00e1gica) por) Dengue)hasta%su%clasificaci\u00f3n%por%el%epidemi\u00f3logo%y%ratificaci\u00f3n%por%el%Comite\u0301\u0301%Estatal.!Caso'probable'de'fiebre'hemorr\u00e1gica'por'Dengue'o'Dengue'hemorr\u00e1gico'Toda! persona! que,! adem\u00e1s! de! un! cuadro! probable! de! Fiebre! por! Dengue,!desarrolle! fiebre! y! una! o! m\u00e1s! de! las! siguientes! caracter\u00edsticas:! datos! de! fuga! de!plasma!(ascitis,!derrame!pleural,!edema,!hipoalbuminemia);!o!datos!de!fragilidad!capilar! (petequias,! equimosis,! hematomas);! hemorragias! (gingivorragia,!hematemesis,!metrorragia)!o!a!cualquier!nivel;!trombocitopenia!menor!a!100!mil!plaquetas! por! ml3!o,! hemoconcentraci\u00f3n! con! uno! o! m\u00e1s! de! los! siguientes! datos:!incremento! del! hematocrito! 20%! o! m\u00e1s! en! la! fase! aguda;! decremento! del!hematocrito! en! 20%! despu\u00e9s! del! tratamiento;! tendencia! del! hematocrito! en!muestras! secuenciales! (por! ejemplo,! 40,! 43,! 45,! etc.);! relaci\u00f3n!!\n134\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###hematocrito/hemoglobina:! sugestivo!3.2! a! 3.4,! indicativo! 3.5! o! mayor;!hipoalbuminemia! o! evidencia! de! fuga! de! l\u00edquidos.! A! todos! ellos! se! les! deber\u00e1n!tomar!muestras!serol\u00f3gicas.!Caso'confirmado'de'Fiebre'Hemorr\u00e1gica'por'Dengue'o'Dengue'Hemorr\u00e1gico'Toda! persona! con! un! cuadro! probable! de! fiebre! hemorr\u00e1gica! por!Dengue!confirmado!por!laboratorio!que!adem\u00e1s!presente!lo!siguiente:!1) Datos!de!fuga!de!plasma!evidenciada!por!cualquiera!de!los!siguientes!datos:!!a. CLINICA:!Edema,!piel!moteada,!ascitis!o!derrame!pleural.!!b. LABORATORIO:!Medici\u00f3n!de!la!HB,!HTO;!elevaci\u00f3n!en!20%!en!etapa!aguda,!o!disminuci\u00f3n!20%!en!etapa!de!convalecencia,!o!elevaci\u00f3n!de!HTO! o! HB! en! forma! secuencial! (a! partir! del! tercer! d\u00eda)! o!hipoalbuminemia.!!c. GABINETE:!Ultrasonido!(l\u00edquido!perivisceral!y!en!cavidad!abdominal!o!tor\u00e1cica)!y!radiolog\u00eda!(derrame!pleural!o!ascitis).!2) M\u00e1s!una!de!los!siguientes!datos:!a) Datos! de! fragilidad! capilar:! Prueba! de! torniquete! positiva! (a! partir!del!tercer!d\u00eda);!(petequias,!equimosis,!hematomas,!etc.).!b) Trombocitopenia!menor!de!100!mil!plaquetas!por!ml3.!!Los!casos!cuyas!determinaciones!de!hematocrito,!hemoglobina,!conteo!plaquetario!y! prueba! de! torniquete! no! sean! realizados! de! acuerdo! a! los! procedimientos!establecidos! en! la! normatividad! vigente! (Manual! de! Vigilancia,! Prevenci\u00f3n! y!Control!de!Dengue),!ser\u00e1n!considerados!como!criterio!positivo!para!la!clasificaci\u00f3n!de!los!casos.!Caso'probable'de'S\u00edndrome'de'Choque'por'Dengue'Toda!persona!con!cuadro!probable!de!fiebre!por!Dengue!o!fiebre!hemorr\u00e1gico!por!Dengue! y! que! presente! s\u00fabitamente! datos! de! insuficiencia! circulatoria! (pulso!r\u00e1pido! y! d\u00e9bil,! extremidades! fr\u00edas);! alteraciones! en! el! estado! de! conciencia!(confusi\u00f3n! mental);! tensi\u00f3n! arterial! disminuida! o! reducci\u00f3n! en! la! tensi\u00f3n!diferencial!sist\u00f3lica!Udiast\u00f3lica!menor!a!20!mm/Hg,!ejemplo!90/80!o!80/70,!etc.,!o!bien!estado!de!choque!profundo.!Caso'confirmado'de'S\u00edndrome'de'Choque'por'Dengue'Todo!caso!probable!de!SCHD!en!el!que!se!confirme!infecci\u00f3n!reciente!por!Dengue!mediante!t\u00e9cnicas!de!laboratorio.!              !\"!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"135\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Anexo\"2.\"Tabla\"de\"Anticuerpos\"monoclonales\"(mAbs)\"descritos\"en\"la\"literatura.\"\"Tabla\"de\"Mabs\"reportados\"en\"la\"literatura.\"Parte\"1\"N\u00fam\"de\"Mab\"Origen\"N\u00famero\"de\"Individuos\"DX\"Infecci\u00f3n\"Fase\"Aislamiento\"Isotipos\"Especificidad\"Referencia\"70\"Humano'5'N.D.'3'donadores'de'Primaria'y'2'donadores'de'secundaria'Convaleciente'Linfocitos'IgG+'de'Memoria'de'PBMC'se'inmortalizaron'con'EBV'y'CpG'68'IgG1(k'y'l),'1'IgG3(k)'y'1'IgG4(l)'E'DI/DII,'DIII,'prM,'NS1'y'Capside'(108)'136\"Humano'8'FD'y'FDH'Secundaria'Aguda'y'convaleciente'Hibridomas''124'IgG,'8'IgA'y'4'no'reaccionaron'con'IgG,'IgA'o'IgM'prote\u00edna'E,'prM,'NS1'y'Capside'(201)'17\"Humano'3'FD'y'FDH'Secundaria'Aguda'Hibridomas''16'IgG1'y'1'IgG4'Prote\u00edna'E'(202)'18\"Murino'N.D.'N.'A.''3'inmunizaciones'Aguda'Hibridomas''IgG2'Prote\u00edna'E,'prM'y'C'(203)'N.D.!No!Descrito!N.A.!No!aplicable!F.D.!Fiebre!por!Dengue!F.D.H.!Fiebre!por!Dengue!Hemorr\u00e1gico#!!!!\n136\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###!Tabla\"de\"Mabs\"reportados\"en\"la\"literatura.\"Parte\"2\"Reactividad\"Neutralizaci\u00f3n\"\"Potenciaci\u00f3n\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"Notas\"\"Referencia\"\"Ensayo\"Resultados\"Ensayo\"Resultados\"Ensayo\"Resultados\"\"\"ELISA\"prote\u00edna\"E,\"NS1\"y\"NS3\"y\"westernTBlot\"para\"prM,\"NS1\"y\"NS3\"13'contra'la'prote\u00edna'E'DIII'(5'serotipo'espec\u00edficos'y'8'con'reactividad'pesada'de'2,'3'o'4'serotipos);'34'contra'la'prote\u00edna'E'DI/DII'(8'serotipo'espec\u00edficos,'1'con'reactividad'cruzada'de'DENV1'y'DENV2''y'el'resto'presentaron'reactividad'cruzada'en'contra'de'los'4'serotipos);'6'contra'la'prote\u00edna'prM'(5'reactividad'cruzada'con'los'4'serotipos'y'1'reactividad'cruzada'DENV1'y'DENV2);7'contra'la'prote\u00edna'NS1'(5'de'NS1'reactividad'cruzada'con'los'4'serotipos'y'2'con'reactividad'cruzada'con'DENV1'y'DENV3);'4'prote\u00edna'NS3'DENV3'espec\u00edficos;'1contra'la'capside'y'reactividad'cruzada'en'contra'de'los'4'serotipos.''Se'midi\u00f3'usando'un'ensayo'basado'en'citometr\u00eda'de'flujo'en'c\u00e9lulas'Vero.'Los'valores'de'la'EC50'fueron'determinados'por'an\u00e1lisis'de'regresi\u00f3n'no'linear''Los'Mabs'en'contra'de'la'prote\u00edna'E'DIII'son'los'm\u00e1s'que'con'mayor'fuerza'neutralizan'la'infecci\u00f3n,'mientras'que'los'que'son'espec\u00edficos'de'E'DII/DI'son'menos'potentes.''Se'usaron'c\u00e9lulas'K562'y'el'n\u00famero'de'c\u00e9lulas'infectadas'se'determino'por'citometr\u00eda'de'flujo.''Todos'los'anticuerpos'monoclonales'neutralizantes'aislados'en'este'estudio'presentaron'potenciaci\u00f3n'a'concentraciones'subneutralizantes,'mientras'que'algunos'Mabs'espec\u00edficos'para'E'y'la'mayor\u00eda'de'los'mAbs'espec\u00edficos'de'prM'potenciaban'la'infecci\u00f3n'y'carec\u00edan'de'actividad'neutralizante.'Las'muestras'de'sangre'se'tomaron'desde'200'd\u00edas'post'infecci\u00f3n'hasta'm\u00e1s'de'8'a\u00f1os'de'presentar'la'infecci\u00f3n'(108)'\nInmunofluorescencia\"Indirecta\"116'clonas'muestran'reactividad'cruzada'contra'los'4'serotipos'(109'fase'aguda'y'7'fase'convaleciente).'Inmunofluorescencia'Indirecta'en'c\u00e9lulas'Vero.'La'neutralizaci\u00f3n'de'los'Mabs'en'el'medio'de'cultivo'se'expreso'como'\"P\"'(<50%)'y'\"+\"'(50P<90%)'o'\"++\"'(>90%)'comparado'con'el'control'negativo'107'clonas'mostraron'm\u00e1s'del'50'%'de'la'reducci\u00f3n'de'la'replicaci\u00f3n'viral'(103'fase'aguda'y'4'fase'convaleciente)'mientras'que'63'clonas'mostraron'm\u00e1s'del'90%'de'la'reducci\u00f3n'de'la'replicaci\u00f3n'viral'(62'fase'aguda'y'1'fase'convaleciente);'de'las'cuales'82'clonas'(81'fase'aguda'y'1'fase'convalescencia)'mostraron'neutralizaci\u00f3n'contra'los'4'serotipos.''N.D'N.D'Los'Mabs'se'clasificaron'en'grupos'del'1'al'10'y'en'grupos'de'la'A'a'la'X'basados'en'la'reactividad'cruzada'con'de'los'4'serotipos'y'en'los'ensayos'de'Inmunofluorescencia'y'neutralizaci\u00f3n.'(201)'!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"137\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Inmunofluorescencia\"Indirecta\"El'mapeo'de'epitopos'muestra'que'13'de'los'Mabs'analizados'reconocieron'la'prote\u00edna'E'entre'los'residuos'52P132'(DominioII)'Inmunoflorescencia'indirecta'en'c\u00e9lulas'Vero.'La'neutralizaci\u00f3n'se'expreso'como'la'concentraci\u00f3n'observada'al'60%'de'la'reducci\u00f3n'de'la'infecci\u00f3n'comparada'con'el'control'negativo'calculada'por'el'm\u00e9todo'de'BeherenPKarber'La'mayor\u00eda''de'los'Mabs'muestra'actividad'neutralizante'fuerte'en'contra'de'DENV2'y'DENV4;'la'neutralizaci\u00f3n'para'DENV1'y'DENV2'es'm\u00e1s'baja.''Se'utilizaron'c\u00e9lulas'THPP1.'Se'extrajo'RNA'total'de'las'c\u00e9lulas'con'Trizol'despu\u00e9s'de'3'd\u00edas'de'incubaci\u00f3n'con'la'mezcla''MabsPDENV2'y'posteriormente'se'realiz\u00f3'un'PCR'tiempo'Real.'Los'resuktados'se'expresaron'como'la'media'con'el'error'estandar'de'los'Ct.'Se'observ\u00f3'potenciaci\u00f3n'en'los'17'Mabs'analizados'en'el'estudio.'No'hubo'diferencias'en'las'actividades'de'neutralizaci\u00f3n'y'potenciaci\u00f3n'entre'los'pacientes'con'FD'y'FHD'en'la'fase'aguda'con'DENV2'en'infecciones'secundarias'Se'demostr\u00f3'que'los'Mabs'examinados'protegen'a'ratones'lactantes'de'la'muerte'causada'por'una'infecci\u00f3n'de'DENV.''(202)'\nInmunoblot,\"ELISA\"de\"captura,\"ELISA\"Indirecta\"En'el'ensayo'de'Inmmunoblot,'2'de'los'18'Mabs'analizados'no'se'les'detecto'reactividad,'se'encontr\u00f3'un'Mabs'con'reactividad'a'prM'y'uno'con'reactividad'a'la'capside,'el'resto'dio'positivo'a'la'prote\u00edna'E'de'DENV2.'En'el'ensayo'de'ELISA'de'captura'todos''los'Mabs'dieron'positivo'a'DENV2.'En'el'ensayo'de'ELISA'indirecta,'se'determino'que'todos'los'Mabs'ten\u00edan'reactividad'cruzada'contra'los'4'serotipos.'Ensayo'de'neutralizaci\u00f3n'por'reducci\u00f3n'de'placas'(PRNT)'medido'en'liquido'de'ascitis'5'de'los'Mabs'descritos'mostraron'm\u00e1s'del'90%'de'PRNT'para'DENV2'N.D.'N.D'En'este'estudio'se'describe'por'primera'vez'el'Mab'1A1DP2.'Mab'utilizado'como'control'positivo'en'muchos'otros'estudios.'En'otros'estudios'se'demuestra'que''este'Mab'neutraliza'DENV2,'DENV1'y'DENV3'(en'orden'de'la'disminuci\u00f3n'de'la'eficacia)'(203)'\nN.D.#No#Descrito#\"!\"\"\"\"!\n138\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Anexo\"3.\"Art\u00edculos\"de\"coTautor\u00eda\"\"A!continuaci\u00f3n!se!adjuntan!los!art\u00edculos!en!los!que!la!alumna!ha!participado!como!coUautora.!!!HybridizationTbased\"antibody\"cDNA\"recovery\"for\"the\"production\"of\"recombinant\"antibodies\"identified\"by\"repertoire\"sequencing.\"\"Vald\u00e9sUAlem\u00e1n! J,! T\u00e9llezUSosa! J,! OvillaUMu\u00f1oz! M,!Godoy\\Lozano# E,! Vel\u00e1zquezURam\u00edrez!D,!ValdovinosUTorres!H,!G\u00f3mezUBarreto!RE,!Mart\u00ednezUBarnetche!J.!MAbs.!2014;6(2):493U501.!doi:!10.4161/mabs.27435.!!!La! secuenciaci\u00f3n! de! alto! rendimiento! del! repertorio! de! anticuerpos! est\u00e1!permitiendo! un! an\u00e1lisis! exhaustivo! de! la! diversidad! de!los! linfocitos!B!y! la!selecci\u00f3n! clonal,! lo! que! puede! mejorar! el! proceso! de! descubrimiento! de!nuevos!anticuerpos.!Te\u00f3ricamente,!un!an\u00e1lisis!bioinform\u00e1tico!adecuado!podr\u00eda!permitir!la!identificaci\u00f3n!de!candidatos!de!anticuerpos!ant\u00edgeno!espec\u00edficos,!lo!que!requerir\u00eda!de!su! producci\u00f3n! recombinante! para! la! validaci\u00f3n! experimental! de!la!especificidad.! La! s\u00edntesis! de! genes! se! utiliza! com\u00fanmente! para! la! generaci\u00f3n! de!anticuerpos! recombinantes! identificados!in( silico.! Nuevas! estrategias! que! pasan!por! alto! la! s\u00edntesis! de! genes! podr\u00edan! ofrecer! alternativas! de! identificaci\u00f3n! de!anticuerpos! y! de! validaci\u00f3n! m\u00e1s! accesibles.!Se! desarroll\u00f3!una! estrategia! de!recuperaci\u00f3n! basada! en! la! hibridaci\u00f3n! que! se! dirige! a! la! regi\u00f3n! determinante! de!complementariedad! 3! (CDRH3)! para! el! enriquecimiento! de!cDNA! de! secuencias!candidatas! de! anticuerpos!ant\u00edgeno!espec\u00edficos.!Se! identificaron! diez! grupos!clonales! de! inter\u00e9s! mediante! el! an\u00e1lisis! bioinform\u00e1tico! del! repertorio! de!anticuerpos! de! cadena! pesada!de!ratones! inmunizados! con! lisozima! de! gallina!(HEL).!Se!recupero!cDNA!a!partir!de!ocho!grupos!clonales!espec\u00edficos!de!manera!eficiente,! dando! lugar! a! la! generaci\u00f3n! de! anticuerpos! recombinantes.! Una!secuencia! de! cadena! pesada! representante! de! cada! grupo! clonal! fue! emparejada!con!cadenas! ligeras! antiUHEL!reportadas! previamente! para! generar! anticuerpos!completos,!posteriormente!se!prob\u00f3!su!capacidad!de!uni\u00f3n!a!HEL.!El!proceso!de!recuperaci\u00f3n! propuesto! representa! una! estrategia! molecular! simple! y! escalable!que! podr\u00eda! mejorar! la! identificaci\u00f3n! de! anticuerpos! y! evaluaci\u00f3n! de! la!especificidad,! lo! que! permite! una! generaci\u00f3n! m\u00e1s! rentable! de! anticuerpos!recombinantes.!!!Differential\"effect\"of\"preTpandemic\"and\"2009\"pandemic\"influenza\"vaccination\"in\"the\"peripheral\"B\"cell\"repertoire.\"\"CortinaUCeballos!B.,!T\u00e9llezUSosa!J.,!S\u00e1manoUS\u00e1nchez!H.,!AguilarUSalgado!AY.,!G\u00f3mezUBarreto! R.,!Godoy\\Lozano# E.,! L\u00f3pez! Mart\u00ednez! I.,! AparicioUAntonio! R.,! Rodr\u00edguez!MH.,!Mart\u00ednezUBarnetche!J.!Manuscrito!en!proceso!(no!se!adjunta).!!!La! variaci\u00f3n! antig\u00e9nica! en! el! virus! de! Influenza! hace! necesario! reformular! las!vacunas! cada! a\u00f1o.! A! pesar! del! potencial! para! producir! anticuerpos! que! pueden!neutralizar! muchos! subtipos! del! virus! (neutralizaci\u00f3n! heterot\u00edpica),! no! hay!conocimiento!de!por!qu\u00e9!la!vacunaci\u00f3n!contra!la!Influenza!induce!una!protecci\u00f3n!predominantemente!contra!las!cepas!virales!utilizadas!(respuesta!homotipica).!La!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"139\"!#Instituto!Nacional!de!Salud!P\u00fablica!###identificaci\u00f3n!de!patrones!estructurales!del!repertorio!de!linfocitos!B!asociados!a!la! neutralizaci\u00f3n! heterot\u00edpica! puede! hacer! que! sea! posible! identificar! ep\u00edtopos!relevantes!de!una!vacuna!universal!contra!la!Influenza.!!Se! obtuvieron! muestras! de! sangre! perif\u00e9rica! de! voluntarios! a! los! que! se! les!administr\u00f3! la! vacuna! inactivada! trivalente! 2008/2009! contra! la! Influenza!estacional! y! la! vacuna! inactivada! 2009! monovalente! contra! la! Influenza!pand\u00e9mica.! La! respuesta! serol\u00f3gica! se! evalu\u00f3! mediante! la! inhibici\u00f3n! de! la!hemaglutinaci\u00f3n!y!ensayos!de!microneutralizaci\u00f3n.!El!RNA!del!d\u00eda!0!(preUinmune)!y! d\u00eda! 7! (postUvacunaci\u00f3n)! se! utiliz\u00f3! para! generar! amplicones! VH! de!compartimiento! de! IgG! que! fueron! secuenciados! utilizando! 454UROCHE.! La!reconstrucci\u00f3n! completa! de! los! repertorios! de! las!muestras!se! realiz\u00f3!con! un!abordaje!bioinform\u00e1tico.!!La! vacuna! inactivada! trivalente!indujo! una! respuesta! serol\u00f3gica!predominantemente!homotipica!neutralizante,!mientras!que!la!vacuna!inactivada!2009!monovalente!indujo!una!respuesta!neutralizante!heterot\u00edpica!en!17%!de!los!individuos.!La! vacuna! inactivada! trivalente!redujo! la!!frecuencia! clonal! del!segmento!IGHV1U69,! aument\u00f3!la! frecuencia! clonal! del! segmento!IGHV4U39,! e!indujo! una! disminuci\u00f3n! de! la! diversidad! idiot\u00edpica.! Por! el! contrario,! la!vacuna!monovalente!aument\u00f3!la!frecuencia!clonal!de!los!segmentos!IGHV1U69!y!IGHV3U7!e!indujo!un!aumento!en!la!diversidad!idiot\u00edpica.!Estos!cambios!sugieren!que!el!virus!pdmH1N1! 2009!de! Influenza!promovi\u00f3! la! selecci\u00f3n! clonal! de!los! linfocitos!B!subdominantes!contra!el!tallo!de!la!hemaglutinina!que!compiten!con!linfocitos!B!inmunodominantes! que! reaccionan! contra! el!dominio! globular!de! la!hemaglutinina.! Adem\u00e1s,! uso! clonal!de! segmentos! IGHV!en! individuos! vacunados!desarrollaron! seroconversi\u00f3n!heterosubt\u00edpica!permitiendo!la! identificaci\u00f3n! de!segmentos!no!pertenecientes!a!la!familia!IGHV1U69!potencialmente!implicados!en!la!neutralizaci\u00f3n!heterot\u00edpica,!que!pueden!contribuir!al!desarrollo!de!una!vacuna!universal!contra!la!Influenza.!!!!!\"\"\" !\" PAPER TY PE\nwww.landesbioscience.com  mAbs 1mAbs 6:1, 1\u20139; March/ April 2014; \u00a9 2014 Landes BioscienceREPORT\nIntroduction\nThe adaptive immune system is capable of generating a vast \nantibody response against a great variety of possible pathogens \nthrough clonal selection. The antibody repertoire is dynamically \nshaped in response to external stimuli. Natural infection or \nimmunization can evoke a strong polarization of the repertoire by \nselecting high affinity antigen-specific clonal groups. The high-\nthroughput sequencing of the antibody transcripts has enabled a \nmore thorough analysis of the immunoglobulin diversity1,2 as a \nmeans to describe the complexity and dynamics of the antibody-\nmediated defense process, which has led to a better understanding \nof the adaptive immune response3-5 and an improved antibody \ndiscovery process.6,7\nUsed as tools for diagnosis, therapy and research, recombinant \nantibodies are indispensable in the biomedical field. Antibodies \ncan be generated against different pathogens and many other \nmolecules of interest, but the production of new recombinant \nantibodies against specific antigens is directly limited by the discovery strategy used to identify such antibodies. Traditionally, \napproaches such as hybridomas8 and phage display have been \nimplemented to address this issue.9 More recently, techniques \nsuch as single B cell expression cloning, B cell immortalization10-13 \nand deep sequencing of the antibody repertoire are improving \nthe analysis of the human antibody response. The analysis of the \nantibody repertoire through high-throughput sequencing has \nbeen used to study the diversity of the immune response, and for \nthe identification of antibodies of interest.6,14-16 With an adequate \nbioinformatic analysis, it is possible to identify putative antigen-\nspecific antibodies from the repertoire sequences based on certain \nparameters such as clonal frequency6 or structural relations \nwith highly mutated antibodies of known specificity, such as \nbroadly neutralizing antibodies against HIV.17 The production of \nrecombinant antibodies based on the bioinformatic analysis of the \nrepertoire relies mainly on the synthesis of DNA of specific light \nand heavy variable regions; however, the cost of the synthesis of \nDNA is a direct constraint affecting the evaluation throughput.6\n*Correspondence to: Jes\u00fas Mart\u00ednez-Barnetche; Email: jmbarnet@insp.mx\nSubmitted: 10/08/2013; Revised: 12/01/2013; Accepted: 12/04/2013\nhttp://dx.doi.org/10.4161/mabs.27435Hybridization-based antibody cDNA recovery \nfor the production of recombinant antibodies \nidentified by repertoire sequencing\nJavier Vald\u00e9s- Alem\u00e1n1,2,\u2020, Juan T\u00e9llez-Sosa1, Marbella Ovilla-Mu\u00f1oz1, Elizabeth Godoy-Lozano1, Daniel Vel\u00e1zquez- Ram\u00edrez1,\u2021, \nHumberto Valdovinos-Torres1, Rosa E G\u00f3mez-Barreto1, and Jes\u00fas Mart\u00ednez-Barnetche1,*\n1Departamento de Inmunolog\u00eda; Centro de Investigaci\u00f3n Sobre Enfermedades Infecciosas; Instituto Nacional de Salud P\u00fablica; Cuernavaca, M\u00e9xico; 2Programa de Ingenier\u00eda \nen Biotecnolog\u00eda; Universidad Polit\u00e9cnica del Estado de Morelos; Jiutepec, M\u00e9xico\nCurrent affiliation: \u2020Janelia Farm Research Campus; Howard Hughes Medical Institute; Ashburn, V A USA; \u2021Universidad del Istmo; Juchit\u00e1n de Zaragoza; Oaxaca, M\u00e9xico\nKeywords:  high-throughput sequencing, repertoire, CDRH3, data mining, enrichment\nAbbreviations:  HEL, hen egg lysozyme; CDRH3, heavy chain complementarity determining region 3; FBS, fetal bovine serum\nHigh-throughput sequencing of the antibody repertoire is enabling a thorough analysis of B cell diversity and clonal \nselection, which may improve the novel antibody discovery process. Theoretically, an adequate bioinformatic analysis could \nallow identification of candidate antigen-specific antibodies, requiring their recombinant production for experimental \nvalidation of their specificity. Gene synthesis is commonly used for the generation of recombinant antibodies identified \nin silico. Novel strategies that bypass gene synthesis could offer more accessible antibody identification and validation \nalternatives. We developed a hybridization-based recovery strategy that targets the complementarity-determining \nregion 3 (CD RH3) for the enrichment of cDN A of candidate antigen-specific antibody sequences. Ten clonal groups of \ninterest were identified through bioinformatic analysis of the heavy chain antibody repertoire of mice immunized with \nhen egg white lysozyme (H EL). cDN A from eight of the targeted clonal groups was recovered efficiently, leading to the \ngeneration of recombinant antibodies. One representative heavy chain sequence from each clonal group recovered was \npaired with previously reported anti-H EL light chains to generate full antibodies, later tested for H EL-binding capacity. \nThe recovery process proposed represents a simple and scalable molecular strategy that could enhance antibody \nidentification and specificity assessment, enabling a more cost-efficient generation of recombinant antibodies.2 mAbs Volume 6 Issue 1The CDRH3 is the region with the highest diversity within \nthe heavy chain variable region (VH) and a major determinant \nof antigen specificity.15,16 Selecting the CDRH3 is an effective \nway to molecularly recover single clonal groups. In this study, \nwe provide a proof-of-principle of targeting the CDRH3 by \nusing restrictive PCR along with a hybridization-based recovery, \nallowing clonal groups with different relative abundances to \nbe enriched and produced recombinantly without the need of \nchemical synthesis of the whole gene.\nResults\nEvidence of selection through enrichment\nAn immunoglobulin sequencing experiment was performed \nby immunizing two BALB-c mice with HEL at days 0 and \n10. Spleens were collected at day 15, which corresponds to the \npeak of germinal center formation, somatic hypermutation and \nclass switching. Spleen total RNA was used to generate IGHV \namplicons of the IgG compartment followed by high throughput \nsequencing with the 454-Roche platform. A total of 45,996 \nand 36,512 reads were obtained from library A (LA) and B \n(LB), respectively. By clustering sequences according to VDJ \nrearrangement, CDRH3 length and identity, 783 (LA) and 902 \n(LB) clonal groups were identified (see Materials and Methods: \nBioinformatics analysis and candidate selection).\nTo simplify the bioinformatic analysis, only the frequency \nof each clonal group was considered in the selection; the five \nmost frequent from each library were selected for recovery \n(2G1\u20132G5, 3G1\u20133G5). The same amplicon libraries used for \npyrosequencing were also used as templates for the amplification \nof the rearrangements found in the clonal groups of interest. \nStructural features of the five most frequent clonal groups in each \nmouse and the CDRH3 used for primers design are described in \nTable  1.\nThe whole enrichment process comprises two main \nselection points ( Fig. 1). The first selection consisted of the \nPCR amplification of the desired rearrangements using IGHV \nand IGJH family-specific primers, for which stringent PCR \nconditions were used to minimize the amplification of undesired Figure \u00a01. Heavy-chain variable region sequence recovery strategy. \nClonal VH sequences are recovered from the whole VH repertoire \nthrough two main molecular selection steps and one following check -\npoint. PC R products representing the VH repertoire are the starting \nmaterial for the enrichment and also used for massive sequencing. \nThe first selection step amplifies through PC R the desired IGHV-IGHJ \nrearrangement, while the second step recovers all molecules with the \ndesired CD RH3 sequence through a hybridization-based strategy. These \ntwo selection steps are determined by the in silico selection that had \nbeen previously performed. A final checkpoint is performed to ensure \nthe presence and overrepresentation of the desired sequences, which \ncan then be used for cloning and recombinant expression.\nTable \u00a01. Primer sequences and V/J usage\nClonal group Probe sequence (5 \u2032-3\u2032) IGHV and IGHJ usage\u2021\n2G1 /B/CAAAGTA  CCCCGTGTT A CCAACATT IGHV14\u20134*02 IGHJ2*01\n2G2 /B/GTAAGTCG TGGT AAGCAA TCCC ACAT IGHV14\u20134*02 IGHJ2*01\n2G3 /B/CCAGG AG TAATGAACAT TACAG IGHV14\u20134*02 IGHJ3*01\n2G4 /B/AAACC CTC CGT ACCCCGC TCTT IGHV1\u201318*01 IGHJ3*01\n2G5 /B/TAACGGG CCGT AGTACC CTC TC IGHV1\u201363*02 IGHJ1*01\n3G1 /B/TACCCGT AGTT ACCCTC TCCTCTTG C IGHV1\u20139*01 IGHJ2*01\n3G2 /B/CCTTCGT AATCATACCC ATCCCCTTC T C IGHV4\u20131*02 IGHJ3*01\n3G3 /B/GTAAG GA GTCGT AATCA TAGCTGC IGHV1\u201385*01 IGHJ3*01\n3G4 /B/AAA GGGC TTCCCC TGC A TAAC IGHV14\u20134*02 IGHJ3*01\n3G5 /B/AACTACC GT AGTAATCT CCCC TCTTG IGHV1\u201376*01 IGHJ2*01\n/B/: Biotin molecule at 5 \u2032 end; bold sequence: sequence within the IGHJ segment; underlined sequence: sequence within the IGHV segment. \u2021 Determined \nby IMGT/V-QU EST.www.landesbioscience.com  mAbs 3but structurally similar rearrangements. Ideally, only sequences \nwith the same IGHV-IGHJ usage to that of the target group \nwould reach this step. The PCR products generated at this point \nserved as the input material for the second selection in which \na biotinylated CDRH3-specific oligonucleotide was used for \nhybridization-based enrichment. After this step, most of the \nrecovered sequences should have the desired rearrangement and \nCDRH3.\nAs a preliminary assessment of the enrichment process, a PCR \ncheckpoint was performed immediately after the second selection \n(Fig. 2). The enrichment products were used as templates in \nPCR with the IGHV- IGHJ and IGHV-CDRH3 primers pairs, \ncomparing the enriched samples and the negative controls \n(mock enrichments). As this system enables the enrichment of \nthe desired sequences instead of a complete isolation of them, \nundesired rearrangements were expected to inevitably yield an \namplification product for the mock enrichments. Therefore, \nit was important to determine the number of amplification \ncycles at which the unwanted sequences (background seen in \nthe mock enrichments) reach a significant amount to minimize \nthe abundance of irrelevant sequences ( Fig. 2A). Additionally, \nthe amplification pattern observed when using IGHV-IGHJ \nand IGHV-CDRH3 primers pairs should be similar, since it \nis expected that the majority of the sequences amplified by the \nIGHV-IGHJ pair are the ones amplified by the IGHV-CDRH3 \npair. Nevertheless, a notable difference in the abundance of PCR \nproduct between the enriched sample and mock enrichment \nwas observed for all clonal groups ( Fig. 2B). This amplification \ndifference is the evidence of enrichment of the desired molecules.\nValidation of the enrichment of desired clonal groups by \nsequence analysis\nOnce the proper number of amplification cycles was \ndetermined for each group, the IGHV-IGHJ amplicon generated under such conditions was cloned into the expression vector. Only \nthose clones with a CDRH3-specific insert detected through \ncolony PCR were Sanger-sequenced. Assuming that those \nsequences amplified with their CDRH3 primer were also subject \nto enrichment in the recovery process, the positive to negative \nCDRH3-specific colony PCR ratio was used as an indicator of \nthe enrichment efficiency ( Fig. 3A).\nThis assumption, however, could consider CDRH3 primer \nmismatch to highly similar but not identical sequences. \nTherefore, 6 to 15 colonies from each of the eight clonal groups \nwere sequenced and aligned against their corresponding target \nsequence. In eight of the ten groups, sequences with a correct \nrearrangement and identical CDRH3 were recovered ( Fig. 3B), \nwith an overall sequence identity of \u2a7e98.6% \u00b1 1.1. Partially \ncomplementary sequences with one or two mismatches in the \nCDRH3 were also recovered for these eight groups. Sequences \nwith three or more mismatches in the CDRH3 were observed \nonly in four of the groups. Nevertheless, some of these mismatches \nwere synonymous, coding for the correct amino acid ( Fig. S1). \nRecovery of groups 3G2 and 3G5 was unsuccessful; only \npartially complementary sequences or wrong rearrangements \nwere obtained.\nExpression of recovered antigen-specific recombinant \nantibodies\nOne sequence for each of the eight clonal groups recovered \nwas selected to be recombinantly expressed in HEK 293T cells. \nAlthough the recovery process considered only VH sequences, \ninterchangeable murine light-chain variable regions (VL) were \nused to generate complete recombinant chimeric IgG.18,19 Because \nwe did not have VL massive sequencing results readily available, \nthe VH recovered were paired with four different VL (HH10, \nHH5,18 D1.320 and F10.6.621) that had been previously reported \nto belong to HEL-binding antibodies. A total of 32 monoclonal Figure \u00a02. PCR checkpoint after clonal enrichment. ( A) An agarose gel stained with ethidium bromide with inverted grayscale showing the PC R products \nof the clonal enrichment of group 2G3 and a negative control (mock enrichment). Two main products were amplified, one covering the whole VH region \n(VH-JH) and the other up to the CD RH3 (IGHV-CD RH3), of approximately 350 and 300 base pair, respectively. Three different amplification cycles were \nused (13X, 15X, and 18X) to determine the amplification threshold required for further processing. In the enriched sample, both products (IGHV-IGHJ \nand IGHV-CD RH3) are present, while they are slightly visible in 18X of the mock control. This difference demonstrates a selection for VH sequences \ncontaining the desired CD RH3. ( B) PC R products of the ten enriched samples and their respective mock controls shown in separate agarose gels stained \nwith ethidium bromide with an inverted grayscale. For each group, the enriched sample (left) and mock control (right) amplifications were performed \nwith the indicated amplification cycles and annealing temperatures. The PC R products from the enriched samples shown here were used for cloning \nand sequencing.\n4 mAbs Volume 6 Issue 1antibodies (plus controls) were generated and evaluated by \nELISA to assess expression and antigen-binding capacity. One \nirrelevant VH (from an unimmunized mouse) was paired with \nthe four VL as negative controls to discard any evident specificity \ncontribution by the VL chosen (data not shown).\nThe VH/VL combinations 2G3/HH10, 3G1/HH5 and 3G1/\nF10.6.6 were positive to the HEL-binding ELISA ( Fig. 3C). In this case, the 3G1 VH showed binding capacity when paired \nseparately with two different VL. Therefore, two of the eight VH \nevaluated showed binding capacity to HEL when paired to some \nof the VL chosen. The antigen-binding capacity of the antibodies \nobtained, however, does not rely on the enrichment process, \nbut depends directly on an effective bioinformatic analysis and \nimmunization protocol.Figure \u00a03. Enrichment assessment through single sequence analysis. ( A) Representation of the concentrations of each of the eight clonal groups that \nwere successfully recovered, before (gray) and after (yellow) the enrichment. Concentrations before enrichment were determined in silico by the analy -\nsis of the massive sequencing results; the number of sequences considered for 2G1\u20132G5 was 46  062, and 36  393 for 3G1\u20133G4. Concentrations after \nenrichment were determined through PC R amplification of the desired IGHV-CD RH3 fragment from cloned enrichment products; N indicates the total \nnumber of clones evaluated in each case. The circle representing the total (blue) is used as a reference of 100% of the area. ( B) CD RH3 conservation after \nenrichment determined through Sanger sequencing. A few clones for each clonal group were sequenced (N) and compared with their respective target \nsequence, showing that most of the sequences obtained had no or little variation in the CD RH3. ( C) HEL-binding ELISA for the three positive combina -\ntions (VH/VL) of the 32 tested. 2G3/HH10, 3G1/HH5 and 3G1/F10.6.6 showed H EL-binding capacity, corresponding to two VH of the eight tested. HH10/\nHH10 served as positive control, and no-DN A transfectant was used as negative control. The y-axis shows the ratio between the OD490 from the H EL-\nbinding ELISA and the OD490 from the IgG detection ELISA of the same sample.\nwww.landesbioscience.com  mAbs 5Discussion\nMassive sequencing provides a broad approach to study the \nrepertoire dynamics in an immune response to an antigen, as \nwell as the identification of antigen-specific sequences. The in \nsilico candidate selection of the target sequences is commonly \nfollowed by synthetic production of the desired genes. The cost \nof gene synthesis, however, limits their experimental specificity \nvalidation and, in some cases, may restrict the selection by relying \non consensus sequences. In this study, we propose a strategy for \nthe recovery of heavy chain variable region cDNA to enrich \nthe sequences of clonal groups of interest and produce them \nrecombinantly, aiding experimental validation for the in silico \nanalysis without the use of synthetic genes.\nTwo main alternative strategies, one mechanical and the other \nmolecular, have been reported that bypass DNA synthesis when \nproducing recombinant antibodies from digital repertoires. In \nthe first case, a micromanipulator was used to retrieve specific \nsequencing beads coated with the desired DNA22 used in the \n454 sequencing platform. This strategy requires a sophisticated \nmanipulating device, and can only be used for the 454 sequencing \nsystem.\nIn the second strategy, a molecular recovery of the specific \nheavy chain antibody sequences was implemented to target \nthe CDRH3 through an overlap PCR.16 However, the use \nof a CDRH3 primer in PCR can artificially add the desired \nsequence to a slightly different CDRH3 with which the primer \ncan still hybridize and extend. Because the IGHV-CDRH3 and \nCDRH3-IGHJ fractions are first amplified and later joined, it \nis possible for two fractions that do not belong to each other to \nbe joined, generating artificial sequences. This particular detail \ndid not represent a problem because this strategy was tested with \nsamples in which diversity was restricted only to the CDRH3. \nThe recovery strategy proposed in our study is not solely based \nin PCR and is capable of retrieving complete biological variable \nregion sequences. Theoretically, its application could be extended \nto other massive sequencing platforms.\nThe recovery process proposed in this study consists of \ntwo main selection points, one for the selection of the desired \nrearrangement through PCR, and the other for the selection of \nCDRH3 through a hybridization-based enrichment. These two \nfilters proved to be sufficient to recover eight of ten expanded \nclonal groups from two diverse samples. The success in the \nfirst selection point relies on the design of the primers and the \namplification conditions. Although the set of primers used in this \nstudy was intended to select specific murine IGHV and IGHJ \nfamilies, amplification was not entirely restricted to them because \nthe primers sequence could also be completely or partially shared \nwith other families. There are several primers set proposed for the \nselective amplification of murine IGHV and IGHJ subfamilies, \nhowever most do not cover the whole variable region, from the \nfirst to the last codon.23-29 Despite the fact that the primers set \nused in this study lacked strict subfamily selectivity, such primer \nrestriction was proven not to be essential. Nevertheless, the \ndesign of an extended and more selective set of primers would \nimprove the overall recovery outcome. A similar approach can be done to amplify human VH sequences to broaden the extent of \nthis strategy trough the design of a new set of primers.\nThe hybridization-based CDRH3 selection represents the \nmain clonal selection step at which a CDRH3-specific probe was \nused to recover each group. Biotinylated oligonucleotides have \nbeen previously used for the enrichment of specific transcripts \nor other target molecules within a mixture,30,31 and for capturing \nCDRs to exploit sequence diversity for combinatorial biology \napproaches.32 However, as far as we know, there are no reports of \na targeted recovery of cDNA of specific antibody variable regions \nwith this strategy, possibly due to the challenge it represents. \nSince the CDRH3 sequence serves as a tag mark to identify \nclonal groups, a unique probe had to be designed for each group. \nThe coverage of the probe was limited mainly to the IGHD and \njunctions (N and P nucleotides) because this region is the most \ndiverse and distinctive for each clonal group within the repertoire. \nInclusion of a high number of positions into the IGHV and IGHJ \nsegments, resulting in the use of large probes, yields partially \ncomplementary sequences and hinders the recovery process (data \nnot shown). Therefore, clonal groups with short and low diversity \nCDRH3 may be more difficult to recover.\nThe CDRH3-specific PCR after the VH cloning served as an \nindicator of the enrichment efficiency. The initial representation \nof the clonal groups before the enrichment started at 2.1% and \nup to 9.5% in the filtered digital repertoire. Thus, the actual \nrepresentation is even lower, considering the sequences that \nwere taken out in the in silico quality filters. At the CDRH3-\nspecific colony PCR, group 2G5 was enriched up to a 100% of \nthe colonies evaluated, and the lowest was 31% for 2G4. The \nabundance achieved after the enrichment varied among the eight \nclonal groups recovered. However, sequences with an identical \nCDRH3 were recovered in each case by testing a few colonies.\nThe presence of an amplification product at the CDRH3-\nspecific colony PCR (checkpoint) did not ensure an identical \nCDRH3. Therefore, the clones were sequenced, showing \nthat identical and nearly identical CDRH3 were recovered. \nThe sequence of group 2G3 that was used in the transfections \ncontained one non-synonymous mismatch (W \u2192L) at the CDRH3 \nand still showed antigen-binding capacity. This indicates that \nsequences with one or two mismatches at the CDRH3 should \nstill be considered for further evaluation, unless an amino acid \nknown to be essential is lost.\nWe managed to recover sequences with a correct rearrangement \nand identical CDRH3 to that of the target molecule, whereas \nfurther variability was found along the rest of the VH region. \nThis particular variety, presumably within the same clonal \ngroup, could be especially convenient when comparing different \nidiotypes with a common clonal origin. Through this approach \none could identify specific positions in the VH of matured \nantibodies that confer them higher affinity when compared with \ntheir precursors.\nWhile the discovery of HEL-binding antibodies from the \nenriched VH sequences does not provide any information \nregarding the recovery success, it does indicate if an appropriate \nbioinformatic selection was performed. The combinations \n2G3/HH10, 3G1/HH5 and 3G1/F10.6.6 were positive to the 6 mAbs Volume 6 Issue 1HEL-binding ELISA. The fact that the same VH paired with two \ndifferent VL retained antigen-binding capacity reaffirmed that \ngeneric VL may be used for screening, as it has been previously \nreported.18,19,33 However, a more diverse and better selected pool \nof VL could allow high-throughput screening. Possibly, some \nof the negative VH recovered sequences could show antigen-\nbinding capacity if paired with other VL sequences. To overcome \nVH-VL mispairing, massive sequencing of native VH-VL pairs \ncould also be incorporated.34 Considering that the bioinformatic \nanalysis was scarce, that the identification was solely based on \nfrequency and no other parameters (e.g., hypermutation rate, \nCDRH3 composition and framework/CDR mutation ratio), and \nthat non-native light chains were used, the observed outcome was \nbetter than expected.\nThe antibody repertoire is a very diverse and complex mixture \nof closely related sequences. Hence, an efficient isolation of \na single sequence from such a complex mixture is not straight \nforward. The method proposed in this study allowed the recovery \nof specific clonal groups with simple molecular techniques. \nThis strategy can yet be further improved and expanded, even \nto similar immune diverse samples, such as the T cell receptor \nrepertoire.35 Coupled with improved bioinformatics methods \nto identify putative antigen-specific antibodies, this recovery \nmethod may also provide the proof of concept for scalable and \nautomated devices for high-throughput antibody production.\nIn summary, ten presumably antigen-specific clonal groups \nwere identified in silico from a VH antibody repertoire. Eight \nof these clonal groups were recovered through a PCR and \nhybridization-based strategy that enabled their recombinant \nexpression. Sequences with the correct rearrangement and \nidentical CDRH3 were recovered in each case. This alternative \nrecovery strategy allows the enrichment of specific clonal groups \nwithout the need of synthetic DNA through the use of everyday \nmolecular biology techniques.\nMaterials and Methods\nMice immunization\nAdult (6\u20138 wk old) male BALB-c mice were immunized \ntwice intraperitoneally with HEL (Cat. L6876, Sigma). The first \nimmunization was performed with 30 \u03bcg of HEL with incomplete \nFreud\u2019s adjuvant. Ten days later, a second immunization was \nperformed with 5 \u03bcg of HEL with the same adjuvant. The spleen \nwas removed 15 d after the first immunization and frozen in \nliquid nitrogen until further processing.\nLibraries preparation and massive sequencing\nTotal RNA was extracted with Trizol from the immunized \nmice spleens. Splenic RNA (1.5 \u03bcg) was used to generate VH \namplicons by a 5 \u2032 RACE-PCR approach. Briefly, total RNA was \nused to generate cDNA with a d(T)30 primer. In the 3 \u2032 end of \nthe cDNA, a universal primer containing the adaptor A sequence \n(454-Roche) was incorporated using the protocol described by \nMatz et al.36 IgG VH amplicons were generated by PCR with IgG-\nspecific barcoded primers fused with adaptor B sequence (454-\nRoche) to allow discrimination of sequencing reads according \nto each mouse (5 \u2032-AdaptorB/4mer-454key/6mer-barcode/ CAGGGG CCAGTGGATA GACHGATGG-3 \u2032). Amplicons \nwere quantified with the Agilent Bioanalyzer and pooled in a \n1:1 molar ratio. Amplicons were sequenced with the GS FLX \nTitanium platform (454-Roche) in a 2-region gasket pooled \nwith other barcoded libraries following the standard amplicon \nsequencing protocol. To have good quality coverage and depth in \nthe CDRH3 region, sequencing was performed from IGHC to \nIGHV direction using primer B.\nBioinformatic analysis and candidate selection\nThe default signal processing pipeline for amplicon was used. \nThe resulting SFF files were filtered using PRINTSEQ37 to filter \nout reads > 200 bp or with average Q values > 30, and were split \naccording library barcode. We have developed a pipeline for \nautomated analysis of clonal diversity in Ig Rep-Seq data (data \nnot shown). To define clonal groups, IGHV and IGHJ segments \nfor each read are mapped with IgBLAST,38 and the CDRH3 \nsequence is extracted with HMMER (http://hmmer.janelia.\norg/). For all the reads sharing the same VDJ rearrangement, the \nalgorithm recursively clusters CDRH3 having \u2a7e98% identical \nlength and \u2a7e98% sequence identity with USEARCH.39 The \nresult is the consensus of each clonal group in FASTA format, \ncomplemented with the number of reads belonging to each \nclonal group that is used as proxy of clonal frequency. Since the \nlibraries are derived from mRNA, clonal groups having several \nreads could be derived from clonal expansion of few plasma cells. \nHigher frequency clonal groups from each mouse were selected as \nputative anti-HEL specific clonal groups as described previously.6\nCDRH3 probes design\nOne CDRH3 probe was designed for each of the ten clonal \ngroups intended to be recovered. They were designed to cover \nmainly the CDRH3 region and a few nucleotides from the end \nof IGHV and the beginning of IGHJ segments, according to \nthe IMGT/V-QUEST annotation.40 Ideally, no more than five \npositions outside the CDRH3 were included in each side, unless \nnecessary to avoid significant secondary structures. These probes \ncontained the complementary sequence of the CDRH3 so they \ncould also be used in PCR as reverse primers along with a forward \nprimer at an upstream position. Each probe was synthesized with \na biotin molecule at its 5 \u2032 end (IDT).\nRearrangement-specific PCR\nThe reactions were performed with the following final \nconcentrations: 1.6 fM VH PCR product as template, 0.5 mM \nIGHV forward primer, 0.5 mM IGHJ reverse primer, 1X PCR \nbuffer, 0.2 mM dNTP\u2019s, 2.5 mM MgSO4 and 0.025 U/ \u03bcL \nPlatinum Taq DNA polymerase High Fidelity (Invitrogen). Three \nforward 5 \u2032-phosphorylated primers for the amplification of murine \nIGHV families IGHV1 (5 \u2032-AATTCAGAGG TCCAGCTGCA \nGCAGTCTGGA-3 \u2032), IGHV4 (5 \u2032-AATTCAGAGG \nTGAAGCTTCT CGAG-3 \u2032) and IGHV14 (5 \u2032-AATTCAGAGG \nTTCAGCTGCA GCAGTCTGGG-3 \u2032) were used separately. \nThree reverse primers were used for the amplification of the IGHJ \nfamilies: IGHJ1 (5 \u2032-CTAGCTGAGG AGACGGTGAC CG-3 \u2032), \nIGHJ2 (5 \u2032-CTAGCTGAGG AGACTGTGAG AGTGGTG-3 \u2032) \nand IGHJ3 (5 \u2032-CTAGCTGCAG AGACAGTGAC CAGA-3 \u2032). \nThese primers contained the partial recognition sites for EcoRI \n(forward) or NheI (reverse), and a phosphate at the 5 \u2032 end to www.landesbioscience.com  mAbs 7allow cohesive-end cloning through Exonuclease III digestion \n(Sigma). Stringent amplification conditions were used through \na touchdown PCR scheme. Amplification started with 95 \u00b0C for \n5 min; 35 cycles of melting at 95 \u00b0C for 30 s, annealing at X \u00b0C \nfor 30 s, and extension at 72 \u00b0C for 30 s; and a final extension \nof 72 \u00b0C for 5 min. The annealing temperature (X) decreased \n2 \u00b0C (X-2 \u00b0C) at cycle six, 1 \u00b0C (X-3 \u00b0C) at cycle 11 and 2 \u00b0C \n(X-5 \u00b0C) at cycle 16. The initial annealing temperature (X) for \nthe primers pairs IGHV1-IGHJ1, IGHV1-IGHJ2, IGHV1-\nIGHJ3, IGHV14-IGHJ2 was 81 \u00b0C; for IGHV4-IGHJ3 was  \n75 \u00b0C; for IGHV1-IGHJ3 was 71 \u00b0C; and for IGHV13-IGHJ3 \nwas 64 \u00b0C. The PCR products were gel-purified before any \nfurther processing.\nClonal group cDNA enrichment\nStreptavidin-coated magnetic beads were used to recover \nthe hybridized target-molecule/biotinylated-probe complexes. \nFive \u03bcL of magnetic beads (Enrichment beads, 454-Roche \nsequencing system) per sample were pre-washed twice with 200 \n\u03bcL of enhancing buffer (454-Roche sequencing system)41 every \ntime, retrieving the beads with a magnetic base (Cat. S1506S, \nNew England Biolabs), and finally resuspended in 10 \u03bcL of \nenhancing buffer per sample. For every clonal group intended \nto recover, 7.5 ng of the corresponding rearrangement-specific \nPCR product were mixed with annealing buffer (454-Roche \nsequencing system) up to 26 \u03bcL and heated at 95 \u00b0C for 5 min, \nfollowed by immediate cooling in ice for 2 min. Four \u03bcL of the \nCDRH3-specific biotinylated probe at 5 pmol/ \u03bcL were added, \nproceeding to an incubation 5 \u00b0C above the corresponding Tm \nfor 8 min and cooling in ice for 2 min. Ten \u03bcL of pre-washed \nmagnetic beads were added to every sample and incubated in \ngentle rotation at room temperature for 7 min. The buffer was \nremoved from the magnetic beads in a magnetic base once the \nsolution had completely cleared ( \u2a7e90 s). The remaining beads \nwere washed ten times with 500 \u03bcL of enhancing buffer. Thirty \n\u03bcL of previously warmed water at 95 \u00b0C were added to the \nbeads and were incubated at 95 \u00b0C for 5 min. The beads were \nimmediately transferred to a magnetic base and the enrichment \nproduct solution was recovered once it had completely cleared \n(90 s). Along with every enriched sample, a mock enrichment \n(negative control) was performed, for which the biotinylated \nprobe was replaced with annealing buffer.\nEnrichment testing and VH cloning\nThe enriched VH sequences were cloned into the expression \nvector pVAJO-CHG1, derived from pFUSEss-CHIg-hG1 \n(InvivoGen), which contains the human IgG1 constant region and \nan omega-cassette42 that confers resistance to chloramphenicol. \nTo generate the inserts, the VH sequences were PCR-amplified \nfrom the enrichment products using the corresponding IGHV \nand IGHJ primers. The amount of template used represented \n10% of the final volume of the reaction; however, various \nseparate reactions were done to cover increasing amplification \ncycles, starting at 13 and up to 20. The amplification started \nat 95 \u00b0C for 5 min; 13 to 20 cycles of 95 \u00b0C for 30 s, X-5 \u00b0C \nfor 30 s, 72 \u00b0C for 30 s; and a final extension of 72 \u00b0C for  \n5 min. The value of X and chemical composition of the reaction \nare as mentioned in the rearrangement-specific PCR methods. Along with every sample, the negative controls of the enrichment \nwere also tested by PCR and analyzed by electrophoresis in a \n1% agarose gel. The amplification products generated from an \nenriched sample were visually compared with the ones generated \nfrom the corresponding mock enrichments. The final number of \ncycles elected was the highest one at which a notable product was \ngenerated from the enriched sample, but none or very scarce was \nobtained from the mock enrichment. Once the final number of \namplification cycles was defined for every sample, the reactions \nwere repeated only for the chosen cycles and using the Direct \nUniversal Cloning System (Sigma). The new PCR products \nwere digested with Exonuclease III, and the pVAJO-CHG1 with \nEcoRI and NheI (Fermentas). Digestion with Exonuclease III and \nthe cloning procedures were as indicated by the manufacturer. \nThe introduction of recombinant plasmids in Escherichia coli  \nstrain TOP10 was performed by electroporation. The TOP10 \nstrain was grown at 37 \u00b0C in Luria-Bertani medium and, when \nrequired, chloramphenicol was added to a final concentration of \n30 \u03bcg/mL.\nTransformants were analyzed by colony PCR for inserts by \nusing in-vector primers, and for the specific CDRH3 by using the \nIGHV and CDRH3 (biotinylated) primers. Only those colonies \npositive for both PCRs were Sanger-sequenced. The clone with \nthe closest sequence to its target was used for transfections. The \nrecovered VH sequences were paired with four VL sequences: \nHH10 [GenBank: M35667.1], D1.3 [PDB: 1FDL_L], HH5 \n[PDB: 1BQL_L] and F10.6.6 [PDB: 2Q76_A], previously \nreported as positive for HEL binding.18,20,21 The VL sequences were \nsynthesized (gBlocks, IDT) and cloned into the expression vector \npVAJO-CLhk, derived from pFUSE2ss-CLIg-hk (InvivoGen), \nwhich contains the human kappa constant region and an omega-\ncassette that confers resistance to chloramphenicol.\nRecombinant antibody expression\nHEK 293T cells (Thermo Scientific) were plated at a density \nof 125  000 cells per well in 24-well plates with DMEM complete \nmedium (supplemented with 100 U/mL penicillin, 100 \u03bcg/mL \nstreptomycin (Life Technologies) and 10% FBS) and incubated \nat 37 \u00b0C and 5% CO2. After 24 h, the cells reached 70\u201380% \nconfluence and the growth medium was replaced with low-\nFBS DMEM (2% FBS). For each well, 2 \u03bcg of total DNA were \nused for transfections. Endotoxin-free plasmids were mixed \nin a 1:3 mass ratio of the heavy and light chains, respectively. \nThe DNA was mixed with 2.5 \u03bcL of 2 M CaCl2 and water to a  \n20 \u03bcL volume. Finally, 20 \u03bcL of 2X HBS (180 mM NaCl, 50 \nmM acid-free HEPES, 2 mM Na2HPO4, pH 7.1) were added and \nthe transfectant was applied to the cells. The growth medium was \nreplaced with low-glucose DMEM (12\u2013725F, Lonza) without \nFBS, 24 h after transfection. The supernatants were harvested and \npassed through 0.2 \u03bcm filters (Advantec) 72 h after transfection. \nSodium azide was added to a final concentration of 0.01% to \neach sample, which were then stored at 4 \u00b0C.\nIgG and HEL-binding ELISA\nELISAs were performed in 96-well plates (Thermo Scientific) \ncoated overnight (4 \u00b0C) with a goat anti-human IgG primary \nantibody (109-005-098, Jackson ImmunoResearch) at  \n10 \u03bcg/mL for the detection of IgG; or HEL (L6876, Sigma) at  8 mAbs Volume 6 Issue 1References\n1. Benichou J, Ben-Hamo R, Louzoun Y, Efroni S. \nRep-Seq: uncovering the immunological repertoire \nthrough next-generation sequencing. Immunology \n2012; 135:183-91;  P M I D: 2 2 0 4 3 8 64 ; http://dx.doi.\norg/10.1111/j.1365-2567.2011.03527.x\n2. Fischer  N. Sequencing antibody repertoires: the next \ngeneration.  MAbs  2011 ; 3:17-20; P MID:2 1 099 3 7 0 ; \nhttp://dx.doi.org/10.4161/mabs.3.1.14169\n3. Arnaout  R, Lee W, Cahill  P, Honan  T, Sparrow  T, \nWeiand  M, Nusbaum  C, Rajewsky  K, Koralov  SB. \nHigh-resolution description of antibody heavy-chain \nrepertoires in humans.  PLoS One  2011 ; 6:e22365 ; \nPMID:21829618 ; http://dx.doi.org/10.1371/journal.\npone.0022365\n4. Boudinot  P, Marriotti-Ferrandiz  ME, Pasquier  \nLD, Benmansour  A, Cazenave  PA, Six A. New \nperspectives for large-scale repertoire analysis of \nimmune receptors.  Mol Immunol  2008 ; 45:2437 -\n45; P M I D : 1 8 2 7 9 9 5 8 ; http://dx.doi.org/10.1016/j.\nmolimm.2007.12.018\n5. Glanville  J, Zhai  W, Berka  J, Telman  D, Huerta  \nG, Mehta  GR, Ni I, Mei L, Sundar  PD, Day GM, \net al.  Precise determination of the diversity of a \ncombinatorial antibody library gives insight into the \nhuman immunoglobulin repertoire.  Proc Natl Acad \nSci U S A  2009 ; 106:20216 -21; P M I D : 1 9 8 7 5 6 9 5 ; \nhttp://dx.doi.org/10.1073/pnas.0909775106\n6. Reddy  ST, Ge X, Miklos  AE, Hughes  RA, Kang  \nSH, Hoi KH, Chrysostomou  C, Hunicke-Smith  SP, \nIverson  BL, Tucker  PW, et al.  Monoclonal antibodies \nisolated without screening by analyzing the variable-\ngene repertoire of plasma cells.  Nat Biotechnol  \n2010 ; 28:965-9; P M I D : 2 0 8 0 2 4 9 5 ; http://dx.doi.\norg/10.1038/nbt.1673\n7. Ravn  U, Didelot  G, Venet  S, Ng KT, Gueneau  F, \nRousseau  F, Calloud  S, Kosco-Vilbois  M, Fischer  \nN. Deep sequencing of phage display libraries to \nsupport antibody discovery.  Methods  2013 ; 60:99-\n110; P M I D : 2 3 5 0 0 6 5 7 ; http://dx.doi.org/10.1016/j.\nymeth.2013.03.001\n8. K\u00f6hler  G, Milstein  C. Continuous cultures of fused \ncells secreting antibody of predefined specificity.  \nNature  1975 ; 256:495-7; P M I D : 1 1 7 2 1 9 1 ; http://\ndx.doi.org/10.1038/256495a0\n9. Wilson  PC, Andrews  SF. Tools to therapeutically \nharness the human antibody response.  Nat Rev \nImmunol  2012 ; 12:709-19; PMID:23007571 ; http://\ndx.doi.org/10.1038/nri3285\n10. Kurosawa  N, Yoshioka  M, Isobe  M. Target-selective \nhomologous recombination cloning for high-\nthroughput generation of monoclonal antibodies \nfrom single plasma cells.  BMC Biotechnol  \n2011 ; 11:39; P M I D : 2 1 4 8 6 4 8 8 ; http://dx.doi.\norg/10.1186/1472-6750-11-39\n11. Kurosawa  N, Yoshioka  M, Fujimoto  R, Yamagishi  \nF, Isobe  M. Rapid production of antigen-specific \nmonoclonal antibodies from a variety of animals.  \nBMC Biol  2012 ; 10:80; P M I D : 2 3 0 1 7 2 7 0 ; http://\ndx.doi.org/10.1186/1741-7007-10-8012. Tiller  T, Meffre  E, Yurasov  S, Tsuiji  M, Nussenzweig  \nMC, Wardemann  H. Efficient generation of \nmonoclonal antibodies from single human B \ncells by single cell RT-PCR and expression vector \ncloning.  J Immunol Methods  2008 ; 329:112-24; \nPMID:17996249 ; http://dx.doi.org/10.1016/j.\njim.2007.09.017\n13. Yoshioka  M, Kurosawa  N, Isobe  M. Target-selective \njoint polymerase chain reaction: a robust and \nrapid method for high-throughput production of \nrecombinant monoclonal antibodies from single cells.  \nBMC Biotechnol  2011 ; 11:75; P M I D : 2 1 7 7 4 8 3 3 ; \nhttp://dx.doi.org/10.1186/1472-6750-11-75\n14. Saggy  I, Wine  Y, Shefet-Carasso  L, Nahary  L, \nGeorgiou  G, Benhar  I. Antibody isolation from \nimmunized animals: comparison of phage display \nand antibody discovery via V gene repertoire \nmining.  Protein Eng Des Sel  2012 ; 25:539-49; \nPMID:22988130 ; http://dx.doi.org/10.1093/\nprotein/gzs060\n15. Venet  S, Ravn  U, Buatois  V, Gueneau  F, Calloud  \nS, Kosco-Vilbois  M, Fischer  N. Transferring the \ncharacteristics of naturally occurring and biased \nantibody repertoires to human antibody libraries \nby trapping CDRH3 sequences.  PLoS One  2012 ; \n7:e43471 ; P M I D : 2 2 9 3 7 0 5 3 ; http://dx.doi.\norg/10.1371/journal.pone.0043471\n16. Ravn  U, Gueneau  F, Baerlocher  L, Osteras  M, \nDesmurs  M, Malinge  P, Magistrelli  G, Farinelli  L, \nKosco-Vilbois  MH, Fischer  N. By-passing in vitro \nscreening--next generation sequencing technologies \napplied to antibody display and in silico candidate \nselection.  Nucleic Acids Res  2010 ; 38:e193 ; \nPMID:20846958 ; http://dx.doi.org/10.1093/nar/\ngkq789\n17. Wu X, Zhou  T, Zhu J, Zhang  B, Georgiev  I, Wang  \nC, Chen  X, Longo  NS, Louder  M, McKee  K, et al. ; \nNISC Comparative Sequencing Program . Focused \nevolution of HIV-1 neutralizing antibodies revealed \nby structures and deep sequencing.  Science  2011 ; \n333:1593 -602; P M I D : 2 1 8 3 5 9 8 3 ; http://dx.doi.\norg/10.1126/science.1207532\n18. Smith-Gill  SJ, Hamel  PA, Lovoie  TB, Dorrington  \nKJ. Contributions of immunoglobulin heavy and \nlight chains to antibody specificity for lysozyme \nand two haptens.  J Immunol  1987 ; 139:4135 -44; \nPMID:2447160\n19. Jackson  KJ, Wang  Y, Gaeta  BA, Pomat  W, Siba \nP, Rimmer  J, Sewell  WA, Collins  AM. Divergent \nhuman populations show extensive shared IGK \nrearrangements in peripheral blood B cells.  \nImmunogenetics  2012 ; 64:3-14; P M I D : 2 1 7 8 9 5 9 6 ; \nhttp://dx.doi.org/10.1007/s00251-011-0559-z\n20. England  P, Nageotte  R, Renard  M, Page AL, Bedouelle  \nH. Functional characterization of the somatic \nhypermutation process leading to antibody D1.3, a \nhigh affinity antibody directed against lysozyme.  J \nImmunol  1999 ; 162:2129 -36; PMID:9973487\n21. Cauerhff  A, Goldbaum  FA, Braden  BC. Structural \nmechanism for affinity maturation of an anti-\nlysozyme antibody.  Proc Natl Acad Sci U S A  2004 ; \n101:3539 -44; P M I D : 1 4 9 8 8 5 0 1 ; http://dx.doi.\norg/10.1073/pnas.040006010122. Matzas  M, St\u00e4hler  PF, Kefer  N, Siebelt  N, Boisgu\u00e9rin  \nV, Leonard  JT, Keller  A, St\u00e4hler  CF, H\u00e4berle  P, \nGharizadeh  B, et al.  High-fidelity gene synthesis by \nretrieval of sequence-verified DNA identified using \nhigh-throughput pyrosequencing.  Nat Biotechnol  \n2010 ; 28:1291 -4; P M I D : 2 1 1 1 3 1 6 6 ; http://dx.doi.\norg/10.1038/nbt.1710\n23. Chard\u00e8s  T, Villard  S, Ferri\u00e8res  G, Piechaczyk  \nM, Cerutti  M, Devauchelle  G, Pau B. Efficient \namplification and direct sequencing of mouse variable \nregions from any immunoglobulin gene family.  FEBS \nLett 1999 ; 452:386-94; PMID:10386627 ; http://\ndx.doi.org/10.1016/S0014-5793(99)00649-3\n24. Dattamajumdar  AK, Jacobson  DP, Hood  LE, \nOsman  GE. Rapid cloning of any rearranged mouse \nimmunoglobulin variable genes.  Immunogenetics  \n1996 ; 43:141-51; P M I D : 8 5 5 0 0 9 8 ; http://dx.doi.\norg/10.1007/BF00176675\n25. Essono  S, Frobert  Y, Grassi  J, Cr\u00e9minon  C, \nBoquet  D. A general method allowing the design \nof oligonucleotide primers to amplify the variable \nregions from immunoglobulin cDNA.  J Immunol \nMethods  2003 ; 279:251-66; P M I D : 1 2 9 6 9 5 6 5 ; \nhttp://dx.doi.org/10.1016/S0022-1759(03)00242-4\n26. Heinrichs  A, Milstein  C, Gherardi  E. Universal \ncloning and direct sequencing of rearranged antibody \nV genes using C region primers, biotin-captured \ncDNA and one-side PCR.  J Immunol Methods  \n1995 ; 178:241-51; P M I D : 7 8 3 6 7 8 6 ; http://dx.doi.\norg/10.1016/0022-1759(94)00262-U\n27. Rohatgi  S, Ganju  P, Sehgal  D. Systematic design \nand testing of nested (RT-)PCR primers for specific \namplification of mouse rearranged/expressed \nimmunoglobulin variable region genes from small \nnumber of B cells.  J Immunol Methods  2008 ; \n339:205-19; P M I D : 1 8 9 2 6 8 2 8 ; http://dx.doi.\norg/10.1016/j.jim.2008.09.017\n28. Seijen  AM, Seijen  HG, Bos NA. Systematic design \nof mouse Vh gene family-specific oligonucleotides.  \nJ Immunol Methods  2001 ; 254:161-8; \nPMID:11406161 ; http://dx.doi.org/10.1016/\nS0022-1759(01)00396-9\n29. Wang  Z, Raifu  M, Howard  M, Smith  L, Hansen  D, \nGoldsby  R, Ratner  D. Universal PCR amplification \nof mouse immunoglobulin gene variable regions: \nthe design of degenerate primers and an assessment \nof the effect of DNA polymerase 3 \u2032 to 5\u2032 exonuclease \nactivity.  J Immunol Methods  2000 ; 233:167-77; \nPMID:10648866 ; http://dx.doi.org/10.1016/\nS0022-1759(99)00184-2\n30. Mangiapan  G, Vokurka  M, Schouls  L, Cadranel  \nJ, Lecossier  D, van Embden  J, Hance  AJ. Sequence \ncapture-PCR improves detection of mycobacterial \nDNA in clinical specimens.  J Clin Microbiol  1996 ; \n34:1209 -15; PMID:8727904\n31. Hansen-Hagge  TE, Trefzer  U, zu Reventlow  AS, \nKaltoft  K, Sterry  W. Identification of sample-specific \nsequences in mammalian cDNA and genomic DNA \nby the novel ligation-mediated subtraction (Limes).  \nNucleic Acids Res  2001 ; 29:E20; PMID:1 1 1 60940 ; \nhttp://dx.doi.org/10.1093/nar/29.4.e2050 \u03bcg/mL for the detection of HEL-binding antibodies. The \nplates were washed three times with PBS/0.1% Tween-20 and \nblocked with PBS/3% BSA (IgG ELISA) or PBS/5% skimmed \nmilk (HEL ELISA) for 1 h at room temperature. After washing \nthe plates three more times, 50 \u03bcL of the supernatants containing \nIgG were transferred to the wells and incubated for 2 h at room \ntemperature with gentle shaking. Bound IgG were detected with \na goat anti-human IgG antibody coupled with HRP (ab98567, \nAbcam). The assay was developed with OPD and H2O2, and  \n15 min later the absorbance was read at 490 nm.Disclosure of Potential Conflicts of Interest\nNo potential conflict of interest was disclosed.\nAcknowledgments\nThis work was supported by Consejo Nacional de Ciencia y \nTecnolog\u00eda [S0008\u2013142120, CB-2009\u201301\u2013133765].\nSupplemental Materials\nSupplemental materials may be found here: \nwww.landesbioscience.com/journals/mabs/article/27435www.landesbioscience.com  mAbs 932. Jirholt  P, Ohlin  M, Borrebaeck  CA, S\u00f6derlind  E. \nExploiting sequence space: shuffling in vivo formed \ncomplementarity determining regions into a master \nframework.  Gene  1998 ; 215:471-6; PMID:9714846 ; \nhttp://dx.doi.org/10.1016/S0378-1119(98)00317-5\n33. Xu JL, Davis  MM . Diversity in the CDR3 region \nof V(H) is sufficient for most antibody specificities.  \nImmunity  2000 ; 13:37-45; PMID:10933393 ; http://\ndx.doi.org/10.1016/S1074-7613(00)00006-6\n34. DeKosky  BJ, Ippolito  GC, Deschner  RP, Lavinder  \nJJ, Wine  Y, Rawlings  BM, Varadarajan  N, Giesecke  \nC, D\u00f6rner  T, Andrews  SF, et al.  High-throughput \nsequencing of the paired human immunoglobulin \nheavy and light chain repertoire.  Nat Biotechnol  \n2013 ; 31:166-9; P M I D : 2 3 3 3 4 4 4 9 ; http://dx.doi.\norg/10.1038/nbt.2492\n35. Morgan  RA, Dudley  ME, Wunderlich  JR, Hughes  \nMS, Yang  JC, Sherry  RM, Royal  RE, Topalian  \nSL, Kammula  US, Restifo  NP, et al.  Cancer \nregression in patients after transfer of genetically \nengineered lymphocytes.  Science  2006 ; 314:126-\n9; PMID:16946036 ; http://dx.doi.org/10.1126/\nscience.112900336. Matz  M, Shagin  D, Bogdanova  E, Britanova  \nO, Lukyanov  S, Diatchenko  L, Chenchik  A. \nAmplification of cDNA ends based on template-\nswitching effect and step-out PCR.  Nucleic Acids Res  \n1999 ; 27:1558 -60; PMID:10037822 ; http://dx.doi.\norg/10.1093/nar/27.6.1558\n37. Schmieder  R, Edwards  R. Quality control \nand preprocessing of metagenomic datasets.  \nBioinformatics  2011 ; 27:863-4; P M I D : 2 1 2 7 8 1 8 5 ; \nhttp://dx.doi.org/10.1093/bioinformatics/btr026\n38. Ye J, Ma N, Madden  TL, Ostell  JM. IgBLAST: \nan immunoglobulin variable domain sequence \nanalysis tool.  Nucleic Acids Res  2013 ; 41:W34-40 ; \nPMID:23671333 ; http://dx.doi.org/10.1093/nar/\ngkt382\n39. Edgar  RC. Search and clustering orders of magnitude \nfaster than BLAST.  Bioinformatics  2010 ; 26:2460 -\n1; P M I D : 2 0 7 0 9 6 9 1 ; http://dx.doi.org/10.1093/\nbioinformatics/btq46140. Brochet  X, Lefranc  MP, Giudicelli  V. IMGT/V-\nQUEST: the highly customized and integrated system \nfor IG and TR standardized V-J and V-D-J sequence \nanalysis.  Nucleic Acids Res  2008 ; 36:W503-8 ; \nPMID:18503082 ; http://dx.doi.org/10.1093/nar/\ngkn316\n41. Leamon  JHGCT , McDade  KEHCT , Fierro  \nJMNHCT , Knight  JRMCT , Charumilind  JNHCT , \nMyers  JREWWDC , Simpson  JWMCT , Volkmer  \nGABFNM . Methods of amplifying and sequencing \nnucleic acids. US, 2009 .\n42. Alexeyev  MF, Shokolenko  IN, Croughan  TP. \nImproved antibiotic-resistance gene cassettes \nand omega elements for Escherichia coli vector \nconstruction and in vitro deletion/insertion \nmutagenesis.  Gene  1995 ; 160:63-7; PMID:7628718 ; \nhttp://dx.doi.org/10.1016/0378-1119(95)00108-ILandes Bioscience www.landesbioscience.com\nSupplemental Material to:  \nJavier Vald\u00e9s-Alem\u00e1n, Juan T\u00e9llez-Sosa, Marbella \nOvilla-Mu\u00f1oz, Elizabeth Godoy-Lozano, Daniel \nVel\u00e1zquez-Ram\u00edrez, Humberto Valdovinos-\nTorres, Rosa E G\u00f3mez-Barreto, and Jes\u00fas \nMart\u00ednez-Barnetche\nHybridization-based antibody cDNA recovery for the \nproduction of recombinant antibodies identi fied by \nrepertoire sequencing\n2013; mAbs 6(2)\nhttp://dx.doi.org/10.4161/mabs.27435\nhttps://www.landesbioscience.com/journals/mabs/article/27435/ \nFigure S1 \u2013 Sequence comparison of the enrichment p roducts and their respective CDRH3 \nprobe. \nNucleotide and amino acid sequence alignments with their CDRH3 probe are shown for every \nclonal group recovered. The percentage of identical  sequences to their probe is shown next to each \nalignment. Sequence of the corresponding capture ol igonucleotide probe is highlighted in red. Note \nthat in some cases (2G1, 2G4 and 3G1) this percenta ge is higher in the amino acid alignments due \nto synonymous mutations, showing that identical and  nearly identical CDRH3 can be achieved from \nrecovered sequences with few nucleotide mismatches.  !\n152\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Bibliograf\u00eda\"!1.!Janeway! CA,! Jr.! 2001.! How! the! immune! system! works! to! protect! the! host!from!infection:!a!personal!view.!Proc(Natl(Acad(Sci(U(S(A!98:!7461U8!2.!Janeway! CA,! Jr.! 2001.! How! the! immune! system! protects! the! host! from!infection.!Microbes(Infect!3:!1167U71!3.!Ribatti!D.!2009.!Sir!Frank!Macfarlane!Burnet!and!the!clonal!selection!theory!of!antibody!formation.!Clin(Exp(Med!9:!253U8!4.!Rajewsky! K.! 1996.! Clonal! selection! and! learning! in! the! antibody! system.!Nature!381:!751U8!5.!Schroeder! HW,! Jr.,! Cavacini! L.! 2010.! Structure! and! function! of!immunoglobulins.!J(Allergy(Clin(Immunol!125:!S41U52!6.!Nescakova!Z,!Bystricky!S.!2011.!B!cells!U!ontogenesis!and!immune!memory!development.!Gen(Physiol(Biophys!30:!1U10!7.!Pieper! K,! Grimbacher! B,! Eibel! H.! 2013.! BUcell! biology! and! development.!J(Allergy(Clin(Immunol!131:!959U71!8.!Edwards!JC,!Cambridge!G.!2006.!BUcell!targeting!in!rheumatoid!arthritis!and!other!autoimmune!diseases.!Nat(Rev(Immunol!6:!394U403!9.!Martensson!IL,!Almqvist!N,!Grimsholm!O,!Bernardi!AI.!2010.!The!preUB!cell!receptor!checkpoint.!FEBS(Lett!584:!2572U9!10.!Almagro! JC.! 2012.! Natural! and! ManUmade! Antibody! Repertories! for!Antibody!Discovery.!Frontiers(in(Immunology!3!11.!SmithUGill! SJ,! Hamel! PA,! Lovoie! TB,! Dorrington! KJ.! 1987.! Contributions! of!immunoglobulin!heavy!and!light!chains!to!antibody!specificity!for!lysozyme!and!two!haptens.!J(Immunol!139:!4135U44!12.!ValdesUAleman!J,!TellezUSosa!J,!OvillaUMunoz!M,!GodoyULozano!E,!VelazquezURamirez!D,!ValdovinosUTorres!H,!GomezUBarreto!RE,!MartinezUBarnetche!J.!2014.! HybridizationUbased! antibody! cDNA! recovery! for! the! production! of!recombinant!antibodies!identified!by!repertoire!sequencing.!MAbs!6:!493U501!13.!Giudicelli! V,! Chaume! D,! Lefranc! MP.! 2005.! IMGT/GENEUDB:! a!comprehensive!database!for!human!and!mouse!immunoglobulin!and!T!cell!receptor!genes.!Nucleic(Acids(Res!33:!D256U61!14.!Nezlin! R.! 2001.! Combinatorial! events! in! generation! of! antibody! diversity.!Comb(Chem(High(Throughput(Screen!4:!377U83!15.!Li!Z,!Woo!CJ,!IglesiasUUssel!MD,!Ronai!D,!Scharff!MD.!2004.!The!generation!of! antibody! diversity! through! somatic! hypermutation! and! class! switch!recombination.!Genes(Dev!18:!1U11!16.!Glanville! J,! Zhai! W,! Berka! J,! Telman! D,!Huerta! G,! Mehta! GR,! Ni! I,! Mei! L,!Sundar!PD,!Day!GM,!Cox!D,!Rajpal!A,!Pons!J.!2009.!Precise!determination!of!the! diversity! of! a! combinatorial! antibody! library! gives! insight! into! the!human!immunoglobulin!repertoire.!Proc(Natl(Acad(Sci(U(S(A!106:!20216U21!17.!Subrahmanyam! R,! Sen! R.! 2010.! RAGs'! eye! view! of! the! immunoglobulin!heavy!chain!gene!locus.!Semin(Immunol!22:!337U45!18.!Chaplin!DD.!2010.!Overview!of!the!immune!response.!J(Allergy(Clin(Immunol!125:!S3U23!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"153\"!#Instituto!Nacional!de!Salud!P\u00fablica!###19.!BoubakourUAzzouz! I,! Bertrand! P,! Claes! A,! Lopez!BS,! Rougeon! F.! 2012.!Terminal! deoxynucleotidyl! transferase! requires! KU80! and! XRCC4! to!promote! NUaddition! at! nonUV(D)J! chromosomal! breaks! in! nonUlymphoid!cells.!Nucleic(Acids(Res!!20.!Schatz! DG,! Swanson! PC.! 2011.! V(D)J! recombination:! mechanisms! of!initiation.!Annu(Rev(Genet!45:!167U202!21.!Defrance! T,! Taillardet! M,! Genestier! L.! 2011.! T! cellUindependent! B! cell!memory.!Curr(Opin(Immunol!23:!330U6!22.!Vinuesa! CG,! Linterman! MA,! Goodnow! CC,! Randall! KL.! 2010.! T! cells! and!follicular!dendritic!cells!in!germinal!center!BUcell!formation!and!selection.!Immunol(Rev!237:!72U89!23.!Goodnow! CC,! Vinuesa! CG,! Randall! KL,! Mackay! F,! Brink! R.! 2010.! Control!systems! and! decision! making! for! antibody! production.!Nat( Immunol!11:!681U8!24.!Oropallo!MA,!Cerutti!A.!2014.!Germinal!center!reaction:!antigen!affinity!and!presentation!explain!it!all.!Trends(Immunol!35:!287U9!25.!Matthews! AJ,! Zheng! S,! DiMenna! LJ,! Chaudhuri! J.! 2014.! Regulation! of!immunoglobulin! classUswitch! recombination:! choreography! of! noncoding!transcription,!targeted!DNA!deamination,!and!longUrange!DNA!repair.!Adv(Immunol!122:!1U57!26.!Schatz!DG,!Ji!Y.!2011.!Recombination!centres!and!the!orchestration!of!V(D)J!recombination.!Nat(Rev(Immunol!11:!251U63!27.!Kothapalli! NR,! Fugmann! SD.! 2011.! Targeting! of! AIDUmediated! sequence!diversification!to!immunoglobulin!genes.!Curr(Opin(Immunol!23:!184U9!28.!Pavri! R,! Nussenzweig! MC.! 2011.! AID! targeting! in! antibody! diversity.!Adv(Immunol!110:!1U26!29.!Zhu!C,!Lee!V,!Finn!A,!Senger!K,!Zarrin!AA,!Du!Pasquier!L,!Hsu!E.!2012.!Origin!of!immunoglobulin!isotype!switching.!Curr(Biol!22:!872U80!30.!Stavnezer! J,! Schrader! CE.! 2014.! IgH! chain! class! switch! recombination:!mechanism!and!regulation.!J(Immunol!193:!5370U8!31.!Pone!EJ,!Xu!Z,!White!CA,!Zan!H,!Casali!P.!2012.!B!cell!TLRs!and!induction!of!immunoglobulin! classUswitch! DNA! recombination.!Front(Biosci((Landmark(Ed)!17:!2594U615!32.!Pone!EJ,!Zhang!J,!Mai!T,!White!CA,!Li!G,!Sakakura!JK,!Patel!PJ,!AlUQahtani!A,!Zan!H,!Xu!Z,!Casali!P.!2012.!BCRUsignalling!synergizes!with!TLRUsignalling!for!induction!of!AID!and!immunoglobulin!classUswitching!through!the!nonUcanonical!NFUkappaB!pathway.!Nat(Commun!3:!767!33.!Pulendran!B,!Oh!JZ,!Nakaya!HI,!Ravindran!R,!Kazmin!DA.!2013.!Immunity!to!viruses:!learning!from!successful!human!vaccines.!Immunol(Rev!255:!243U55!34.!Rothstein!TL,!Griffin!DO,!Holodick!NE,!Quach!TD,!Kaku!H.!2013.!Human!BU1!cells!take!the!stage.!Ann(N(Y(Acad(Sci!1285:!97U114!35.!Warter! L,! Appanna! R,! Fink! K.! 2012.! Human! polyU!and! crossUreactive! antiUviral!antibodies!and!their!impact!on!protection!and!pathology.!Immunol(Res!53:!148U61!36.!Griffin! DO,! Holodick! NE,! Rothstein! TL.! 2011.! Human! B1! cells! in! umbilical!cord!and!adult!peripheral!blood!express!the!novel!phenotype!CD20+!CD27+!CD43+!CD70.!J(Exp(Med!208:!67U80!!\n154\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###37.!Panda! S,! Ding! JL.! 2015.! Natural! Antibodies! Bridge! Innate! and! Adaptive!Immunity.!J(Immunol!194:!13U20!38.!Balakrishnan!T,!BelaUOng!DB,!Toh!YX,!Flamand!M,!Devi!S,!Koh!MB,!Hibberd!ML,! Ooi! EE,!Low! JG,! Leo! YS,! Gu! F,! Fink! K.! 2011.! Dengue! virus! activates!polyreactive,!natural!IgG!B!cells!after!primary!and!secondary!infection.!PLoS(One!6:!e29430!39.!Xu!M,!Hadinoto!V,!Appanna!R,!Joensson!K,!Toh!YX,!Balakrishnan!T,!Ong!SH,!Warter! L,! Leo! YS,! Wang! CI,!Fink! K.! 2012.! Plasmablasts! generated! during!repeated! dengue! infection! are! virus! glycoproteinUspecific! and! bind! to!multiple!virus!serotypes.!J(Immunol!189:!5877U85!40.!Ichiyoshi!Y,!Casali!P.!1994.!Analysis!of!the!structural!correlates!for!antibody!polyreactivity! by! multiple! reassortments! of! chimeric! human!immunoglobulin!heavy!and!light!chain!V!segments.!J(Exp(Med!180:!885U95!41.!Pappas! L,! Foglierini! M,! Piccoli! L,! Kallewaard! NL,! Turrini! F,! Silacci! C,!FernandezURodriguez! B,! Agatic! G,! GiacchettoUSasselli! I,! Pellicciotta! G,!Sallusto! F,! Zhu! Q,! Vicenzi! E,! Corti! D,! Lanzavecchia! A.! 2014.! Rapid!development! of! broadly! influenza! neutralizing! antibodies! through!redundant!mutations.!Nature!516:!418U22!42.!Mallajosyula!VV,!Citron!M,!Ferrara!F,!Lu!X,!Callahan!C,!Heidecker!GJ,!Sarma!SP,! Flynn! JA,! Temperton! NJ,! Liang! X,! Varadarajan! R.! 2014.! Influenza!hemagglutinin! stemUfragment! immunogen! elicits! broadly! neutralizing!antibodies! and! confers! heterologous! protection.!Proc( Natl( Acad( Sci( U( S( A!111:!E2514U23!43.!Kepler! TB,! Liao! HX,! Alam! SM,! Bhaskarabhatla! R,! Zhang! R,! Yandava! C,!Stewart!S,!Anasti!K,!Kelsoe!G,!Parks!R,!Lloyd!KE,!Stolarchuk!C,!Pritchett!J,!Solomon!E,!Friberg!E,!Morris!L,!Karim!SS,!Cohen!MS,!Walter!E,!Moody!MA,!Wu!X,!AltaeUTran!HR,!Georgiev!IS,!Kwong!PD,!Boyd!SD,!Fire!AZ,!Mascola!JR,!Haynes! BF.! 2014.! Immunoglobulin! gene! insertions! and! deletions! in! the!affinity! maturation! of! HIVU1! broadly! reactive! neutralizing! antibodies.!Cell(Host(Microbe!16:!304U13!44.!WHO.!2012.!Global(strategy(for(dengue(prevention(and(control,!World!Health!Organization,!Geneva!45.!Holmes!E,!Twiddy!S.!2003.!The!origin,!emergence!and!evolutionary!genetics!of!dengue!virus.!Infection,(Genetics(and(Evolution!3:!19U28!46.!WHO.!2012.!Dengue(and(severe(dengue,!World!Health!Organization!47.!Thomas! SJ,! Endy! TP.!2011.! Vaccines! for! the! prevention! of! dengue:!development!update.!Hum(Vaccin!7:!674U84!48.!Guzman!MG,!Harris!E.!2014.!Dengue.!Lancet!!49.!Stoddard!ST,!Forshey!BM,!Morrison!AC,!PazUSoldan!VA,!VazquezUProkopec!GM,!Astete!H,!Reiner!RC,!Jr.,!Vilcarromero!S,!Elder!JP,!Halsey!ES,!Kochel!TJ,!Kitron!U,!Scott!TW.!2013.!HouseUtoUhouse!human!movement!drives!dengue!virus!transmission.!Proc(Natl(Acad(Sci(U(S(A!110:!994U9!50.!Alen!MM,!Schols!D.!2012.!Dengue!virus!entry!as!target!for!antiviral!therapy.!J(Trop(Med!2012:!628475!51.!Guilarde!AO,!Turchi!MD,!Siqueira!JB,!Jr.,!Feres!VC,!Rocha!B,!Levi!JE,!Souza!VA,! Boas! LS,! Pannuti! CS,! Martelli! CM.! 2008.! Dengue! and! dengue!hemorrhagic! fever! among! adults:! clinical! outcomes! related! to! viremia,!serotypes,!and!antibody!response.!J(Infect(Dis!197:!817U24!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"155\"!#Instituto!Nacional!de!Salud!P\u00fablica!###52.!Gubler!DJ.!1998.!Dengue!and!dengue!hemorrhagic!fever.!Clin(Microbiol(Rev!11:!480U96!53.!Horstick! O,! Farrar! J,! Lum! L,! Martinez! E,! San! Martin! JL,! Ehrenberg! J,!Velayudhan!R,!Kroeger!A.!2012.!Reviewing!the!development,!evidence!base,!and!application!of!the!revised!dengue!case!classification.!Pathog(Glob(Health!106:!94U101!54.!Kalayanarooj! S.! 2011.! Dengue! classification:! current! WHO! vs.! the! newly!suggested!classification!for!better!clinical!application?!J(Med(Assoc(Thai!94!Suppl!3:!S74U84!55.!Guzman! A,! Isturiz! RE.! 2010.! Update! on! the! global! spread! of! dengue.!Int(J(Antimicrob(Agents!36!Suppl!1:!S40U2!56.!CENAVECE.!2009.!Definiciones!operacionales.!!57.!WHO.! 2009.!Dengue.( Guidelines( for( Diagnosis,( Treatment,( prevention( and(Control(K(New(edition.,!World!Health!Organization,!Geneva!58.!Henchal!EA,!Putnak!JR.!1990.!The!dengue!viruses.!Clin(Microbiol(Rev!3:!376U96!59.!Solomon! T,! Mallewa! M.! 2001.! Dengue! and! other! emerging! flaviviruses.!J(Infect!42:!104U15!60.!Guzman! MG,! Halstead! SB,! Artsob! H,!Buchy! P,! Farrar! J,! Gubler! DJ,!Hunsperger!E,!Kroeger!A,!Margolis!HS,!Martinez!E,!Nathan!MB,!Pelegrino!JL,!Simmons!C,!Yoksan!S,!Peeling!RW.!2010.!Dengue:!a!continuing!global!threat.!Nat(Rev(Microbiol!8:!S7U16!61.!Acosta!EG,!Kumar!A,!Bartenschlager!R.!2014.!Revisiting!dengue!virusUhost!cell!interaction:!new!insights!into!molecular!and!cellular!virology.!Adv(Virus(Res!88:!1U109!62.!Mukhopadhyay!S,!Kuhn!RJ,!Rossmann!MG.!2005.!A!structural!perspective!of!the!flavivirus!life!cycle.!Nat(Rev(Microbiol!3:!13U22!63.!Neuberger! MS.! 2008.! Antibody! diversification! by! somatic! mutation:! from!Burnet!onwards.!Immunol(Cell(Biol!86:!124U32!64.!Tang! ES,! Martin! A.! 2007.! Immunoglobulin! gene! conversion:! synthesizing!antibody!diversification!and!DNA!repair.!DNA(Repair((Amst)!6:!1557U71!65.!RodenhuisUZybert! IA,! Wilschut! J,! Smit! JM.! 2010.! Dengue! virus! life! cycle:!viral!and!host!factors!modulating!infectivity.!Cell(Mol(Life(Sci!67:!2773U86!66.!Welsch!S,!Miller!S,!RomeroUBrey!I,!Merz!A,!Bleck!CK,!Walther!P,!Fuller!SD,!Antony!C,!KrijnseULocker!J,!Bartenschlager!R.!2009.!Composition!and!threeUdimensional!architecture!of!the!dengue!virus!replication!and!assembly!sites.!Cell(Host(Microbe!5:!365U75!67.!RodenhuisUZybert! IA,! Moesker! B,! da! Silva! Voorham! JM,! van! der! EndeUMetselaar!H,!Diamond!MS,!Wilschut!J,!Smit!JM.!2011.!A!fusionUloop!antibody!enhances!the!infectious!properties!of!immature!flavivirus!particles.!J(Virol!85:!11800U8!68.!Guabiraba! R,! Ryffel! B.!2014.! Dengue! virus! infection:! current! concepts! in!immune! mechanisms! and! lessons! from! murine! models.!Immunology!141:!143U56!69.!Zompi!S,!Harris!E.!2012.!Animal!models!of!dengue!virus!infection.!Viruses!4:!62U82!70.!Rothman! AL.! 2010.! Cellular! immunology! of!sequential! dengue! virus!infection!and!its!role!in!disease!pathogenesis.!Curr(Top(Microbiol(Immunol!338:!83U98!!\n156\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###71.!Wu! SJ,! Hayes! CG,! Dubois! DR,! Windheuser! MG,! Kang! YH,! Watts! DM,!Sieckmann!DG.!1995.!Evaluation!of!the!severe!combined!immunodeficient!(SCID)!mouse!as!an!animal!model!for!dengue!viral!infection.!Am(J(Trop(Med(Hyg!52:!468U76!72.!Lin!YL,!Liao!CL,!Chen!LK,!Yeh!CT,!Liu!CI,!Ma!SH,!Huang!YY,!Huang!YL,!Kao!CL,!King!CC.!1998.!Study!of!Dengue!virus!infection!in!SCID!mice!engrafted!with!human!K562!cells.!J(Virol!72:!9729U37!73.!An! J,! KimuraUKuroda! J,! Hirabayashi! Y,! Yasui! K.! 1999.! Development! of! a!novel!mouse!model!for!dengue!virus!infection.!Virology!263:!70U7!74.!Blaney!JE,!Jr.,!Johnson!DH,!Manipon!GG,!Firestone!CY,!Hanson!CT,!Murphy!BR,!Whitehead!SS.!2002.!Genetic!basis!of!attenuation!of!dengue!virus!type!4!small! plaque! mutants! with! restricted! replication! in! suckling! mice! and! in!SCID!mice!transplanted!with!human!liver!cells.!Virology!300:!125U39!75.!Bente! DA,! Melkus! MW,! Garcia! JV,! RicoUHesse! R.! 2005.! Dengue!fever! in!humanized!NOD/SCID!mice.!J(Virol!79:!13797U9!76.!Kuruvilla!JG,!Troyer!RM,!Devi!S,!Akkina!R.!2007.!Dengue!virus!infection!and!immune! response! in! humanized! RAG2(U/U)gamma(c)(U/U)! (RAGUhu)! mice.!Virology!369:!143U52!77.!Shresta! S,! Sharar! KL,! Prigozhin! DM,! Beatty! PR,! Harris! E.! 2006.! Murine!model! for! dengue! virusUinduced! lethal! disease! with! increased! vascular!permeability.!J(Virol!80:!10208U17!78.!Balsitis!SJ,!Williams!KL,!Lachica!R,!Flores!D,!Kyle!JL,!Mehlhop!E,!Johnson!S,!Diamond! MS,! Beatty! PR,! Harris!E.! 2010.! Lethal! antibody! enhancement! of!dengue! disease! in! mice! is! prevented! by! Fc! modification.!PLoS( Pathog!6:!e1000790!79.!Zellweger!RM,!Prestwood!TR,!Shresta!S.!2010.!Enhanced!infection!of!liver!sinusoidal! endothelial! cells! in! a! mouse! model! of! antibodyUinduced! severe!dengue!disease.!Cell(Host(Microbe!7:!128U39!80.!Shresta! S,! Kyle! JL,! Robert! Beatty! P,! Harris! E.! 2004.! Early! activation! of!natural!killer!and!B!cells!in!response!to!primary!dengue!virus!infection!in!A/J!mice.!Virology!319:!262U73!81.!Huang! KJ,!Li! SY,! Chen! SC,! Liu! HS,! Lin! YS,! Yeh! TM,! Liu! CC,! Lei! HY.! 2000.!Manifestation! of! thrombocytopenia! in! dengueU2UvirusUinfected! mice.!J(Gen(Virol!81:!2177U82!82.!Chen!ST,!Lin!YL,!Huang!MT,!Wu!MF,!Cheng!SC,!Lei!HY,!Lee!CK,!Chiou!TW,!Wong!CH,!Hsieh!SL.!2008.!CLEC5A!is!critical!for!dengueUvirusUinduced!lethal!disease.!Nature!453:!672U6!83.!Chen!HC,!Lai!SY,!Sung!JM,!Lee!SH,!Lin!YC,!Wang!WK,!Chen!YC,!Kao!CL,!King!CC,! WuUHsieh! BA.! 2004.! Lymphocyte! activation! and! hepatic! cellular!infiltration!in!immunocompetent!mice!infected!by!dengue!virus.!J(Med(Virol!73:!419U31!84.!Chen!HC,!Hofman!FM,!Kung!JT,!Lin!YD,!WuUHsieh!BA.!2007.!Both!virus!and!tumor!necrosis!factor!alpha!are!critical!for!endothelium!damage!in!a!mouse!model!of!dengue!virusUinduced!hemorrhage.!J(Virol!81:!5518U26!85.!Renneson!J,!Guabiraba!R,!Maillet!I,!Marques!RE,!Ivanov!S,!Fontaine!J,!Paget!C,! Quesniaux! V,! Faveeuw! C,! Ryffel! B,! Teixeira! MM,! Trottein! F.! 2011.! A!detrimental! role! for! invariant! natural! killer! T! cells! in! the! pathogenesis! of!experimental!dengue!virus!infection.!Am(J(Pathol!179:!1872U83!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"157\"!#Instituto!Nacional!de!Salud!P\u00fablica!###86.!Guabiraba! R,! Besnard! AG,! Marques! RE,! Maillet! I,! Fagundes! CT,! Conceicao!TM,! Rust! NM,! Charreau! S,! Paris! I,! Lecron! JC,! Renauld! JC,! Quesniaux! V,! Da!Poian! AT,! Arruda! LB,! Souza! DG,! Ryffel! B,! Teixeira! MM.! 2013.! ILU22!modulates!ILU17A!production!and!controls!inflammation!and!tissue!damage!in!experimental!dengue!infection.!Eur(J(Immunol!43:!1529U44!87.!Guabiraba! R,! Marques! RE,! Besnard! AG,! Fagundes! CT,! Souza! DG,! Ryffel! B,!Teixeira!MM.!2010.!Role!of!the!chemokine!receptors!CCR1,!CCR2!and!CCR4!in!the!pathogenesis!of!experimental!dengue!infection!in!mice.!PLoS(One!5:!e15680!88.!Costa! VV,! Fagundes! CT,! Valadao! DF,! Cisalpino! D,! Dias! AC,! Silveira! KD,!Kangussu! LM,! Avila! TV,! Bonfim! MR,! Bonaventura! D,! Silva! TA,! Sousa! LP,!Rachid!MA,!Vieira!LQ,!Menezes!GB,!de!Paula!AM,!Atrasheuskaya!A,!Ignatyev!G,! Teixeira! MM,! Souza! DG.! 2012.! A! model! of! DENVU3! infection! that!recapitulates!severe!disease!and!highlights!the!importance!of!IFNUgamma!in!host!resistance!to!infection.!PLoS(Negl(Trop(Dis!6:!e1663!89.!Fagundes!CT,!Costa!VV,!Cisalpino!D,!Amaral!FA,!Souza!PR,!Souza!RS,!Ryffel!B,! Vieira! LQ,! Silva! TA,! Atrasheuskaya! A,! Ignatyev! G,! Sousa! LP,! Souza! DG,!Teixeira! MM.! 2011.! IFNUgamma! production! depends! on! ILU12! and! ILU18!combined!action!and!mediates!host!resistance!to!dengue!virus!infection!in!a!nitric!oxideUdependent!manner.!PLoS(Negl(Trop(Dis!5:!e1449!90.!Paes!MV,!Lenzi!HL,!Nogueira!AC,!Nuovo!GJ,!Pinhao!AT,!Mota!EM,!BasilioUdeUOliveira! CA,! Schatzmayr! H,! Barth! OM,! Alves! AM.! 2009.! Hepatic! damage!associated!with!dengueU2!virus!replication!in!liver!cells!of!BALB/c!mice.!Lab(Invest!89:!1140U51!91.!AssuncaoUMiranda! I,! Amaral! FA,! Bozza! FA,! Fagundes! CT,! Sousa! LP,! Souza!DG,!Pacheco!P,!BarbosaULima!G,!Gomes!RN,!Bozza!PT,!Da!Poian!AT,!Teixeira!MM,! Bozza! MT.! 2010.! Contribution! of! macrophage! migration! inhibitory!factor!to!the!pathogenesis!of!dengue!virus!infection.!FASEB(J!24:!218U28!92.!Souza!DG,!Fagundes!CT,!Sousa!LP,!Amaral!FA,!Souza!RS,!Souza!AL,!Kroon!EG,!Sachs! D,! Cunha! FQ,! Bukin! E,! Atrasheuskaya! A,! Ignatyev! G,! Teixeira! MM.!2009.! Essential! role! of! plateletUactivating! factor! receptor! in! the!pathogenesis! of! Dengue! virus! infection.!Proc( Natl( Acad( Sci( U( S( A!106:!14138U43!93.!Whitehorn!J,!Farrar!J.!2010.!Dengue.!Br(Med(Bull!95:!161U73!94.!Halstead!SB.!2007.!Dengue.!The(Lancet!370:!1644U52!95.!Whitehead! SS,! Blaney! JE,! Durbin! AP,! Murphy! BR.! 2007.! Prospects! for! a!dengue!virus!vaccine.!Nat(Rev(Microbiol!5:!518U28!96.!Sierra!B,!Garcia!G,!Perez!AB,!Morier!L,!Rodriguez!R,!Alvarez!M,!Guzman!MG.!2002.!LongUterm!memory!cellular!immune!response!to!dengue!virus!after!a!natural!primary!infection.!Int(J(Infect(Dis!6:!125U8!97.!Wahala!WM,!Silva!AM.!2011.!The!human!antibody!response!to!dengue!virus!infection.!Viruses!3:!2374U95!98.!Anderson! KB,! Gibbons! RV,! Cummings! DA,! Nisalak! A,! Green! S,! Libraty! DH,!Jarman!RG,!Srikiatkhachorn!A,!Mammen!MP,!Darunee!B,!Yoon!IK,!Endy!TP.!2014.!A!Shorter!Time!Interval!Between!First!and!Second!Dengue!Infections!Is!Associated!With!Protection!From!Clinical!Illness!in!a!SchoolUbased!Cohort!in!Thailand.!J(Infect(Dis!209:!360U8!99.!Montoya!M,!Gresh!L,!Mercado!JC,!Williams!KL,!Vargas!MJ,!Gutierrez!G,!Kuan!G,!Gordon!A,!Balmaseda!A,!Harris!E.!2013.!Symptomatic!versus!inapparent!!\n158\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###outcome!in!repeat!dengue!virus!infections!is!influenced!by!the!time!interval!between!infections!and!study!year.!PLoS(Negl(Trop(Dis!7:!e2357!100.!Pierson! TC,! Diamond! MS.! 2008.! Molecular! mechanisms!of! antibodyUmediated!neutralisation!of!flavivirus!infection.!Expert(Rev(Mol(Med!10:!e12!101.!Rothman! AL.! 2011.! Immunity! to! dengue! virus:! a! tale! of! original! antigenic!sin!and!tropical!cytokine!storms.!Nat(Rev(Immunol!11:!532U43!102.!Wahala!WM,!Kraus!AA,!Haymore!LB,!AccavittiULoper!MA,!de!Silva!AM.!2009.!Dengue! virus! neutralization! by! human! immune! sera:! role! of! envelope!protein!domain!IIIUreactive!antibody.!Virology!392:!103U13!103.!Matsui! K,! Gromowski! GD,! Li! L,! Barrett! AD.! 2010.! Characterization! of! a!dengue!typeUspecific! epitope! on! dengue! 3! virus! envelope! protein! domain!III.!J(Gen(Virol!91:!2249U53!104.!de!Alwis!R,!Smith!SA,!Olivarez!NP,!Messer!WB,!Huynh!JP,!Wahala!WM,!White!LJ,!Diamond!MS,!Baric!RS,!Crowe!JE,!Jr.,!de!Silva!AM.!2012.!Identification!of!human! neutralizing! antibodies! that! bind! to! complex! epitopes! on! dengue!virions.!Proc(Natl(Acad(Sci(U(S(A!109:!7439U44!105.!Lin!HE,!Tsai!WY,!Liu!IJ,!Li!PC,!Liao!MY,!Tsai!JJ,!Wu!YC,!Lai!CY,!Lu!CH,!Huang!JH,!Chang!GJ,!Wu!HC,!Wang!WK.!2012.!Analysis!of!epitopes!on!dengue!virus!envelope! protein! recognized! by! monoclonal! antibodies! and! polyclonal!human!sera!by!a!high!throughput!assay.!PLoS(Negl(Trop(Dis!6:!e1447!106.!Deng!YQ,!Dai!JX,!Ji!GH,!Jiang!T,!Wang!HJ,!Yang!HO,!Tan!WL,!Liu!R,!Yu!M,!Ge!BX,! Zhu! QY,! Qin! ED,! Guo! YJ,! Qin!CF.! 2011.! A! broadly! flavivirus! crossUneutralizing! monoclonal! antibody! that! recognizes! a! novel! epitope! within!the!fusion!loop!of!E!protein.!PLoS(One!6:!e16059!107.!Christian! EA,! Kahle! KM,! Mattia! K,! Puffer! BA,! Pfaff! JM,! Miller! A,! Paes! C,!Davidson!E,!Doranz!BJ.!2013.!AtomicUlevel!functional!model!of!dengue!virus!Envelope!protein!infectivity.!Proc(Natl(Acad(Sci(U(S(A!110:!18662U7!108.!Beltramello! M,! Williams! KL,! Simmons! CP,! Macagno! A,! Simonelli! L,! Quyen!NT,!SukupolviUPetty!S,!NavarroUSanchez!E,!Young!PR,!de!Silva!AM,!Rey!FA,!Varani!L,!Whitehead!SS,!Diamond!MS,!Harris!E,!Lanzavecchia!A,!Sallusto!F.!2010.!The!human!immune!response!to!Dengue!virus!is!dominated!by!highly!crossUreactive! antibodies! endowed! with! neutralizing! and! enhancing!activity.!Cell(Host(Microbe!8:!271U83!109.!Valdes!K,!Alvarez!M,!Pupo!M,!Vazquez!S,!Rodriguez!R,!Guzman!MG.!2000.!Human! Dengue! antibodies! against! structural! and! nonstructural! proteins.!Clin(Diagn(Lab(Immunol!7:!856U7!110.!Hu!D,!Di!B,!Ding!X,!Wang!Y,!Chen!Y,!Pan!Y,!Wen!K,!Wang!M,!Che!X.!2011.!Kinetics!of!nonUstructural!protein!1,!IgM!and!IgG!antibodies!in!dengue!type!1!primary!infection.!Virol(J!8:!47!111.!Green!S,!Rothman!A.!2006.!Immunopathological!mechanisms!in!dengue!and!dengue!hemorrhagic!fever.!Curr(Opin(Infect(Dis!19:!429U36!112.!Whitehorn! J,! Simmons! CP.! 2011.! The! pathogenesis! of! dengue.!Vaccine!29:!7221U8!113.!Wan!SW,!Lin!CF,!Yeh!TM,!Liu!CC,!Liu!HS,!Wang!S,!Ling!P,!Anderson!R,!Lei!HY,!Lin! YS.! 2013.! Autoimmunity! in! dengue! pathogenesis.!J( Formos( Med( Assoc!112:!3U11!114.!Dejnirattisai! W,! Wongwiwat! W,! Supasa! S,! Zhang! X,! Dai! X,! Rouvinsky! A,!Jumnainsong!A,!Edwards!C,!Quyen!NT,!Duangchinda!T,!Grimes!JM,!Tsai!WY,!Lai! CY,! Wang! WK,! Malasit! P,! Farrar! J,! Simmons! CP,! Zhou! ZH,! Rey! FA,!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"159\"!#Instituto!Nacional!de!Salud!P\u00fablica!###Mongkolsapaya!J,!Screaton!GR.!2015.!A!new!class!of!highly!potent,!broadly!neutralizing!antibodies!isolated!from!viremic!patients!infected!with!dengue!virus.!Nat(Immunol!16:!170U7!115.!Coloma!J,!Harris!E.!2015.!Broad!and!strong:!the!ultimate!antibody!to!dengue!virus.!Nat(Immunol!16:!135U7!116.!Rouvinski! A,! GuardadoUCalvo! P,! BarbaUSpaeth! G,! Duquerroy! S,! Vaney! MC,!Kikuti!CM,!Navarro!Sanchez!ME,!Dejnirattisai!W,!Wongwiwat!W,!Haouz!A,!GirardUBlanc! C,! Petres! S,! Shepard! WE,! Despres! P,! ArenzanaUSeisdedos! F,!Dussart! P,! Mongkolsapaya! J,! Screaton! GR,! Rey! FA.! 2015.! Recognition!determinants! of! broadly! neutralizing! human! antibodies! against! dengue!viruses.!Nature!!117.!Halstead!SB.!2009.!Antibodies!determine!virulence!in!dengue.!Ann(N(Y(Acad(Sci!1171!Suppl!1:!E48U56!118.!RicoUHesse!R.!2010.!Dengue!virus!virulence!and!transmission!determinants.!Curr(Top(Microbiol(Immunol!338:!45U55!119.!Hawkes!RA.!1964.!Enhancement!of!the!Infectivity!of!Arboviruses!by!Specific!Antisera!Produced!in!Domestic!Fowls.!Aust(J(Exp(Biol(Med(Sci!42:!465U82!120.!Hawkes! RA,! Lafferty! KJ.! 1967.! The! enchancement! of! virus! infectivity! by!antibody.!Virology!33:!250U61!121.!Kurane! I.! 2007.! Dengue! hemorrhagic! fever! with! special! emphasis! on!immunopathogenesis.!Comp(Immunol(Microbiol(Infect(Dis!30:!329U40!122.!Guzman! MG,! Vazquez! S.! 2010.! The! complexity! of! antibodyUdependent!enhancement!of!dengue!virus!infection.!Viruses!2:!2649U62!123.!Halstead!SB.!2002.!Dengue!hemorrhagic!fever:!two!infections!and!antibody!dependent!enhancement,!a!brief!history!and!personal!memoir.!Rev(Cubana(Med(Trop!54:!171U9!124.!Thomas! S,! Redfern! JB,! Lidbury! BA,! Mahalingam! S.! 2006.! AntibodyUdependent! enhancement! and! vaccine! development.!Expert(Rev(Vaccines!5:!409U12!125.!Davenport! FM,! Hennessy! AV,! Francis! T,! Jr.! 1953.! Epidemiologic! and!immunologic! significance! of! age! distribution! of! antibody!to! antigenic!variants!of!influenza!virus.!J(Exp(Med!98:!641U56!126.!Murphy! BR,! Whitehead! SS.! 2011.! Immune! response! to! dengue! virus! and!prospects!for!a!vaccine.!Annu(Rev(Immunol!29:!587U619!127.!Mongkolsapaya! J,! Dejnirattisai! W,! Xu! XN,! Vasanawathana! S,!Tangthawornchaikul!N,!Chairunsri!A,!Sawasdivorn!S,!Duangchinda!T,!Dong!T,!RowlandUJones!S,!Yenchitsomanus!PT,!McMichael!A,!Malasit!P,!Screaton!G.!2003.!Original!antigenic!sin!and!apoptosis!in!the!pathogenesis!of!dengue!hemorrhagic!fever.!Nat(Med!9:!921U7!128.!Rothman! AL.! 2004.! Dengue:! defining! protective! versus! pathologic!immunity.!Journal(of(Clinical(Investigation!113:!946U51!129.!Li! L,! Lok! SM,! Yu! IM,! Zhang! Y,! Kuhn! RJ,! Chen! J,! Rossmann! MG.! 2008.! The!flavivirus! precursor! membraneUenvelope! protein! complex:! structure! and!maturation.!Science!319:!1830U4!130.!Yu!IM,!Zhang!W,!Holdaway!HA,!Li!L,!Kostyuchenko!VA,!Chipman!PR,!Kuhn!RJ,!Rossmann!MG,!Chen!J.!2008.!Structure!of!the!immature!dengue!virus!at!low!pH!primes!proteolytic!maturation.!Science!319:!1834U7!!\n160\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###131.!RodenhuisUZybert! IA,! van! der! Schaar! HM,! da! Silva! Voorham! JM,! van! der!EndeUMetselaar! H,! Lei! HY,! Wilschut! J,! Smit! JM.! 2010.! Immature! dengue!virus:!a!veiled!pathogen?!PLoS(Pathog!6:!e1000718!132.!Dejnirattisai!W,!Jumnainsong!A,!Onsirisakul!N,!Fitton!P,!Vasanawathana!S,!Limpitikul! W,! Puttikhunt! C,! Edwards! C,! Duangchinda! T,! Supasa! S,!Chawansuntati! K,! Malasit! P,! Mongkolsapaya! J,! Screaton! G.! 2010.! CrossUreacting!antibodies!enhance!dengue!virus!infection!in!humans.!Science!328:!745U8!133.!Wrammert! J,! Onlamoon! N,! Akondy!RS,! Perng! GC,! Polsrila! K,! Chandele! A,!Kwissa! M,! Pulendran! B,! Wilson! PC,! Wittawatmongkol! O,! Yoksan! S,!Angkasekwinai! N,! Pattanapanyasat! K,! Chokephaibulkit! K,! Ahmed! R.! 2012.!Rapid! and! massive! virusUspecific! plasmablast! responses! during! acute!dengue!virus!infection!in!humans.!J(Virol!86:!2911U8!134.!Fink!K.!2012.!Origin!and!Function!of!Circulating!Plasmablasts!during!Acute!Viral!Infections.!Front(Immunol!3:!78!135.!Weiskopf!D,!Sette!A.!2014.!TUcell!immunity!to!infection!with!dengue!virus!in!humans.!Front(Immunol!5:!93!136.!Paessler!S,!Walker!DH.!2013.!Pathogenesis!of!the!viral!hemorrhagic!fevers.!Annu(Rev(Pathol!8:!411U40!137.!Kelley! JF,! Kaufusi! PH,! Nerurkar! VR.! 2012.! Dengue! hemorrhagic! feverUassociated! immunomediators! induced! via! maturation! of! dengue! virus!nonstructural!4B!protein!in!monocytes!modulate!endothelial!cell!adhesion!molecules! and! human! microvascular! endothelial! cells! permeability.!Virology!422:!326U37!138.!Avirutnan! P,! Punyadee! N,! Noisakran! S,! Komoltri! C,! Thiemmeca! S,!Auethavornanan! K,! Jairungsri! A,! Kanlaya! R,! Tangthawornchaikul! N,!Puttikhunt! C,! Pattanakitsakul! SN,! Yenchitsomanus! PT,! Mongkolsapaya! J,!Kasinrerk! W,! Sittisombut! N,! Husmann! M,! Blettner! M,! Vasanawathana! S,!Bhakdi! S,! Malasit! P.! 2006.! Vascular! leakage! in! severe! dengue! virus!infections:!a! potential! role! for! the! nonstructural! viral! protein! NS1! and!complement.!J(Infect(Dis!193:!1078U88!139.!Slifka! MK.! 2014.! VaccineUmediated! immunity! against! dengue! and! the!potential!for!longUterm!protection!against!disease.!Front(Immunol!5:!195!140.!Sabchareon!A,!Wallace!D,!Sirivichayakul!C,!Limkittikul!K,!Chanthavanich!P,!Suvannadabba! S,! Jiwariyavej! V,! Dulyachai! W,! Pengsaa! K,! Wartel! TA,!Moureau!A,!Saville!M,!Bouckenooghe!A,!Viviani!S,!Tornieporth!NG,!Lang!J.!2012.! Protective! efficacy! of! the! recombinant,! liveUattenuated,! CYD!tetravalent!dengue!vaccine!in!Thai!schoolchildren:!a!randomised,!controlled!phase!2b!trial.!Lancet!380:!1559U67!141.!Villar! L,! Dayan! GH,! ArredondoUGarcia! JL,! Rivera! DM,! Cunha! R,! Deseda! C,!Reynales!H,!Costa!MS,!MoralesURamirez!JO,!Carrasquilla!G,!Rey!LC,!Dietze!R,!Luz! K,! Rivas! E,! Miranda! Montoya! MC,! Cortes! Supelano! M,! Zambrano! B,!Langevin!E,!Boaz!M,!Tornieporth!N,!Saville!M,!Noriega!F,!Group!CYDS.!2015.!Efficacy!of!a!tetravalent!dengue!vaccine!in!children!in!Latin!America.!N(Engl(J(Med!372:!113U23!142.!Ciupe!SM,!Devlin!BH,!Markert!ML,!Kepler!TB.!2013.!Quantification!of!total!TUcell!receptor!diversity!by!flow!cytometry!and!spectratyping.!BMC(Immunol!14:!35!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"161\"!#Instituto!Nacional!de!Salud!P\u00fablica!###143.!Mehr! R,! SternbergUSimon! M,! Michaeli! M,! Pickman! Y.! 2012.! Models! and!methods! for! analysis! of! lymphocyte! repertoire! generation,! development,!selection!and!evolution.!Immunol(Lett!148:!11U22!144.!Wardemann! H,! Kofer! J.! 2013.! Expression! cloning! of! human! B! cell!immunoglobulins.!Methods(Mol(Biol!971:!93U111!145.!Benichou! J,! BenUHamo! R,! Louzoun! Y,! Efroni! S.! 2012.! RepUSeq:! uncovering!the! immunological! repertoire! through! nextUgeneration! sequencing.!Immunology!135:!183U91!146.!Kircher! M,! Kelso! J.! 2010.! HighUthroughput! DNA! sequencingUUconcepts! and!limitations.!Bioessays!32:!524U36!147.!Boyd!SD,!Gaeta!BA,!Jackson!KJ,!Fire!AZ,!Marshall!EL,!Merker!JD,!Maniar!JM,!Zhang!LN,!Sahaf!B,!Jones!CD,!Simen!BB,!Hanczaruk!B,!Nguyen!KD,!Nadeau!KC,!Egholm!M,!Miklos!DB,!Zehnder!JL,!Collins!AM.!2010.!Individual!variation!in! the! germline! Ig! gene! repertoire! inferred! from! variable! region! gene!rearrangements.!J(Immunol!184:!6986U92!148.!Briney!BS,!Willis!JR,!Crowe!JE,!Jr.!2012.!Human!peripheral!blood!antibodies!with!long!HCDR3s!are!established!primarily!at!original!recombination!using!a!limited!subset!of!germline!genes.!PLoS(One!7:!e36750!149.!Briney! BS,! Willis! JR,! McKinney! BA,! Crowe! JE,! Jr.! 2012.! HighUthroughput!antibody! sequencing! reveals! genetic! evidence!of! global! regulation! of! the!naive! and! memory! repertoires! that! extends! across! individuals.!Genes(Immun!13:!469U73!150.!Wu! YC,! Kipling! D,! Leong! HS,! Martin! V,! Ademokun! AA,! DunnUWalters! DK.!2010.! HighUthroughput! immunoglobulin! repertoire! analysis! distinguishes!between! human! IgM! memory! and! switched! memory! BUcell! populations.!Blood!116:!1070U8!151.!Yaari! G,! Uduman! M,! Kleinstein! SH.! 2012.! Quantifying! selection! in! highUthroughput!Immunoglobulin!sequencing!data!sets.!Nucleic(Acids(Res!!152.!Parameswaran!P,!Liu!Y,!Roskin!KM,!Jackson!KK,!Dixit!VP,!Lee!JY,!Artiles!KL,!Zompi! S,! Vargas! MJ,! Simen! BB,! Hanczaruk! B,! McGowan! KR,! Tariq! MA,!Pourmand! N,! Koller! D,! Balmaseda! A,! Boyd! SD,! Harris! E,! Fire! AZ.! 2013.!Convergent! antibody! signatures! in! human! dengue.!Cell( Host( Microbe!13:!691U700!153.!Andraud! M,! Hens! N,! Marais! C,! Beutels! P.! 2012.! Dynamic! epidemiological!models! for! dengue! transmission:! a! systematic! review! of! structural!approaches.!PLoS(One!7:!e49085!154.!Kato! L,! Stanlie! A,! Begum! NA,! Kobayashi! M,! Aida! M,! Honjo! T.! 2012.! An!evolutionary! view! of! the! mechanism! for! immune! and! genome! diversity.!J(Immunol!188:!3559U66!155.!Weinstein! JA,! Jiang! N,! White! RA,! 3rd,! Fisher! DS,! Quake! SR.! 2009.! HighUthroughput! sequencing! of! the! zebrafish! antibody! repertoire.!Science!324:!807U10!156.!Mora! T,! Walczak! AM,! Bialek! W,! Callan! CG,! Jr.! 2010.! Maximum! entropy!models!for!antibody!diversity.!Proc(Natl(Acad(Sci(U(S(A!107:!5405U10!157.!Boyd!SD,!Marshall!EL,!Merker!JD,!Maniar!JM,!Zhang!LN,!Sahaf!B,!Jones!CD,!Simen! BB,! Hanczaruk! B,! Nguyen! KD,! Nadeau! KC,! Egholm! M,! Miklos! DB,!Zehnder!JL,!Fire!AZ.!2009.!Measurement!and!clinical!monitoring!of!human!lymphocyte!clonality!by!massively!parallel!VDJ!pyrosequencing.!Sci(Transl(Med!1:!12ra23!!\n162\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###158.!Wu!X,!Zhou!T,!Zhu!J,!Zhang!B,!Georgiev!I,!Wang!C,!Chen!X,!Longo!NS,!Louder!M,!McKee!K,!O'Dell!S,!Perfetto!S,!Schmidt!SD,!Shi!W,!Wu!L,!Yang!Y,!Yang!ZY,!Yang!Z,!Zhang!Z,!Bonsignori!M,!Crump!JA,!Kapiga!SH,!Sam!NE,!Haynes!BF,!Simek! M,! Burton! DR,! Koff! WC,! DoriaURose! NA,! Connors! M,! Program! NCS,!Mullikin!JC,!Nabel!GJ,!Roederer!M,!Shapiro!L,!Kwong!PD,!Mascola!JR.!2011.!Focused!evolution!of!HIVU1!neutralizing!antibodies!revealed!by!structures!and!deep!sequencing.!Science!333:!1593U602!159.!Krause!JC,!Tsibane!T,!Tumpey!TM,!Huffman!CJ,!Briney!BS,!Smith!SA,!Basler!CF,! Crowe! JE,! Jr.! 2011.! EpitopeUspecific! human! influenza! antibody!repertoires! diversify! by! B! cell! intraclonal! sequence! divergence! and!interclonal!convergence.!J(Immunol!187:!3704U11!160.!Jiang!N,!He!J,!Weinstein!JA,!Penland!L,!Sasaki!S,!He!XS,!Dekker!CL,!Zheng!NY,!Huang!M,!Sullivan!M,!Wilson!PC,!Greenberg!HB,!Davis!MM,!Fisher!DS,!Quake!SR.!2013.!Lineage!structure!of!the!human!antibody!repertoire!in!response!to!influenza!vaccination.!Sci(Transl(Med!5:!171ra19!161.!Jackson!KJ,!Liu!Y,!Roskin!KM,!Glanville!J,!Hoh!RA,!Seo!K,!Marshall!EL,!Gurley!TC,!Moody!MA,!Haynes!BF,!Walter!EB,!Liao!HX,!Albrecht!RA,!GarciaUSastre!A,!ChaparroURiggers! J,! Rajpal! A,! Pons! J,! Simen! BB,! Hanczaruk! B,! Dekker! CL,!Laserson!J,!Koller!D,!Davis!MM,!Fire!AZ,!Boyd!SD.!2014.!Human!responses!to!influenza! vaccination! show! seroconversion! signatures! and! convergent!antibody!rearrangements.!Cell(Host(Microbe!16:!105U14!162.!Schroeder! HW,! Jr.,! Zemlin! M,! Khass! M,! Nguyen! HH,! Schelonka! RL.! 2010.!Genetic! control! of! DH! reading! frame! and! its! effect! on! BUcell! development!and!antigenUspecifc!antibody!production.!Crit(Rev(Immunol!30:!327U44!163.!Rogosch!T,!Kerzel!S,!Hoi!KH,!Zhang!Z,!Maier!RF,!Ippolito!GC,!Zemlin!M.!2012.!Immunoglobulin! analysis! tool:! a! novel! tool! for! the! analysis! of! human! and!mouse!heavy!and!light!chain!transcripts.!Front(Immunol!3:!176!164.!Michaeli!M,!Barak!M,!Hazanov!L,!Noga!H,!Mehr!R.!2013.!Automated!analysis!of!immunoglobulin!genes!from!highUthroughput!sequencing:!life!without!a!template.!J(Clin(Bioinforma!3:!15!165.!D'Angelo!S,!Glanville!J,!Ferrara!F,!Naranjo!L,!Gleasner!CD,!Shen!X,!Bradbury!AR,!Kiss!C.!2014.!The!antibody!mining!toolbox:!an!open!source!tool!for!the!rapid!analysis!of!antibody!repertoires.!MAbs!6:!160U72!166.!Six!A,!MariottiUFerrandiz!ME,!Chaara!W,!Magadan!S,!Pham!HP,!Lefranc!MP,!Mora!T,!ThomasUVaslin!V,!Walczak!AM,!Boudinot!P.!2013.!The!past,!present,!and! future! of! immune! repertoire! biology!U!the! rise! of! nextUgeneration!repertoire!analysis.!Front(Immunol!4:!413!167.!Thomas!PG,!Handel!A,!Doherty!PC,!La!Gruta!NL.!2013.!Ecological!analysis!of!antigenUspecific!CTL!repertoires!defines!the!relationship!between!naive!and!immune!TUcell!populations.!Proc(Natl(Acad(Sci(U(S(A!110:!1839U44!168.!Zompi! S,! Montoya! M,! Pohl! MO,! Balmaseda! A,! Harris! E.! 2012.! Dominant!crossUreactive! B! cell! response! during! secondary! acute! dengue! virus!infection!in!humans.!PLoS(Negl(Trop(Dis!6:!e1568!169.!GarciaUBates! TM,! Cordeiro! MT,! Nascimento! EJ,! Smith! AP,! Soares! de! Melo!KM,! McBurney! SP,! Evans! JD,! Marques! ET,! Jr.,! BarrattUBoyes! SM.! 2013.!Association!between!magnitude!of!the!virusUspecific!plasmablast!response!and!disease!severity!in!dengue!patients.!J(Immunol!190:!80U7!170.!Kalinke! U,! Bucher! EM,! Ernst! B,! Oxenius! A,! Roost! HP,! Geley! S,! Kofler! R,!Zinkernagel!RM,!Hengartner!H.!1996.!The!role!of!somatic!mutation!in!the!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"163\"!#Instituto!Nacional!de!Salud!P\u00fablica!###generation! of! the! protective! humoral! immune! response! against! vesicular!stomatitis!virus.!Immunity!5:!639U52!171.!Kalinke!U,!Oxenius!A,!LopezUMacias!C,!Zinkernagel!RM,!Hengartner!H.!2000.!Virus! neutralization! by! germUline! vs.! hypermutated! antibodies.!Proc( Natl(Acad(Sci(U(S(A!97:!10126U31!172.!SzomolanyiUTsuda!E,!Le!QP,!Garcea!RL,!Welsh!RM.!1998.!TUCellUindependent!immunoglobulin!G!responses!in!vivo!are!elicited!by!liveUvirus!infection!but!not! by! immunization! with! viral! proteins! or! virusUlike! particles.!J(Virol!72:!6665U70!173.!Toyama!H,!Okada!S,!Hatano!M,!Takahashi!Y,!Takeda!N,!Ichii!H,!Takemori!T,!Kuroda! Y,! Tokuhisa! T.! 2002.! Memory! B! cells! without! somatic!hypermutation!are!generated!from!Bcl6Udeficient!B!cells.!Immunity!17:!329U39!174.!Kaji! T,! Ishige! A,! Hikida! M,! Taka! J,! Hijikata! A,! Kubo! M,! Nagashima! T,!Takahashi!Y,!Kurosaki!T,!Okada!M,!Ohara!O,!Rajewsky!K,!Takemori!T.!2012.!Distinct! cellular! pathways! select! germlineUencoded! and! somatically!mutated!antibodies!into!immunological!memory.!J(Exp(Med!209:!2079U97!175.!Kaplinsky! J,! Li! A,! Sun! A,! Coffre! M,! Koralov! SB,! Arnaout! R.! 2014.! Antibody!repertoire! deep! sequencing! reveals! antigenUindependent! selection! in!maturing!B!cells.!Proc(Natl(Acad(Sci(U(S(A!111:!E2622U9!176.!Hangartner! L,! Zinkernagel! RM,! Hengartner! H.! 2006.! Antiviral! antibody!responses:!the!two!extremes!of!a!wide!spectrum.!Nat(Rev(Immunol!6:!231U43!177.!Ekiert! DC,! Bhabha! G,! Elsliger! MA,! Friesen! RH,! Jongeneelen! M,! Throsby! M,!Goudsmit! J,! Wilson! IA.! 2009.! Antibody! recognition! of! a! highly! conserved!influenza!virus!epitope.!Science!324:!246U51!178.!Lingwood!D,!McTamney!PM,!Yassine!HM,!Whittle!JR,!Guo!X,!Boyington!JC,!Wei! CJ,! Nabel! GJ.! 2012.! Structural! and! genetic! basis! for! development! of!broadly!neutralizing!influenza!antibodies.!Nature!489:!566U70!179.!Sasso! EH,! Ghillani! P,! Musset! L,! Piette! JC,! Cacoub! P.! 2001.! Effect! of! 51p1Urelated! gene! copy! number! (V1U69! locus)! on! production! of! hepatitis! CUassociated!cryoglobulins.!Clin(Exp(Immunol!123:!88U93!180.!Breden! F,! Lepik! C,! Longo! NS,! Montero! M,! Lipsky! PE,! Scott! JK.! 2011.!Comparison! of! antibody! repertoires! produced! by! HIVU1! infection,! other!chronic!and!acute!infections,!and!systemic!autoimmune!disease.!PLoS(One!6:!e16857!181.!Lerner!RA.!2011.!Rare!antibodies!from!combinatorial!libraries!suggests!an!S.O.S.! component! of! the! human! immunological! repertoire.!Mol( Biosyst!7:!1004U12!182.!Smith!SA,!Zhou!Y,!Olivarez!NP,!Broadwater!AH,!de!Silva!AM,!Crowe!JE,!Jr.!2012.! Persistence! of! circulating! memory! B! cell! clones! with! potential! for!dengue! virus! disease! enhancement! for! decades! following! infection.!J(Virol!86:!2665U75!183.!Prabakaran! P,! Chen! W,! Singarayan! MG,! Stewart! CC,! Streaker! E,! Feng! Y,!Dimitrov! DS.! 2012.! Expressed! antibody! repertoires! in! human! cord! blood!cells:! 454! sequencing! and! IMGT/HighVUQUEST! analysis! of! germline! gene!usage,! junctional! diversity,! and! somatic! mutations.!Immunogenetics!64:!337U50!!\n164\"An\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"!#Instituto!Nacional!de!Salud!P\u00fablica!###184.!Bikos!V,!Darzentas!N,!Hadzidimitriou!A,!Davis!Z,!Hockley!S,!TraverseUGlehen!A,!Algara!P,!Santoro!A,!Gonzalez!D,!Mollejo!M,!Dagklis!A,!Gangemi!F,!Bosler!DS,! Bourikas! G,! Anagnostopoulos! A,! Tsaftaris! A,! Iannitto! E,! Ponzoni! M,!Felman! P,! Berger! F,! Belessi! C,! Ghia! P,! Papadaki! T,! Dogan! A,! Degano! M,!Matutes!E,!Piris!MA,!Oscier!D,!Stamatopoulos!K.!2012.!Over!30%!of!patients!with! splenic! marginal! zone! lymphoma! express! the! same! immunoglobulin!heavy!variable!gene:!ontogenetic!implications.!Leukemia!26:!1638U46!185.!Warsame!AA,!Aasheim!HC,!Nustad!K,!Troen!G,!Tierens!A,!Wang!V,!Randen!U,!Dong!HP,!Heim!S,!Brech!A,!Delabie!J.!2011.!Splenic!marginal!zone!lymphoma!with! VH1U02! gene! rearrangement! expresses! polyU!and! selfUreactive!antibodies!with!similar!reactivity.!Blood!118:!3331U9!186.!Bikos! V,! Stalika! E,! Baliakas! P,! Darzentas! N,! Davis! Z,! TraverseUGlehen! A,!Dagklis!A,!Kanellis!G,!Anagnostopoulos!A,!Tsaftaris!A,!Ponzoni!M,!Berger!F,!Felman!P,!Ghia!P,!Papadaki!T,!Oscier!D,!Belessi!C,!Stamatopoulos!K.!2012.!Selection!of!antigen!receptors!in!splenic!marginalUzone!lymphoma:!further!support! from! the! analysis! of! the! immunoglobulin! lightUchain! gene!repertoire.!Leukemia!26:!2567U9!187.!Cerutti!A,!Cols!M,!Puga!I.!2013.!Marginal!zone!B!cells:!virtues!of!innateUlike!antibodyUproducing!lymphocytes.!Nat(Rev(Immunol!13:!118U32!188.!Fecteau! JF,! Cote! G,! Neron! S.! 2006.! A! new! memory! CD27UIgG+! B! cell!population!in!peripheral!blood!expressing!VH!genes!with!low!frequency!of!somatic!mutation.!J(Immunol!177:!3728U36!189.!Berkowska! MA,! Driessen! GJ,! Bikos! V,! GrosserichterUWagener! C,!Stamatopoulos! K,! Cerutti! A,! He! B,! Biermann! K,! Lange! JF,! van! der! Burg! M,!van!Dongen!JJ,!van!Zelm!MC.!2011.!Human!memory!B!cells!originate!from!three! distinct! germinal! centerUdependent! and!Uindependent! maturation!pathways.!Blood!118:!2150U8!190.!Wei! C,! Anolik! J,! Cappione! A,! Zheng! B,! PughUBernard! A,! Brooks! J,! Lee! EH,!Milner! EC,! Sanz! I.! 2007.! A! new! population! of! cells! lacking! expression! of!CD27!represents!a!notable!component!of!the!B!cell!memory!compartment!in!systemic!lupus!erythematosus.!J(Immunol!178:!6624U33!191.!Tsai!YT,!Chang!SY,!Lee!CN,!Kao!CL.!2009.!Human!TLR3!recognizes!dengue!virus!and!modulates!viral!replication!in!vitro.!Cell(Microbiol!11:!604U15!192.!Nasirudeen!AM,!Wong!HH,!Thien!P,!Xu!S,!Lam!KP,!Liu!DX.!2011.!RIGUI,!MDA5!and! TLR3! synergistically! play! an! important! role! in! restriction! of! dengue!virus!infection.!PLoS(Negl(Trop(Dis!5:!e926!193.!Raval!FM,!Mishra!R,!Garcea!RL,!Welsh!RM,!SzomolanyiUTsuda!E.!2013.!LongUlasting! T! cellUindependent! IgG! responses! require! MyD88Umediated!pathways! and! are! maintained! by! high! levels! of! virus! persistence.!MBio!4:!e00812U13!194.!Srikiatkhachorn! A,! Wichit! S,! Gibbons! RV,! Green! S,! Libraty! DH,! Endy! TP,!Ennis!FA,! Kalayanarooj! S,! Rothman! AL.! 2012.! Dengue! viral! RNA! levels! in!peripheral! blood! mononuclear! cells! are! associated! with! disease! severity!and!preexisting!dengue!immune!status.!PLoS(One!7:!e51335!195.!EcklUDorna! J,! Batista! FD.! 2009.! BCRUmediated! uptake! of! antigen! linked! to!TLR9!ligand!stimulates!BUcell!proliferation!and!antigenUspecific!plasma!cell!formation.!Blood!113:!3969U77!!\nAn\u00e1lisis\"estructural\"y\"funcional\"del\"repertorio\"de\"anticuerpos\"en\"pacientes\"con\"Dengue\"Cl\u00e1sico\"y\"Dengue\"Hemorr\u00e1gico\"165\"!#Instituto!Nacional!de!Salud!P\u00fablica!###196.!Coller! BA,! Clements! DE,! Bett! AJ,! Sagar! SL,! Ter! Meulen! JH.! 2011.! The!development! of! recombinant! subunit! envelopeUbased! vaccines!to! protect!against!dengue!virus!induced!disease.!Vaccine!29:!7267U75!197.!Zhang!S,!Liang!M,!Gu!W,!Li!C,!Miao!F,!Wang!X,!Jin!C,!Zhang!L,!Zhang!F,!Zhang!Q,! Jiang! L,! Li! M,! Li! D.! 2011.! Vaccination! with! dengue! virusUlike! particles!induces!humoral!and!cellular!immune!responses!in!mice.!Virol(J!8:!333!198.!Galson! JD,! Pollard! AJ,! Truck!J,! Kelly! DF.! 2014.! Studying! the! antibody!repertoire! after! vaccination:! practical! applications.!Trends( Immunol!35:!319U31!199.!Bartram!AK,!Lynch!MD,!Stearns!JC,!MorenoUHagelsieb!G,!Neufeld!JD.!2011.!Generation!of!multimillionUsequence!16S!rRNA!gene!libraries!from!complex!microbial! communities! by! assembling! pairedUend! illumina! reads.!Appl(Environ(Microbiol!77:!3846U52!200.!Li!H.!2012.!Seqtk.!Cambridge,!MA,!USA!201.!Setthapramote! C,! Sasaki! T,! Puiprom! O,! Limkittikul! K,! Pitaksajjakul! P,!Pipattanaboon! C,! Sasayama! M,! Leuangwutiwong! P,! Phumratanaprapin! W,!Chamnachanan! S,! Kusolsuk! T,! Jittmittraphap! A,! Asai! A,! Arias! JF,! Hirai! I,!Kuhara! M,! Okuno! Y,! Kurosu! T,! Ramasoota! P,! Ikuta! K.! 2012.! Human!monoclonal! antibodies! to! neutralize! all! dengue! virus! serotypes! using!lymphocytes! from! patients! at! acute! phase! of! the! secondary! infection.!Biochem(Biophys(Res(Commun!423:!867U72!202.!Sasaki! T,! Setthapramote! C,! Kurosu! T,! Nishimura! M,! Asai! A,!Omokoko! MD,!Pipattanaboon!C,!Pitaksajjakul!P,!Limkittikul!K,!Subchareon!A,!Chaichana!P,!Okabayashi! T,! Hirai! I,! Leaungwutiwong! P,! Misaki! R,! Fujiyama! K,! Ono! K,!Okuno! Y,! Ramasoota! P,! Ikuta! K.! 2013.! Dengue! virus! neutralization! and!antibodyUdependent! enhancement! activities! of! human! monoclonal!antibodies! derived! from! dengue! patients! at! acute! phase! of! secondary!infection.!Antiviral(Res!98:!423U31!203.!Roehrig!JT,!Bolin!RA,!Kelly!RG.!1998.!Monoclonal!antibody!mapping!of!the!envelope!glycoprotein!of!the!dengue!2!virus,!Jamaica.!Virology!246:!317U28!!", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}